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ABSTRACT 
Background 
Whether the epidemiological association between antiretroviral therapy and increased blood 
pressure is of a causal nature remains largely unknown. The transition from association to 
causation could represent a fundamental step for taking preventive measures against hypertension 
and its untoward effects. Such preventive measures are especially crucial for people living with 
HIV in sub-Saharan African countries, where HIV is most widespread, trends in cardiovascular 
disease risk factors are rising persistently, and antiretroviral treatment coverage rates are rapidly 
increasing. 
 
Aims and objectives 
• To review the evidence for the epidemiological associations of antiretroviral therapy with 
increased blood pressure and other cardiovascular disease risk factors, and to obtain 
comprehensive estimates of the strengths of these associations in people living with HIV 
worldwide (Evidence synthesis). 
• To examine the epidemiological association between antiretroviral therapy and increased blood 
pressure using Hill’s criteria of causation (mini-review). 
• To investigate a plausible causal link between antiretroviral therapy and increased blood pressure 
among HIV-infected patients in a sub-Saharan setting using appropriate statistical methods 
(primary data analysis). 
 
Methods 
Evidence synthesis: A series of systematic reviews with meta-analyses were conducted to 
examine the associations of antiretroviral therapy with cardiovascular disease risk factors. Studies 
were sought from electronic databases and cross-references of relevant articles. Studies in which 
blood pressure and other cardio-metabolic outcomes were compared between HIV-infected adults 
naïve and exposed to antiretroviral therapy were eligible for the meta-analyses. The data from 
these studies were combined using random-effects meta-analyses to obtain pooled estimates of 
the associations between antiretroviral therapy and each cardio-metabolic outcome. 
 
Mini-review: Each of Hill’s criteria of causation was examined separately with regards to the 
association between antiretroviral therapy and increased blood pressure. 
 
Primary data analysis: Four hundred and six HIV-infected adults―306 antiretroviral-exposed 
and 100 antiretroviral-naïve―were recruited from a tertiary HIV clinic in semi-urban Nigeria 
between August and November 2014 as part of a cross-sectional study. To assess if antiretroviral 
xxx  
therapy improves the prediction of hypertension, candidate logistic regression models for 
predicting hypertension were compared using Nagelkerke’s R2 and parameter estimates. 
Structural equation models were fitted to determine the indirect effects of antiretroviral therapy 
on blood pressure through body mass index, waist circumference, blood glucose level, and 
sleep quality, while controlling for socio-demographic and clinical characteristics. A propensity 
score matching model was fitted to examine the average treatment effects on the treated (ATT) 
of antiretroviral therapy on systolic and diastolic blood pressure. 
 
Results 
Evidence synthesis: Ninety-one observational studies comprising data for 83,669 HIV-infected 
patients were included in the meta-analyses. Cardio-metabolic measures were significantly higher 
among antiretroviral-exposed patients, compared to their naïve counterparts as shown in the forest 
plots below: 
 
Summary estimates of the pooled associations between antiretroviral therapy and cardio-
metabolic outcomes (continuous) 
 
ART, antiretroviral therapy; CI, confidence interval; N, number of studies included in the meta-analyses. Summary plot shows 
ART is significantly associated with increases in all cardio-metabolic outcome measures.   
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Summary estimates of the pooled associations between antiretroviral therapy and cardio-
metabolic outcomes (categorical) 
 
CI, confidence interval; N, number of studies included in the meta-analyses. With the exception of combined overweight/obesity, 
ART is significantly associated with increased risk of cardio-metabolic disorders. 
 
 
Mini-review: The association between antiretroviral therapy and increased blood pressure fulfilled all 
of Hill’s criteria of causation, with the exception of ‘specificity’. Nonetheless, one would not expect 
the exposure to be specific in the context of a multifactorial condition, such as high blood pressure. 
 
Primary data analysis: Of 400 HIV-infected patients with reported hypertension status, 60 (15%) were 
diagnosed as hypertensive. Other important findings of primary data analysis include the following: 
• Without considering antiretroviral treatment status, the best parsimonious model for predicting 
hypertension comprised age, body mass index, family history of hypertension, and sleep quality 
(R2 = 0.265). The extent to which these variables fit within the predictive model was improved 
slightly when antiretroviral treatment status was included (R2  = 0.274). 
• The indirect effects of antiretroviral therapy on systolic (coefficient = 0.94, 95% CI = 0.73 to 
2.43) and diastolic blood pressure (coefficient = 0.64, 95% CI = 0.16 to 2.09) through waist 
circumference remained statistically significant after adjusting for age, sex, lifestyle factors, CD4 
cell count, and HIV infection duration. 
• After propensity score-matching, 25% of the initial population sample were dropped, so that 229 
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patients on antiretroviral therapy were matched to 74 antiretroviral-naïve patients. In this 
propensity score-matched sample, the estimated ATT of the effects of antiretroviral therapy on 
systolic (7.85 mmHg, 95% CI = 3.72 to 15.68) and diastolic blood pressure (7.45 mmHg, 95% CI 
= 4.99 to 13.61) remained statistically significant after achieving a balanced distribution of 
baseline covariates between antiretroviral-naïve and exposed patients. 
 
Conclusion 
Overall, antiretroviral therapy is potentially the single most consistent correlate of high blood 
pressure (and other cardiovascular disease risk factors) in people living with HIV. These findings 
also suggest a high probability that the epidemiological association between antiretroviral therapy 
and increased blood pressure may be causal. People living with HIV in sub-Saharan African 
countries may benefit from regular hypertension screening and other cardiovascular risk 
assessments after the commencement of antiretroviral therapy. Future studies should identify what 
phenotypes on the HIV clinical spectrum are most susceptible to the effects of antiretroviral 
therapy on blood pressure and other cardio-metabolic parameters, as well as the efficacies of 
targeted interventions on these phenotypes. 
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CHAPTER ONE 
 
INTRODUCTION 
 
In this chapter, I briefly set the stage for the thesis, highlighted my personal and 
professional motivations for my research interest, and presented a brief synopsis of the 
thesis structure. 
 
 
 
1.1 INTRODUCTION 
 
HIV-infected persons now live relatively longer since the advent of highly active 
antiretroviral therapy (HAART) (Joint United Nations Program on HIV/AIDS 
[UNAIDS], 2014a; Sabin, 2013; Stanley & Grinspoon, 2012). However, morbidity and 
mortality rates within this high-risk population remain higher than those observed in the 
general population (Sabin, 2013). The increasing occurrence of non-AIDS-defining 
illnesses, such as cardiovascular diseases and cardiovascular disease risk factors, has been 
identified as one of the underlying factors that may account for this observation (Dau & 
Holodniy, 2008; Hooshyar et al., 2007; Sabin, 2013; Stanley & Grinspoon, 2012). 
Importantly, the increased life-expectancy among people living with HIV may be 
associated with substantial blood pressure changes, which are essentially attributable to 
the direct endothelial-damaging effects of antiretroviral drugs (Seaberg et al., 2005; Stein, 
2003; Thiebaut et al., 2005). Given that more than 35 million people ― mostly young 
and middle-aged adults ― live with HIV worldwide (UNAIDS, 2014a), concerns that 
even small antiretroviral-associated changes in blood pressure may portend considerable 
public health impact on the incidence and prevalence of hypertension and its untoward 
effects may be valid, especially as antiretroviral treatment coverage rates continue to
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increase globally (UNAIDS, 2014a; UNAIDS, 2014b; World Health Organisation, 
2015a). 
 
The associated cardiovascular effects of antiretroviral therapy may potentially constitute 
a substantial public health burden for the 25 million people who currently live with HIV 
in sub-Saharan Africa (Mills et al, 2011; UNAIDS, 2014a), where antiretroviral treatment 
coverage rates continue to increase to meet the overwhelming demands associated with 
increasing HIV prevalence, and where the burden of traditional cardiovascular disease 
risk factors in people living with HIV continues to grow in the context of an ongoing 
demographic and epidemiological transition (Bloomfield & Velazquez, 2013; 
Bloomfield, Hogan & Keter, 2011; Julius, Basu & Ricci, 2011). 
 
 
 
The overarching purpose of this study is to examine the epidemiological nature of the 
association between antiretroviral therapy and cardiovascular disease risk factors, with 
particular emphasis on investigating the possibility of a causal link between antiretroviral 
therapy and increased blood pressure in persons living with HIV in semi-urban Nigeria. 
High blood pressure is widely acknowledged as the most common cardiovascular disorder 
and the leading risk factor for all-cause mortality (Mathers, Stevens & Mascarehas, 2009; 
World Heart Federation, 2015; World Health Organization, 2015b). Owing to several 
factors such as the ongoing nutritional transition, increasing trends in sedentary lifestyle, 
and other modifiable risk factors, and inadequate health care systems, populations in low- 
and middle-income countries may bear a higher burden of the disease, compared with the 
global average (Sarki et al., 2015). However, the burden of hypertension is more severe 
among people living with HIV, compared to the general population (Triant et al., 2007): 
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a trend that has largely been attributed to the advent of HAART (Hooshyar et al., 2007; 
Dau & Holodniy, 2008). Although several studies have examined the association between 
antiretroviral therapy (or HAART) and blood pressure changes among people living with 
HIV in sub-Saharan African countries (Ayodele et al., 2013; Dimodi et al., 2014; Ekali 
et al., 2013; Manuthu et al., 2008; Muhammad, Sani & Okeahialam, 2013a; Muhammad, 
Sani & Okeahialam, 2013b; Ngala & Fianko, 2013; Ogundahunsi et al., 2008), the 
epidemiological mechanisms involved are less clear. In order to guide the prevention of 
hypertension and its complications in people living with HIV on antiretroviral therapy in 
these countries, the causal pathways between antiretroviral therapy and blood pressure 
changes need to be understood. To the best of the author’s knowledge, this study is the 
first of its kind to determine whether there is a high probability that the epidemiological 
association between antiretroviral therapy and increased blood pressure is causal. 
 
 
 
1.2 PERSONAL AND PROFESSIONAL MOTIVATIONS FOR THE STUDY 
 
My commitment to research in chronic non-communicable disease epidemiology in 
people living with HIV in low- and middle-income countries informs the topic of this 
dissertation, and derives from my education and the appropriate field experiences. After 
my medical training (MBBS) and a short time practicing as a primary care physician in 
Nigeria, I studied for a Master’s in Public Health (MPH) degree at the University of 
Warwick, achieving a distinction. I went on to work as an HIV/AIDS consultant on a 
Centre for Disease Prevention and Control/United States Agency for International 
Development (CDC/USAID) funded project in Nigeria. I was one of two physicians 
treating HIV-infected patients in a rural facility with a patient-base of about 5000. I 
assessed adult and pediatric HIV-infected patients for eligibility to commence 
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antiretroviral therapy, while monitoring their response to the treatments. I also 
supervised prevention-of-mother-to-child-transmission (PMTCT) services, which 
entailed antiretroviral prophylaxis for all pregnant mothers and newborns, as well as 
preliminary and confirmatory testing for infants born to HIV-infected mothers. 
 
Technically, my introduction to the field of cardiovascular disease epidemiology in 
people living with HIV began with the Masters in Public Health professional project, 
which was a systematic review and study-by-study analysis of randomized controlled 
trials appraising the effectiveness of risk factor interventions for preventing 
cardiovascular events in people living with HIV on antiretroviral therapy. My research 
projects have since been focused on cardiovascular disease risk factors in persons living 
with HIV. 
 
 
Working with HIV-infected patients in clinical settings in Nigeria and Kenya, I have 
gained first-hand experience of the devastating effects of HIV infection in these high 
risk and ― and often impoverished ― populations. In addition to the social stigma that 
these patients are often forced to endure in the community, they are marginalised by a 
health system that knows very little about the potential public health implications of 
expanding antiretroviral treatment coverage, notably the rising occurrence of cardio-
metabolic disorders with their complications. Therefore, a number of cardio-metabolic 
disorders, such as dyslipidaemias and diabetes mellitus, tend to be underdiagnosed 
following enrolment into treatment. Even when cardio-metabolic disorders are 
eventually detected (such as high blood pressure), they (cardio-metabolic disorders) are 
often treated in isolation from the potential complications of HIV infection and 
antiretroviral therapy. Based on my clinical experience, benefits derived from such 
treatments are usually not sustainable long term, most probably because the treatment 
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choices are not informed by an understanding of the complex epidemiological pathways 
between antiretroviral therapy and increased blood pressure. 
 
 
It is clear that the care and treatment of most persons living with HIV in Nigeria (and 
several other sub-Saharan African countries) do not extend beyond antiretroviral 
therapy, surveillance of clinical indications for the commencement of antiretroviral 
therapy, and the treatment of opportunistic infections. Barring the austere political 
climate and other social factors in the country, it is plausible that the reasons why HIV-
infected patients do not generally get the extra care for hypertension and other cardio-
metabolic disorders after the commencement of antiretroviral therapy may rely heavily 
on the dearth of evidence ― especially data originating from the sub-Saharan African 
region ― uncovering the complex nature of the epidemiological associations between 
antiretroviral therapy and cardio-metabolic changes. It is my goal that antiretroviral-
associated increases in blood pressure and other cardio-metabolic parameters be no 
longer neglected in sub-Saharan African settings because of a lack of evidence, but be 
recognised as potential public health problems with dire consequences if left 
unaddressed. It is also my goal that country-specific guidelines for the care and 
treatment of people living with HIV across the sub-Saharan African region entail 
comprehensive baseline and routine cardiovascular risk assessments. Drawing on all of 
the above, I sought to answer the research questions posed in the thesis. 
 
 
1.3 A BRIEF SYNOPSIS OF THE THESIS STRUCTURE 
 
 
PART A: Introduction (Chapters 1 to 3) 
 
In this section, I set the stage for my doctoral dissertation, while highlighting the 
motivation and theoretical basis for conducting the research. The scientific context for 
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the thesis is explained comprehensively, including an account of the epidemiology of 
cardiovascular disease risk factors in persons living with HIV in the era of highly active 
antiretroviral therapy, current treatment strategies for cardio-metabolic disorders in 
persons living with HIV on antiretroviral treatment, the potential consequences of 
antiretroviral-associated cardio-metabolic disorders from a public health perspective, and 
the underlying issues that may perpetuate the potential double burden of HIV and 
antiretroviral-associated cardio-metabolic disorders in sub-Saharan African countries, 
where health indices are worse off. The research questions, overall aims and objectives 
of the dissertation are outlined in this section. The study hypotheses and conceptual 
framework are also illustrated. 
 
PART B: Global evidence synthesis of the association between antiretroviral therapy 
and cardiovascular disease risk factors (Chapters 4 to 11). 
The evidence for the associations of antiretroviral therapy with increased blood pressure 
and other cardiovascular disease risk factors in people living with HIV are reviewed. 
Meta-analyses of the pooled estimates of these associations are also presented. 
Background, methods and results chapters are presented in this section. 
 
PART C: An Epidemiological Examination of the Association between 
Antiretroviral Therapy and Blood Pressure Changes using Hill’s Criteria of 
Causation (mini-review) (Chapters 12 to 14). 
Each of Hill’s criteria of causation is examined in relation to the association between 
antiretroviral therapy and increased blood pressure. Background, methods and results 
chapters are also presented in this section. 
 
PART D: Primary data collection and analysis in a resource-limited setting 
(Chapters 15 to 21). 
7  
In this section, alternative causal pathways between antiretroviral therapy and increased 
blood pressure among people living with HIV in semi-urban Nigeria are examined based 
on appropriate statistical analyses of primary observational data collected by me. The 
activities of this section also entail a background, methods and results chapters. 
 
PART E: Discussions of the findings and recommendations (Chapters 22 to 26). 
In this section, I interpret the results of the dissertation, highlighting its practical and 
research implications, limitations and strengths. I also the findings of the dissertation, 
while reinforcing the main ideas. 
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CHAPTER TWO 
 
BACKGROUND 
 
In this chapter, I describe the scientific context of the thesis, including a succinct 
description of the problem, certain epidemiological facts about the problem, current 
treatment strategies, consequences / associated burden, and any underlying social issues 
that may perpetuate the problem in sub-Saharan African settings, where health indices 
tend to be worse off. 
 
 
 
2.1 ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR DISEASE RISK 
FACTORS 
Deaths arising from the Acquired Immune Deficiency Syndrome (AIDS) have declined 
substantially since the advent of highly active antiretroviral therapy (HAART) (Joint 
United Nations Program on HIV/AIDS [UNAIDS], 2014a; Van Vugt et al., 2007). 
HAART entails the treatment of HIV infection using two or more drugs from different 
antiretroviral drug classes, notably the protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors. Other benefits of HAART include suppression of viral load, 
improvements in cell-mediated immunity, and decreased occurrence of opportunistic 
infections (Dagogo-Jack, 2008). However, the improved life-expectancy among persons 
living with HIV may be associated with a high occurrence of cardiovascular disease risk 
factors, such as high blood pressure (Seaberg et al., 2005; Thiébaut et al., 2005), raised 
serum lipid levels (Dubé et al., 2003; Shlay et al., 2007), high blood glucose 
concentrations (Dagogo-Jack, 2008; Kalra et al., 2011), body fat changes (Grunfeld et al., 
2010; Shlay et al., 2007), and metabolic syndrome (Krishnan et al., 2012). Of note, 
HAART exacerbates the severity and prevalence of these non-AIDS-defining    illnesses 
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(Dillon et al., 2013). However, it is difficult to differentiate the clinical presentations of 
antiretroviral-associated cardio-metabolic disorders from cardio-metabolic conditions of 
other origins ― a problem which potentially complicates the clinical diagnoses and 
subsequent treatment of cardiovascular conditions in HIV-infected patients receiving 
antiretroviral therapy (Yarasheski et al. 1999; Dagogo-Jack, 2008). 
 
 
2.2 EPIDEMIOLOGICAL TRENDS 
 
2.2.1 Mechanisms of cardio-metabolic changes in people living with HIV 
Antiretroviral therapy underlies the pathogenesis of cardio-metabolic disorders in a 
substantial proportion of people living with HIV, and this through different mechanisms 
that may not be linked to specific classes of antiretroviral drugs (Kalra et al. 2011). For 
instance, both reverse transcriptase and protease inhibitors directly damage the 
endothelial linings of blood vessels, subsequently inhibiting the production of biological 
markers that help to regulate blood pressure, such as nitric oxide (Seaberg et al., 2005; 
Stein, 2003). Regardless of the class to which antiretroviral drugs belong, they also cause 
blood pressure changes by increasing large arterial wall stiffness, which has been 
identified as a causative factor in hypertension (Ngatchou et al., 2013; Wagenseil & 
Mecham, 2012). Both nucleoside reverse transcriptase inhibitors and protease inhibitors 
alter lipid metabolism by inhibiting mitochondrial function, which in turn, increases 
biosynthesis and reduces hepatic clearance of low density lipoprotein (LDL) cholesterol 
(Fleischman et al., 2007; Stein, 2003). Although the mechanisms of antiretroviral-
induced changes in serum lipoprotein levels may overlap between different antiretroviral 
drug classes, the degree to which serum lipoproteins are altered may differ between 
antiretroviral drugs and antiretroviral classes. For instance, total cholesterol and LDL 
cholesterol levels are increased more markedly following treatment using efavirenz, 
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lopinavir and ritonavir, as opposed to atazanavir and darunavir (Daar et al., 2011; Molina 
et al, 2010). Indinavir interferes with glucose metabolism by inducing insulin resistance 
without any indirect effects on lipid metabolism, whereas lopinavir and ritonavir alter 
lipid metabolism without mediating insulin resistance (Kalra et al., 2013; Woerle et al., 
2003). Protease inhibitors and nucleoside reverse transcriptase inhibitors also inhibit 
glucose metabolism by mediating mitochondrial dysfunction (Dagogo-Jack, 2008; Kalra 
et al., 2013). Occasionally, antiretroviral treatment using either protease inhibitors or 
reverse transcriptase inhibitors may overstimulate the immune system, consequently 
increasing the production of autoantibodies that target the enzyme: glutamic acid 
decarboxylase (GAD) in persons who would later develop type 1 (or autoimmune) 
diabetes mellitus (Takarabe et al., 2010). Both isoforms of glutamic acid decarboxylase 
(GAD67 and GAD65) are present in the pancreas, and are responsible for the synthesis of 
gamma aminobutyric acid (GABA), which is an important neurotransmitter in the 
pancreatic islet cells (Gilliam, Palmer & Lernmark, 2004). Hence, an autoimmune 
response against GAD in the pancreatic cells interferes with insulin production, leading 
to type 1 diabetes (Baekkeskov et al., 1990; Kaufman et al., 1992). Although the 
underlying mechanisms explaining the association between antiretroviral therapy and 
body fat changes are unclear, evidence suggests a plausible link between antiretroviral 
drugs and raised serum cortisol levels, suggestive of Cushing’s disease (Stanley & 
Grinspoon, 2012): a metabolic disorder that invariably presents with central adiposity and 
relative weight gain. In spite of the similarities in the mechanisms by which protease 
inhibitors and reverse transcriptase inhibitors may increase cardiovascular risk in persons 
living with HIV, evidence in the available literature allude to differential cardio-metabolic 
effects between both classes of antiretroviral drugs, with protease inhibitors associated 
with a more acute symptomatology than reverse transcriptase inhibitors (Kalra et al., 
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2013; Shlay et al., 2007). While there are newer classes of antiretroviral drugs ― such as 
the integrase inhibitors, fusion inhibitors, and chemokine receptor antagonists ― that are 
less likely to be associated with adverse cardio-metabolic effects (Rathbun, Liedtke & 
Lockhart, 2013), it is worth emphasizing that these newer drugs are not widely available 
because they have not been approved for use in most countries (Deeks et al., 2008; 
Rathbun, Liedtke & Lockhart, 2013). In fact, the newer classes of antiretroviral drugs 
have not been rolled out in any low- or middle-income country.  
 
HIV infection, in itself, may aggravate the effects of antiretroviral drugs on 
cardiovascular disease risk factors, through its chronic inflammatory and platelet 
activating effects (Dau & Holodniy, 2008; Mutimura et al., 2008). Although these 
mechanisms have not been fully elucidated, a recurring hypothesis revolves around a 
relationship between high viral loads and increased inflammation (Strategies for 
Management of Antiretroviral Therapy [SMART] Study Group, 2006). 
 
 
 
2.2.2 Blood pressure changes / hypertension in people living with HIV 
 
According to the World Heart Federation (2015b), at least 970 million people of the 
general population have hypertension, with the largest prevalence in the African 
continent. Although the worldwide burden of hypertension in high-risk populations such 
as people living HIV remains largely unknown, it is considered to be more severe when 
compared with the general population. A secondary analysis of data on a large number of 
patients stratified by HIV status revealed a significantly higher prevalence of 
hypertension among HIV-seropositive patients, compared to seronegative patients 
(21.2% versus 15.9%; P < 0.001) (Triant et al., 2007). Kaplan et al. (2007) found the age- 
adjusted prevalence of hypertension to be 24% in a cohort of 2386 HIV-infected subjects. 
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However, the higher prevalence of hypertension in HIV-infected persons, compared to 
the general population, may largely be attributable to the effects of antiretroviral 
therapy. For instance, findings from the Multicentre AIDS Cohort Study (MACS) 
revealed that the risk of hypertension increased 1.5 fold in HIV-infected men following 
the commencement of HAART (Seaberg et al., 2005). Chow et al. (2003) also found 
statistically significant increases in systolic and diastolic blood pressure for every 
additional year of HAART, even after adjusting for age, blood pressure at baseline and 
CD4 cell count. HIV-infected patients exposed to HAART may be up to ten times more 
likely to be hypertensive, compared with HIV-infected patients who are naïve to 
antiretroviral treatment (Ekali et al., 2013). 
 
 
2.2.3 Blood glucose changes / diabetes mellitus in people living with HIV 
 
Triant et al. (2007) also found a significantly higher prevalence of Type 2 diabetes 
mellitus in HIV-infected patients, compared to those who were HIV-negative (11.5% 
versus 6.6%; P < 0.001). Brown et al. (2005) also found HIV-infected patients to be 
approximately four times more likely to develop Type 2 diabetes, compared with HIV- 
negative individuals. Yarasheski et al. (1999) suggested that genetic predisposition was 
the single most consistent predictor of diabetes among people living with HIV; however, 
this assertion was made early on in the HAART era, so that there was a dearth of studies 
reporting abnormalities of glucose metabolism associated with antiretroviral therapy at 
the time. A literature search did not find studies published prior to the year 2000 that had 
examined the associations between antiretroviral therapy and diabetes mellitus risk. 
Antiretroviral therapy has been identified as a major predictor of diabetes mellitus in 
people living with HIV (Larsson et al., 2006): about one in ten HIV-infected patients on 
antiretroviral therapy may present with diabetes mellitus (Calza et al., 2011; Kalra & 
Agrawal, 2013). HIV-infected patients are also likely to develop diabetes mellitus as a 
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result of the increased body weight that often follows antiretroviral treatment (Dagogo- 
Jack, 2008; Kalra et al., 2011). The clinical presentation of antiretroviral-associated 
diabetes mellitus is often consistent with type 2 diabetes (Dagogo-Jack, 2008; Kalra et 
al., 2011). However, a few patients may present with a form of type 1 diabetes that is 
autoimmune-related: the outcome of an exaggerated immune response to antiretroviral 
treatment (Kalra et al., 2011; Takarabe et al., 2010). 
 
 
2.2.4 Serum lipid changes / dyslipidaemias in people living with HIV 
 
Interestingly, evidence from the pre-HAART era reported decreases in serum cholesterol 
levels and slight increases in serum triglycerides among HIV-infected patients prior to 
developing AIDS (Grunfeld et al., 1991; Grunfeld et al., 1992; Shor-Posner et al., 1993). 
Mujawar et al. (2006) had suggested that the inhibition of cholesterol efflux from human 
macrophages by the human immunodeficiency virus was a plausible mechanism 
explaining why HIV infection causes a shift in serum lipoprotein levels, however, there 
is no consensus regarding this hypothesis. Regardless of antiretroviral treatment status, 
previous studies have consistently reported higher prevalence estimates of dyslipidaemia 
in HIV-infected patients, compared to non-infected patients. For instance, Triant et al. 
(2007) reported a significantly higher prevalence of dyslipidaemia in HIV-infected 
patients, compared to non-infected patients (23.3% versus 17.6%; P < 0.001). However, 
it is clear that antiretroviral therapy exacerbates the abnormalities of lipid metabolism in 
HIV-infected patients (Carey et al., 2010; Daar et al., 2011; Dillon et al., 2013; Dube & 
Fenton, 2003; Fleischman et al, 2007; Fontas et al., 2004; Molina et al, 2010; Pujari et 
al., 2005; Riddler et al., 2003; Riddler et al., 2007; Stein, 2003). For example, in a Multi- 
center AIDS Cohort Study (MACS), Riddler et al. (2003) observed significant declines 
in mean serum concentrations of total cholesterol, HDL cholesterol, and LDL cholesterol 
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among HIV-infected men followed-up for a mean duration of eight years, compared to 
pre-seroconversion concentrations. However, the subsequent initiation of antiretroviral 
therapy was associated with increases in serum concentrations of total cholesterol and 
LDL cholesterol, but no significant change in HDL cholesterol levels (Riddler et al., 
2003). Furthermore, prevalence estimates of dyslipidaemia among people living with HIV 
on antiretroviral therapy may be as high as 80% ― depending on the characteristics of 
the study population (Troll, 2011). 
 
 
2.2.5 Body fat changes in people living with HIV 
 
Although antiretroviral-naive HIV-infected patients are more likely to develop body fat 
changes, compared to non-infected patients, exposure to antiretroviral therapy may 
exacerbate these changes (Shlay et al., 2007). More than one in two HIV-infected patients 
may develop body fat changes, especially central fat accumulation, soon after 
commencing HAART (Grunfeld et al., 2010; Shlay et al., 2007). Evidence from more 
recent studies suggest that antiretroviral-exposed patients may be up to five times more 
likely than those naïve to treatment to become overweight or obese (Peck et al., 2014), 
and more than two times more likely to become centrally obese (Blass et al., 2008; 
Muhammad, Sani & Okeahialam, 2013a; Muhammad, Sani & Okeahialam, 2013b). 
 
 
2.2.6 Metabolic syndrome in people living with HIV 
 
Metabolic syndrome is a constellation of prediabetes, dyslipidaemia, central obesity, and 
high blood pressure. More recently, there have been other metabolic abnormalities 
proposed to be included in the definition of metabolic syndrome, including 
hyperuricaemia (an excess of uric acid in the blood), microalbuminuria (small increases 
in the albumin levels in urine), hypercoagulability (coagulopathy that increases the risk 
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of clot formation in blood vessels), and vascular inflammation (vascular condition 
characterized by formation of atheromatous plaques in arterial walls) (Blaton, Korita & 
Bulo, 2008). Like its individual components, metabolic syndrome as a pathophysiological 
entity increases the risk of cardiovascular disease in the general population; however, 
among persons living with HIV, the presence of metabolic syndrome as an entity is no 
better than the sum of its individual components in predicting cardiovascular risk 
(Worm et al., 2009). The direct effects of antiretroviral drugs on endothelial and 
adipocyte function, lipid metabolism, and mitochondrial dysfunction sufficiently explain 
the link between antiretroviral therapy and metabolic syndrome; however, the role of a 
genetic predisposition to metabolic syndrome in persons living with HIV on 
antiretroviral therapy has also been suggested (Babaro & Lacobelli, 2009). The 
prevalence of metabolic syndrome in people living with HIV on antiretroviral therapy 
has been shown to vary widely between 18% and 83%, with higher prevalence estimates 
found among older persons; patients on protease inhibitor-based antiretroviral regimens; 
and patients exposed to antiretroviral treatment for longer durations (Babaro & 
Lacobelli, 2009). 
 
 
2.2.7 The role of lifestyle factors in people living with HIV 
 
Lifestyle factors such as smoking, heavy alcohol drinking and poor dietary habits may 
also underlie the aetiology of cardio-metabolic disorders among people living with HIV 
on antiretroviral therapy. Savès et al. (2003) reported significantly higher prevalence rates 
of smoking in HIV-infected men (56.6% versus 32.7%; P < 0.001) and women (58% 
versus 28%; P < 0.001) who received antiretroviral treatment, compared to their 
respective counterparts in the general population. Smoking also reduces the potency of 
antiretroviral drugs, causing HIV-infected patients who smoke to become more 
susceptible to the inflammatory effects of the virus, compared to HIV-infected patients 
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who do not smoke (Crothers et al., 2005; Feldman et al., 2006). Similarly, Baum et al. 
(2010) found a correlation between alcohol abuse and increased viral load among HIV- 
infected patients on antiretroviral therapy (P = 0.046), which may explain by the 
connection between alcohol abuse and sub-optimal antiretroviral adherence (Samet et al., 
2004). In other words, the role of alcohol abuse in increasing the risk of cardio-metabolic 
disorders is somewhat coherent with evidence from the SMART trial suggesting a 
relationship between high viral loads and increased inflammation (SMART Study Group, 
2006). Increased dietary fat intake ― found to be more prevalent in HIV-infected patients 
compared to the general population ― has also been identified as a significant contributor 
to the high prevalence of dyslipidaemia and central obesity among HIV-infected patients 
in the HAART era (Jaime et al., 2006; Joy et al., 2007). 
 
 
2.2.8 The role of socioeconomic factors in people living with HIV 
 
Socioeconomic factors may also play an important role in the epidemiology of 
hypertension and other cardiovascular disease risk factors in people living with HIV. For 
instance, as observed in the general population, persons living with HIV in socially 
deprived settings may be more likely to be at risk of cardiovascular diseases, compared 
to HIV-infected persons who live in less deprived areas (Marmot et al., 1997; Wilkinson 
& Marmot, 2003). Wester et al. (2011) further supports this claim by showing higher 
incidence rates of cardiovascular diseases among antiretroviral-exposed HIV-infected 
patients living in Botswana, compared with those in the United States (8.4 versus 5.0 per 
1,000 person-years). It is also plausible that the link between socioeconomic status and 
lifestyle, as observed in landmark studies investigating the socioeconomic and 
psychosocial determinants of health inequalities (Hemingway & Marmot, 1999; Marmot 
et al., 1997; Wilkinson & Marmot, 2003), may partially account for this phenomenon. 
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For instance, Batista et al. (2013) found that HIV-infected patients who were lower 
income earners and without any formal education were more likely to be current smokers, 
compared to their counterparts who were higher income earners and educated. 
 
 
2.2.9 The role of non-traditional risk factors in people living with HIV 
 
Other factors such as sleep problems (Hoevenaar-Blom et al., 2011; Stranges et al., 2008), 
depressive symptoms (Joynt, Whellan & O’Connor, 2003; Wassertheil-Smoller et al., 
2004), and impaired health-related quality of life (Stranges et al., 2015) which are 
known to be associated with increased risk of hypertension and other cardio-metabolic 
disorders in the general population, have not been sufficiently explored in relation to 
cardio-metabolic health in people living with HIV. Nonetheless, these factors may 
potentially contribute to the aetiology of cardio-metabolic disorders in HIV-infected 
persons on antiretroviral therapy, given their high occurrence in this high-risk subgroup 
(Wibbeler et al., 2012). For instance, approximately 59% of HIV-infected patients in a 
cross-sectional study were assessed to have poor sleep quality, the odds of which were 
more than four times higher among patients exposed to HAART, compared to HAART-
naïve patients (Oshinaike et al., 2014). Similarly, prevalence estimates of depression, 
which is considered the most common mood disorder among people living with HIV, 
may be as high as 50% in people living with HIV on antiretroviral therapy (Hartzell, 
Janke & Weintrob, 2008). Although there is a lack of data for comparisons of mood 
disorders between HAART-exposed and HAART-naïve patients, HAART-exposed 
patients may be up to four times more likely to have mood disorders, compared with the 
general population (Pence et al., 2006). 
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2.3 CURRENT TREATMENT STRATEGIES 
 
In spite of the accompanying adverse effects, withholding antiretroviral treatment cannot 
be an option, given that most people living with HIV who are eligible to commence 
HAART succumb to AIDS within two to three years without treatment (Dau & Holodniy, 
2008). Antiretroviral non-adherence may also increase cardiovascular risk through 
mechanisms earlier described: the SMART Study Group (2006) exemplifies this 
dilemma, having found a higher risk of cardiovascular disease associated with 
interrupting antiretroviral treatment (Hazard Ratio = 1.6, 95% CI = 1.0 to 2.5, P = 0.05). 
Evidence from randomized clinical trials suggest that therapeutic lifestyle interventions, 
including dietary modification and increased physical activity are effective in preventing 
cardio-metabolic disorders in HIV-infected patients on HAART (Balasubramanyam et 
al., 2011; Baril et al., 2007; Fitch et al., 2006). Interventions such as anti-hypertensive 
drugs, lipid lowering medications, and oral hypoglycaemic agents have also been 
effective in treating HAART-exposed patients presenting with hypertension, 
dyslipidaemia, and type 2 diabetes mellitus respectively (Calza, Manfredi & Chiodo, 
2003; Calza et al., 2005). However, these pharmacological agents may be more effective 
than standard treatment when they are intensified to target lower reference values for 
blood pressure, serum lipoprotein levels, and other cardiovascular risk parameters (Masia 
et al., 2009). Furthermore, antiretroviral switch therapy, where antiretroviral drugs 
associated with adverse cardio-metabolic effects are replaced with those that have better 
side-effect profiles, may also be more effective than standard treatment in managing 
antiretroviral-associated cardio-metabolic disorders (Masia et al., 2009; Rasmussen et al., 
2011). The second generation protease inhibitors (e.g. atazanavir, darunavir), as well as 
the newer classes of antiretroviral drugs (e.g. integrase inhibitors, fusion inhibitors and 
chemokine  receptor   antagonists)  may  represent   the  drugs  of   choice  for    treating 
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antiretroviral-associated cardio-metabolic disorders in people living with HIV (Deeks et 
al., 2008; Rathbun, Liedtke & Lockhart, 2013). 
 
 
2.4 CONSEQUENCES (ASSOCIATED BURDEN) 
 
Overall, previous studies suggest that about 60% of persons living with HIV on 
antiretroviral therapy may develop one or more risk factors for cardiovascular diseases 
(Carr et al., 1998; Dube & Sattler, 1998; SoRelle, 1998; Troll, 2011), approximately half 
of whom may progress to coronary heart disease, stroke or cardiovascular mortality 
(Friis-Møller et al., 2003). Although there is a dearth of studies reporting quality and 
disability-adjusted life-years associated with antiretroviral-associated cardiovascular 
disease risk factors, HIV and cardiovascular disease remain two major causes of 
morbidity and mortality worldwide, and potentially constitute a double burden, especially 
in sub-Saharan African countries (Bloomfield & Velazquez, 2013). Projections anticipate 
that HIV and cardiovascular disease could account for the majority of global morbidity 
and mortality by the year 2030, which would remain largely driven by morbidity and 
mortality rates in low- and middle-income countries (Mathers & Loncar, 2005; Kearney 
et al., 2005). Furthermore, the UNAIDS’s (2014a) commitment to end the AIDS epidemic 
by 2030 through strategic scale-up of antiretroviral treatment services may portend a 
substantial public health burden with respect to a potential growth to epidemic 
proportions of antiretroviral-associated cardio-metabolic disorders, and potentially 
worsening the already-existing global burden of hypertension, diabetes, and other cardio- 
metabolic disorders with their complications. With approximately 36 million people 
currently living with HIV worldwide, 13 million people with access to antiretroviral 
treatment, and a projected 18 million incident cases by 2030 (UNAIDS 2014b), concerns 
that antiretroviral-associated cardio-metabolic disorders may become epidemic are valid. 
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2.5 THE SUB-SAHARAN AFRICAN CONTEXT 
 
At least 25 million people are living with HIV across the sub-Saharan African region, 
which accounts for more than 70% of the global population of HIV-infected persons. In 
the past decade, there have been at least 1.3 million new HIV infections across sub-
Saharan African countries every year, which also accounts for approximately 70% of the 
global incidence of HIV infection. Although AIDS-specific mortality rates have fallen 
by 27% since the advent of HAART in sub-Saharan Africa in 2001, the region still 
accounts for more than 70% of the global total of AIDS-related deaths. Two out of three 
HIV-infected patients across sub-Saharan African countries who are eligible to 
commence HAART do not have access to treatment, even though 75% of the global 
total of people living with HIV on antiretroviral therapy reside in these countries, and 
recent trends confirm sustained increases in antiretroviral coverage rates since the 
introduction of HAART in the region (UNAIDS 2013; UNAIDS 2014b; World Health 
Organization, 2015a). 
 
 
Unlike the developed world, there are hardly any surveillance systems in place for 
monitoring cardio-metabolic disorders in people living with HIV in sub-Saharan African 
countries. Care and treatment guidelines for HIV-infected patients in most of these 
countries do not entail baseline or routine cardiovascular risk assessments. In addition, 
the governments of these countries, as well as the various international donor agencies, 
do not usually subsidise investigations required for comprehensive cardiovascular risk 
assessments (Bloomfield & Velazquez, 2013), potentially constituting significant direct 
costs to the patients, most of whom are socio-economically deprived and required to pay 
out-of-pocket for health care. 
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While antiretroviral switch therapies are widely used to treat HAART-associated cardio- 
metabolic disorders in developed countries (Calza et al., 2005; Masia et al., 2009; 
Rasmussen et al., 2011), such treatment options are not readily available in sub-Saharan 
African countries. The non-nucleoside reverse transcriptase inhibitor-based HAART 
regimens are used as first line treatment for HIV infection in sub-Saharan African 
countries, whereas the protease inhibitor-based HAART regimens are used in cases of 
first line treatment failure (Federal Ministry of Health Nigeria, 2012; Ministry of Medical 
Services Kenya, 2011; UNAIDS & World Health Organisation, 2006). The more 
expensive newer classes of antiretroviral drugs (such as the integrase inhibitors, fusion 
inhibitors, and chemokine receptor antagonists) have yet to be approved for use in sub- 
Saharan African countries, potentially resulting in an overreliance on antihypertensive, 
hypoglycaemic and lipid lowering medications, which are modestly effective for 
modifying cardio-metabolic risk (Glass et al., 2006; Nuesch et al., 2013), and potentially 
interact with antiretroviral drugs (Dau & Holodniy, 2008). 
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CHAPTER THREE 
 
RESEARCH QUESTIONS, AIMS AND OBJECTIVES, AND HYPOTHESES 
 
In this chapter, I describe the research questions, the overall aims and objectives, and 
hypotheses of the thesis. I also present a conceptual framework upon which the 
hypotheses were based. 
 
 
3.1 RESEARCH QUESTIONS 
 
I. What is the impact of antiretroviral therapy on cardiovascular disease risk factors in 
people living with HIV? 
II. Is there a plausible causal link in the epidemiological association between antiretroviral 
therapy and increased blood pressure? 
 
 
3.2 AIMS AND OBJECTIVES 
 
 
3.2.1 First aim (Global evidence synthesis) 
 
To examine the impact of antiretroviral therapy on cardiovascular disease risk factors in 
people living with HIV. 
 
3.2.1.1 Objectives 
 
I. To conduct a series of systematic reviews and meta-analyses of studies examining the 
epidemiological associations between antiretroviral therapy and changes in the 
following cardio-metabolic parameters: 
• Blood pressure and hypertension. 
 
• Serum lipoprotein levels and dyslipidaemias. 
 
• Blood glucose levels and diabetes mellitus. 
 
• Body fat measures, combined overweight/obesity, and central obesity. 
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• Metabolic syndrome. 
 
II. To examine the epidemiological association between antiretroviral therapy and 
increased blood pressure using Hill’s criteria of causation. 
 
 
3.2.2 Second Aim (Primary data collection and analysis in a resource-limited 
setting) 
To investigate a plausible causal link between antiretroviral therapy and increased blood 
pressure in a sub-Saharan African setting. 
 
3.2.2.1 Objectives 
 
I. To examine the impact of antiretroviral treatment status on the clinical prediction of 
hypertension in people living with HIV in a sub-Saharan African setting. 
II. To examine alternative causal pathways that potentially mediate the effects of 
antiretroviral therapy on blood pressure in people living with HIV in a sub-Saharan 
African setting. 
III. To estimate the causal average treatment effect of antiretroviral therapy on blood 
pressure in people living with HIV in a sub-Saharan African setting. 
 
 
3.3 HYPOTHESES AND CONCEPTUAL FRAMEWORK 
 
Figure 3.1 illustrates the conceptual framework upon which the research hypotheses are 
based. The hypotheses outlined below are based on the relationships depicted in the 
conceptual framework: 
I. Antiretroviral therapy is associated with cardiovascular disease risk factors in people 
living with HIV (not shown in the diagram). 
II. Antiretroviral treatment status improves the clinical prediction of hypertension in people 
living with HIV in a sub-Saharan African setting. 
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III. Measures of relative weight (such as body mass index) and body fat distribution (such 
as waist circumference) mediate the total effects of antiretroviral therapy on systolic and 
diastolic blood pressure. 
IV. Blood glucose level mediates the total effects of antiretroviral therapy on systolic and 
diastolic blood pressure. 
V. Sleep quality mediates the total effects of antiretroviral therapy on systolic and diastolic 
blood pressure. 
VI. The average treatment effects of antiretroviral therapy on systolic and diastolic blood 
pressure are statistically different from the null effect (not shown in the diagram). 
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Figure 3.1: A conceptual framework of the study hypotheses 
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Paths AB shows the indirect effects of antiretroviral therapy on systolic and diastolic blood pressure through 
body mass index, waist circumference, blood glucose, and sleep quality, controlled for potential confounders. 
Path C’ shows a direct effect of antiretroviral therapy on systolic and diastolic blood pressure. 
Path C (not shown) represents the total effect of antiretroviral therapy on systolic and diastolic blood pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antiretroviral 
Therapy 
↑ Systolic BP 
 
↑ Systolic BP 
 
 
Potential Confounders 
Age 
Gender 
Smoking status 
Drinking status 
Physical activity 
CD4 cell count 
HIV infection duration 
 
↑ Waist Circumference 
↑ Blood Glucose 
↓ Sleep Quality 
27  
 
 
 
 
 
 
 
 
 
 
 
 
 
PART B 
 
 
GLOBAL EVIDENCE SYNTHESIS OF THE 
ASSOCIATIONS BETWEEN ANTIRETROVIRAL 
THERAPY AND CARDIOVASCULAR DISEASE RISK 
FACTORS 
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CHAPTER FOUR 
 
BACKGROUND 
 
In this chapter, I set the stage for a series of systematic reviews and meta-analyses 
conducted to examine the evidence for the associations of antiretroviral therapy with 
increased blood pressure and other cardiovascular disease risk factors in people living 
with HIV worldwide. I go on to justify the rationale and outline the objectives of the 
systematic reviews and meta-analyses. 
 
 
 
4.1 BACKGROUND 
 
The adverse cardio-metabolic effects of antiretroviral drugs have been well-documented 
(Barbaro, 2003; Carr & Cooper, 2000; Currier, 2015; Dagogo-Jack, 2008; Dau & 
Holodniy, 2008; Grinspoon, 2009). Although there have been various primary studies 
evaluating the impact of antiretroviral therapy on cardio-metabolic changes in HIV- 
infected patients, the reported effects have been rather inconsistent, with certain studies 
showing statistically significant associations of antiretroviral exposure with worsening 
cardiovascular effects (Grandominico & Fichtenbaum, 2008; Thiebaut et al., 2005; 
Shapiro et al., 2012) and others showing no significant associations (Bergersen et al., 
2003; Medina-Torne et al., 2012; Wilson et al., 2009). In addition, there is no systematic 
evidence providing comprehensive estimates of the associations between antiretroviral 
therapy and cardiovascular disease risk factors in people living with HIV worldwide. The 
systematic reviews and meta-analyses described in this chapter fills this gap in the current 
body of evidence. In addition, I sought to examine factors that may potentially influence 
the associations between antiretroviral therapy and cardiovascular disease risk factors. 
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4.2. RATIONALE FOR METHODOLOGY 
 
A systematic review with meta-analysis entails pooling data from several quantitative 
primary studies ― often with disparate findings ― to provide a comprehensive and more 
consistent evidence that is of a higher level, compared to the individual primary studies 
(Hemingway & Brereton, 2009). The reasons for combining the results from multiple 
individual studies using systematic reviews with meta-analyses have been well 
established (Higgins & Green, 2011; Mulrow, 1994). For instance, a systematic review 
with meta-analysis is appropriate to obtain pooled estimates of the impact of antiretroviral 
therapy on cardiovascular risk factors in people living with HIV. Given that HIV-infected 
adult patients with reported antiretroviral treatment status represent a very specific 
population, the sample sizes of individual primary studies addressing this question are 
likely to be too small to detect a statistically significant effect. By performing a meta- 
analysis, the statistical power ― which is the chance of detecting an effect as statistically 
significant if it truly exists ― is increased (Higgins & Green, 2011). Performing meta- 
analysis would also improve precision, where the estimate of the pooled association is 
less variable (Higgins & Green, 2011). Furthermore, one cannot make any conclusive 
inferences if the effect estimates from individual primary studies suggest different 
interpretations of the associations between antiretroviral therapy and cardiovascular 
disease risk factors. Such inconsistencies are appropriately resolved by performing a 
meta-analysis of the individual effect (Higgins & Green, 2011; Mulrow, 1994). 
 
 
4.3 AIMS AND OBJECTIVES 
 
4.3.1 Aims 
 
I. To estimate the overall impact of antiretroviral therapy on cardiovascular disease risk 
factors in people living with HIV worldwide. 
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II. To examine factors that may potentially influence the epidemiological associations 
between antiretroviral therapy and cardiovascular disease risk factors in people living 
with HIV worldwide. 
 
 
4.3.2 Objectives 
 
I. To develop a search strategy for identifying potentially relevant studies examining the 
associations between antiretroviral therapy and cardiovascular disease risk factors in 
people living with HIV. 
II. To select eligible studies based on pre-defined inclusion and exclusion criteria. 
 
III. To appraise the methodological quality of each included study. 
 
IV. To pool the associations between antiretroviral therapy and cardiovascular disease risk 
factors by conducting meta-analyses. 
V. To perform tests for small-study effects in order to account for evidence (or lack thereof) 
of publication bias. 
VI. To perform sensitivity analyses in order to ascertain whether the pooled associations 
between antiretroviral therapy and cardiovascular disease risk factors were influenced 
by individual studies. 
VII. pool the associations between antiretroviral therapy and cardiovascular disease risk 
factors by different study-level characteristics and perform meta-regression analyses to 
identify potential effect-modifiers of the pooled associations. 
VIII. To interpret and summarise the results with due consideration of the strengths and 
limitations. 
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CHAPTER FIVE 
 
METHODS 
 
In this chapter, I present the methods of the systematic reviews and meta-analyses, 
including the search strategies, quality assessment criteria for selected studies, data 
synthesis, subgroup analysis, meta-regression analysis, sensitivity analysis and analysis 
of publication bias. I also describe the rationales for these methods. 
 
 
 
 
5.1 PROTOCOL FOR SYSTEMATIC REVIEW AND META-ANALYSIS 
 
The study background, rationale, and methods were specified in advance and documented 
in a study protocol registered in the PROSPERO database (CRD42014008855). The 
systematic review and meta-analysis methods are reported in accordance with the 
preferred reporting items for systematic review and meta-analysis (PRISMA) guideline. 
 
 
5.2 DATA SOURCES AND SEARCH STRATEGY 
 
Studies eligible for the systematic review and meta-analysis were sought from Embase, 
MEDLINE (OVID) and the Scientific Electronic Library Online (SciELO). The search 
was limited to articles published between 1 January 1997 and 22 March 2016. The 
electronic searches were conducted using the following medical subject heading (MeSH) 
terms and keywords, while controlling for different spellings and using appropriate 
truncations and ‘wildcards’: exp *HIV/, HIV infect$.mp./, HIV-1.mp./, exp *human 
immunodeficiency virus 1/, exp *human immunodeficiency virus/, exp *human 
immunodeficiency virus infection/, exp *highly active antiretroviral therapy/, 
antiretroviral therapy.mp./, exp *antiretrovirus agent/, antiretroviral treatment$.mp./, 
protease inhibitor$.mp./, exp *proteinase inhibitor/, HAART-naive.mp./, non-nucleoside 
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reverse transcriptase inhibitor$.mp./, exp *nonnucleoside reverse transcriptase inhibitor/, 
exp *blood pressure/, exp *systolic blood pressure/, exp *diastolic blood pressure/,   exp 
*hypertension/, exp *lipid/, exp *lipoprotein/, exp *dyslipidemia/, dyslipid?emia$.mp./, 
exp *hyperlipidemia/, total cholesterol.mp./, exp *cholesterol blood level/, LDL 
cholesterol.mp./, exp *low density lipoprotein cholesterol/,  HDL cholesterol.mp./,   exp 
*high  density  lipoprotein  cholesterol/,  triglyceride$.mp./,  exp  *triacylglycerol/,   exp 
 
*hypercholesterolemia/,  hypercholesterol?emia$.mp./,  hypertriglycerid?emia.mp./, exp 
 
*hypertriglyceridemia/, exp *blood glucose/, exp *glucose blood level/, exp *diabetes 
mellitus/, exp *type II diabetes mellitus/, waist circumference$.mp./, exp *obesity/,  exp 
*waist circumference/, exp *body fat/, exp *anthropometry/, exp *adipose tissue/, central 
obesity.mp/, exp *metabolic syndrome X/. All MeSH terms were exploded ― as denoted 
by adding ‘exp’ ― to retrieve more specific terms. 
 
 
The search terms were combined using Boolean operators: MeSH terms and keywords of 
HIV infection, antiretroviral therapy, and cardiovascular disease risk factors were each 
combined using the ‘OR’ Boolean operator, and all three groups were combined 
subsequently using the ‘AND’ Boolean operator. The database searches were limited to 
studies on adult humans published after December 1996 in the English language.  Boxes 
5.1 and 5.2 present examples of the EMBASE and Medline (OVID) search histories. 
 
Additional studies were also sought by scanning through the bibliographies of relevant 
articles identified from the database search. 
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Box 5.1: Embase search history 
 
 
Database: Embase Classic+Embase <1947 to 2016 Week 08> 
1 HIV.mp. or exp *Human immunodeficiency virus/ (319197) 
2 HIV-1.mp. or exp *Human immunodeficiency virus 1/ (88618) 
3 exp *Human immunodeficiency virus infection/ or HIV-infect$.mp. (266345) 
4 exp *highly active antiretroviral therapy/ (9132) 
5 antiretroviral therapy.mp. (55235) 
6 exp *antiretrovirus agent/ or antiretroviral treatment$.mp. (74113) 
7 protease inhibitor$.mp. or exp *proteinase inhibitor/ (130916) 
8 non-nucleoside reverse transcriptase inhibitor$.mp. or exp *nonnucleoside reverse 
transcriptase inhibitor/ (10305) 
9 exp *blood pressure/ (119692) 
10 exp *systolic blood pressure/ (4764) 
11 exp *diastolic blood pressure/ (2755) 
12 exp *hypertension/ (271699) 
13 exp *lipid/ or exp *lipoprotein/ or exp *dyslipidemia/ or dyslipid?emia$.mp. or exp 
*hyperlipidemia/ (698329) 
14 total cholesterol.mp. or exp *cholesterol blood level/ (64912) 
15 LDL cholesterol.mp. or exp *low density lipoprotein cholesterol/ (33560) 
16 HDL cholesterol.mp. or exp *high density lipoprotein cholesterol/ (38872) 
17 triglyceride$.mp. or exp *triacylglycerol/ (133822) 
18 exp *hypercholesterolemia/ or hypercholesterol?emia$.mp. (67835) 
19 hypertriglycerid?emia.mp. or exp *hypertriglyceridemia/ (24171) 
20 blood glucose.mp. or exp *glucose blood level/ (111595) 
21 diabetes mellitus.mp. or exp *diabetes mellitus/ (737196) 
22 body mass index.mp. (168936) 
23 waist circumference$.mp. or exp *obesity/ or exp *waist circumference/ or exp 
*body fat/ or exp *anthropometry/ or exp *adipose tissue/ (245654) 
24 exp *metabolic syndrome X/ or central obesity.mp. (32453) 
25 1 or 2 or 3 (380677) 
26 4 or 5 or 6 or 7 or 8 (223953) 
27 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 
or 24 (2038115) 
28 25 and 26 and 27 (6332) 
29 limit 28 to (human and english language and yr="1996 - 2016" and (adult <18 to 64 
years> or aged <65+ years>)) (2826) 
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Box 5.2: MEDLINE (OVID) search history 
 
 
Database: Ovid MEDLINE(R) <1946 to March Week 3 2016> 
1 HIV infection$.mp. or exp *HIV Infections/ (235290) 
2 exp *Antiretroviral Therapy, Highly Active/ or antiretroviral therapy.mp. 
(33964) 
3 protease inhibitor$.mp. or exp *Protease Inhibitors/ (122448) 
4 exp *HIV/ or exp *Anti-HIV Agents/ or exp *Reverse Transcriptase Inhibitors/ 
or exp *HIV Protease Inhibitors/ or non-nucleoside reverse transcriptase 
inhibitor$.mp. or exp *HIV-1/ (100639) 
5 exp *Blood Pressure/ (76277) 
6 exp *Hypertension/ or systolic blood pressure.mp. (190644) 
7 diastolic blood pressure.mp. (24671) 
8 dyslipid?emia$.mp. or exp *Dyslipidemias/ (60848) 
9 hypercholesterol?emia$.mp. or exp *Hypercholesterolemia/ (36471) 
10 hypertriglycerid?emia.mp. or exp *Hypertriglyceridemia/ (11851) 
11 exp *Triglycerides/ or exp *Lipids/ or exp *Lipoproteins/ or exp *Cholesterol/ 
or total cholesterol.mp. or exp *Cholesterol, HDL/ (622164) 
12 exp *Cholesterol, LDL/ (5755) 
13 exp *Blood Glucose/ (41588) 
14 exp *Diabetes Mellitus/ (271317) 
15 exp *Body Mass Index/ (14024) 
16 exp *Body Composition/ or waist circumference$.mp. or exp *Obesity/ or exp 
*Waist Circumference/ or exp *Adipose Tissue/ or exp *Anthropometry/ (233766) 
17 central obesity.mp. or exp *Obesity, Abdominal/ (3803) 
18 body fat measure$.mp. or exp *Adiposity/ (3886) 
19 exp *Diabetes Mellitus, Type 2/ or exp *Metabolic Syndrome X/ or metabolic 
syndrome.mp. (106782) 
20 2 or 3 or 4 (227221) 
21 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
(1371227) 
22 1 and 20 and 21 (2782) 
23 limit 22 to (english language and humans and yr="1996 - 2016" and "all adult 
(19 plus years)") (1590) 
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5.3 CRITERIA FOR SELECTING ELIGIBLE STUDIES 
 
 
5.3.1 Inclusion criteria 
 
Studies with the following characteristics were included in the systematic review and 
meta-analyses: 
I. Participants: HIV-infected adults at least 18 years of age. 
 
II. Exposure criterion: highly active antiretroviral therapy (a study was considered eligible 
if it had both antiretroviral-exposed and antiretroviral-naïve patients). 
III. Outcomes: systolic blood pressure, diastolic blood pressure, hypertension, total 
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, hypercholesterolaemia, 
hypertriglyceridaemia, combined dyslipidaemia, fasting plasma glucose levels, diabetes 
mellitus (Types 1 and 2), body mass index, waist circumference, combined 
overweight/obesity, central obesity and metabolic syndrome. 
IV. Study type: cross-sectional studies, case-control studies, cohort studies, randomised 
controlled trials, abstracts, published data, and studies published after 1996: the year 
marking the advent of HAART (Hooshyar et al., 2007) 
 
 
5.3.2 Exclusion criteria 
 
Studies excluded from the systematic review and meta-analysis had the following 
characteristics: 
I. Participants: HIV-negative individuals, HIV-positive adolescents and children. 
 
II. Exposure criterion: a study was excluded from the search if it did not include 
antiretroviral-exposed and naïve participants. 
III. Outcomes: coronary heart diseases and strokes were outside the scope the thesis. 
 
IV. Study type: expert reviews, policy reports, unpublished data and studies published prior 
to 1996. 
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5.4 QUALITY ASSESSMENT IN EACH INCLUDED STUDY 
 
Appraising the methodological quality of each included study entailed assessing the risks 
of bias in each study using a checklist adapted after the Cochrane risk of bias tool for non- 
randomised studies (Sterne, Higgins & Reves, 2014). The risk of bias assessment tool is 
shown in Box 5.3. Five potential sources of bias were explored: selection of participants 
(selection bias), assessment of exposure (information bias), assessment of the outcomes 
(information bias), adjustment for confounding, and follow-up of participants (attrition 
bias―applicable only to randomised controlled trials and cohort studies). 
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Box 5.3: Risk of bias assessment tool 
 
Domain Assessment criteria 
 
 
 
 
 
 
Sampling of participants 
(Selection bias) 
Low risk: 
Participants were all included or sampled randomly 
Similar recruitment strategy for ART-exposed and naïve 
participants 
The sample size was justified 
 
High risk: 
Participants were not selected randomly 
ART-exposed and naïve participants recruited differently 
The sample size was not justified 
 
Unclear risk: 
Sampling strategy was not described 
The sample size was not calculated 
 
 
 
 
 
Assessment of exposure 
(Information bias) 
Low risk: 
Exposure criterion well defined, in which case, ART-naïveté only 
refers to patients who have never been exposed to ART 
 
High risk: 
Exposure criterion not well defined, e.g. studies may define ART 
exposure based on treatment duration of at least one month; this 
misclassifies certain ART- exposed patients as ART-naïve 
 
Unclear risk: 
Exposure criterion not clearly stated 
 
 
 
 
 
Assessment of outcomes 
(Information bias) 
Low risk: 
Cardiovascular risk factors assessed similarly between ART- 
exposed and ART-naïve participants 
Cardiovascular risk factors measured using a validated tool 
 
High risk: 
Cardiovascular risk factors not assessed similarly between ART- 
exposed and ART-naïve participants 
Cardiovascular risk factors not measured using a validated tool 
 
Unclear risk: 
Methods of measuring cardiovascular risk factors not described 
 
 
Adjustment for 
confounding 
Low risk: 
Adjusted for at least one major confounder 
 
High risk: 
No attempt at adjusting for confounders 
 
Follow-up of participants 
– 
for cohort studies and 
RCTs (Attrition bias) 
Low risk: 
Less than 20% loss to follow-up 
 
High risk: 
Loss to follow-up ≥ 20% 
Adapted from Sterne, Higgins & Reves (2014). ART, antiretroviral therapy; RCTs, randomised controlled trials 
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5.5 DATA EXTRACTION 
 
Data on study characteristics and outcome measures were extracted from each study using 
a data extraction form based on guidance by the University of York Centre for Reviews 
and Dissemination (2008) (Appendix 1). The extracted data included: article citation, 
country of origin, country income group, geographical region, study design, sample size, 
mean age, proportion of females, proportions of current smokers and drinkers, mean 
duration of antiretroviral therapy, antiretroviral regimen, numbers of patients exposed or 
naïve to antiretroviral therapy, and the mean CD4 (cluster of differentiation 4) cell counts. 
Of note, CD4 cells, also called T4 cells or CD4+ T cells, are white blood cells that fight 
infection, and a CD4 count is the number of CD4 cells in a sample of blood. In other 
words, the CD4 count is a measure of the immune status of an individual, where higher 
CD4 counts correspond to higher levels of immunity against infections and vice versa. 
However, the human immunodeficiency virus specifically targets these CD4 cells and 
destroys them, consequently lowering the CD4 cell count as well as the body’s innate 
ability to fight infections (AIDS Info, 2009). 
 
 
Data on outcome measures for antiretroviral-exposed and antiretroviral-naïve patients 
were also extracted: mean systolic and diastolic blood pressure levels, hypertension 
prevalence, mean serum lipoprotein levels, prevalence estimates of hypercholesterolemia 
hypertriglyceridemia and combined dyslipidaemia, mean fasting blood glucose 
concentration, mean body mass index, mean waist circumference, prevalence estimates 
of combined overweight/obesity and central obesity, and prevalence estimates of 
metabolic syndrome. 
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Country income groups were defined according to World Bank development indicators 
(The World Bank Group, 2016). Hypertension was defined as blood pressure of at least 
140/90 mmHg or the use of antihypertensive medication (World Health Organisation, 
1999). Hypercholesterolemia was defined as serum total cholesterol levels no less than 
240 mg/dL and hypertriglyceridemia as serum triglyceride levels no less than 150 mg/dL 
(Adult Treatment Panel III, 2001). Diabetes mellitus was defined as fasting blood glucose 
concentration no less than 7 mmol/L (126 mg/dL) or a two-hour post-prandial blood 
glucose level no less than 11.1 mmol/L (200 mg/dL) (World Health Organization & 
International Diabetes Federation, 2006). Combined overweight/obesity was defined as 
body mass index no less than 25 kg/m2, whereas abdominal obesity was assessed as waist 
circumference no less than 80 cm for women and no less than 94 cm for men (National 
Institute for Health and Clinical Excellence, 2011). Metabolic syndrome was defined as 
any combination of three or more cardio-metabolic abnormalities (Kaur, 2014). 
 
 
5.6 SUMMARY MEASURES 
 
For continuous outcome variables, effect was quantified using the mean difference and 
meta-analysis provides the pooled mean difference. For dichotomous categorical 
variables, effect was quantified using the odds ratio and meta-analysis provides the 
pooled odds ratio. All data were analysed using Stata version 14 for Windows (Stata 
Corp, College Station, Texas). 
 
 
5.7 DATA SYNTHESIS 
 
Due to the anticipated differences in characteristics between individual studies, meta- 
analysis was performed using the random-effects model proposed by DerSimonian & 
Laird (1986). For instance, in the proposed meta-analysis, the effect size might be of 
greater magnitude among HIV-infected patients who are older, or have lower CD4   cell 
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counts, or on protease inhibitor-based antiretroviral treatment etc. Using a random effects 
model, the individual studies in the meta-analysis are assumed to represent a random 
distribution of the individual effect sizes, so that the true effect size varies between these 
studies, and the pooled effect estimate represents the mean effect size in this distribution. 
In contrast, a fixed-effect meta-analysis assumes that there are no characteristic 
differences between studies, so that any observed heterogeneity in the results are entirely 
due to chance (Higgins & Green, 2011). In a fixed-effect model, it is assumed that there 
is one true effect size that is common to all the included studies in a fixed effect meta- 
analysis, in which case the pooled effect is an estimate of this common effect size 
(Borenstein, Hedges & Rothstein, 2007). The implication of these differences with regard 
to estimating the pooled effect is that studies with relatively larger sample sizes may be 
assigned significantly more weight and small studies could be assigned weights that are 
potentially negligible in fixed-effect meta-analyses; whereas, the weight assigned to 
studies pooled using random effects meta-analyses tend to be more balanced, so that 
larger studies are less likely to drive the pooled effect estimates and smaller studies are 
less likely to be ignored (Borenstein, Hedges & Rothstein, 2007).  
 
 
5.8 EXPLORING HETEROGENEITY ACROSS INCLUDED STUDIES 
Heterogeneity across studies included in the meta-analyses was measured using the chi- 
squared (chi2) test for heterogeneity, and at a statistical significance level of 5% (Higgins 
et al., 2003). It is worth noting that the chi2 test for heterogeneity is often influenced by 
the number of studies included in a meta-analysis. For instance, a meta-analysis of a small 
number of studies would not be adequately powered to detect statistically significant 
heterogeneity in the effect estimates across the included studies, whereas when there are 
many studies included in a meta-analysis, the chi2  test for heterogeneity is adequately 
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powered to detect even a small amount of statistical heterogeneity in the effect estimates 
that may not be clinically significant (Higgins & Green, 2011). However, a chi2 statistic 
that is statistically non-significant may not necessarily indicate the absence of 
heterogeneity, given that methodological differences between studies in any meta- 
analysis are bound to occur (Higgins et al., 2003). Nevertheless, the chi2 test for 
heterogeneity may be complemented with the I-squared (I2) statistic, which measures the 
proportion of between-study variability in the effect estimates that accounts for 
heterogeneity across the pooled studies (Higgins & Green, 2011). The I2 statistic, which is 
often reported in the forest plot when computing a meta-analysis, is calculated using the 
formula: I2 = (! − #$ !)×100%, where !	is the chi2 statistic and #$ stands for the degree 
of freedom (Higgins & Thompson, 2002; Higgins et al., 2003). In the present meta-
analysis, an I2 statistic explaining no less than 75% of between-study variability in the 
effect estimates implied considerable heterogeneity (Higgins & Green, 2011; Higgins & 
Thompson, 2002). 
 
 
5.9 SUBGROUP ANALYSIS 
 
To investigate how study-level characteristics influenced the impact of antiretroviral 
therapy on cardio-metabolic effects in the meta-analyses, the studies included in each 
meta-analysis were divided according to categories or subgroups of each study-level 
characteristic as follows: 
I. Region – Each of the five subgroups within this study-level characteristic corresponded 
to a particular region, so that estimates from studies conducted with HIV-infected 
populations in sub-Saharan African countries were pooled as one subgroup, and the other 
four subgroups comprised studies of HIV-infected populations in Europe, South-East 
Asia, The Americas and Western Pacific respectively. 
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II. Country income group – The two subgroups within this study-level characteristic 
included studies conducted in high-income countries, and studies conducted in low- and 
middle-income countries (The World Bank Group, 2016). 
III. Age group – Subgroups included studies in which the mean age of the participants was 
40 years or more, and studies in which the mean age was less than 40 years. The cut-off 
age of 40 years was based on previous studies that found age above 40 years to be an 
important predictor of cardiovascular disorders among people living with HIV (Awotedu 
et al., 2015; Kagaruki et al., 2014; Kaplan et al., 2007; Petoumenos et al., 2014). 
IV. Gender – Subgroups included studies with fewer women (< 50%) than men, and studies 
with more women than men. 
V. Smoking status – Subgroups included studies with fewer smokers (< 50%) than non- 
smokers, and studies with more smokers than non-smokers. 
VI. CD4 cell count – Subgroups included studies in which the mean CD4 count of all HIV- 
infected patients was no greater than 350 cells/mm3, and studies in which the mean CD4 
count was greater than 350 cells/mm3. The cut-off CD4 cell count of 350 cells/mm3 
represents the threshold below which antiretroviral therapy must be initiated to 
significantly reduce HIV-related morbidity and mortality (World Health Organization, 
2013). Although more recent evidence suggests that initiating antiretroviral therapy at a 
higher cut-off value of 500 cells/mm3 may confer additional benefits, including reduced 
incidence of certain opportunistic infections, notably pulmonary tuberculosis, and 
decreased risk of sexual transmission of HIV infection (World Health Organization, 
2016), this threshold is yet to be adopted in many low- and middle-income countries. 
VII. Duration of HIV infection – Subgroups included studies in which the mean duration of 
HIV infection was less than 60 months, and studies in which mean HIV duration was no 
less than 60 months. In a secondary analysis of data from eight cohorts comprising over 
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18,000 HIV-infected patients, Lyons et al. (2015) found a significant increase in the risk 
of cardiovascular disease for every five years of exposure, and independent of age, 
hence the choice of this threshold in the present study. 
VIII. Antiretroviral regimens – Subgroups included studies in which HIV-infected patients 
received protease inhibitor-based treatment regimens, and studies in which all HIV- 
infected participants received other antiretroviral regimens. 
IX. Duration of antiretroviral therapy – Subgroups included studies in which the mean 
duration of antiretroviral therapy was less than 18 months, and studies in which mean 
antiretroviral treatment duration was no less than 18 months. Lai et al. (2009) found that 
the risk of cardiovascular disease was increased more than seven folds among HIV- 
infected patients who had been on antiretroviral therapy for longer than 18 months, 
compared to HIV-infected patients who had received antiretroviral therapy for less than 
18 months, hence the choice of this threshold in the present study. 
X. Study design – Each subgroup comprised studies of a certain design, e.g. cross-sectional 
studies, cohort studies etc. 
XI. Sample size – An arbitrary cut-off of 200 participants was used to divide the studies into 
subsets, so that the subgroups comprised studies with 200 participants or more, and 
studies with less than 200 participants. 
XII. Year of publication – Subgroups included studies published prior to 2010, and studies 
published from 2010 onwards. The selection of 2010 as the basis for grouping the studies 
into subsets was arbitrary. 
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5.10 STUDY-LEVEL FACTORS ASSOCIATED WITH THE POOLED 
ESTIMATES (META-REGRESSION ANALYSIS) 
Random-effects meta-regression analyses were performed on all study-level 
characteristics to examine for potential effect-modifiers of the pooled associations 
between antiretroviral therapy and cardiovascular disease risk factors. Random-effects 
meta-regression, as opposed to the fixed-effect model, was appropriate to account for any 
unexplained heterogeneity in the effect estimates (Higgins & Green, 2011; Higgins & 
Thompson, 2002). In investigating potential sources of heterogeneity across the included 
studies, meta-regression analyses also identified study-level variables that modified the 
pooled association. 
 
 
The degree to which such study-level variables fit within the meta-regression models 
corresponds to the amount of variability in the effect estimate between the included 
studies, and is denoted R-squared (R2). Meta-regression models are quite similar to the 
ordinary least squares (OLS) regression models in the sense that the outcome variables 
(the pooled effect estimates) are regressed on the predictor variables (subgroups of the 
study-level characteristics or potential effect-modifiers) (Higgins & Green, 2011). 
 
 
The results revealed whether the differences between subgroup estimates of the pooled 
associations ― as determined in the subgroup analyses ― were statistically significant. 
In other words, meta-regression analyses were an extension of the subgroup analyses, so 
that the results of these analyses were presented simultaneously (Thompson & Higgins, 
2002). Where the effect estimate in the meta-regression model was an odds ratio, the 
log-transformed value of the effect estimate was regressed on each study-level 
characteristic.  The statistical significance of the subgroup differences in the pooled
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associations were put at 5% significance level, so that the pooled association between 
antiretroviral therapy and each cardio-metabolic outcome was modified by a study-level 
characteristic when the P value for interaction between subgroup estimates was less than 
0.05. In accordance with standard practice, meta-regression analyses were only performed 
when there were ten or more studies, in order to effectively examine potential effect- 
modifiers (Higgins & Green, 2011; Higgins & Thompson, 2002; Thompson & Green, 
2002). 
 
 
5.11 SENSITIVITY ANALYSIS 
 
Leave-one-out sensitivity analyses were performed to investigate the validity and 
robustness of the meta-analyses: sensitivity analyses ensure that the findings of a meta- 
analysis are not dependent on any particular study. Essentially, the included studies were 
omitted one at a time, while iteratively computing the meta-analyses. For each study 
outcome, meta-analysis was considered valid and robust if the confidence intervals of all 
the pooled effect estimates did not change considerably as to alter the interpretation of the 
result following serial omission of the included studies (Higgins & Green, 2011). 
It is worth noting that the results for each sensitivity analysis undertaken were presented 
in a summary table. In fact, the Cochrane Collaboration stipulates that the results of 
sensitivity analyses be summarised in tabular formats, and considers it redundant to 
compute individual forest plots for each sensitivity analysis (Higgins & Green, 2011). 
 
 
5.12 ANALYSIS OF PUBLICATION BIAS 
 
Rothstein, Sutton & Borenstein (2005) emphasize that publication bias must be addressed 
as its presence arguably poses the single greatest threat to the validity of the results in a 
meta-analysis. Publication bias was investigated using the Egger’s regression test for
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small-study effects, complemented by visual interpretations of funnel plots. A funnel plot 
is a scatterplot of the sample size of each included study in a meta-analysis against the 
effect estimate of that study (Egger et al., 1997; Sterne et al., 2011). Generally, larger 
studies tend to have more precise estimates of the effect size, compared to smaller studies, 
so that the effect estimates from smaller studies are scattered widely at the bottom of the 
plot, whereas, estimates from larger studies tend to have a narrower spread (Sterne & 
Harbord, 2004). Therefore, in the absence of publication bias, the plot resembles a 
symmetrical inverted funnel. Conversely, the presence of publication bias, for instance, 
when smaller studies showing no statistically significant associations between 
antiretroviral therapy and cardiovascular risk parameters are not included in the meta- 
analysis because they remain unpublished, results in an asymmetrical appearance of the 
inverted funnel. The more pronounced the funnel plot asymmetry, the more likely it is 
that publication bias is substantial (Sterne & Harbord, 2004). However, funnel plot 
inspection is innately subjective because it is prone to observer error. On the other hand, 
the Egger’s test for small study effects (or Egger’s regression test for funnel plot 
asymmetry) examines whether the association between the effect estimates and the 
sample size is greater than what is expected to occur by chance, in which case, the P value 
for Egger’s regression test at 5% significance level would be less than 0.05 in the presence 
of publication bias, and vice versa in the absence of publication bias (Harbord, Harris & 
Sterne, 2009). 
 
 
Where publication bias was present, its potential impact on each pooled estimate was 
ascertained by imputing ‘missing’ studies and re-computing the pooled effect estimate 
using Stata’s metatrim command. This method of adjusting the meta-analysis for 
publication bias is termed the ‘trim and fill’ analysis of publication bias, proposed by 
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Duval and Tweedie (2000). Adding the imputed ‘missing’ studies to the original dataset 
creates an ‘unbiased’ dataset (or a trimmed and filled dataset). The pooled effect estimate 
of the ‘unbiased’ dataset should not be significantly different from the pooled estimate of 
the original dataset in the sense that the overall interpretation of the association between 
antiretroviral therapy and cardiovascular disease risk factors is not altered. A funnel plot 
of the unbiased dataset should also appear more symmetrical than the original data. 
Conversely, if the differences in the pooled estimates between the original and unbiased 
dataset are significantly different, then it becomes evident that the pooled association was 
influenced by publication bias (Steichen, Egger & Sterne, 1998). 
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CHAPTER SIX 
 
RESULTS – DESCRIPTION OF THE INCLUDED STUDIES 
 
In this chapter, I describe the results of the search strategies, characteristics of the included 
studies, risk of bias assessment within each included study. 
 
 
6.1 STUDY SELECTION 
 
The details of the study selection process are illustrated in the flow diagram shown in 
Figure 6.1. From 920 records yielded by the database search (881 records) and cross- 
references of articles identified from database searching (39 records), 804 articles were 
excluded by their titles and abstracts and 17 duplicate records were withdrawn. Of the 99 
remaining articles assessed to determine eligibility for inclusion, eight additional articles 
were withdrawn after reviewing the full texts (Ahoua et al., 2011; Feleke, Fekade & 
Mezegebu, 2012; Gedefaw et al., 2013; Kinabo et al., 2013; Mercier et al., 2009; Nzou 
et al., 2010; PrayGod et al., 2011; Scarcella et al., 2011), leaving 91 studies considered 
to be eligible for inclusion in the systematic review and meta-analyses. 
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Figure 6.1: Flow diagram showing study selection 
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6.2 CHARACTERISTICS OF THE INCLUDED STUDIES 
 
Table 6.1 summarizes the baseline characteristics of all 91 studies, which comprised a 
total of 83,669 HIV-positive patients. Overall, female participants accounted for 42% of 
the meta-analysis study population; mean age of the study population was 39.1 ± 9.3 
years; proportions of current smokers and current drinkers were 31% and 17% 
respectively; mean CD4 cell count was 341 ± 178 cells/mm3; proportion with one or more 
AIDS-defining illnesses was 34%; mean duration of HIV infection was 66.4 ± 43.9 
months; mean duration of antiretroviral therapy was 32.4 ± 16.1 months; proportion of 
antiretroviral-exposed patients receiving protease inhibitor-based antiretroviral regimen 
was 28%; and there were more than twice as many antiretroviral-exposed patients as there 
were antiretroviral-naïve patients. 
 
 
Thirty-three of the 91 included studies were conducted in sub-Saharan African countries, 
including Benin (Zannou et al., 2009), Botswana (Shapiro et al., 2012), Cameroon 
(Dimodi et al., 2014; Ekali et al., 2013; Mbunkah et al., 2014; Ngondi et al., 2007), 
Ethiopia (Abebe et al., 2014; Mohammed et al., 2015; Tadewos et al., 2012; Tesfaye et 
al., 2014), Ghana (Ngala & Fianko, 2013; Owiredu et al., 2011), Kenya (Manuthu et al., 
2008); Nigeria (Adewole et al., 2010; Akinboro et al., 2013; Ayodele et al., 2013; Denue 
et al., 2012; Denue at al., 2013; Denue, Ikunaiye & Denue, 2013; Muhammad, Sani & 
Okeahialam, 2013a; Muhammad, Sani & Okeahialam, 2013b; Mustapha et al., 2011; 
Ogundahunsi et al., 2008; Ogunmola et al., 2014), South Africa (Abrahams et al., 2015; 
Awotedu et al., 2010; Esposito et al., 2008; Goedecke et al., 2013; Jaff et al., 2015), 
Tanzania (Peck et al., 2014), Uganda (Buchacz et al., 2008; Scholten et al., 2011), and 
Zambia (Kiage et al., 2013). However, studies conducted in European countries (n = 27) 
were generally larger in size (N = 50,683 participants) compared to studies from the other 
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geographical regions. Patients from sub-Saharan African countries were younger than 
patients from other geographical regions, and were mostly females. 
 
 
The reported outcomes included: systolic blood pressure, diastolic blood pressure, 
hypertension, LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides, 
hypercholesterolaemia, hypertriglyceridaemia, combined dyslipidaemia, fasting blood 
glucose, diabetes mellitus, body mass index, combined overweight/obesity, waist 
circumference, central obesity and metabolic syndrome. 
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Table 6.1: Characteristics of the included studies 
 
Authour Year Study design Country Income 
group 
Region N F 
(%) 
Age 
(years) 
HIV duration 
(months) 
CD4 count 
(cells/mm3) 
Smokers 
(%) 
Drinkers 
(%) 
AIDS 
(%) 
ART duration 
(months) 
PI 
(%) 
Abebe 2014 Cross-sectional Ethiopia Low/middle SSA 232 72.3 35.3±10 20.7±14.7 364±199     0 
Abrahams 2015 Cohort South Africa Low/middle SSA 103 100 33.5  372±52.5    16±4 0 
Aboud 2010 Cross-sectional UK High Europe 963 26    37.1     
Adewole 2010 Cohort Nigeria Low/middle SSA 130 69    23 31  7±2.8 0 
Akinboro 2013 Cohort Nigeria Low/middle SSA 140 68 35±8.8  288±232   31.5 5.6±2.7 0 
Arruda Junior (a) 2010 Case-control Brazil Low/middle America 570 39 39.5±10  314±159 2.7 13.9  49.5±27.4 12 
Arruda Junior (b) 2010 Case-control Brazil Low/middle America 633 41.7         
Awotedu 2010 Cross-sectional South Africa Low/middle SSA 196 81 36.9±10.4        
Ayodele 2013 Cross-sectional Nigeria Low/middle SSA 265 67.5 38.7±8.7  313±230 1.9 7.2  17.3±11 0 
Baekken 2008 Cohort Norway High Europe 542 27.1 42.9±9.9        
Bajaj 2013 Cross-sectional India Low/middle S/E Asia 70 28.6       49.5±27  
Bergersen 2003 Cross-sectional Norway High Europe 283 20 43.1±10.2 77±56 384±206 54.5  30 33±2  
Bergersen 2004 Cross-sectional Norway High Europe 283 20 42.7±10.2      33.6±15.3  
Bergersen 2006 Cross-sectional Norway High Europe 263 19.4 43.1±20.1  313±230 1.9 7.2  2  
Blass 2008 Cross-sectional Germany High Europe 44 18.2 40±7.1  441±265    43.5±17.3 67.9 
Blumer 2008 Cohort Netherlands High Europe 39  42.3±7  260±148   18 3 100 
Bonfati 2007 Cross-sectional Italy High Europe 1243 28.2 43.2   60.2     
Bonfati 2012 Cohort Italy High Europe 188 24.5 39.5±11.1      18.5±8.8 46.5 
Buchacz 2008 Cohort Uganda Low/middle SSA 374 49 39      24  
Calza 2011 Cross-sectional Italy High Europe 755  37        
Carey 2013 Cross-sectional India Low/middle S/E Asia 108 53.8 36.3±7.6 46     32±20.3  
Ceccato 2011 Cohort Brazil Low/middle America 620 33.5 39.2±9.9      28.2±15.5 32.1 
Chow 2003 Cohort USA High America 237 11.4 39.5±7.9        
Denue 2012 Cohort Nigeria Low/middle SSA 227 49 40.3±9.3 56±53 246±168 5.3  81.05 24 0 
Denue (a) 2013 Cohort Nigeria Low/middle SSA 229 51.1 43.5±9.3  246±166 5.7 4.9 45.9 24 0 
Denue (b) 2013 Cohort Nigeria Low/middle SSA 107 68.2 39.4±9.3  229±174   61.67 16.5±6 0 
Dimodi 2014 Cross-sectional Cameroon Low/middle SSA 463 74.7    5.05 35.2 8.06  3.2 
Domingos 2009 Cross-sectional Brazil Low/middle America 292 40 41±13 46.6  15.4   40.4 60.2 
Eira 2012 Cross-sectional Brazil Low/middle America 56  42.8±7.1 101.4±51 328±183 57.14   92.4±40.8  
Ekali 2013 Cross-sectional Cameroon Low/middle SSA 143 72 39.5±9.8  253±167    43.5±21.3 0 
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Authour Year Study design Country Income 
group 
Region N F 
(%) 
Age 
(years) 
HIV duration 
(months) 
CD4 count 
(cells/mm3) 
Smokers 
(%) 
Drinkers 
(%) 
AIDS 
(%) 
ART duration 
(months) 
PI 
(%) 
Esposito 2008 Cohort South Africa Low/middle SSA 30 100 30.9±5.6  164±69    3.5±1.3 0 
Fontas 2004 Cohort Multi-centre High Europe 7483 24 38±2.5  470±90   19.9 48±8 78.4 
Friis-Møller 2003 Cohort Multi-centre High Europe 17852 24 39±2.8  430±88   24.8 26.4±4.1 71.7 
Goedecke 2013 Cross-sectional South Africa Low/middle SSA 744 100 33±5.3  371±143    24.5±9 20.9 
Gowdaiah 2013 Cohort India Low/middle S/E Asia 100 35 36.2±6.2      2.4  
Grandominico 2008 Cohort USA High America 52 9.6 35.9±10.1  298±163 57.1  14 6 55.5 
Hansen 2009 Cross-sectional Denmark High Europe 466 18.6 45.5±10.2 115.2±81.6 519±233   20.3 60±51.5 72.98 
Howard 2014 Cross-sectional UK High Europe 100         40.74 
Jaff 2015 Cross-sectional South Africa Low/middle SSA 86 100 47±5.1        
Jain 2013 Cross-sectional India Low/middle S/E Asia 85 22.4 34.4±8.3      10.4±5.9  
Jantarapakde 2014 Cross-sectional Thailand Low/middle W/Pacific 580 53.8 37±8.2 60±62.2 406±208 16.3  40.2 37.8±30.2 14.9 
Jerico 2005 Cross-sectional Spain High Europe 710 28 42±9.2 110±62.2 489±284 69.5  32.7 70.5±45.9 74.7 
Kiage 2013 Cohort Zambia Low/middle SSA 118 55.9 7.9  136±50 4.4 9.6  3 0 
Kingsley 2008 Cross-sectional USA High America 615 0      14   
Koethe 2015 Cohort Multi-centre High America 14084 13 40        
Koppel 2000 Cross-sectional Sweden High Europe 340 4.1 40.5±8.5 88.5±54.5 484±236    27±7  
Lekakis 2009 Case-control Greece High Europe 56 4 40±13 42±27.5 452±260 73    73 
Levy 2005 Cohort Canada High America 679 9 39±8.9  255±222    45.5±24.4 100 
Lin 2011 Cohort Taiwan High W/Pacific 1344  49.5±27        
Magenta 2011 Cohort Switzerland High Europe 74 12 10  258±112 65   20.4±8.3 100 
Malapati 2014 Cohort India Low/middle W/Pacific 229  46.3±9.3  246±167    12 0 
Maloberti 2013 Cross-sectional Italy High Europe 108  43.6±7.7        
Manuthu 2008 Cross-sectional Kenya Low/middle SSA 290 58.1 37.1        
Mariz 2011 Cross-sectional Brazil Low/middle America 2018 37.86    27 33.9 86.45   
Mbunkah 2014 Cross-sectional Cameroon Low/middle SSA 173 71.1 38.7±11.4  332±168 2.9 8.1   28.9 
Medina-Torne 2012 Cross-sectional USA High America 707 8 41±7.4   57.14     
Mital 2013 Cross-sectional India Low/middle S/E Asia 200   35.4±7.9  17.5 11.5   0 
Mittal 2013 Cross-sectional India Low/middle S/E Asia 40 32.5 36.1±7.2      39.6±16.5 100 
Mohammed 2015 Cross-sectional Ethiopia Low/Middle SSA 393 66.9         
Montes 2005 Cohort Spain High Europe 107 30 47.5±39.3  105±116    53±7 2.5 
Muhammad (a) 2013 Cross-sectional Nigeria Low/middle SSA 200 53 32.5±7.6 72.5±35.8 319±206 9   45±19.5 1 
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Authour Year Study design Country Income 
group 
Region N F 
(%) 
Age 
(years) 
HIV duration 
(months) 
CD4 count 
(cells/mm3) 
Smokers 
(%) 
Drinkers 
(%) 
AIDS 
(%) 
ART duration 
(months) 
PI 
(%) 
Muhammad (b) 2013 Cross-sectional Nigeria Low/middle SSA 200 53 32.5±7.6 72.5±35.8 319±206 9   45±19.5 1 
Mustapha 2011 Cross-sectional Nigeria Low/middle SSA 100  32.9±7.5      45.0±19.5 0 
Ngala 2013 Cross-sectional Ghana Low/middle SSA 305 61 38.5±8.7      17.0±6.3 0 
Ngondi 2007 Cohort Cameroon Low/middle SSA 138 57.97 36.1±7.1  209±222   13.78 12 0 
Ogundahunsi 2008 Cross-sectional Nigeria Low/middle SSA 110  38.7±10.1  355±185    60.3±12 0 
Ogunmola 2014 Cross-sectional Nigeria Low/middle SSA 250 62.4 37.6±8.6  374±223      
Owiredu 2011 Cross-sectional Ghana Low/middle SSA 442 74 35.2±17.3        
Palacios 2006 Cohort Spain High Europe 95 18 40±10.1 56.1±57.1 165±125 68  44 12 48 
Peck 2014 Cross-sectional Tanzania Low/middle SSA 301 67.8 40.3±7.8  314±159 2.7 13.9  49.5±24.7 12 
Pefura Yone 2011 Cross-sectional USA High America 276 60.5 39.7±8.7  308±186    30.2±13.1 0 
Samaras 2007 Case-control Multi-centre High/middle Intercontinental 788 16 43.5±9 95.4±54   20.7   50.4 
Scholten 2011 Cross-sectional Uganda Low/middle SSA 199 57.4    69.5     
Shahmanesh 2004 Cross-sectional UK High Europe 55 18.2 40±10.4  424±225 41.8   39.8±8.8 37.5 
Shapiro 2012 Cross-sectional Botswana Low/middle SSA 62 100 31   41.5     
Silva 2009 Cross-sectional Brazil Low/middle America 319 38.9 39.5 51.6 531.9±422.4 26.7     
Silva 2010 Cross-sectional Brazil Low/middle America 314 44.6 37.7±7.9 51±46.2 531±313 26.7   52.8±42  
Singh 2014 Cohort India Low/middle S/E Asia 100 35 36.4±9.6  151±67    6 0 
Smith 2004 Cross-sectional UK High Europe 394 15  84±15 426±87 45 7 30  27 
Soares 2015 Cross-sectional Brazil Low/middle America 152 33 42.5±8.5 72±48 444±88    64±48  
Sogaard 2010 Cohort Denmark High Europe 95 15.8 48.7±4.1  571±99 35.8  22.1   
Sreekantamurthy 2014 Cross-sectional India Low/middle S/E Asia 101 0 43.5±6.3 64.9±30.2     67.8±16.5 30.38 
Tadewos 2012 Cross-sectional Ethiopia Low/middle SSA 226 65.1 35.5±8.5  408±219 11.5   49.4±16.5 0 
Tesfaye 2014 Cross-sectional Ethiopia Low/middle SSA 374 68 32.6        
Thiebaut 2005 Cohort Multi-centre High Europe 16770 24 39.3±8.2  438±260      
van Leth 2004 Cohort Multi-centre High Europe 706 36.8 35±7.4      11.5±2.7  
Wanke 2005 Cohort USA High America 49 14.29 40.6±8  205 35   5.7±1.7 100 
Weerakkody 2013 Cross-sectional Sri Lanka Low/middle S/E Asia 268 42.2 39.5±9.6 42.5±36.2 390±243 20.1   33±23 7.3 
Wilson 2009 Cross-sectional UK High Europe 458 16.81 39.5±8.9 66±48.8 545±83 41.5 21.8  77.4±33 39 
Zannou 2009 Cohort Benin Low/middle SSA 79 59.5 38±9.7  105±69 8.9 22.8 48.1 23±1.04 0 
Zeng 2010 Cross-sectional China Low/middle W/Pacific 82 39 38.4±6.4  405±191 50   34.7±17.1 7.3 
All studies      83669 42.2 39.1±9.3 66.4±43.9 341±178 30.8 16.6 34.3 32.4±16.1 28 
ART, antiretroviral therapy; F, females; N, total number of participants included in the analysis; PI, protease inhibitors; S/E Asia, South-East Asia; SSA, sub-Saharan Africa; UK, United Kingdom; USA, Unites States of America; 
W/Pacific, Western Pacific; Age, HIV duration, CD4 count and ART duration were reported as mean ± standard deviation 
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6.3 RISKS OF BIAS IN INCLUDED STUDIES 
 
Table 6.2 presents the results of the risk of bias assessment for each included study. The 
risk of selection bias was low in 31 studies (34%). Exposure criterion was well-defined 
in all 91 studies. Outcome measurements were validated in 77 studies, indicating that the 
risk of information bias (with respect to the assessments of outcomes) was low in 85% of 
the included studies. Sixty-eight studies (75%) adjusted for one or more important 
confounders. Loss to follow-up was less than 20% in 23 of the 31 included cohort studies, 
suggesting a low risk of attrition bias in these studies. 
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Table 6.2: Results of risk of bias assessment for each included study 
 
 
Study Sampling 
(selection bias) 
Exposure assessment 
(information bias) 
Outcome assessment 
(information bias) 
Adjust for 
confounders 
Loss to follow-up 
(attrition bias) 
Abebe 2014 high risk low risk low risk low risk not applicable 
Abrahams 2015 high risk low risk low risk low risk low risk 
Aboud 2010 low risk low risk low risk low risk not applicable 
Arruda Junior 2010a high risk low risk low risk low risk not applicable 
Arruda Junior 2010b unclear low risk low risk low risk not applicable 
Adewole 2010 low risk low risk low risk low risk unclear 
Akinboro 2013 unclear low risk low risk low risk not applicable 
Awotedu 2010 high risk low risk low risk low risk not applicable 
Ayodele 2013 unclear low risk low risk low risk not applicable 
Baekken 2008 unclear low risk low risk low risk not applicable 
Bajaj 2013 unclear low risk low risk low risk not applicable 
Bergersen 2003 low risk low risk low risk low risk not applicable 
Bergersen 2004 low risk low risk low risk low risk not applicable 
Bergersen 2006 unclear low risk low risk low risk not applicable 
Blass 2008 low risk low risk low risk low risk not applicable 
Blumer 2008 low risk low risk low risk low risk low risk 
Bonfati 2007 high risk low risk low risk low risk not applicable 
Bonfati 2012 unclear low risk low risk low risk low risk 
Buchacz 2008 low risk low risk low risk low risk unclear 
Calza 2011 high risk low risk low risk low risk not applicable 
Carey 2013 low risk low risk low risk high risk not applicable 
Ceccato 2011 unclear low risk low risk high risk low risk 
Chow 2003 high risk low risk unclear low risk low risk 
Denue 2012 unclear low risk low risk low risk low risk 
Denue 2013a unclear low risk low risk low risk low risk 
Denue 2013b unclear low risk low risk low risk low risk 
Dimodi 2014 unclear low risk low risk low risk not applicable 
Domingos 2009 unclear low risk unclear high risk not applicable 
Eira 2012 unclear low risk unclear low risk not applicable 
Ekali 2013 unclear low risk low risk low risk not applicable 
Esposito 2008 high risk low risk low risk unclear low risk 
Fontas 2004 low risk low risk low risk low risk low risk 
Friis-Møller 2003 low risk low risk low risk low risk low risk 
Goedecke 2013 unclear low risk low risk low risk not applicable 
Gowdaiah 2013 unclear low risk unclear high risk unclear 
Grandominico 2008 unclear low risk low risk low risk high risk 
Hansen 2009 unclear low risk unclear low risk not applicable 
Howard 2014 low risk low risk low risk low risk not applicable 
Jaff 2015 unclear low risk low risk low risk not applicable 
Jain 2013 unclear low risk low risk low risk not applicable 
Jantarapakde 2014 unclear low risk unclear low risk not applicable 
Jerico 2005 unclear low risk low risk low risk not applicable 
Kiage 2013 unclear low risk low risk high risk low risk 
Kingsley 2008 unclear low risk low risk low risk not applicable 
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Study Sampling 
(selection bias) 
Exposure assessment 
(information bias) 
Outcome assessment 
(information bias) 
Adjust for 
confounders 
Loss to follow-up 
(attrition bias) 
Koethe 2015 low risk low risk low risk low risk low risk 
Koppel 2000 unclear low risk low risk low risk not applicable 
Lekakis 2009 unclear low risk low risk low risk not applicable 
Levy 2005 low risk low risk low risk low risk low risk 
Lin 2011 unclear low risk low risk unclear unclear 
Magenta 2011 low risk low risk low risk low risk low risk 
Malapati 2014 unclear low risk low risk low risk low risk 
Maloberti 2013 unclear low risk low risk low risk not applicable 
Manuthu 2008 unclear low risk unclear low risk not applicable 
Mariz 2011 low risk low risk low risk low risk not applicable 
Mbunkah 2014 unclear low risk low risk low risk not applicable 
Medina-Torne 2012 unclear low risk low risk unclear not applicable 
Mital 2013 unclear low risk unclear high risk not applicable 
Mittal 2013 unclear low risk unclear high risk not applicable 
Mohammed 2015 low risk low risk low risk low risk not applicable 
Montes 2005 unclear low risk low risk low risk low risk 
Muhammad 2013a high risk low risk low risk high risk not applicable 
Muhammad 2013b high risk low risk low risk high risk not applicable 
Mustapha 2011 unclear low risk low risk high risk not applicable 
Ngala 2013 unclear low risk low risk low risk not applicable 
Ngondi 2007 unclear low risk low risk high risk unclear 
Ogundahunsi 2008 high risk low risk low risk high risk not applicable 
Ogunmola 2014 unclear low risk low risk high risk not applicable 
Owiredu 2011 unclear low risk low risk low risk not applicable 
Palacios 2006 unclear low risk low risk low risk low risk 
Peck 2014 low risk low risk low risk low risk not applicable 
Pefura Yone 2011 low risk low risk low risk high risk not applicable 
Samaras 2007 unclear low risk low risk low risk not applicable 
Shahmanesh 2004 high risk low risk low risk low risk not applicable 
Silva 2009 high risk low risk low risk low risk not applicable 
Silva 2010 unclear low risk unclear high risk not applicable 
Singh 2014 unclear low risk low risk high risk low risk 
Smith 2004 low risk low risk high risk low risk not applicable 
Scholten 2011 unclear low risk low risk low risk not applicable 
Shapiro 2012 high low risk low risk low risk not applicable 
Soares 2015 high risk low risk low risk high risk high risk 
Søgaard 2010 low risk low risk low risk low risk low risk 
Sreekantamurthy 2014 low risk low risk unclear high risk not applicable 
Tadewos 2012 low risk low risk low risk low risk not applicable 
Tesfaye 2014 low risk low risk low risk low risk not applicable 
Thiebaut 2005 low risk low risk low risk low risk low risk 
van Leth 2004 low risk low risk low risk low risk high risk 
Wanke 2005 high risk low risk low risk low risk low risk 
Weerakkody 2013 low risk low risk unclear high risk not applicable 
Wilson 2009 low risk low risk low risk low risk not applicable 
Zannou 2009 low risk low risk unclear low risk low risk 
Zeng 2010 unclear low risk low risk high risk not applicable 
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CHAPTER SEVEN 
 
RESULTS – THE IMPACT OF ANTIRETROVIRAL THERAPY ON BLOOD 
PRESSURE AND HYPERTENSION RISK 
In this chapter, I present meta-analyses of the associations of antiretroviral therapy with 
blood pressure and hypertension risk. I also identify study-level factors that may influence 
these pooled associations. 
 
 
 
 
7.1 OVERALL ASSOCIATIONS OF ANTIRETROVIRAL THERAPY WITH 
BLOOD PRESSURE AND HYPERTENSION RISK 
7.1.1 Increase in systolic blood pressure 
 
Nineteen studies compared systolic blood pressure changes between patients naïve and 
exposed to antiretroviral therapy, nine of which reported significantly higher mean 
systolic blood pressure in antiretroviral-exposed patients compared with antiretroviral 
naïve patients (Arruda Junior et al., 2010a; Dimodi et al., 2014; Fontas et al., 2004; 
Grandominico et al., 2008; Kingsley et al., 2008; Mital et al., 2013; Ngala et al., 2013; 
Palacios et al., 2006) (Figure 7.1). Mean systolic blood pressure was also higher in eight 
of the remaining ten studies ― albeit non-significantly (Ayodele et al., 2013; Bergersen 
et al., 2006; Bonfati et al., 2012; Ekali et al., 2013; Lekakis et al., 2009; Manuthu et al., 
2008; Medina-Torne et al., 2012; Jerico et al., 2005), leaving only two small-sized studies 
with higher systolic blood pressure in antiretroviral-naïve patients, compared to patients 
exposed to antiretroviral therapy (Wilson et al., 2009; Zeng et al., 2010). Overall, mean 
systolic blood pressure was significantly higher among patients exposed to antiretroviral 
therapy compared with treatment-naïve patients (Pooled MD 4.52 mmHg, 95% CI 2.65 
to 6.39). Heterogeneity across the studies included in the meta-analysis was statistically 
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significant (P < 0.001 for Chi2 test for heterogeneity), and accounted for a moderate 
amount of the variability in the effect estimates between these studies (I2 = 68%). Funnel 
plot asymmetry was absent, suggesting no evidence of publication bias in the observed 
association between antiretroviral therapy and increased systolic blood pressure (P = 0.43 
for Egger’s regression test for funnel plot asymmetry) (Figure 7.2). Sensitivity analysis 
revealed no instance in which the exclusion of a study altered the interpretation of the 
pooled association (Table 7.1). 
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Figure 7.1: Meta-analysis of the association between antiretroviral therapy and systolic blood 
pressure 
 
ART, antiretroviral therapy; CI, confidence interval; SBP, systolic blood pressure. The forest plot above shows 
19 black circles plotted on 19 horizontal lines, which correspond to the 19 studies included in the meta-analysis. 
Each black circle represents the mean difference in systolic blood pressure between antiretroviral-exposed and 
antiretroviral-naïve patients for each included study. The ends of each horizontal line correspond to the 95% 
confidece intervals of each mean difference. The diamond at the bottom of the graph shows the pooled mean 
difference in SBP for all 19 studies: the dashed vertical line through the diamond represents the pooled WMD, 
whereas the two lateral vertices of the diamond represent the 95% confidence intervals of the pooled WMD. 
The solid vertical line through zero represents no effect. 
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Figure 7.2: Analysis of publication bias regarding association between exposure to 
antiretroviral therapy and mean systolic blood pressure 
 
 
 
 
 
Funnel plot showing mean difference in systolic blood pressure for each of the 19 included studies plotted against the 
standard errors. The 19 circles correspond to the 19 studies included meta-analysis. The solid vertical line represents 
the pooled effect of antiretroviral therapy on systolic blood pressure. The two interrupted diagonal lines represent the 
95% confidence intervals around the pooled effect. The smaller studies represented by circles towards the bottom of 
the graph are not biased towards a larger effect of   antiretroviral   therapy   on   systolic   blood   pressure. P = 0.43 
for Egger’s test for small study effects. 
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7.1.2 Increase in diastolic blood pressure 
 
Eight of 16 studies reported significantly higher mean diastolic blood pressure in patients 
exposed to antiretroviral therapy, compared to antiretroviral-naïve patients (Arruda Junior 
et al., 2010a; Ayodele et al., 2013; Fontas et al., 2004; Grandominico et al., 2008; 
Kingsley et al., 2008; Mital et al., 2013; Ngala et al., 2013; Palacios et al., 2006) (Figure 
7.3). Four of the other eight studies reported non-significant increases in mean diastolic 
pressure among antiretroviral-exposed patients compared to antiretroviral-naïve patients 
(Bergersen et al., 2006; Ekali et al., 2013; Jerico et al., 2005; Lekakis et al., 2009), leaving 
four studies with higher mean diastolic blood pressure measurements in antiretroviral- 
naïve compared to antiretroviral-exposed patients (Bonfati et al., 2012; Manuthu et al., 
2008; Wilson et al., 2009; Zeng et al., 2010). However, the mean diastolic blood pressure 
for patients exposed to antiretroviral therapy was significantly higher, compared to 
antiretroviral-naïve patients, overall (Pooled MD 3.17 mmHg, 95% CI 1.71 to 4.64). 
Heterogeneity across the included studies was statistically significant (P < 0.001 for Chi2 
test for heterogeneity), and accounted a substantial amount of between-study variability 
in the effect estimates (I2 = 72.5%). There was also no evidence of funnel plot asymmetry 
or publication bias (P = 0.56 for Egger’s regression test for asymmetry) (Figure 7.4). 
Sensitivity analysis revealed no instance in which the exclusion of a study altered the 
interpretation of the pooled association (Table 7.1). 
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Figure 7.3: Meta-analysis of the association between antiretroviral therapy and diastolic 
blood pressure 
 
 
ART, antiretroviral therapy; CI, confidence interval; DBP, diastolic blood pressure. The forest plot above shows 16 black 
circles plotted on 16 horizontal lines, which correspond to the 16 studies included in the meta-analysis. Each black circle 
represents the mean difference in diastolic blood pressure between antiretroviral-exposed and antiretroviral-naïve patients for 
each included study. The ends of each horizontal line correspond to the 95% confidece intervals of each mean difference. The 
diamond at the bottom of the graph shows the pooled mean difference in DBP for all 16 studies: the dashed vertical line 
through the diamond represents the pooled mean difference, whereas the two lateral vertices of the diamond represent the 
95% confidence intervals of the pooled mean difference. The solid vertical line through zero represents no effect.  
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Figure 7.4: Analysis of publication bias regarding association between exposure to 
antiretroviral therapy and mean diastolic blood pressure 
 
 
 
Funnel plot showing mean difference in diastolic blood pressure for each of the 16 included studies plotted against the 
standard errors. The 16 circles correspond to the 16 studies included meta-analysis. The solid vertical line represents 
the pooled effect of antiretroviral therapy on diastolic blood pressure. The two interrupted diagonal lines represent the 
95% confidence intervals around the pooled effect. The smaller studies represented by circles towards the bottom of 
the  graph   are   not   biased   towards   a   larger   effect   of   antiretroviral   therapy   on   diastolic   blood   pressure. 
P = 0.56 for Egger’s test for small study effects. 
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7.1.3 Increase in hypertension risk 
 
Prevalence estimates of hypertension were compared between antiretroviral-exposed and 
antiretroviral-naïve HIV-infected patients in 32 studies, 28 of which reported higher 
estimates in the antiretroviral-exposed group. Overall, hypertension was reported in 4,195 
of 28,908 (14.5%) antiretroviral-exposed patients, as opposed to 950 of 9,086 (10.5%) 
antiretroviral-naïve patients, such that the odds of hypertension was significantly higher 
in antiretroviral-exposed patients (Pooled OR 1.68, 95% CI 1.35 to 2.10; P < 0.001) 
(Figure 7.5). Heterogeneity across the 32 studies was statistically significant (P < 0.001 
for Chi2 test for heterogeneity) and accounted for a considerable amount of between-study 
variability in the effect estimates (I2 = 81.5%). Although funnel plot revealed a rather high 
tendency for smaller studies to report larger effects of antiretroviral therapy on 
hypertension risk (P = 0.006 for Egger’s regression test for funnel plot asymmetry) 
(Figure 7.6), correction for publication bias using the trim and fill analysis did not alter 
the overall interpretation of the pooled association. The trim and fill analysis imputed 12 
‘missing’ studies to the original dataset; however, the pooled estimate for the trimmed 
and filled dataset remained statistically significant (P < 0.001). The variance between 
studies (0.000) and heterogeneity (P = 1.000) remained the same in both original and 
filled datasets. The funnel plot for the filled dataset was approximately symmetrical 
(Figure 7.7). Sensitivity analysis revealed no instance in which the sequential exclusion 
of studies altered the interpretation of the pooled association (Table 7.1). 
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Figure 7.5: Meta-analysis of the association between antiretroviral therapy and 
hypertension risk 
 
 
ART, antiretroviral therapy; CI, confidence interval; HTN, hypertension; OR, odds ratio. The black circles and horizontal 
lines represent the OR with 95% CI for hypertension in each study. The dashed vertical line through the diamond represents 
the pooled OR, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled OR. The solid vertical line 
through one represents no effect.  
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Figure 7.6: Analysis of publication bias in the association between antiretroviral 
therapy and hypertension 
 
 
 
 
Funnel plot showing odds ratios of hypertension for each of the 32 included studies plotted against the standard errors. 
The 32 circles correspond to the 32 studies included in the meta-analysis. The smaller studies represented by circles 
towards the bottom of the graph appear biased towards larger odds ratios. 
P = 0.006 for Egger’s test for small study effects. 
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Figure 7.7: Filled funnel plot for analysis of trimmed and filled dataset for the 
association between antiretroviral therapy and hypertension risk 
 
Filled funnel plot with pseudo 95% confidence limits 
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Symmetrical funnel plot showing the final filled effect estimate (represented by the horizontal line) and the imputed 
data (represented by the 12 squares around the circular data symbols). The diagonal lines represent the 95% 
confidence intervals around the final filled estimate. Theta stands for the log scale of the effect estimate. 
 
 
 
 
 
Table 7.1: Sensitivity analysis of the pooled associations of antiretroviral therapy 
with increased blood pressure and hypertension risk 
 
 
 
 
 
Cardio-metabolic 
 
Pooled estimate prior to 
serial exclusion of 
individual studies 
 
Range of pooled 
estimate following 
serial exclusion of 
Instance in which 
exclusion of a study 
changed interpretation of 
the pooled association 
outcomes Pooled ES (95% CI) individual studies Pooled ES (95% CI) 
 
Systolic blood pressure 
 
4.52 (2.65 to 6.39) 
 
4.22 to 4.74 
 
None 
Diastolic blood pressure 3.17 (1.71 to 4.64) 3.01 to 3.47 None 
Hypertension 1.68 (1.35 to 2.10) 1.61 to 1.73 None 
CI, confidence interval; Pooled ES, Pooled estimate. 
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7.2. FACTORS THAT MAY INFLUENCE THE ASSOCIATIONS OF 
ANTIRETROVIRAL THERAPY WITH INCREASED BLOOD PRESSURE AND 
HYPERTENSION RISK 
Table 7.2 presents the results of subgroup and meta-regression analyses of the association 
between antiretroviral therapy and systolic blood pressure. Antiretroviral therapy was 
significantly associated with higher systolic blood pressure levels across subgroups of 
different study-level characteristics, including country income group, sex, smoking status, 
HIV infection duration, study design, year of publication and risk of selection bias. In 
addition, no statistically significant difference in the pooled estimate was observed 
between subgroups of these characteristics. With the exception of geographical region, 
antiretroviral therapy was also associated with higher systolic blood pressure levels across 
other study-level characteristics. However, these associations were not significant across 
subgroups of these characteristics. For instance, antiretroviral therapy was significantly 
associated with increased systolic blood pressure among HIV-infected patients who were 
40 years of age and older (Pooled MD 4.88 mmHg, 95% CI 3.01 to 6.76), but not 
among HIV-infected patients who were younger than 40 years (Pooled MD 3.41 mmHg, 
95% CI -0.93 to 7.75). Nonetheless, the difference between both subgroup estimates was 
not statistically significant (P = 0.565 for interaction). Similarly, antiretroviral therapy 
was significantly associated with increased systolic blood pressure among HIV-infected 
patients with CD4 cell counts below 350 cells/mm3  (Pooled MD 4.28 mmHg, 95% CI 
1.86 to 6.71), but in those with greater CD4 cell counts (Pooled MD 2.98 mmHg, 95% CI 
 
-0.17 to 6.13) (P = 0.547 for interaction). Antiretroviral therapy was also significantly 
associated with increased systolic blood pressure among HIV-infected patients on 
treatment for 18 months or longer (Pooled MD 4.03 mmHg, 95% CI 1.59 to 6.48), but 
not among patients with antiretroviral treatment duration of less than 18 months (Pooled 
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MD 6.13 mmHg, 95% CI -0.25 to 12.52) (P = 0.383 for interaction). Although subgroup 
analysis by geographical region revealed a significant association between antiretroviral 
therapy and decreased systolic blood pressure (MD -7.00, 95% CI -13.06 to -0.94) 
among patients in the Western Pacific region, it is worth emphasizing that this finding 
was solely based on one study (Zang et al., 2010). 
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Table 7.2: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and systolic blood pressure 
 
 
 
Meta-regression 
Subgroups N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
The Americas 
South-East Asia 
Western Pacific 
 
5 
8 
4 
1 
1 
 
7.90 (2.18 to 13.62) 
3.69 (1.75 to 5.63) 
6.36 (4.26 to 8.46) 
12.72 (9.10 to 16.34) 
-7.00 (-13.06 to -0.94) 
 
 
 
 
 
 
 
0.865 
 
 
 
 
 
 
 
0 
Income group 
High income 
Low/middle income 
 
11 
8 
 
3.98 (2.55 to 5.42) 
4.69 (0.74 to 8.65) 
 
 
 
0.703 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
11 
6 
 
3.05 (0.82 to 5.28) 
6.80 (3.05 to 10.54) 
 
 
 
0.089 
 
 
 
18.9 
Age 
< 40 years 
≥ 40 years 
 
8 
10 
 
3.41 (-0.93 to 7.75) 
4.88 (3.01 to 6.76) 
 
 
 
0.565 
 
 
 
0 
Smokers 
< 50% 
≥ 50% 
 
8 
7 
 
3.05 (0.46 to 5.65) 
5.24 (3.12 to 7.37) 
 
 
 
0.413 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
9 
7 
 
4.28 (1.86 to 6.71) 
2.98 (-0.17 to 6.13) 
 
 
 
0.547 
 
 
 
0 
HIV duration 
< 60 months 
≥ 60 months 
 
5 
7 
 
4.36 (1.93 to 6.80) 
3.88 (2.22 to 5.54) 
 
 
 
0.847 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
4 
11 
 
6.13 (-0.25 to 12.52) 
4.03 (1.59 to 6.48) 
 
 
 
0.383 
 
 
 
4.6 
Study design 
Cohort 
Cross-sectional 
 
4 
15 
 
4.55 (2.21 to 6.89) 
4.29 (1.94 to 6.64) 
 
 
 
0.768 
 
 
 
0 
Selection bias 
Low risk 
High/unclear risk 
 
8 
11 
 
3.91 (2.48 to 5.32) 
4.30 (1.01 to 7.59) 
 
 
 
0.782 
 
 
 
0 
Publication year 
2000 – 2009 
2010 – 2015 
 
10 
9 
 
4.29 (2.71 to 5.88) 
4.54 (1.17 to 7.91) 
 
 
 
0.867 
 
 
 
0 
ART, antiretroviral therapy; CI, confidence interval; MD, mean difference, N, number of studies; R2, amount of 
explained variability 
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Antiretroviral therapy was significantly associated with increased diastolic blood pressure 
across subgroups of different study-level characteristics including country income group, 
sex, age, smoking status, antiretroviral treatment duration, risk of selection bias and year 
of publication (Table 7.3). With the exception of smoking status, no statistically 
significant difference in the pooled estimate was observed between subgroups of these 
characteristics. Estimates of the pooled association of antiretroviral therapy with 
increased diastolic blood pressure were significantly higher in studies with more smokers 
than non-smokers (Pooled MD 5.46 mmHg, 95% CI 3.86 to 7.06), compared to studies 
with fewer smokers than non-smokers (Pooled MD 1.65 mmHg, 95% CI 0.08 to 3.23) (P 
= 0.025 for interaction). Meta-regression also revealed that study-level differences in the 
proportions of smokers accounted approximately for 67% of the variability between 
studies included in the meta-analysis. 
 
Mean diastolic blood pressure levels were also higher among antiretroviral-exposed 
patients, compared to antiretroviral-naïve patients across subgroups of CD4 cell count, 
HIV infection duration and study design. However, some of these associations were not 
statistically significant. For instance, antiretroviral therapy was significantly associated 
with increased diastolic blood pressure among HIV-infected patients with CD4 cell 
counts below 350 cells/mm3 (Pooled MD 2.82 mmHg, 95% CI 1.46 to 4.18), but not 
among HIV-infected patients with CD4 cell counts greater than 350 cells/mm3 (Pooled 
MD 2.73 mmHg, 95% CI -0.58 to 6.05). Nonetheless, the difference between both 
subgroup estimates was not statistically significant (P = 0.928 for interaction). Similarly, 
antiretroviral therapy was significantly associated with increased diastolic blood pressure 
among patients who had been living with HIV for less than 60 months (Pooled MD 3.22 
mmHg, 95% CI 0.89 to 5.56), but not among patients who had been infected for 60 
months or longer (Pooled MD 2.71 mmHg, 95% CI -0.05 to 5.47) (P = 0.733 for 
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interaction). Unlike cohort studies (Pooled MD 3.31 mmHg, 95% CI -1.00 to 7.62), cross- 
sectional studies were likely to report a significant association between antiretroviral 
therapy and increased diastolic blood pressure (Pooled MD 3.18 mmHg, 95% CI 1.56 to 
4.79), however, the difference between both subgroup estimates was not statistically 
significant (P = 0.983 for interaction). 
74  
Table 7.3: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and diastolic blood pressure 
 
 
 
Meta-regression 
Subgroups N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
The Americas 
South-East Asia 
Western Pacific 
 
4 
7 
3 
1 
1 
 
3.04 (0.02 to 6.07) 
2.49 (0.51 to 4.46) 
4.62 (2.85 to 6.39) 
7.57 (5.00 to 10.15) 
-3.00 (-7.35 to 1.35) 
 
 
 
 
 
 
 
1.000 
 
 
 
 
 
 
 
0 
Income group 
High income 
Low/middle income 
 
9 
7 
 
2.98 (1.26 to 4.69) 
3.37 (0.62 to 6.13) 
 
 
 
0.779 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
10 
6 
 
2.64 (0.67 to 4.60) 
3.98 (1.56 to 6.36) 
 
 
 
0.403 
 
 
 
0 
Age 
< 40 years 
≥ 40 years 
 
8 
8 
 
2.55 (0.27 to 4.83) 
3.73 (1.66 to 5.79) 
 
 
 
0.460 
 
 
 
0 
Smokers 
< 50% 
≥ 50% 
 
7 
5 
 
1.65 (0.08 to 3.23) 
5.46 (3.86 to 7.06) 
 
 
 
0.025 
 
 
 
66.9 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
8 
6 
 
2.82 (1.46 to 4.18) 
2.73 (-0.58 to 6.05) 
 
 
 
0.928 
 
 
 
0 
HIV duration 
< 60 months 
≥ 60 months 
 
4 
5 
 
3.22 (0.89 to 5.56) 
2.71 (-0.05 to 5.47) 
 
 
 
0.733 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
4 
9 
 
4.85 (2.01 to 7.69) 
2.80 (0.97 to 4.64) 
 
 
 
0.309 
 
 
 
8.9 
Study design 
Cohort 
Cross-sectional 
 
3 
13 
 
3.31 (-1.00 to 7.62) 
3.18 (1.56 to 4.79) 
 
 
 
0.983 
 
 
 
0 
Sampling bias 
Low risk 
High/unclear risk 
 
2 
14 
 
2.91 (0.09 to 5.61) 
3.17 (1.62 to 4.76) 
 
 
 
0.760 
 
 
 
0 
Publication year 
2000 – 2009 
2010 – 2015 
 
9 
7 
 
4.29 (2.71 to 5.88) 
3.36 (1.81 to 4.90) 
 
 
 
0.926 
 
 
 
0 
ART, antiretroviral therapy; CI, confidence interval; MD, mean difference, N, number of studies; R2, amount of 
explained variability. 
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With the exception of geographical region and antiretroviral treatment duration, 
antiretroviral therapy was significantly associated with increased risk of hypertension 
across the subgroups of all study-level characteristics, with no evidence of a statistically 
significant difference between subgroup estimates of the pooled association (Table 7.4). 
The odds of hypertension were significantly higher among antiretroviral-exposed patients 
who had been on treatment for no less than 18 months, compared to antiretroviral-naïve 
patients (Pooled OR 2.23, 95% CI 1.55 to 3.20), whereas the odds of hypertension were 
not statistically significantly different between HIV-infected patients exposed to 
antiretroviral therapy for less than 18 months and HIV-infected patients who were naïve 
to antiretroviral therapy (Pooled OR 1.81, 95% CI 0.65 to 5.04). However, meta- 
regression analysis revealed no statistically significant difference between both subgroup 
estimates (P = 0.603 for interaction). Similarly, while antiretroviral therapy was 
significantly associated with increased risk of hypertension among HIV-infected patients 
resident in sub-Saharan African countries (Pooled OR 1.99, 95% CI 1.33 to 2.98) and the 
Americas (Pooled OR 2.37, 95% CI 1.30 to 4.31), no statistically significant association 
was observed among HIV-infected patients resident in Europe (Pooled OR 1.42, 95% CI 
0.99 to 2.05), South-East Asia (Pooled OR 1.39, 95% CI 0.81 to 2.39), and the Western 
Pacific region (OR 1.59, 95% CI 0.87 to 2.91) (P = 0.865 for interaction). 
76  
Table 7.4: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and hypertension risk 
 
 
 
Meta-regression 
Subgroups N Pooled OR (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
The Americas 
South-East Asia 
Western Pacific 
 
8 
14 
6 
3 
1 
 
1.99 (1.33 to 2.98) 
1.42 (0.99 to 2.05) 
2.37 (1.30 to 4.31) 
1.39 (0.81 to 2.39) 
1.59 (0.87 to 2.91) 
 
 
 
 
 
 
 
0.865 
 
 
 
 
 
 
 
0 
Income group 
High income 
Low/middle income 
 
18 
14 
 
1.52 (1.10 to 2.09) 
1.89 (1.40 to 2.56) 
 
 
 
0.767 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
17 
11 
 
1.61 (1.16 to 2.24) 
1.83 (1.26 to 2.65) 
 
 
 
0.636 
 
 
 
0 
Age 
< 40 years 
≥ 40 years 
 
14 
10 
 
1.60 (1.07 to 2.39) 
2.03 (1.36 to 3.02) 
 
 
 
0.739 
 
 
 
0 
Smokers 
< 50% 
≥ 50% 
 
14 
7 
 
1.67 (1.09 to 2.57) 
2.18 (1.61 to 2.97) 
 
 
 
0.558 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
7 
11 
 
2.96 (1.53 to 5.72) 
1.73 (1.12 to 2.69) 
 
 
 
0.586 
 
 
 
0 
HIV duration 
< 60 months 
≥ 60 months 
 
4 
9 
 
1.64 (1.04 to 2.58) 
2.01 (1.30 to 3.01) 
 
 
 
0.733 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
3 
15 
 
1.81 (0.65 to 5.04) 
2.23 (1.55 to 3.20) 
 
 
 
0.603 
 
 
 
0 
Study design 
Cohort 
Cross-sectional 
 
8 
24 
 
1.37 (1.15 to 1.63) 
1.75 (1.31 to 2.33) 
 
 
 
0.971 
 
 
 
0 
Selection bias 
Low risk 
High/unclear risk 
 
8 
24 
 
1.52 (1.14 to 2.04) 
1.65 (1.27 to 2.24) 
 
 
 
0.520 
 
 
 
0 
Publication year 
2000 – 2009 
2010 – 2015 
 
14 
18 
 
1.62 (1.11 to 2.36) 
1.68 (1.31 to 2.14) 
 
 
 
0.705 
 
 
 
0 
ART, antiretroviral therapy; CI, confidence interval; N, number of studies; OR, odds ratio; R2, amount of explained 
variability 
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CHAPTER EIGHT 
 
RESULTS – THE IMPACT OF ANTIRETROVIRAL THERAPY ON SERUM 
LIPOPROTEIN LEVELS AND DYSLIPIDAEMIAS 
In this chapter, I present meta-analyses of the associations of antiretroviral therapy with 
serum lipid levels. I also identify study-level factors that may influence these pooled 
associations. 
 
 
 
8.1 OVERALL ASSOCIATIONS OF ANTIRETROVIRAL THERAPY WITH 
SERUM LIPOPROTEIN LEVELS AND DYSLIPIDAEMIAS 
 
8.1.1 Increase in serum levels of total cholesterol 
 
Serum total cholesterol concentrations were compared between patients naïve and 
exposed to antiretroviral therapy in 45 studies, 40 of which reported significantly higher 
mean concentrations in antiretroviral-exposed persons (Figure 8.1). Mean total 
cholesterol levels were also higher ― albeit statistically non-significantly ― among 
antiretroviral-exposed patients, compared to their naïve counterparts in four of the five 
remaining studies. The difference was not statistically significant in the one study that 
reported higher mean total cholesterol in antiretroviral-naïve patients compared with 
antiretroviral-exposed patients (Adewole et al., 2010). Overall, the mean total cholesterol 
level was significantly higher among HIV-infected patients on antiretroviral therapy 
compared with treatment-naïve patients (Pooled MD 29.33 mg/dL, 95% CI 26.27 to 
32.35). Heterogeneity was statistically significant across all 45 studies included in the 
meta-analysis (P < 0.001 for Chi2 test for heterogeneity). I2 statistic was 82.6%, indicating 
that heterogeneity across the studies accounted for a considerable amount of the 
variability in the effect estimates obtained from each study. There was no evidence of 
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publication bias, as shown by the absence of funnel plot asymmetry (Figure 8.2) and 
Egger’s regression test for funnel plot asymmetry (p= 0.097). Sensitivity analysis 
revealed no instance in which the sequential exclusion of studies altered the 
interpretation of the pooled association (Table 8.1). 
 
Figure 8.1: Meta-analysis of the association between antiretroviral therapy and total 
cholesterol  
 
 
 
ART, antiretroviral therapy; CI, confidence interval; TC, total cholesterol. The black boxes and horizontal lines 
represent the mean difference in TC with 95% CI in each study. The dashed vertical line through the diamond 
represents the pooled mean difference, whereas the two lateral vertices of the diamond represent the 95% CI of the 
pooled mean difference. The solid vertical line through zero represents no effect.  
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Figure 8.2: Analysis of publication bias regarding association between antiretroviral 
therapy and total cholesterol level 
 
 
Funnel plot showing mean difference in total cholesterol for each of the 45 included studies plotted against the standard 
errors. The 45 circles correspond to the 45 studies included in the meta-analysis. The solid vertical line represents the 
pooled effect of antiretroviral therapy on total cholesterol. The two dashed lines represent the 95% confidence intervals 
around the pooled effect. The smaller studies represented by circles towards the bottom of the graph are not biased 
towards a larger effect of antiretroviral therapy on total cholesterol. 
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8.1.2 Increase in serum levels of low density lipoprotein cholesterol 
 
Thirty-seven studies compared mean serum levels of LDL cholesterol between 
antiretroviral-exposed and antiretroviral-naïve patients, 24 of which reported significantly 
higher mean serum LDL cholesterol levels in antiretroviral-exposed patients, compared 
with their treatment-naïve counterparts (Figure 8.3). Overall, the mean serum level of 
LDL cholesterol among antiretroviral-exposed patients was significantly higher than that 
among antiretroviral-naïve patients (Pooled MD 14.64 mg/dL, 95% CI 10.83 to 18.45). 
Heterogeneity across the 37 studies was statistically significant (P < 0.001 for Chi2 test 
for heterogeneity), and accounted for 86.3% of the variability in the effect estimates 
between the studies. Funnel plot asymmetry was absent (P = 0.290 for Egger’s regression 
test) (Figure 8.4). Sensitivity analysis revealed no instance in which the sequential 
exclusion of studies altered the interpretation of the pooled association (Table 8.1).
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Figure 8.3: Meta-analysis of the association between antiretroviral therapy and low density 
lipoprotein cholesterol level 
 
 
ART, antiretroviral therapy; CI, confidence interval; LDLc, low density lipoprotein cholesterol. The black boxes and horizontal 
lines represent the mean difference in LDLc with 95% CI in each study. The dashed vertical line through the diamond represents the 
pooled mean difference, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled mean difference. The 
solid vertical line through zero represents no effect.  
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Figure 8.4: Analysis of publication bias regarding association between antiretroviral 
therapy and low-density lipoprotein cholesterol 
 
 
Funnel plot showing mean difference in low density lipoprotein cholesterol for each study plotted against the standard 
errors. The circles correspond to each study included in the meta-analysis. The solid vertical line represents the pooled 
effect of antiretroviral therapy on low density lipoprotein cholesterol. The two dashed lines represent the 95% 
confidence intervals around the pooled effect. The smaller studies represented by circles towards the bottom of the 
graph are not biased towards a larger effect of antiretroviral therapy on low density lipoprotein cholesterol. 
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8.1.3 Increase in serum levels of high density lipoprotein cholesterol 
 
Forty-three studies compared mean serum levels of HDL cholesterol between 
antiretroviral-exposed and antiretroviral-naïve patients. Overall, patients exposed to 
antiretroviral therapy had significantly higher mean serum HDL cholesterol 
concentrations compared with patients naïve to antiretroviral therapy (Pooled MD 5.00 
mg/dL, 95% CI 1.96 to 8.03) (Figure 8.5). Heterogeneity was statistically significant 
across the included studies (P < 0.001 for Chi2 test for heterogeneity), and accounted for 
98.2% of between-study variability in the effect estimates. Funnel plot was symmetrical 
(P = 1.0 for Egger’s regression test for funnel plot asymmetry) (Figure 8.6). Sensitivity 
analysis revealed no instance in which the sequential exclusion of studies altered the 
interpretation of the pooled association (Table 8.1). 
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Figure 8.5: Meta-analysis of the association between antiretroviral therapy and high density 
lipoprotein cholesterol level 
 
 
 
ART, antiretroviral therapy; CI, confidence interval; HDLc, low density lipoprotein cholesterol. The black boxes and horizontal lines 
represent the mean difference in HDLc with 95% CI in each study. The dashed vertical line through the diamond represents the 
pooled mean difference, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled mean difference. The 
solid vertical line through zero represents no effect.  
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Figure 8.6: Analysis of publication bias regarding association between antiretroviral 
therapy and mean high-density lipoprotein cholesterol 
 
 
 
Funnel plot showing mean difference in high density lipoprotein cholesterol for each study plotted against the standard 
errors. The circles correspond to each study included in the meta-analysis. The solid vertical line represents the pooled 
effect of antiretroviral therapy on high density lipoprotein cholesterol. The two interrupted diagonal lines represent the 
95% confidence intervals around the pooled effect. The smaller studies represented by circles towards the bottom of 
the graph are not biased towards a larger effect of antiretroviral therapy on high density lipoprotein cholesterol. 
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8.1.4 Increase in serum levels of triglycerides 
 
Twenty-seven of 43 studies reported significantly higher mean concentrations of serum 
triglycerides in patients on antiretroviral therapy, compared to patients who are 
antiretroviral-naïve (Figure 8.7). Thirteen of the remaining 16 studies also reported higher 
mean concentrations of serum triglycerides in antiretroviral-exposed patients, even 
though the differences were not statistically significant. Overall, mean serum 
concentrations of triglycerides were significantly higher in antiretroviral-exposed patients 
compared to antiretroviral-naïve patients (Pooled MD 46.64, 95% CI 37.45 to 58.84). 
Heterogeneity across all 43 studies was statistically significant (P < 0.001 for Chi2 test 
for heterogeneity) and I2 statistic was 97.1%. Funnel plot was symmetrical (P = 0.161 for 
Egger’s regression test for funnel plot asymmetry), indicating absence of publication bias 
(Figure 8.8). Sensitivity analysis revealed no instance in which the sequential exclusion 
of studies altered the interpretation of the pooled association (Table 8.1). 
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Figure 8.7: Meta-analysis of the association between antiretroviral therapy and serum 
triglyceride levels 
 
 
ART, antiretroviral therapy; CI, confidence interval. The black boxes and horizontal lines represent the mean 
difference in triglyceride levels with 95% CI in each study. The dashed vertical line through the diamond represents 
the pooled mean difference, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled mean 
difference. The solid vertical line through zero represents no effect. 
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Figure 8.8: Analysis of publication of bias in the association between antiretroviral 
therapy and serum triglyceride levels 
 
 
Funnel plot showing mean difference in triglyceride levels for each study plotted against the standard errors. The circles 
correspond to each study included in the meta-analysis. The solid vertical line represents the pooled effect of 
antiretroviral therapy on triglycerides. The two dashed lines represent the 95% confidence intervals around the pooled 
effect. 
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8.1.5 Increase in the risk of hypercholesterolaemia 
 
Twenty-five studies compared prevalence estimates of hypercholesterolaemia between 
patients naïve and exposed to antiretroviral therapy, 21 of which reported statistically 
significantly higher estimates among those exposed to treatment (Figure 8.9). The other 
four studies also reported higher prevalence estimates of hypercholesterolaemia in 
antiretroviral-exposed patients than their naïve counterparts, although these differences 
were not statistically significant (Jain et al., 2013; Mital et al., 2013; Riddler et al., 2007; 
Zannou et al., 2009). Overall, hypercholesterolaemia was found in 5,433 (27.2%) of 
19,967 HIV-infected patients exposed to antiretroviral therapy hypercholesterolaemia 
compared to 539 (9.3%) of 5,801 HIV-infected patients naïve to antiretroviral therapy, so 
that the odds of hypercholesterolaemia were almost four times higher among 
antiretroviral-treated patients than their naïve counterparts (Pooled OR 3.84, 95% CI 3.12 
to 4.74). Heterogeneity across all 25 studies was statistically significant (P < 0.001), and 
explained 60% of the variability in the odds ratios between individual studies. Funnel plot 
was symmetrical (P = 0.212 for Egger's regression test for funnel plot asymmetry), 
indicating the absence of publication bias (Figure 8.10). Sensitivity analysis revealed no 
instance in which the sequential exclusion of studies altered the interpretation of the 
pooled association (Table 8.1). 
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Figure 8.9: Meta-analysis of the association between antiretroviral therapy and 
hypercholesterolaemia 
 
 
ART, antiretroviral therapy; CI, confidence interval. The black boxes and horizontal lines represent the odds ratios of 
hypercholesterolaemia with 95% CI in each study. The interrupted vertical line through the diamond represents the 
pooled odds ratio, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled odds ratio. The 
solid vertical line through zero represents no effect.  
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Figure 8.10: Analysis of publication bias in the association between antiretroviral 
therapy and the risk of hypercholesterolemia 
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8.1.6 Increase in the risk of hypertriglyceridaemia 
 
Prevalence estimates of hypertriglyceridaemia were compared between antiretroviral- 
exposed and antiretroviral-naïve HIV-infected patients in 21 studies, 12 of which reported 
significantly higher estimates in the antiretroviral-exposed group (Figure 8.11). Seven of 
the remaining nine studies also reported higher prevalence estimates of 
hypertriglyceridaemia in antiretroviral-exposed patients compared to their naïve 
counterparts, however these differences were not statistically significant. Although 
prevalence estimates of hypertriglyceridaemia were lower among antiretroviral-exposed 
patients than their naïve counterparts in two studies, these differences were not 
statistically significant (Ayodele et al., 2013; Ekali et al., 2013). Overall, 
hypertriglyceridaemia was reported in 6,879 of 18,523 (37.1%) antiretroviral-exposed 
patients, as opposed to 845 of 4,770 (17.7%) antiretroviral-naïve patients, such that the 
odds of hypertriglyceridaemia were more than two times higher in antiretroviral-exposed 
patients compared with their naïve counterparts (Pooled OR 2.23, 95% CI 1.71 to 2.92). 
Heterogeneity across the 21 studies was statistically significant (P < 0.001 for Chi2 test 
for heterogeneity) and accounted for a considerable amount of between-study variability 
in the effect estimates (I2 = 81.7%). Funnel plot was symmetrical (P = 0.191 for Egger’s 
regression test for funnel plot asymmetry) (Figure 8.12). Sensitivity analysis revealed no 
instance in which the sequential exclusion of studies altered the interpretation of the 
pooled association (Table 8.1). 
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Figure 8.11: Meta-analysis of the association between antiretroviral therapy and 
hypertriglyceridaemia 
 
 
ART, antiretroviral therapy; CI, confidence interval. The black boxes and horizontal lines represent the odds ratios 
of hypertriglyceridaemia with 95% CI in each study. The dashed vertical line through the diamond represents the 
pooled odds ratio, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled odds ratio. 
The solid vertical line through zero represents no effect. 
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Figure 8.12: Analysis of publication bias regarding the association between 
antiretroviral therapy and the risk of hypertriglyceridaemia 
 
 
 
96  
8.1.7 Increase in the risk of combined dyslipidaemia 
 
Eight studies compared prevalence estimates of combined dyslipidaemia between 
antiretroviral-exposed and antiretroviral-naïve patients (Adewole et al., 2010; Ayodele et 
al., 2013; Buchacz et al., 2008; Lekkaki et al., 2009; Levy et al., 2005; Mital et al., 2013; 
Muhammad et al., 2013a; Ngala et al., 2013). Prevalence estimates of combined 
dyslipidaemia were higher among patients on antiretroviral therapy compared with 
antiretroviral-naïve patients in all eight studies, six of which reported a statistically 
significant difference (Ayodele et al., 2013; Buchacz et al., 2008; Lekkaki et al., 2009; 
Mital et al., 2013; Muhammad et al., 2013a; Ngala et al., 2013) (Figure 8.13). Overall, 
combined dyslipidaemia was reported in 855 of 2,383 (35.9%) antiretroviral-exposed 
HIV-infected patients, as opposed to 275 of 1,563 (17.6%) antiretroviral-naïve patients, 
so that the odds of having dyslipidaemia were more than three times higher in 
antiretroviral-treated patients than in antiretroviral-naïve patients (Pooled OR 3.51, 95% 
CI 2.57 to 4.79). Heterogeneity across the eight studies was not statistically significant (P 
= 0.051), but accounted for 50% of between-study variability in the effect estimates. No 
evidence of publication bias was found (P = 0.927 for Egger’s regression test for funnel 
plot asymmetry) (Figure 8.14). Sensitivity analysis revealed no instance in which the 
sequential exclusion of studies altered the interpretation of the pooled association (Table 
8.1). 
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Figure 8.13: Meta-analysis of the association between antiretroviral therapy and combined 
dyslipidaemia 
 
 
 
ART, antiretroviral therapy; CI, confidence interval. The grey boxes and horizontal lines represent the odds ratios of 
dyslipidaemia with 95% CI in each study. The dashed vertical line through the diamond represents the pooled odds ratio, 
whereas the two lateral vertices of the diamond represent the 95% CI of the pooled odds ratio. The solid vertical line 
through zero represents no effect. 
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Figure 8.14: Analysis of publication bias in the association between antiretroviral therapy and 
combined dyslipidaemia 
 
P = 0.927 for Egger’s test for small-study effects. 
 
 
 
Table 8.1: Sensitivity analysis of the pooled associations of antiretroviral therapy 
with increased serum lipoprotein levels and dyslipidaemias 
 
 
 
 
 
Cardio-metabolic 
 
Pooled estimate prior to 
serial exclusion of 
individual studies 
 
Range of pooled 
estimate following 
serial exclusion of 
Instance in which 
exclusion of a study 
changed interpretation of 
the pooled association 
outcomes Pooled ES (95% CI) individual studies Pooled ES (95% CI) 
 
Total cholesterol 
 
29.41 (26.47 to 32.35) 
 
28.76 to 30.25 
 
None 
LDL cholesterol 14.85 (11.23 to 18.47) 14.33 to 15.89 None 
HDL cholesterol 4.94 (2.03 to 7.85) 4.49 to 5.80 None 
Triglycerides 46.81 (37.38 to 55.84) 41.52 to 48.22 None 
Hypercholesterolaemia 3.84 (3.12 to 4.74) 3.70 to 4.00 None 
Hypertriglyceridaemia 2.23 (1.71 to 2.92) 2.08 to 2.33 None 
Combined dyslipidaemia 3.51 (2.57 to 4.79) 3.51 to 3.96 None 
CI, confidence interval; Pooled ES, Pooled estimate; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
0
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8.2 FACTORS THAT MAY INFLUENCE THE ASSOCIATIONS OF 
ANTIRETROVIRAL THERAPY WITH INCREASED SERUM LIPID LEVELS 
Table 8.2 presents the results of subgroup and meta-regression analyses of the association 
between antiretroviral therapy and total cholesterol levels. There were significant 
differences in the impact of antiretroviral therapy on total cholesterol levels by country 
income group, age group, smoking status, CD4 cell count, antiretroviral regimen, and 
year of publication. The, studies conducted in high-income countries reported a stronger 
association between antiretroviral therapy and increased total cholesterol levels (Pooled 
MD 36.53 mg/dL, 95% CI 32.62 to 40.41), compared to studies conducted in low- and 
middle-income countries (Pooled 25.37 mg/dL, 95% CI 21.57 to 28.95) (P = 0.002 for 
interaction). The impact of antiretroviral therapy on total cholesterol was significantly 
higher among studies where the average age of the participants was 40 years or more 
(Pooled MD 35.43 mg/dL, 95% CI 29.58 to 41.22), compared to studies where the average 
age was below 40 years old (Pooled MD 27.41 mg/dL, 95% CI 23.97 to 30.83) (P = 0.027 
for interaction). Studies comprising larger proportions of smokers than non-smokers 
reported significantly higher increases in serum total cholesterol levels associated with 
antiretroviral therapy (Pooled MD 39.16 mg/dL, 95% CI 23.17 to 55.14), compared to 
studies comprising smaller proportions of smokers than non-smokers (Pooled MD 24.22 
mg/dL, 95% CI 18.42 to 30.03) (P = 0.048 for interaction). Studies where mean CD4 cell 
count was 350 cells/mm3 or greater reported stronger association between antiretroviral 
therapy and increased serum total cholesterol level (Pooled MD 33.81 mg/dL, 95% CI 
29.50 to 38.13), compared to studies with mean CD4 count less than 350 cells/mm3 
(Pooled MD 25.78 mg/dL, 95% CI 22.37 to 29.18) (P = 0.043 for interaction). The pooled 
association between antiretroviral therapy and increased total cholesterol level was also 
significantly stronger with the use of protease inhibitors (Pooled MD 32.29 mg/dL, 95% 
10
0 
 
CI 28.43 to 36.16), as opposed to the use of non-protease inhibitor-based antiretroviral 
regimens (Pooled MD 24.25 mg/dL, 95% CI 19.41 to 29.09) (P = 0.037 for interaction). 
Studies published prior to 2010 reported a significantly larger impact of antiretroviral 
therapy on total cholesterol level (Pooled MD 34.7 mg/dL, 95% CI 31.0 to 38.3), 
compared to studies published from 2010 onwards (Pooled MD 24.9 mg/dL, 95% CI 20.5 
to 29.2) (P = 0.005 for interaction). Among these study level factors, differences by 
country income group accounted for most of the variability between studies in the effects 
of antiretroviral therapy on total cholesterol levels (R2 = 24%). Importantly, given that 
the risk of selection bias was high or unclear in 74% of all the studies, the impact of 
selection bias on the pooled association was also examined using subgroup and meta- 
regression analyses, which revealed no statistically significant difference between studies 
assessed to have high or unclear risk of bias (Pooled MD 27.31 mg/dL, 95% CI 25.32 to 
29.30) and studies assessed to have a low risk of selection bias (Pooled MD 33.42 mg/dL, 
95% CI 32.20 to 34.51) (P = 0.585 for interaction). There was also no significant variation 
in the pooled association between antiretroviral therapy and total cholesterol levels by 
other study-level subgroups, including geographical region, sex, duration of HIV 
infection, duration of antiretroviral therapy and study design. 
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Table 8.2: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and serum total cholesterol level 
 
Meta-regression 
Subgroup N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
 
14 
15 
9 
5 
1 
 
23.06 (17.44 to 28.68) 
36.77 (32.74 to 48.80) 
29.68 (22.57 to 36.79) 
26.26 (20.15 to 32.37) 
4.64 (-8.67 to 17.96) 
 
 
 
 
 
 
 
0.834 
 
 
 
 
 
 
 
0 
Income group 
High income 
Low/middle 
 
17 
28 
 
36.53 (32.62 to 40.41) 
25.37 (21.57 to 28.95) 
 
 
 
0.002 
 
 
 
24 
Females 
< 50% 
≥ 50% 
 
28 
13 
 
31.66 (28.26 to 35.07) 
24.50 (17.85 to 31.16) 
 
 
 
0.118 
 
 
 
6.7 
Age group 
< 40 years 
≥ 40 years 
 
26 
17 
 
27.41 (23.97 to 30.83) 
35.43 (29.58 to 41.22) 
 
 
 
0.027 
 
 
 
11.5 
Smokers 
< 50% 
≥ 50% 
 
17 
6 
 
24.22 (18.42 to 30.03) 
39.16 (23.17 to 55.14) 
 
 
 
0.048 
 
 
 
17.3 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
18 
17 
 
25.78 (22.37 to 29.18) 
33.81 (29.50 to 38.13) 
 
 
 
0.043 
 
 
 
14.8 
HIV duration 
< 60 months 
≥ 60 months 
 
5 
9 
 
34.77 (23.87 to 45.67) 
33.57 (24.78 to 42.37) 
 
 
 
0.871 
 
 
 
0 
ART regimen 
PI-based 
Non-PI-based 
 
19 
19 
 
32.29 (28.43 to 36.16) 
24.25 (19.41 to 29.09) 
 
 
 
0.037 
 
 
 
9.7 
ART duration 
< 18 months 
≥ 18 months 
 
11 
31 
 
23.07 (13.79 to 32.35) 
30.12 (26.99 to 33.26) 
 
 
 
0.114 
 
 
 
2.7 
Study design 
Cross-sectional 
Cohort 
 
26 
19 
 
30.82 (26.15 to 35.41) 
27.73 (23.62 to 31.93) 
 
 
 
0.484 
 
 
 
0 
Selection bias 
Low risk 
High/unclear risk 
 
17 
27 
 
33.42 (32.20 to 34.51) 
27.31 (25.32 to 29.30) 
 
 
 
0.585 
 
 
 
0 
Publication year 
2000–2009 
2010–2014 
 
20 
25 
 
34.74 (30.96 to 38.31) 
24.86 (20.49 to 29.24) 
 
 
 
0.005 
 
 
 
19.1 
ART, antiretroviral therapy; MD, mean difference; N, number of studies; PI, protease inhibitor; R2, explained 
variability 
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Table 8.3 presents the results of subgroup and meta-regression analyses of the association 
between antiretroviral therapy and LDL cholesterol level. The impact of antiretroviral 
therapy on LDL cholesterol level was significantly higher among studies with 200 
participants or more (Pooled MD 17.62 mg/dL, 95% CI 13.24 to 21.99), compared to 
studies with less than 200 participants (Pooled MD 10.29 mg/dL 4.27 to 16.31) (P = 0.046 
for interaction). Studies published prior to 2010 were more likely to report a stronger 
association between antiretroviral therapy and increased LDL cholesterol levels (Pooled 
MD 20.38 mg/dL, 95% CI 16.02 to 24.78), compared to studies published from 2010 
onwards (Pooled MD 11.97 mg/dL, 95% CI 7.61 to 16.42) (P = 0.030 for interaction). 
Difference in the pooled association by country income group was of borderline statistical 
significance: studies conducted in high income countries were more likely to report 
stronger associations between antiretroviral therapy and increased LDL cholesterol 
Pooled (MD 21.42 mg/dL, 95% CI 16.21 to 26.52), compared to studies conducted in 
low- and middle-income countries (Pooled MD 12.88 mg/dL, 95% CI 8.67 to 17.09)  (P 
= 0.056 for interaction). Of note, there was no statistically significant difference in the 
pooled association between studies assessed to have high or unclear risk of selection bias 
(Pooled MD 15.83 mg/dL, 95% CI 13.91 to 17.62) and studies assessed to have low risk 
of selection bias (Pooled MD 16.32 mg/dL, 95% CI 14.53 to 18.01) (P = 0.881 for 
interaction). 
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Table 8.3: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and serum low-density lipoprotein cholesterol level 
 
Meta-regression 
Subgroup N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
 
13 
8 
8 
6 
1 
 
15.36 (7.37 to 23.36) 
21.77 (16.13 to 21.42) 
12.40 (9.03 to 15.76) 
7.53 (4.35 to 10.72) 
-6.57 (-16.58 to 3.43) 
 
 
 
 
 
 
 
0.083 
 
 
 
 
 
 
 
8.3 
Income group 
High 
Low/middle 
 
10 
26 
 
21.42 (16.21 to 26.52) 
12.88 (8.67 to 17.09) 
 
 
 
0.056 
 
 
 
11.2 
Females 
< 50% 
> 50% 
 
20 
12 
 
14.85 (10.27 to 19.42) 
13.24 (4.93 to 21.55) 
 
 
 
0.670 
 
 
 
0 
Age group 
< 40 years 
≥ 40 years 
 
23 
12 
 
14.23 (9.89 to18.63) 
19.69 (16.52 to 23.98) 
 
 
 
0.208 
 
 
 
5.1 
Smokers 
< 50% 
≥ 50% 
 
16 
3 
 
11.46 (5.02 to 17.89) 
1.68 (-13.60 to 16.95) 
 
 
 
0.314 
 
 
 
4.2 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
17 
11 
 
16.63 (12.32 to 20.95) 
16.64 (9.05 to 24.24) 
 
 
 
0.988 
 
 
 
0 
HIV duration 
< 60 months 
≥ 60 months 
 
5 
6 
 
12.16 (7.77 to 16.55) 
19.95 (3.43 to 24.47) 
 
 
 
0.681 
 
 
 
0 
ART regimen 
PI-based 
Non-PI-based 
 
14 
18 
 
12.56 (6.83 to 18.30) 
15.75 (10.05  to 21.44) 
 
 
 
0.447 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
19 
25 
 
10.03 (0.93 to 19.14) 
16.09 (11.86 to 20.31) 
 
 
 
0.159 
 
 
 
3.2 
Study design 
Cross-sectional 
Cohort 
 
20 
17 
 
15.24 (9.79 to 20.48) 
14.51 (9.30 to 19.69) 
 
 
 
0.859 
 
 
 
0 
Selection bias 
Low risk 
High/unclear risk 
 
14 
22 
 
15.83 (13.91 to 17.62) 
16.32 (14.53 to 18.01) 
 
 
 
0.881 
 
 
 
0 
Year of publication 
2000–2009 
2010–2015 
 
13 
24 
 
20.38 (16.02 to 24.78) 
11.97 (7.61 to 16.42) 
 
 
 
0.030 
 
 
 
15 
ART, antiretroviral therapy; MD, mean difference; N, number of studies; PI, protease inhibitor; R2, explained 
variability 
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Table 8.4 presents the results of subgroup and meta-regression analyses of the association 
between antiretroviral therapy and HDL cholesterol level. Antiretroviral therapy was 
associated with a statistically significant increase in HDL cholesterol level across 
subgroups of different study-level characteristics including age group, smoking status, 
HIV infection duration and antiretroviral treatment duration. In addition, no statistically 
significant difference in the pooled estimate was observed between subgroups of these 
characteristics. 
Antiretroviral therapy was also associated with increased HDL cholesterol levels across 
subgroups of other study-level characteristics, however some of these associations were 
not statistically significant. For instance, antiretroviral therapy was significantly 
associated with increased HDL cholesterol levels among studies with more women than 
men (Pooled MD 8.65 mg/dL, 95% CI 5.63 to 11.63), but not among studies with fewer 
women than men (Pooled MD 3.92 mg/dL, 95% CI -0.22 to 8.06). Nonetheless, the 
difference between both subgroup estimates was not statistically significant (P = 0.157 
for interaction). Similarly, antiretroviral therapy was significantly associated with 
increased HDL cholesterol levels among HIV-infected patients with CD4 cell counts 
greater than 350 cells/mm3 (Pooled MD 5.89 mg/dL, 95% CI 1.02 to 10.76), but not 
among HIV-infected patients with CD4 cell counts less than 350 cells/mm3  (Pooled MD 
4.69 mg/dL, 95% CI -2.80 to 12.18) (P = 0.687 for interaction). Antiretroviral therapy 
was also significantly associated with increased HDL cholesterol levels among HIV- 
infected patients on non-protease inhibitor-based antiretroviral regimens (Pooled MD 
7.25 mg/dL, 95% CI 3.39 to 11.12), but not among those on protease inhibitors (Pooled 
MD 1.87, 95% CI -3.85 to 7.59) (P = 0.115 for interaction). 
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Table 8.4: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and high-density lipoprotein cholesterol level 
 
Meta-regression 
Subgroup N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
 
13 
13 
10 
5 
1 
 
9.51 (4.38 to 14.65) 
4.60 (-2.30 to 11.49) 
1.20 (-2.41 to 4.81) 
3.10 (0.47 to 5.73) 
3.48 (-2.43 to 9.39) 
 
 
 
 
 
 
 
0.066 
 
 
 
 
 
 
 
5.9 
Income group 
High 
Low/middle 
 
15 
28 
 
4.23 (-2.20 to 10.61) 
5.29 (2.83 to 7.84) 
 
 
 
0.692 
 
 
 
11.2 
Females 
< 50% 
≥ 50% 
 
26 
12 
 
3.92 (-0.22 to 8.06) 
8.65 (5.63 to 11.63) 
 
 
 
0.157 
 
 
 
2.8 
Age group 
< 40 years 
≥ 40 years 
 
25 
15 
 
4.89 (0.71 to 9.20) 
3.91 (2.20 to 5.56) 
 
 
 
0.832 
 
 
 
5.1 
Smokers 
< 50% 
≥ 50% 
 
18 
5 
 
7.74 (3.45 to 12.03) 
5.50 (3.41 to 7.59) 
 
 
 
0.506 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
16 
16 
 
4.69 (-2.80 to 12.18) 
5.89 (1.02 to 10.76) 
 
 
 
0.687 
 
 
 
0 
HIV duration 
< 60 months 
≥ 60 months 
 
6 
9 
 
4.30 (0.45 to 8.15) 
4.88 (2.29 to 7.47) 
 
 
 
0.807 
 
 
 
0 
ART regimen 
PI-based 
Non-PI-based 
 
17 
19 
 
1.87 (-3.85 to 7.59) 
7.25 (3.39 to 11.12) 
 
 
 
0.115 
 
 
 
4.5 
ART duration 
< 18 months 
≥ 18 months 
 
10 
30 
 
7.58 (1.94 to 13.22) 
3.82 (0.03 to 7.62) 
 
 
 
0.278 
 
 
 
0.4 
Study design 
Cross-sectional 
Cohort 
 
25 
18 
 
5.13 (1.52 to 8.67) 
4.82 (0.41 to 9.16) 
 
 
 
0.919 
 
 
 
0 
Selection bias 
Low risk 
High/unclear risk 
 
16 
26 
 
5.75 (5.26 to 6.23) 
3.41 (2.73 to 4.12) 
 
 
 
0.109 
 
 
 
4.6 
Year of publication 
2010–2014 
2000–2009 
 
25 
18 
 
5.10 (2.67 to 7.51) 
4.49 (-1.22 to 10.18) 
 
 
 
0.790 
 
 
 
0 
ART, antiretroviral therapy; MD, mean difference; N, number of studies; PI, protease inhibitor; R2, explained 
variability 
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Table 8.5 presents the results of subgroup and meta-regression analyses of the association 
between antiretroviral therapy and triglyceride levels. Significant regional differences in 
the impact of antiretroviral therapy on serum triglyceride levels were observed, 
accounting for 28% of between-study variability. With the one study from the Western 
Pacific region reporting a massive difference in mean serum triglyceride levels between 
antiretroviral-exposed and antiretroviral-naïve patients (537.89 mg/dL versus 163.87 
mg/dL) (Zeng et al., 2010), it may appear that differences across regions were driven by 
the effect estimate from the Western Pacific region: the mean difference in serum 
triglyceride levels between HIV-infected patients naïve and exposed to antiretroviral 
therapy obtained in the Western Pacific region was no less than six times greater than the 
pooled mean differences obtained from the other regions (P < 0.001 for interaction). 
However, regional differences persisted even after excluding Zeng et al. (2010) from the 
meta-analysis (P = 0.029 for interaction; R2 = 9.7%). Studies comprising larger 
proportions of smokers than non-smokers reported significantly higher increases in serum 
total cholesterol levels associated with antiretroviral therapy (Pooled MD 141.54 mg/dL, 
95% CI 39.48 to 243.60), compared to studies comprising smaller proportions of smokers 
than non-smokers (Pooled MD 34.08 mg/dL, 95% CI 19.53 to 48.63) (P = 0.005 for 
interaction). Studies with mean CD4 cell counts of 350 cells/mm3 were more likely to 
report stronger associations between antiretroviral therapy and increased serum 
triglyceride levels (Pooled MD 72.85 mg/dL, 95% CI 54.92 to 90.79), compared to studies 
with mean CD4 cell counts less than 350 cells/mm3  (Pooled MD 29.39 mg/dL, 95%   CI 
16.96 to 41.83) (P = 0.055 for interaction). 
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Table 8.5: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and serum triglyceride level 
 
Meta-regression 
Subgroup N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
 
14 
14 
8 
4 
1 
 
18.97 (1.71 to 36.24) 
61.47 (44.12 to 78.82) 
51.36 (34.35 to 68.40) 
39.66 (15.43 to 63.89) 
365.91 (314.21 to 417.60) 
 
 
 
 
 
 
 
0.000 
 
 
 
 
 
 
 
28.4 
Income group 
Low/middle 
High 
 
28 
15 
 
40.91 (29.45 to 52.42) 
61.39 (44.44 to 78.50) 
 
 
 
0.324 
 
 
 
0.5 
Females 
< 50% 
≥ 50% 
 
26 
12 
 
54.64 (41.48 to 67.80) 
33.56 (12.27 to 54.85) 
 
 
 
0.265 
 
 
 
0.8 
Age group 
< 40 years 
≥ 40 years 
 
24 
15 
 
45.23 (31.52 to 58.78) 
52.77 (40.84 to 64.67) 
 
 
 
0.507 
 
 
 
0 
Smokers 
< 50% 
≥ 50% 
 
17 
5 
 
34.08 (19.53 to 48.63) 
141.54 (39.48 to 243.60) 
 
 
 
0.005 
 
 
 
35.0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
18 
15 
 
29.39 (16.96 to 41.83) 
72.85 (54.92 to 90.79) 
 
 
 
0.055 
 
 
 
11.4 
HIV duration 
< 60 months 
≥ 60 months 
 
7 
8 
 
62.99 (34.20 to 91.78) 
58.14 (31.08 to 85.20) 
 
 
 
0.759 
 
 
 
0 
ART regimen 
PI-based 
Non-PI-based 
 
17 
20 
 
70.79 (55.36 to 84.21) 
24.70 (13.48 to 35.91) 
 
 
 
0.005 
 
 
 
21.0 
ART duration 
< 18 months 
≥ 18 months 
 
11 
28 
 
30.16 (17.22 to 43.10) 
52.96 (40.72 to 65.20) 
 
 
 
0.322 
 
 
 
0 
Study design 
Cross-sectional 
Cohort 
 
25 
18 
 
62.54 (44.67 to 80.31) 
29.71 (21.03 to 38.42) 
 
 
 
0.133 
 
 
 
4.1 
Selection bias 
Low risk 
High/unclear risk 
 
16 
26 
 
38.1 (36.3 to 39.9) 
20.7 (18.7 to 22.7) 
 
 
 
0.544 
 
 
 
0 
Year of publication 
2010–2015 
2000–2009 
 
25 
18 
 
46.42 (33.89 to 58.78) 
49.11 (34.08 to 64.21) 
 
 
 
0.902 
 
 
 
0 
ART, antiretroviral therapy; MD, mean difference; N, number of studies; PI, protease inhibitor; R2, explained 
variability 
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Table 8.6 presents the results of subgroup and meta-regression analyses of the association 
between antiretroviral therapy and the odds of hypercholesterolaemia. The results showed 
no statistically significant difference between subgroup estimates of the association of 
antiretroviral therapy with increased risk of hypercholesterolaemia. The duration of 
antiretroviral therapy accounted for most of the between-study variability, with the impact 
of antiretroviral therapy on the risk of hypercholesterolaemia being approximately twice 
as high among HIV-infected patients who received antiretroviral therapy for 18 months 
or more (Pooled OR 3.86, 95% CI 3.28 to 4.55), compared to HIV-infected patients on 
antiretroviral therapy for less than 18 months (Pooled OR 2.02, 95% CI 0.83 to 7.02). 
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Table 8.6: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and the odds of hypercholesterolaemia 
 
Meta-regression 
Subgroup N Pooled OR (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
 
12 
5 
4 
4 
 
3.66 (2.55to 5.27) 
4.43 (3.04 to 6.46) 
4.41 (1.72 to 11.26) 
3.98 (2.15 to 7.37) 
 
 
 
 
 
 
0.419 
 
 
 
 
 
 
0 
Income group 
High 
Low/middle 
 
7 
18 
 
3.61 (2.10 to 6.08) 
3.64 (2.82 to 4.82) 
 
 
 
0.512 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
11 
12 
 
4.04 (3.09 to 5.26) 
4.00 (2.78 to 5.75) 
 
 
 
0.141 
 
 
 
5.8 
Age group 
< 40 years 
≥ 40 years 
 
17 
5 
 
3.73 (2.84 to 4.83) 
3.67 (2.03 to 6.82) 
 
 
 
0.928 
 
 
 
0 
Smokers 
< 50% 
≥ 50% 
 
11 
2 
 
3.72 (2.66 to 5.21) 
3.11 (1.18 to 8.20) 
 
 
 
0.635 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
9 
9 
 
2.93 (1.86 to 4.60) 
4.27 (3.35 to 5.42) 
 
 
 
0.203 
 
 
 
4.3 
ART regimen 
PI-based 
Non-PI-based 
 
7 
13 
 
4.30 (3.43 to 5.38) 
3.48 (2.35 to 5.16) 
 
 
 
0.713 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
4 
17 
 
2.02 (0.83 to 7.02) 
3.86 (3.28 to 4.55) 
 
 
 
0.094 
 
 
 
9.4 
Study design 
Cohort 
Cross-sectional 
 
8 
17 
 
3.52 (2.63 to 4.56) 
3.78 (2.64 to 5.51) 
 
 
 
0.643 
 
 
 
0 
Year of publication 
2000–2009 
2010–2015 
 
10 
15 
 
4.80 (3.04 to 7.82) 
3.13 (2.32 to 4.23) 
 
 
 
0.820 
 
 
 
0 
ART, antiretroviral therapy; N, number of studies; OR, odds ratio; PI, protease inhibitor; R2, explained variability. 
HIV infection duration was reported in less than ten studies and was excluded from the meta-regression analyses. 
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Table 8.7 presents the results of subgroup and meta-regression analyses of the association 
between antiretroviral therapy and the odds of hypertriglyceridaemia. With the exception 
of CD4 cell count, there was no statistically significant difference between subgroup 
estimates of the association of antiretroviral therapy with increased risk of 
hypertriglyceridaemia. CD4 cell count accounted for most of the between-study 
variability in the association between antiretroviral therapy and hypertriglyceridaemia, 
with the impact of antiretroviral therapy on the risk of hypercholesterolaemia being more 
than twice as high among HIV-infected patients with CD4 counts greater than 350 
cells/mm3 (Pooled OR 3.32, 95% CI 2.66 to 4.14), compared to HIV-infected patients 
with CD4 cell counts less than 350 cells/mm3  (Pooled OR 1.44, 95% CI 1.03 to 2.01) (P 
= 0.02 for interaction). 
 
Meta-regression analysis to determine factors that may potentially influence the 
association between antiretroviral therapy and the odds of dyslipidaemia was not 
performed because the number of observations required for this analysis were insufficient. 
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Table 8.7: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and the odds of hypertriglyceridaemia 
 
 
Meta-regression 
Subgroup N Pooled OR (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
America 
 
11 
4 
4 
2 
 
1.43 (1.11 to 1.84) 
3.89 (2.61 to 5.79) 
3.54 (1.90 to 6.58) 
3.27 (2.02 to 5.32) 
 
 
 
 
 
 
0.217 
 
 
 
 
 
 
3.1 
Income group 
High 
Low/middle 
 
5 
16 
 
3.82 (2.82 to 5.14) 
1.80 (1.41 to 2.43) 
 
 
 
0.692 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
9 
10 
 
2.86 (1.84 to 4.45) 
1.71 (1.23 to 2.36) 
 
 
 
0.242 
 
 
 
2.5 
Age group 
< 40 years 
≥ 40 years 
 
15 
3 
 
2.33 (1.60 to 3.12) 
3.03 (2.07 to 4.38) 
 
 
 
0.891 
 
 
 
0 
Smokers 
< 50% 
≥ 50% 
 
8 
2 
 
2.06 (1.27 to 3.34) 
3.72 (2.40 to 5.75) 
 
 
 
0.711 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
8 
7 
 
1.44 (1.03 to 2.01) 
3.32 (2.66 to 4.14) 
 
 
 
0.020 
 
 
 
30.9 
ART regimen 
PI-based 
Non-PI-based 
 
6 
12 
 
2.99 (1.89 to 4.74) 
1.63 (1.18 to 2.27) 
 
 
 
0.631 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
4 
13 
 
2.16 (0.71 to 6.59) 
2.15 (1.58 to 2.93) 
 
 
 
0.080 
 
 
 
13.7 
Study design 
Cohort 
Cross-sectional 
 
5 
16 
 
2.20 (1.14 to 4.42) 
2.31 (1.67 to 3.09) 
 
 
 
0.768 
 
 
 
0 
Year of publication 
2000–2009 
2010–2015 
 
9 
12 
 
2.83 (1.78 to 4.20) 
1.91 (1.27 to 2.73) 
 
 
 
0.662 
 
 
 
0 
ART, antiretroviral therapy; N, number of studies; OR, odds ratio; PI, protease inhibitor; R2, explained variability. 
HIV infection duration was reported in less than ten studies and was excluded from the meta-regression analyses. 
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CHAPTER NINE 
 
RESULTS – THE IMPACT OF ANTIRETROVIRAL THERAPY ON FASTING 
BLOOD GLUCOSE LEVELS AND DIABETES RISK 
In this chapter, I present meta-analyses of the associations of antiretroviral therapy with 
fasting blood glucose concentrations and diabetes mellitus risk. I also identify study-level 
factors that may influence these pooled associations. 
 
 
 
9.1 OVERALL ASSOCIATIONS OF ANTIRETROVIRAL THERAPY WITH 
FASTING BLOOD GLUCOSE CONCENTRATION AND DIABETES RISK 
9.1.1 Increase in fasting blood glucose concentration 
 
Mean fasting plasma glucose levels were compared between antiretroviral-exposed and 
antiretroviral-naïve patients in 24 studies, 12 of which reported significantly higher mean 
concentrations among antiretroviral-exposed patients (Abebe et al., 2014; Denue et al., 
2013a; Eira et al., 2012; Jantarapakde et al., 2014; Kiage et al., 2013; Malapati et al., 
2014; Ngala et al., 2013; Shahmanesh et al., 2004; Silva et al., 2009; Silva et al., 2010; 
Sreekantamurthy et al., 2014; Weerakkody et al., 2013) (Figure 9.1). Overall, mean 
fasting plasma glucose levels remained significantly higher in ART-exposed patients, 
compared to their naïve counterparts (Pooled MD 4.66 mg/dL, 95% CI 2.52 to 6.80). 
Heterogeneity across the included studies was considerable (I2 = 81.2 %) and statistically 
significant (P < 0.001). Analysis of publication bias revealed a symmetrical funnel plot 
(Figure 9.2). Sensitivity analysis revealed no instance in which the sequential exclusion 
of studies altered the interpretation of the pooled association (Table 9.1). 
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Figure 9.1: Meta-analysis of the association between antiretroviral therapy 
and blood glucose level 
 
ART, antiretroviral therapy; CI, confidence interval; FBG, fasting blood glucose. The black boxes and horizontal 
lines represent the mean difference in FBG with 95% CI in each study. The dashed vertical line through the 
diamond represents the pooled mean difference, whereas the two lateral vertices of the diamond represent the 
95% CI of the pooled mean difference. The solid vertical line through zero represents no effect. 
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Figure 9.2: Analysis of publication bias in the association of antiretroviral therapy 
with increasing fasting blood glucose levels 
 
P-value for Egger’s regression asymmetry test = 0·789  
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9.1.2 Increase in diabetes mellitus risk 
 
The prevalence estimates of diabetes were compared between antiretroviral-exposed and 
antiretroviral-naïve patients in ten studies, five of which revealed significantly higher 
odds of diabetes in the antiretroviral-exposed group (Fontas et al., 2004; Lin et al., 2011; 
Ngala et al., 2013; Jantarapakde et al., 2014; Mohammed et al., 2015). Among 7,946 
participants with reported diabetes status in the antiretroviral-exposed groups, 519 (6.5%) 
had diabetes, as opposed to 63 of 3,379 (1.9%) in the antiretroviral-naïve groups. Overall, 
the odds ratios of diabetes were approximately four times higher among antiretroviral- 
exposed patients, compared to their naïve counterparts (Pooled OR 3.85, 95% CI 2.93 to 
5.07) (Figure 9.3). Studies included in the meta-analysis were not heterogeneous (I2 = 
0%). No evidence of publication bias was found (P = 0.31 for Egger’s test for funnel plot 
asymmetry) (Figure 9.4). Sensitivity analysis revealed no instance in which the sequential 
exclusion of studies altered the interpretation of the pooled association (Table 9.1). 
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Figure 9.3: Meta-analysis of the association between antiretroviral therapy and the 
odds of diabetes mellitus 
 
 
 
 
ART, antiretroviral therapy; CI, confidence interval. The grey boxes and horizontal lines represent the odds ratios of 
dyslipidaemia with 95% CI in each study. The dashed vertical line through the diamond represents the pooled odds 
ratio, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled odds ratio. The solid vertical 
line through zero represents no effect. 
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Figure 9.4: Analysis of publication bias in the association between antiretroviral therapy and 
increased diabetes risk 
                                                               
P value for Egger’s regression asymmetry test = 0.310 
 
 
 
 
Table 9.1: Sensitivity analysis of the pooled associations of antiretroviral therapy 
with increased blood glucose levels and diabetes risk 
 
 
 
 
Cardio-metabolic 
 
Pooled estimate prior to 
serial exclusion of 
individual studies 
 
Range of pooled 
estimate following 
serial exclusion of 
Instance in which 
exclusion of a study 
changed interpretation of 
the pooled association 
outcomes Pooled ES (95% CI) individual studies Pooled ES (95% CI) 
 
Fasting blood glucose 
 
4.66 (2.52 to 6.80) 
 
4.49 to 5.08 
 
None 
Diabetes mellitus 3.85 (2.93 to 5.07) 3.81 to 3.85 None 
CI, confidence interval; Pooled ES, Pooled estimate 
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9.2 FACTORS THAT MAY INFLUENCE THE EFFECT OF ANTIRETROVIRAL 
THERAPY ON BLOOD GLUCOSE LEVEL 
Table 9.2 presents the results of subgroup and meta-regression analyses. With the 
exception of antiretroviral treatment duration, the association of antiretroviral therapy 
with increased blood glucose concentration was significant across subgroups of all study- 
level characteristics. In addition, no statistically significant difference was observed 
between study-level subgroup estimates of the pooled association of antiretroviral therapy 
with increased fasting plasma glucose concentration. Antiretroviral therapy was 
significantly associated with increased blood glucose levels in studies where the mean 
antiretroviral treatment duration was at least 18 months (Pooled MD 4.97 mg/dL, 95% CI 
3.10 to 6.84), whereas no significant association was observed in studies where the mean 
antiretroviral treatment duration was less than 18 months (Pooled MD 4.40 mg/dL, 95% 
CI -0.59 to 9.38) (P = 0.615 for interaction). Meta-regression analysis to determine factors 
that may potentially influence the association between antiretroviral therapy and the odds 
of diabetes mellitus was not performed because the number of observations required for 
this analysis were insufficient. 
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Table 9.2: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and blood glucose level 
 
Meta-regression 
Subgroup N Pooled MD (95% CI) 
P-value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
 
9 
5 
5 
4 
1 
 
3.29 (0.48 to 7.06) 
3.34 (1.15 to 5.53) 
5.89 (2.67 to 9.10) 
7.92 (5.40 to 10.44) 
6.90 (4.89 to 8.91) 
 
 
 
 
 
 
 
0.313 
 
 
 
 
 
 
 
3.1 
Income group 
High income 
Low/middle 
 
5 
19 
 
3.34 (1.15 to 5.53) 
5.07 (2.45 to 7.69) 
 
 
 
0.469 
 
 
 
3 
Females 
≤ 50% 
> 50% 
 
10 
10 
 
5.69 (3.86 to 7.51) 
3.80 (0.04 to 7.56) 
 
 
 
0.341 
 
 
 
0 
Age group 
< 40 years 
≥ 40 years 
 
13 
9 
 
4.46 (1.43 to 7.49) 
5.44 (3.39 to 7.49) 
 
 
 
0.502 
 
 
 
0 
Smokers 
≤ 50% 
> 50% 
 
11 
3 
 
5.17 (3.43 to 6.91) 
4.13 (0.04 to 8.29) 
 
 
 
0.692 
 
 
 
0 
CD4 cell count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
10 
7 
 
4.10 (1.91 to 6.30) 
5.62 (3.89 to 7.34) 
 
 
 
0.371 
 
 
 
12.4 
HIV duration 
< 60 months 
≥ 60 months 
 
6 
6 
 
5.63 (3.10 to 8.15) 
4.83 (2.00 to 7.67) 
 
 
 
0.714 
 
 
 
0 
ART regimen 
PI-based 
Non-PI-based 
 
15 
5 
 
4.45 (1.62 to 7.27) 
3.79 (0.66 to 6.93) 
 
 
 
0.839 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
7 
14 
 
4.40 (-0.59 to 9.38) 
4.97 (3.10 to 6.84) 
 
 
 
0.615 
 
 
 
0 
Study design 
Cohort 
Cross-sectional 
 
7 
17 
 
4.11 (-0.75 to 8.96) 
4.93 (3.23 to 6.62) 
 
 
 
0.479 
 
 
 
0 
Selection bias 
High/unclear 
Low 
 
19 
5 
 
4.61 (2.08 to 7.14) 
3.70 (1.04 to 6.36) 
 
 
 
0.832 
 
 
 
0 
ART, antiretroviral therapy; MD, mean difference; N, number of studies; PI, protease inhibitor; R2, explained 
variability 
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CHAPTER TEN 
 
RESULTS – THE IMPACT OF ANTIRETROVIRAL THERAPY ON BODY FAT 
MEASURES 
In this chapter, I present meta-analyses of the associations of antiretroviral therapy with 
different measures of body fat, including body mass index and waist circumference. I also 
present meta-analyses of the associations of antiretroviral therapy with combined 
overweight/obesity and central obesity, and identify study-level factors that may 
influence these pooled associations. 
 
 
 
10.1 OVERALL ASSOCIATIONS OF ANTIRETROVIRAL THERAPY WITH 
DIFFERENT MEASURES OF BODY FAT 
 
10.1.1 Increase in body mass index 
 
Mean body mass index was compared between antiretroviral-exposed and antiretroviral- 
naïve patients in 50 studies. Thirty seven of these studies reported larger body mass 
indices among patients on antiretroviral therapy (Figure 10.1). Overall, the mean body 
mass index among patients on antiretroviral therapy was significantly higher, compared 
to that among patients who were naïve to antiretroviral therapy (Pooled MD 0.74 kg/m2, 
95% CI 0.36 to 1.11, 17,041 participants). Heterogeneity across the 50 studies was 
statistically significant (P < 0.001 for Chi2 test for heterogeneity) and explained 90% of 
variability in the mean differences between individual studies. Although funnel plot 
revealed an underrepresentation of smaller studies (P = 0.02 for Egger’s regression test 
for funnel plot asymmetry), there was no observed tendency for larger studies to report a 
significant association between antiretroviral therapy and body mass index (Figure 10.2). 
Moreover, correction for publication bias using the trim and fill analysis did not alter the 
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overall interpretation of the pooled association as the filled dataset remained unchanged 
from the original dataset (Figure 10.3). Hence, publication bias did not have a significant 
impact of the pooled association between antiretroviral therapy and body mass index. 
Sensitivity analysis revealed no indication that any of the included studies had undue 
influence on the pooled estimate as to alter the interpretation of the association (Table 
10.1). 
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Figure 10.1: Meta-analysis of the association between antiretroviral therapy and 
body mass index 
 
                 
ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval. The grey boxes and horizontal lines 
represent the mean difference with 95% CI for each study. The dashed vertical line through the diamond represents the 
pooled mean difference, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled mean 
difference. The solid vertical line through zero represents no effect.
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Figure 10.2: Analysis of publication bias in the association between antiretroviral 
therapy and body mass index 
 
Funnel plot showing an underrepresentation of smaller studies towards the base of the graph.                                                  P = 0.02 for 
Egger’s regression test for funnel plot asymmetry. 
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Figure 10.3: Filled analysis of publication bias in the association between 
antiretroviral therapy and body mass index 
 
Filled funnel plot with pseudo 95% confidence limits 
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10.1.2 Increase in waist circumference 
 
Seventeen studies compared waist circumference measurements between antiretroviral- 
exposed and naïve patients. Fourteen of these studies reported a larger mean waist 
circumference in patients on antiretroviral therapy, compared to treatment-naïve patients. 
Overall, the mean waist circumference of antiretroviral-exposed patients was significantly 
larger in comparison to that for patients who were naïve to antiretroviral therapy (Pooled 
MD 2.19 cm, 95% CI 0.73 to 3.64, 3641 participants) (Figure 10.4). Heterogeneity was 
statistically significant across all 17 studies (P < 0.001 for Chi2 test for heterogeneity) and 
explained a considerable amount of between-study variability in individual mean 
differences (I2 = 72.8%). Funnel plot asymmetry was absent (P = 0.65 for Egger’s 
regression test), suggesting no evidence of publication bias (Figure 10.5). Sensitivity 
analysis revealed no indication that any of the included studies had undue influence on 
the pooled estimate as to alter the interpretation of the association (Table 10.1). 
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Figure 10.4: Meta-analysis of the association between antiretroviral therapy and waist 
circumference 
  
 
ART, antiretroviral therapy; CI, confidence interval; WC, waist circumference. The grey boxes and horizontal lines represent 
the mean difference with 95% CI for each study. The dashed vertical line through the diamond represents the pooled mean 
difference, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled mean difference. The solid 
vertical line through zero represents no effect. 
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Figure 10.5: Analysis of publication bias in the association between antiretroviral therapy 
and waist circumference 
 
P = 0.65 for Egger’s test for small study effects 
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10.1.3 Increase in the risk of overweight/obesity 
 
Prevalence estimates of combined overweight/obesity were compared between 
antiretroviral-exposed and antiretroviral-naïve patients in 21 studies. Although 13% 
(4441 of 34,166) of patients on antiretroviral therapy were either overweight or obese, 
compared to 9.9% (1,797 of 18,220) in the antiretroviral-naïve group, the difference was 
not statistically significant (pooled OR 1.36, 95% CI 0.99 to 1.86) (Figure 33). Sensitivity 
analysis revealed no indication that any of the included studies had undue influence on 
the pooled estimate as to alter the interpretation of the association (Table 10.1). 
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Figure 10.6: Meta-analysis of the association between antiretroviral therapy and 
combined overweight/obesity 
 
 
 
ART, antiretroviral therapy; CI, confidence interval. The grey boxes and horizontal lines represent the odds ratios of 
overweight/obesity with 95% CI in each study. The interrupted vertical line through the diamond represents the pooled odds 
ratio, whereas the two lateral vertices of the diamond represent the 95% CI of the pooled odds ratio. The solid vertical line 
through 1 represents no effect.   
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10.1.4 Increase in the risk of central obesity 
 
Eleven of the 13 studies that compared prevalence estimates of central obesity between 
antiretroviral-exposed and antiretroviral-naïve patients reported higher proportions in the 
former. Overall, 609 (32.3%) of 1888 HIV-infected patients on antiretroviral therapy were 
centrally obese, compared to 244 (25.3%) of 963 antiretroviral-naïve patients (Pooled OR 
1.49; 95% CI 1.16 to 1.90) (Figure 10.7). Heterogeneity across all 13 studies was not 
statistically significant and only accounted for a small amount of between-study 
variability (I2 = 34.7%). No evidence of publication bias was found (P = 0.35 for Egger’s 
test for small-study effects) (Figure 10.8). Sensitivity analysis revealed no indication that 
any of the included studies had undue influence on the pooled estimate as to alter the 
interpretation of the association (Table 10.1). 
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Figure 10.7: Meta-analysis of the association between antiretroviral therapy and central obesity 
 
 
 
 
ART, antiretroviral therapy; CI, confidence interval. The grey boxes and horizontal lines represent the odds ratios of central 
obesity with 95% CI in each study. The dashed vertical line through the diamond represents the pooled odds ratio, whereas 
the two lateral vertices of the diamond represent the 95% CI of the pooled odds ratio. The solid vertical line through 1 
represents no effect.   
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Figure 10.8: Analysis of publication bias in the association between antiretroviral therapy and 
central obesity 
 
 
P = 0.35 for Egger’s test for small study effects 
 
 
 
 
 
Table 10.1: Sensitivity analysis of the pooled associations of antiretroviral therapy 
with body mass index and waist circumference 
 
 
 
 
Cardio-metabolic 
 
Pooled estimate prior to 
serial exclusion of 
individual studies 
 
Range of pooled 
estimate following 
serial exclusion of 
Instance in which 
exclusion of a study 
changed interpretation of 
the pooled association 
outcomes Pooled ES (95% CI) individual studies Pooled ES (95% CI) 
 
Body mass index 
 
0.74 (0.36 to 1.11) 
 
0.64 to 0.79 
 
None 
Waist circumference 2.19 (0.73 to 3.64) 2.13 to 2.22 None 
Overweight/obesity 1.36 (0.99 to 1.86) 1.31 to 1.42 None 
Central obesity 1.49 (1.16 to 2.27) 1.45 to 1.55 None 
CI, confidence interval; Pooled ES, Pooled estimate; 
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10.2 FACTORS THAT MAY INFLUENCE THE EFFECTS OF 
ANTIRETROVIRAL THERAPY ON BODY MASS INDEX AND WAIST 
CIRCUMFERENCE 
Table 10.2 presents results of the subgroup and meta-regression analyses of the 
association between antiretroviral therapy and body mass index. Estimates of the pooled 
association were significantly different between subgroups of geographical region, CD4 
cell count, antiretroviral regimen and study design. Body mass indices were significantly 
higher among antiretroviral-exposed patients than their naïve counterparts in studies 
conducted in sub-Saharan African countries (Pooled MD 1.36 kg/m2, 95% CI 0.81 to 
1.91), but not in studies conducted in countries of other geographical regions (P = 0.002 
for interaction). Antiretroviral therapy was associated with a statistically significant 
increase in body mass index among HIV-infected patients with CD4 counts below 350 
cells/mm3 (Pooled MD 1.53 kg/m2, 95% CI 1.10 to 1.96), whereas no statistically 
significant association was observed among HIV-infected patients with CD4 counts 
greater than 350 cells/mm3 (Pooled MD 0.04 kg/m2, 95% CI -0.43 to 0.51) (P = 0.001 for 
interaction). Antiretroviral therapy was also associated with significant increase in body 
mass index among HIV-infected patients on non-protease inhibitor-based antiretroviral 
treatment regimens (Pooled MD 1.43 kg/m2, 95% CI 0.82 to 2.05), but not among HIV- 
infected patients on protease inhibitors (Pooled MD 0.44 kg/m2, 95% CI -0.18 to 1.06) (P 
= 0.049 for interaction). Antiretroviral therapy was associated with more than two times 
the increase in body mass index among HIV infected patients on (antiretroviral) treatment 
for less than 18 months (Pooled MD 1.59 kg/m2, 95% CI 0.78 to 2.41), compared to HIV- 
infected patients who have received treatment for more than 18 months (Pooled MD 0.60 
kg/m2, 95% CI 0.14 to 1.06) (P = 0.047 for interaction). Cohort studies were more likely 
to report statistically significant associations between antiretroviral therapy and increased 
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body mass indices (Pooled MD 1.48 kg/m2, 95% CI 0.77 to 2.19), compared to cross- 
sectional studies (Pooled MD 0.25 kg/m2, 95% CI -0.23 to 0.74) (P = 0.020 for 
interaction). The differences between studies in mean CD4 cell counts explained most of 
the variability between studies. No statistically significant differences in the pooled 
association were observed between subgroups of other study-level characteristics. 
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Table 10.2: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and body mass index 
 
Meta-regression 
Subgroup N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
 
24 
13 
8 
4 
1 
 
1.36 (0.81 to 1.91) 
0.17 (-0.32 to 0.67) 
0.44 (-0.77 to 1.66) 
0.26 (-0.51 to 1.03) 
-4.00 (-5.31 to -2.69) 
 
 
 
 
 
 
 
0.002 
 
 
 
 
 
 
 
23.9 
Income group 
High income 
Low/middle 
 
15 
35 
 
0.21 (-0.26 to 0.68) 
0.90 (0.33 to 1.47) 
 
 
 
0.216 
 
 
 
3.3 
Females 
< 50% 
≥ 50% 
 
21 
23 
 
0.22 (-0.28 to 0.71) 
1.11 (0.48 to 1.73) 
 
 
 
0.070 
 
 
 
9.8 
Age group 
< 40 years 
≥ 40 years 
 
30 
18 
 
0.66 (0.26 to 1.07) 
0.67 (-0.11 to 1.45) 
 
 
 
0.937 
 
 
 
0 
Smokers 
< 50% 
≥ 50% 
 
18 
7 
 
0.72 (-0.16 to 1.60) 
0.38 (-1.67 to 2.43) 
 
 
 
0.726 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
22 
18 
 
1.53 (1.10 to 1.96) 
0.04 (-0.43 to 0.51) 
 
 
 
0.001 
 
 
 
34.5 
HIV duration 
< 60 months 
≥ 60 months 
 
8 
9 
 
0.49 (-0.41 to 1.40) 
-0.22 (-0.55 to 0.11) 
 
 
 
0.199 
 
 
 
7.3 
ART regimen 
PI-based 
Non-PI-based 
 
18 
22 
 
0.44 (-0.18 to 1.06) 
1.43 (0.82 to 2.05) 
 
 
 
0.049 
 
 
 
9.1 
ART duration 
< 18 months 
≥ 18 months 
 
14 
28 
 
1.59 (0.78 to 2.41) 
0.60 (0.14 to 1.06) 
 
 
 
0.047 
 
 
 
9.6 
Study design 
Cohort 
Cross-sectional 
 
19 
31 
 
1.48 (0.77 to 2.19) 
0.25 (-0.23 to 0.74) 
 
 
 
0.006 
 
 
 
13.4 
Selection bias 
Low risk 
High/unclear risk 
 
16 
34 
 
0.24 (0.03 to 0.45) 
0.13 (0.01 to 0.24) 
 
 
 
0.384 
 
 
 
0 
Publication year 
2000–2009 
2010–2014 
 
17 
33 
 
0.36 (-0.03 to 0.74) 
0.81 (0.18 to 1.44) 
 
 
 
0.492 
 
 
 
0 
ART, antiretroviral therapy; MD, mean difference; N, number of studies; PI, protease inhibitor; R2, explained 
variability. 
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Table 10.3 presents the results of the subgroup and meta-regression analyses of the 
association between antiretroviral therapy and waist circumference. While these results 
showed no evidence of a statistically significant differential between subgroup estimates 
of the pooled association, meta-regression analyses revealed that differences among 
studies in mean age (R2 = 18.5%), mean CD4 cell count (R2 = 8.0%), antiretroviral 
treatment regimen (R2 = 8.2%), and mean duration of antiretroviral therapy (R2 = 4.2%) 
accounted for some of the between-study variability in the association between 
antiretroviral therapy and waist circumference. Of note, meta-regression analyses were 
not performed on the proportions of smokers and the mean duration of HIV because these 
study-level factors were reported in fewer than 10 studies. 
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Table 10.3: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and waist circumference 
 
Meta-regression 
Subgroup N Pooled MD (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
 
8 
3 
4 
2 
 
2.56 (0.19 to 4.92) 
1.14 (-0.89 to 3.18) 
1.25 (-0.92 to 3.42) 
3.12 (0.84 to 5.39) 
 
 
 
 
 
 
0.679 
 
 
 
 
 
 
0 
Income group 
High income 
Low/middle 
 
3 
14 
 
1.14 (-0.89 to 3.18) 
2.31 (0.66 to 3.96) 
 
 
 
0.615 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
6 
9 
 
2.16 (0.90 to 3.43) 
2.64 (0.49 to 4.80) 
 
 
 
0.681 
 
 
 
0 
Age group 
< 40 years 
≥ 40 years 
 
11 
5 
 
3.16 (1.72 to 4.60) 
0.36 (-2.32 to 3.03) 
 
 
 
0.092 
 
 
 
18.5 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
7 
5 
 
1.75 (0.55 to 2.95) 
3.19 (0.60 to 5.77) 
 
 
 
0.253 
 
 
 
8.0 
ART regimen 
PI-based 
Non-PI-based 
 
4 
8 
 
3.96 (0.40 to 7.66) 
2.13 (0.05 to 4.21) 
 
 
 
0.358 
 
 
 
8.2 
ART duration 
< 18 months 
≥ 18 months 
 
4 
11 
 
3.67 (1.00 to 6.35) 
2.40 (1.07 to 3.72) 
 
 
 
0.338 
 
 
 
4.2 
Study design 
Cohort 
Cross-sectional 
 
2 
15 
 
2.57 (0.49 to 4.65) 
2.08 (0.44 to 3.72) 
 
 
 
0.751 
 
 
 
0 
Selection bias 
Low risk 
High/unclear risk 
 
2 
15 
 
0.30 (-0.02 to 0.63) 
0.19 (0.05 to 0.33) 
 
 
 
0.620 
 
 
 
0 
Publication year 
2000–2009 
2010–2014 
 
4 
12 
 
1.42 (-0.50 to 3.35) 
2.24 (0.52 to 3.95) 
 
 
 
0.806 
 
 
 
0 
ART, antiretroviral therapy; MD, mean difference; N, number of studies; PI, protease inhibitor; R2, explained 
variability. HIV duration was excluded from meta-regression analyses because less than 10 studies reported the 
mean duration of HIV infection. 
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Pooled estimates of the association between antiretroviral therapy and combined 
overweight/obesity were not significantly different between study-level subgroups (Table 
10.4). However, estimates for studies conducted in sub-Saharan Africa (Pooled OR 1.96, 
95% CI 1.44 to 2.67), studies in which the mean age of the participants was 40 years or 
more (Pooled OR 1.77, 95% CI 1.01 to 3.11), studies in which the mean CD4 cell count 
was less than 350 cells/mm3 (pooled OR 2.00, 95% CI 1.28 to 3.14), studies with more 
women than men (Pooled OR 1.73, 95% CI 1.11 to 2.71), studies in which all 
antiretroviral-exposed participants received non-protease inhibitor-based antiretroviral 
regimens (Pooled OR 1.60, 95% CI 1.25 to 2.04), and studies in which the mean duration 
of antiretroviral therapy was less than 18 months (Pooled OR 1.62, 95% CI 1.06 to 2.47) 
indicated higher odds of combined overweight/obesity for antiretroviral-exposed patients 
than their naive counterparts. Conversely, subgroups such as studies conducted outside 
the sub-Saharan African region, mean age < 40 years, fewer women than men, mean CD4 
cell count ≥ 350 cells/mm3, and protease inhibitors (Pooled OR 1.04, 95% CI 0.54 to 
1.99), did not show any statistically significant association between antiretroviral therapy 
and combined overweight/obesity. CD4 count differences across studies accounted for 
the majority of between-study variability in the association between antiretroviral therapy 
and the odds of overweight/obesity (R2 = 16.2%). Meta-regression analyses could not be 
performed on smoking status because none of the included studies in these analyses 
comprised more smokers than non-smokers. 
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Table 10.4: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and combined overweight/obesity 
 
Meta-regression 
Subgroup N Pooled OR (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
 
11 
3 
2 
5 
 
1.96 (1.44 to 2.67) 
0.71 (0.56 to 0.89) 
0.55 (0.37 to 0.83) 
1.12 (0.69 to 2.01) 
 
 
 
 
 
 
0.061 
 
 
 
 
 
 
12.8 
Income group 
High income 
Low/middle 
 
5 
16 
 
1.05 (0.51 to 2.18) 
1.48 (1.07 to 2.03) 
 
 
 
0.275 
 
 
 
1.0 
Females 
< 50% 
≥ 50% 
 
8 
11 
 
1.03 (0.61 to 1.72) 
1.73 (1.11 to 2.71) 
 
 
 
0.061 
 
 
 
14.3 
Age group 
< 40 years 
≥ 40 years 
 
12 
5 
 
1.35 (0.95 to 1.94) 
1.77 (1.01 to 3.11) 
 
 
 
0.453 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
7 
8 
 
2.00 (1.28 to 3.14) 
1.01 (0.70 to 1.45) 
 
 
 
0.093 
 
 
 
16.2 
ART regimen 
PI-based 
Non-PI-based 
 
6 
10 
 
1.04 (0.54 to 1.99) 
1.60 (1.25 to 2.04) 
 
 
 
0.745 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
3 
11 
 
1.62 (1.06 to 2.47) 
1.31 (0.83 to 2.06) 
 
 
 
0.971 
 
 
 
0 
Study design 
Cohort 
Cross-sectional 
 
4 
17 
 
1.50 (0.65 to 3.44) 
1.31 (0.98 to 1.75) 
 
 
 
0.899 
 
 
 
0 
Selection bias 
Low risk 
High/unclear risk 
 
7 
14 
 
1.42 (0.81 to 2.49) 
1.27 (0.95 to 1.69) 
 
 
 
0.543 
 
 
 
0 
Publication year 
2000–2009 
2010–2014 
 
6 
15 
 
0.81 (0.63 to 1.05) 
1.58 (1.14 to 2.18) 
 
 
 
0.113 
 
 
 
9.5 
ART, antiretroviral therapy; OR, odds ratio; N, number of studies; PI, protease inhibitor; R2, explained variability. 
Smoking status and HIV duration were excluded from meta-regression analyses because less than ten studies reported 
the proportions of smokers and the mean duration of HIV infection. 
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Table 10.5 presents results of the subgroup and meta-regression analyses of the 
association between antiretroviral therapy and the risk of central obesity. Regional 
variations in the pooled estimate accounted for the largest amount of variability between 
studies, with antiretroviral therapy associated with a statistically significant increase in 
the risk of central obesity in HIV-infected populations in sub-Saharan African countries 
(Pooled OR 1.82, 95% CI 1.43 to 2.32); whereas, no significant association was 
observed in the other regions (P = 0.036 for interaction, R2  = 63.7%). While there was 
no evidence of a statistically significant difference between other subgroup estimates of 
the pooled association, it is worth noting that the antiretroviral therapy was associated 
with a significant increase in the risk of central obesity in HIV-infected patients who 
were 40 years and above (Pooled OR 1.69, 95% CI 1.17 to 2.45), but not among HIV- 
infected patients who were less than 40 years old (Pooled OR 1.36, 95% CI 0.94 to 
1.96). Likewise, studies with more women than men reported significant association 
between antiretroviral therapy and increased risk of central obesity (Pooled OR 1.57, 
95% CI 1.17 to 2.09); whereas, studies with fewer women than men reported no 
significant association between antiretroviral therapy and central obesity (Pooled OR 
1.14, 95% CI 0.58 to 2.23). Antiretroviral therapy was also associated with an increased 
risk of central obesity among HIV-infected patients with CD4 cell counts less than 350 
cells/mm3 (Pooled OR 1.78, 95% CI 1.32 to 2.40); whereas, no significant association 
was observed among HIV-infected patients with CD4 cell counts greater than 350 
cells/mm3 (Pooled OR 1.09, 95% CI 0.66 to 1.80). While the difference between these 
subgroup estimates were not statistically significant (P = 0.221 for interaction), it 
accounted for 36.9% of between-study variability in the effect estimates. Subgroup and 
meta-regression analyses of the association between antiretroviral therapy and central 
obesity could not be performed on smoking status because none of the studies included 
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in these analyses comprised more smokers than non-smokers, so that comparison with 
studies comprising fewer smokers than non-smokers was not possible. Similarly, the 
mean duration of HIV infection was greater than 60 months in all of the included 
studies, so that subgroup and meta-regression analyses could not be performed on HIV- 
infection duration. 
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Table 10.5: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and the odds of central obesity 
 
Meta-regression 
Subgroup N Pooled OR (95% CI) P value R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
 
8 
3 
1 
1 
 
1.82 (1.43 to 2.32) 
1.36 (0.57 to 3.21) 
0.84 (0.57 to 1.24) 
1.21 (0.59 to 2.49) 
 
 
 
 
 
 
0.036 
 
 
 
 
 
 
63.7 
Income group 
High income 
Low/middle 
 
3 
10 
 
1.52 (1.17 to 1.97) 
1.36 (0.57 to 3.21) 
 
 
 
0.886 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
3 
9 
 
1.14 (0.58 to 2.23) 
1.57 (1.17 to 2.09) 
 
 
 
0.425 
 
 
 
0 
Age group 
< 40 years 
≥ 40 years 
 
8 
3 
 
1.36 (0.94 to 1.96) 
1.69 (1.17 to 2.45) 
 
 
 
0.602 
 
 
 
0 
CD4 count 
< 350 cells/mm3 
≥ 350 cells/mm3 
 
4 
6 
 
1.78 (1.32 to 2.40) 
1.09 (0.66 to 1.80) 
 
 
 
0.221 
 
 
 
36.9 
ART regimen 
PI-based 
Non-PI-based 
 
6 
5 
 
1.37 (0.89 to 2.10) 
1.74 (1.18 to 2.57) 
 
 
 
0.501 
 
 
 
0 
ART duration 
< 18 months 
≥ 18 months 
 
2 
8 
 
1.53 (0.78 to 3.03) 
1.37 (0.95 to 1.97) 
 
 
 
0.975 
 
 
 
0 
Study design 
Cohort 
Cross-sectional 
 
2 
11 
 
0.95 (0.39 to 2.31) 
1.56 (1.21 to 2.01) 
 
 
 
0.224 
 
 
 
5.8 
Selection bias 
Low risk 
High/unclear risk 
 
4 
9 
 
1.51 (0.87 to 2.62) 
1.48 (1.10 to 1.98) 
 
 
 
0.971 
 
 
 
0 
Year of publication 
2000–2009 
2010–2014 
 
9 
4 
 
1.97 (0.86 to 4.50) 
1.46 (1.12 to 1.91) 
 
 
 
0.885 
 
 
 
0 
ART, antiretroviral therapy; OR, odds ratio; N, number of studies; PI, protease inhibitor; R2, explained variability. 
Smoking status, CD4 count and HIV duration were excluded from meta-regression analyses because less than ten 
studies reported the proportions of smokers, mean CD4 count, and mean duration of HIV infection. 
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CHAPTER ELEVEN 
 
RESULTS – THE IMPACT OF ANTIRETROVIRAL THERAPY ON 
METABOLIC SYNDROME 
In this chapter, I present a meta-analysis of the association between antiretroviral therapy 
and metabolic syndrome. I also identify study-level factors that may influence the pooled 
estimate. 
 
 
 
11.1 OVERALL ASSOCIATION BETWEEN ANTIRETROVIRAL THERAPY 
AND METABOLIC SYNDROME 
 
11.1.1 Increase in the risk of metabolic syndrome 
 
Prevalence estimates of metabolic syndrome were compared between antiretroviral- 
exposed and antiretroviral-naïve patients in 18 studies, 14 of which reported higher 
estimates among antiretroviral-exposed patients (Awotedu et al., 2010; Bergersen et al., 
2006; Dimodi et al., 2014; Eira et al., 2012; Hansen et al., 2009; Howard et al., 2014; 
Jantarapakde et al., 2014; Jerico et al., 2005; Maloberti et al., 2013; Mbunkah et al., 2014; 
Muhammad et al., 2013; Samaras et al., 2007; Silva et al., 2009; Tesfaye et al., 2014) 
(Figure 11.1). Among 5,548 antiretroviral-exposed patients with reported metabolic 
syndrome status, 1048 (18.9%) were diagnosed with metabolic syndrome, compared to 
214 (14.2%) of 1,506 patients in the antiretroviral-naïve group. Overall, the odds ratios 
of metabolic syndrome were significantly higher among antiretroviral-exposed patients, 
compared to their antiretroviral-naïve counterparts (Pooled OR 1.45, 95% CI 1.03 to 
2.03). Heterogeneity across the included studies was substantial (I2 = 69.4%) and 
statistically significant (P < 0.001). Funnel plot asymmetry was absent, suggesting no 
evidence of publication bias (P = 0.175 for Egger’s regression test for funnel plot 
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asymmetry) (Figure 11.2). Sensitivity analysis revealed no significant change in the pooled 
estimate following sequential omission of the included studies (Table 11.1). 
 
Figure 11.1: Meta-analysis of the association between antiretroviral therapy and 
metabolic syndrome 
 
 
ART, antiretroviral therapy; CI, confidence interval; MS, metabolic syndrome; N, total number of participants in each 
group; OR, odds ratio. The grey boxes and horizontal lines represent the odds ratios of metabolic syndrome with 95% CI 
in each study. The interrupted vertical line through the diamond represents the pooled odds ratio, whereas the two lateral 
vertices of the diamond represent the 95% CI of the pooled odds ratio. The solid vertical line through 1 represents no 
effect.   
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Figure 11.2: Analysis of publication bias in the association between antiretroviral 
therapy and metabolic syndrome 
 
Funnel plot showing odds ratios of metabolic syndrome for each of the nine included studies plotted against the standard 
errors of the log odds ratio. The eighteen grey circles correspond to the eighteen studies included in the meta-analysis.  
P = 0.175 for Egger’s test for small-study effects.                                                                                                                                        
 
 
 
 
 
Table 11.1: Sensitivity analysis of the association between antiretroviral therapy and 
metabolic syndrome 
 
 
 
Cardio-metabolic 
outcomes 
 
Pooled OR (95% CI) 
prior to serial exclusion 
of individual studies 
Range of pooled OR 
following serial 
exclusion of 
individual studies 
Instance in which 
exclusion of a study 
significantly changed the 
pooled OR 
Metabolic syndrome 1.45 (1.03 to 2.03) 1.42 to 1.59 None 
CI, confidence interval; OR, odds ratio. 
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145  
11.2 FACTORS THAT MAY INFLUENCE THE EFFECT OF 
ANTIRETROVIRAL THERAPY ON METABOLIC SYNDROME 
 
Subgroup and meta-regression analyses revealed no significant differences between 
subgroup estimates of the pooled association between antiretroviral therapy and metabolic 
syndrome (Table 11.2). Nonetheless, the analyses revealed qualitative differences in the 
pooled effect between study-level subgroups of age, sex and country income group. For 
instance, antiretroviral therapy was significantly associated increased risk of metabolic 
syndrome among patients who were 40 years of age and older (Pooled OR 2.34, 95% CI 
1.22 to 4.49), but not among patients who were younger (Pooled OR 1.14, 95% CI 0.67 
to 1.95). Studies with more women than men reported a significant pooled association of 
antiretroviral therapy with increased risk of metabolic syndrome (Pooled OR 1.66, 95% 
CI 1.28 to 2.14), whereas no significant association was observed in studies with fewer 
women than men (Pooled OR 1.49, 95% CI 0.81 to 2.72). Antiretroviral therapy was also 
associated with increased risk of metabolic syndrome among HIV-infected patients 
resident in low- and middle-income countries (Pooled OR 1.61, 95% CI 1.26 to 2.04), but 
not among those resident in high-income settings (Pooled OR 1.27, 95% CI 0.63 to 2.53). 
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Table 11.2: Subgroup estimates and meta-regression analyses of the association 
between antiretroviral therapy and metabolic syndrome 
 
 
Meta-regression 
 
Study-level characteristics 
 
N 
 
Pooled OR (95% CI) 
 
P-value 
 
R2 (%) 
Region 
Sub-Saharan Africa 
Europe 
South-East Asia 
The Americas 
Western Pacific 
Multi-regional 
 
5 
8 
1 
2 
1 
1 
 
1.62 (1.19 to 2.20) 
1.27 (0.63 to 2.53) 
0.85 (0.25 to 2.91) 
1.20 (0.60 to 2.40) 
1.75 (1.10 to 2.80) 
12.78 (1.75 to 93.14) 
 
 
 
 
 
 
 
 
 
0.818 
 
 
 
 
 
 
 
 
 
0 
Income group 
High income 
Low/middle 
 
8 
10 
 
1.27 (0.63 to 2.53) 
1.61 (1.26 to 2.04) 
 
 
 
0.841 
 
 
 
0 
Females 
< 50% 
≥ 50% 
 
7 
6 
 
1.49 (0.81 to 2.72) 
1.66 (1.28 to 2.14) 
 
 
 
0.701 
 
 
 
0 
Age group 
< 40 years 
≥ 40 years 
 
8 
7 
 
1.14 (0.67 to 1.95) 
2.34 (1.22 to 4.49) 
 
 
 
0.845 
 
 
 
0 
Study design 
Case-control 
Cohort 
Cross-sectional 
 
1 
1 
16 
 
12.78 (1.75 to 93.14) 
0.43 (0.14 to 1.08) 
1.45 (1.04 to 2.02) 
 
 
 
 
0.610 
 
 
 
 
3.1 
Selection bias 
High/unclear risk 
Low risk 
 
15 
3 
 
1.41 (0.97 to 2.06) 
1.94 (0.54 to 6.97) 
 
 
 
0.769 
 
 
 
0 
N, number of studies; OR, odds ratio; R2, explained variability. Smoking status, HIV duration, antiretroviral regimen 
and antiretroviral treatment duration were excluded because data on these characteristics were insufficient to perform 
meta-regression analyses. 
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PART C 
 
 
 
AN EPIDEMIOLOGICAL EXAMINATION OF THE 
ASSOCIATION BETWEEN ANTIRETROVIRAL 
THERAPY AND INCREASED BLOOD PRESSURE 
USING HILL’S CRITERIA OF CAUSATION 
(MINI-REVIEW) 
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CHAPTER TWELVE 
 
BACKGROUND 
 
In this chapter, I briefly set the stage for examining the extent to which the 
epidemiological association of antiretroviral therapy with increased blood pressure fulfills 
Hill’s criteria of causation. 
 
 
 
12.1 BACKGROUND 
 
Although blood pressure changes have a multifactorial aetiology among people living 
with HIV, greater emphasis seems to be placed on the role of antiretroviral therapy, as 
opposed to other risk factors (Dau & Holodniy, 2008). In non-communicable disease 
epidemiology, the transition from association to causation cannot be overemphasized, and 
is seen as a necessary step for implementing preventive interventions at the population 
level (Lucas & McMichael, 2005). However, this transition is yet to come about with 
regards to the association between antiretroviral therapy and high blood pressure. 
For more than half a century, the “Bradford Hill Criteria” have provided the background 
framework for assessing the causal nature of epidemiological associations (Hill, 1965). 
Basically, the evidence base for concluding that there is a high probability that a cause 
and an effect exists in an observed epidemiological association is determined by these 
criteria, which are outlined in Box 12.1 below. Therefore, it would be remiss of the author 
not to detail these criteria and how they may be applied to the association of antiretroviral 
therapy with increased blood pressure in people living with HIV. 
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Box 12.1: Hill’s criteria of causation and their definitions 
 
Criteria Definitions 
1.   Temporal relationship The exposure always precedes the outcome. 
2.   Strength The size of the association as measured by appropriate statistical 
tests. 
3. Dose-response 
relationship 
An increasing measure of the exposure (in amount or time) 
increases the outcome measure 
4.   Consistency The association between the exposure and the outcome is 
replicated across different studies, settings, and times. 
5.   Biological plausibility The association between the exposure and the outcome is 
compatible with currently accepted understanding of the 
pathological mechanisms. 
6.   Analogy The extent to which alternate explanations of the association 
between a characteristically similar exposure and the outcome 
have been ruled out. 
7.   Experiment Evidence that the outcome can be modified or prevented using an 
appropriate experimental regimen. 
8.   Specificity Besides the outcome in question, the exposure produces no other 
outcome. Similarly, the aetiology outcome is not multifactorial. 
9.   Coherence The association between the exposure and the outcome is 
consistent with existing theory and knowledge. 
Adapted from Hill (1965) and Mirtz et al. (2009). 
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CHAPTER THIRTEEN 
 
METHODS 
 
In this chapter, I describe the search strategy for identifying studies potentially relevant 
to the purpose of this mini-review. I also explain how each criterion of causation was to 
be assessed with respect to the association of antiretroviral therapy with increased blood 
pressure. 
 
 
 
13.1 METHODS 
 
I searched the databases of Embase, MEDLINE (OVID) and SciELO for studies 
considered eligible for inclusion in this review. The searches were limited to studies 
published between January 1997 and March 2016, and were conducted using the 
following MeSH terms and keywords: *highly active antiretroviral therapy/, antiretroviral 
therapy.mp./, *blood pressure/, *systolic blood pressure/, *diastolic blood pressure/, high 
blood pressure.mp/, *hypertension/, temporality.mp./, temporal relationship.mp./, odds 
ratio.mp./, *risk/, relative risk.mp./, *effect size/, biological plausibility.mp./, 
coherence.mp./, and analogy.mp./. The MeSH terms ― denoted by the prefix ‘*’ ― were 
exploded to yield more specific terms; all the search terms were combined using Boolean 
operators. Additionally, data from the main findings of the meta-analyses of the 
associations between antiretroviral therapy and blood pressure/hypertension reported in 
the previous chapter were identified as pertinent to the purpose of the present review. To 
reiterate, the meta-analyses in question represent the most comprehensive evidence yet 
regarding the impact of antiretroviral therapy on blood pressure changes (and 
hypertension risk), providing the best possible source of information for the present 
review. 
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Each criterion of causation (Hill, 1965) was examined as follows: 
 
I. Temporal relationship: This criterion was fulfilled if antiretroviral therapy always 
preceded increases in blood pressure, and never the other way around. Hill (1965) 
considered the criterion absolutely essential for establishing a causal inference. In other 
words, the absence of this criterion detracted much from the cause-effect relationship 
between antiretroviral therapy and increased blood pressure. 
II. Strength: This criterion was fulfilled if the mean blood pressure or prevalence of 
hypertension was many times greater among antiretroviral-exposed patients, compared to 
their naïve counterparts. The larger the mean difference in blood pressure or the risk of 
hypertension, the more likely that exposure to antiretroviral therapy caused high blood 
pressure. 
III. Dose-response relationship: This criterion was fulfilled if there was a direct association 
between increasing durations of antiretroviral therapy and increasing levels of blood 
pressure or prevalence estimates of hypertension. Conversely, the absence of this 
association detracted from the causal nature of antiretroviral therapy and increased blood 
pressure. 
IV. Consistency: This criterion was fulfilled if the associations of antiretroviral therapy with 
increasing blood pressure and hypertension risk were replicated across many studies of 
different designs, and in different geographic or income settings, and at different times. 
V. Biologic plausibility: This criterion was fulfilled if the association of antiretroviral 
therapy with increased blood pressure was coherent with current knowledge of the 
pathogenic mechanisms. 
VI. Analogy / consideration of alternate explanations: This criterion was fulfilled if 
hypotheses   of   the   hypertensive   effects   of   other   pharmacologic   agents   besides 
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antiretroviral therapy ― preferably prescription drugs ― or other potential factors with 
hypertensive effects were ruled out in HIV-infected patients. 
VII. Experiment: This criterion was fulfilled if there was experimental evidence alluding to 
the prevention or reversal of increased blood pressure in HIV-infected patients (or animal 
models) following modification of antiretroviral therapy. Of note, modifications to 
antiretroviral treatment would not entail the complete withdrawal of this treatment in 
human subjects, given that HIV-infected patients eligible to commence antiretroviral 
therapy would succumb to AIDS without treatment. 
VIII. Specificity: This criterion was fulfilled if there was a one-to-one cause-effect relationship 
between antiretroviral therapy and increased blood pressure. In other words, no other 
factor, besides antiretroviral therapy, was associated with increased blood pressure among 
people living with HIV. However, this criterion is considered to be the weakest of all the 
criteria, in the context of chronic multifactorial conditions such as high blood pressure, 
so that its absence does not detract from the cause-effect relationship between 
antiretroviral therapy and increased blood pressure. 
IX. Coherence: This criterion was fulfilled if the association between antiretroviral therapy 
and increased blood pressure was consistent with existing knowledge within the field. 
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CHAPTER FOURTEEN 
 
RESULTS 
 
In this chapter, I report the results of the epidemiological examination of the association 
between antiretroviral therapy and increased blood pressure based on each of Hill’s 
criteria of causation. 
 
 
 
14.1 RESULTS 
 
I. Hill’s criteria and the temporal relationship between antiretroviral therapy and 
increased blood pressure. 
Antiretroviral therapy always precedes increases in blood pressure; it is theoretically 
impossible that the reverse could ever be the case. Although the literature search did not 
yield any temporal sequence studies, the Multicentre AIDS Cohort Study, which is the 
largest ongoing prospective study designed to examine the natural history of HIV 
infection and AIDS, reported a temporal relationship between the exposure to 
antiretroviral therapy and increases in the incidence of systolic and diastolic hypertension 
(Seaberg et al., 2005). 
 
 
II. Hill’s criteria and the strength of association between antiretroviral therapy and 
increased blood pressure. 
Antiretroviral-exposed HIV-infected patients may be up to ten times more likely to be 
hypertensive, compared to their naïve counterparts (OR 10.04, 95% CI 2.25 to 44.71) 
(Ekali et al., 2013). The mean systolic (MD 12.72 mmHg, 95% CI 9.10 to 16.34) and 
diastolic blood pressure (MD 7.57 mmHg, 95% CI 5.00 to 10.14) have been reported to 
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be substantially greater in antiretroviral-exposed patients than antiretroviral-naïve 
patients by more than 12 mmHg and 7 mmHg respectively (Mital et al., 2013). More 
precisely, the mean systolic (MD 4.52 mmHg, 95% CI 2.65 to 6.39) and diastolic blood 
pressure (MD 3.17 mmHg, 95% CI 1.71 to 4.64) were greater in antiretroviral-exposed 
patients, compared to their naïve counterparts, by more than 4mmHg and 3 mmHg 
respectively, after pooling the effect estimates from different studies.    
 
 
III. Hill’s criteria and the dose-response relationship between antiretroviral therapy and 
increased blood pressure. 
Data from the MACS study revealed increases in the incidence of systolic and diastolic 
hypertension as the duration of antiretroviral therapy increased (Seabgerg et al., 2005). 
Figure 14.1 below is a graphical illustration of the prevalence of systolic and diastolic 
hypertension by duration of antiretroviral therapy as depicted in the MACS study 
(Seaberg et al., 2005). Furthermore, subgroup and meta-regression analyses performed in 
the evidence synthesis to examine the impact of antiretroviral treatment duration on the 
pooled association between antiretroviral therapy and hypertension risk revealed a 
significantly higher risk of hypertension in HIV-infected patients on antiretroviral 
therapy for more than 18 months (pooled OR 2.23, 95% CI 1.55 to 3.20); whereas no 
significant association was observed on antiretroviral therapy for less than 18 months 
(pooled OR 1.81, 95% CI 0.65 to 5.04) 
(see Table 7.4). 
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Figure 14.1: Prevalence of systolic hypertension (SH) and diastolic hypertension 
(DH) by HIV sero-status and therapy, and relative to the time of highly active 
antiretroviral therapy (HAART) initiation 
 
 
 
The dotted lines represent the mean prevalence of SH and DH for the three categories of the duration of HAART 
exposure included in the multiple regression analyses: less than 2 years, 2 to 5 years, and more than 5 years. ART, 
antiretroviral therapy. 
Source: Multicentre AIDS Cohort Study (Seaberg et al., 2005). 
 
 
 
 
IV. Hill’s criteria and consistency in the association between antiretroviral therapy and 
increased blood pressure. 
The pooled associations of antiretroviral therapy with increased systolic (pooled MD 4.52 
mmHg, 95% CI 2.65 to 3.69) and diastolic blood pressure (pooled MD 3.17 mmHg, 95% 
CI 1.71 to 4.64) and hypertension risk (pooled OR 1.68, 95% CI 1.35 to 2.10) were 
statistically significant across different studies (see meta-analyses in Figures 7.1, 7.3 & 
7.5).  In addition, the pooled associations in the evidence synthesis were statistically 
significant across study 
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designs, geographical regions, country income groups, and publication years (see results 
of subgroup and meta-regression analyses in Tables 7.2 to 7.4). 
 
 
V. Hill’s criteria and the biological plausibility of the association between antiretroviral 
therapy and increased blood pressure. 
The pathologic basis of antiretroviral-associated increases in blood pressure has been 
linked to direct damage to the endothelial linings of blood vessels by antiretroviral drugs, 
which subsequently interferes with the production of biological markers known to 
regulate blood pressure ― notably nitric oxide (Ngatchou et al., 2013; Seaberg et al., 
2005; Stein, 2003). Rising blood pressure levels may also be symptomatic of an 
exaggerated inflammatory response following the initiation of antiretroviral therapy in 
the advanced stages of HIV infection (Bosamiya, 2011). 
 
 
VI. Hill’s criteria and the consideration of alternate hypotheses of the association 
between antiretroviral therapy and increased blood pressure. 
The iatrogenic causes of hypertension in the general population have been well 
documented. For instance, one in five patients treated with synthetic steroids presents 
with hypertension (Grossman & Messerli, 2004). Given the increased potential for 
steroidal abuse, this proportion may be underestimated. In high-risk groups, the 
prevalence of prescription drug abuse tends to be higher in comparison with the general 
population. For instance, prescription drugs have been identified as the most common 
drugs of abuse among people living with HIV, accounting for a pooled prevalence 
estimate of 42.7% (Nduka et al., 2015a). However, the literature search yielded no studies 
that offered a consistent analogy linking high blood pressure with other prescription drugs 
such as corticosteroids or anabolic steroids in HIV-infected patients. 
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VII. Hill’s criteria and the experimental evidence for the association between 
antiretroviral therapy and increased blood pressure. 
In a clinical trial aimed to examine the effectiveness of switching antiretroviral 
regimens on lipids and cardiovascular risk in HIV-infected patients, Rokx et al. 
(2015) found that switching from a first generation to a second generation non-
nucleoside reverse transcriptase inhibitor-based treatment produced a statistically 
significant decrease in systolic blood pressure (MD -6 mmHg, 95% CI -1.7 to -10.3; P 
= 0.007). However, this was a single small study comprising just 50 participants, and given the 
wide confidence intervals of the effect estimate, it is not clear how replicable this finding is. In 
addition, evidence that is obtained from small trials tend to be susceptible to publication and 
selective reporting biases (Loannidis, Cappelleri & Lau, 1998), and small trials may erroneously 
show larger treatment effects (Pereira, Horwitz & Loannidis, 2012). No experimental animal 
studies were found that examined the effects of complete withdrawal of antiretroviral 
therapy on blood pressure changes. 
 
 
VIII. Hill’s criteria and the specificity of the association between antiretroviral 
therapy and increased blood pressure. 
The association of antiretroviral therapy with increased blood pressure does not satisfy 
Hill’s criterion of specificity. For instance, antiretroviral therapy has been associated 
with several other cardio-metabolic conditions besides increased blood pressure, such 
as: dyslipidaemia, overweight/obesity, diabetes mellitus, and metabolic syndrome 
(Dau & Holodniy, 2008; Dagogo-Jack, 2008; Troll, 2011). Similarly, the aetiology of 
high blood pressure, especially among people living with HIV, is multifactorial. For 
instance, HIV- infected patients are more likely to smoke, drink hazardously, and 
consume larger quantities of dietary fat, compared to HIV-negative individuals (Jaime 
et al., 2006; Joy et al., 2007; Saves et al., 2003). Nonetheless, it is worth noting that 
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these traditional risk factors of hypertension may be limited in predicting blood 
pressure changes among people living with HIV on antiretroviral therapy (Troll, 
2011). Moreover, this criterion of causation is considered the weakest of all the 
criteria, especially in the context of chronic multifactorial conditions such as high 
blood pressure, so that its absence does not detract from the cause-effect relationship 
between antiretroviral therapy and increased blood pressure (Hill, 1965). 
 
 
IX. Hill’s criteria and coherence in the association between antiretroviral therapy and 
increased blood pressure. 
In addition to antiretroviral-induced endothelial dysfunction, the association between 
antiretroviral therapy and increased blood pressure is coherent with the temporal rise in 
the latter that has taken place since the advent of HAART two decades ago, among HIV- 
infected people (Hooshyar et al., 2007; Seaberg et al., 2005). 
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CHAPTER FIFTEEN 
 
BACKGROUND, AIMS AND OBJECTIVES 
 
In this chapter, I describe the scientific context for investigating a plausible causal link 
between antiretroviral therapy and increased blood pressure using appropriate statistical 
methods. I also outline the specific objectives of this section. 
 
 
15.1 BACKGROUND 
 
The nature of the epidemiological association between antiretroviral therapy and 
increased blood pressure is complex and has not been fully elucidated. For instance, it 
remains largely unknown whether the association between antiretroviral therapy and 
increased blood pressure is causal in nature. A plausible reason for this trend might be 
that the available studies on the subject tend to be observational. It is widely 
acknowledged that randomised controlled trials provide a higher level of evidence 
suggestive of causality, compared to observational studies. However, what happens when 
it becomes impractical to answer certain research questions using controlled experiments? 
Such questions have led to a growing interest in using observational data to infer or rule 
out causal effects (Austin, 2011a; Austin, 2011b; Kenny, 2015; Thenappan et al., 2014). 
Nonetheless, technically, it is not so much a growing interest than it is a renewed interest, 
given that the primary objective of observational studies has always been to infer causality 
in those situations where controlled experimentation proves unrealistic (Cochran, 1965). 
The association between antiretroviral therapy and increased blood pressure falls within 
this category, given that the random assignment of HIV-infected subjects ― who might 
be eligible to commence antiretroviral treatment ― to a control group, where they are 
administered placebos would inevitably raise significant ethical concerns. 
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Furthermore, as modern-day epidemiology continues to evolve, the interpretations of 
causality continue to expand, above and beyond the simple direct relationships that fulfil 
Hill’s criteria of causation, to account for the multifactorial aetiology of most chronic 
diseases (Lucas & McMichael, 2005; Mirtz et al., 2009). Statistical methods have become 
increasingly fundamental to this purpose by identifying different potential causal 
pathways that reflect the complex interplay of risk factors that explain the pathogenic 
processes associated with most chronic diseases nowadays (Henneken & Buring, 1987; 
Kenny, 2015; Lucas & McMichael, 2005; Mirtz et al., 2009). However, these statistical 
concepts have not been applied to the epidemiological association between antiretroviral 
therapy and increased blood pressure. Unfortunately, statistical methods in previous 
studies that have examined this association have been limited to standard regression 
techniques, which do not elucidate the potential mechanisms through which blood 
pressure changes may occur following antiretroviral therapy. 
Of note, it was essential to address this gap in the current body of evidence, as the findings 
could be useful in uncovering the complex epidemiology of hypertension and other 
cardio-metabolic disorders among people living with HIV in the sub-Saharan African 
region, which in turn, may guide preventive action. 
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15.2 AIMS AND OBJECTIVES 
 
There are three aims in this section. 
 
 
15.2.1 The first aim 
 
To examine the impact of antiretroviral treatment status on the clinical prediction of 
hypertension in people living with HIV in a sub-Saharan African setting. 
15.2.1.1 Objectives 
 
I. To develop the best parsimonious model for predicting hypertension using traditional 
(and non-traditional) risk factors in people living with HIV in a sub-Saharan African 
setting. 
II. To examine whether or not the addition of antiretroviral treatment status to the predictive 
model improves the clinical prediction of hypertension in people living with HIV in a 
sub-Saharan African setting. 
 
 
15.2.2 The second aim 
 
To examine alternative causal pathways that potentially mediate the effects of 
antiretroviral therapy on blood pressure in people living with HIV in a sub-Saharan 
African setting. 
15.2.2.1 Objectives 
 
I. To examine the indirect effects of antiretroviral therapy on blood pressure through 
changes in body fat measures in people living with HIV in a sub-Saharan African setting. 
II. To examine the indirect effects of antiretroviral therapy on blood pressure through 
changes in blood glucose concentration in people living with HIV in a sub-Saharan 
African setting. 
III. To examine the indirect effects of antiretroviral therapy on blood pressure through 
changes in sleep quality in people living with HIV in a sub-Saharan African setting. 
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15.2.3 The third aim 
 
To estimate the average treatment effect on the treated (ATT) of antiretroviral therapy on 
blood pressure in people living with HIV in a sub-Saharan African setting. 
15.2.3.1 Objectives 
 
I. To match the characteristics of HIV-infected patients naïve and exposed to antiretroviral 
therapy based on estimated propensity scores. 
II. To estimate the ATT of antiretroviral therapy on blood pressure in the propensity score- 
matched sample. 
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CHAPTER SIXTEEN 
 
METHODS 
 
In this chapter, I specify the methods for primary data collection and analysis. I also 
describe the rationales for these methods. 
 
 
16.1 STUDY DESIGN 
 
A cross-sectional design was deemed appropriate to achieve the study aims and 
objectives. A prospective cohort study may provide the highest level of evidence among 
observational studies, especially by eliminating the potential for reverse causality since 
the design inherently entails a temporal relationship between antiretroviral therapy and 
blood pressure changes. However, blood pressure changes do not lead to antiretroviral 
exposure, so that reverse causality in the association between antiretroviral therapy and 
blood pressure changes is biologically impossible, and was unlikely to invalidate the 
findings of the present study. Furthermore, the cross-sectional design was a pragmatic 
choice, given that it is relatively inexpensive and more compatible with the timeframe of 
a doctoral programme. 
 
 
16.2 STUDY SETTING 
 
Consenting HIV-infected patients attending the HIV clinic at the Benue State University 
Teaching Hospital in Makurdi, Nigeria were recruited between August and November 
2014, as part of a cross-sectional study. During this period, over 700,000 people were 
reported to be living with HIV in Benue state, accounting for 5.6% of the resident 
population in the state, and is higher than the current national average of 3.6% (National 
Agency for the Control of AIDS, 2014). The Benue State University Teaching Hospital 
is one of two tertiary health institutions providing HIV/AIDS care and treatment services 
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for the resident population of Benue. Approximately 50 patients visit the HIV clinic on a 
typical day and enrolment into care usually coincides with the date HIV-infection was 
first diagnosed. Until two years ago, Benue state had consistently recorded the highest 
prevalence of HIV across all states in Nigeria, accounting for more than 10% of its 
resident population throughout the preceding decade (National Agency for the Control of 
AIDS, 2012). Between 2003 and 2010, HIV prevalence in Benue state increased by more 
than 2% (10.5% to 12.7%), with all-cause mortality more than doubling (1.1 to 2.4 per 
100,000 people); whereas, the national prevalence of HIV decreased by 0.9% (5.0% to 
4.1%) during the same period (National Agency for the Control of AIDS, 2012). Figure 
16.1 is an image showing the most recent mapping of HIV prevalence by state in Nigeria. 
 
 
 
Figure 16.1: Map of Nigeria showing HIV prevalence by state (2014) 
 
 
 
Source: National Agency for the Control of AIDS, 2014. 
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Located in the Mid-East region of Nigeria, Benue state is endowed with more varieties of 
agricultural products than any other state in Nigeria (National Bureau of Statistics, 2012). 
However, the food supply in Benue state has not translated into higher living standards 
for the resident population. In 2007, the Gross Domestic Product (GDP) Income Per 
Capita of the state was $1,592 (National Bureau of Statistics, 2012), which is low by 
World Bank (2015) standards. Such high levels of socio-economic deprivation in Benue 
contribute substantially to the HIV epidemic in the state (Utulu & Lawoyin, 2007). 
 
 
The Benue State University Teaching Hospital is located in the capital city of Makurdi, 
which is home to approximately 10% of the five million people domiciled in the state 
(National Bureau of Statistics, 2012). Makurdi is located close to other cities with high 
HIV prevalence such as Abuja (8.6%), Calabar (7.1%) and Jos (7.7%) (National Agency 
for the Control of AIDS, 2014), and there are high volumes of traffic between these cities, 
mainly for economic reasons. In other words, the high prevalence of HIV in Benue state 
may also be partially attributed to the close proximity and interaction of Makurdi with 
these cities (Djukpen, 2012). Furthermore, certain “socio-cultural practices such as 
wife/widow inheritance, spouse sharing, female circumcision and polygamy” are quite 
prevalent in Makurdi as they are in its neighbouring cities, further propagating the HIV 
disease epidemic in Benue state (Djukpen, 2012; p. 118). 
 
 
Importantly, patients attending the HIV clinic at the Benue state University Teaching 
Hospital are somewhat comparable to those attending other HIV clinics in the state and 
across the country: HIV infection is as much an infectious disease of poverty in Benue 
state as it is in other states in Nigeria, as well as in other countries in sub-Saharan Africa. 
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16.3 CRITERIA FOR SELECTING STUDY PARTICIPANTS 
 
16.3.1 Inclusion criteria 
 
I. HIV-infected patients 
 
II. 18 years old and above 
 
III. Naïve or exposed to highly active antiretroviral therapy (HAART). However, patients 
exposed to HAART had to be on antiretroviral treatment for at least three months 
IV. Nigerian pidgin or English speaking 
 
V. HIV-infected patients in clinical stages I and II as classified by the World Health 
Organization (2005). Patients in HIV clinical stage I are usually asymptomatic, but may 
present with persistent generalized lymph nodes, with predilection for the axillary, 
cervical and inguinal regions of the body. Patients in HIV clinical stage II present with 
one or more of the following relatively mild illnesses: moderate unexplained weight loss 
that is less than 10% of presumed or measured body weight; recurrent respiratory tract 
infections (such as sinusitis, bronchitis, otitis media, pharyngitis); herpes zoster infection; 
angular cheilitis (an inflammatory condition affecting the corners of the mouth); recurrent 
oral ulcerations; papular pruritic eruptions; seborrhoeic dermatitis (a condition where the 
skin appears erythematous, inflamed and itchy); and fungal infections affecting the nails 
of the fingers (World Health Organisation 2005). 
 
 
16.3.2 Exclusion criteria 
 
I. Adolescents and children 
 
II. Sub-optimal adherence to regular follow-up visits at the HIV clinic. Antiretroviral 
adherence levels in such patients were likely to be suboptimal, which may have precluded 
the essence of antiretroviral exposure, given that antiretroviral medications were only re- 
filled during follow-up visits.  Adherence levels to follow-up visits at the clinic were 
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determined from patients’ medical records, and were considered inadequate if the last two 
follow-up visits ― usually one month apart ― prior to the study were missed 
consecutively. It is worth emphasizing that this definition is somewhat arbitrary, given 
that there is no universally accepted definition for antiretroviral adherence (University of 
California, San Francisco [UCSF] Centre for HIV Information, 2016). 
III. Pregnant and lactating mothers: as part of the prevention of mother-to-child transmission 
of HIV (PMTCT) guidelines, all pregnant and breastfeeding mothers must be 
administered antiretroviral prophylaxis (World Health Organisation, 2010a). 
IV. HIV-infected patients for whom their most recent CD4 cell count assessments were 
carried out more than three months prior to commencing the study. According to the 
HIV/AIDS care and treatment guidelines in Nigeria, HIV-infected patients are required 
to undergo CD4 count testing every three months (Federal Ministry of Health Nigeria, 
2012). 
V. Patients presenting with persistent decline in CD4 cell counts or with clinically 
symptomatic HIV infection while on antiretroviral therapy for no less than three months. 
Such patients, upon identification, were diagnosed of antiretroviral treatment failure 
(AIDS info, 2015). 
VI. Patients presenting in any of the more advanced clinical stages of HIV/AIDS often 
characterized by the presence of opportunistic infections: World Health Organisation 
clinical stage III and stage IV. Such patients were deemed ineligible for the study ab initio 
because they were more likely to be in pain and clinically unstable (subnormal or elevated 
body temperatures, pulse rates, respiratory rates and blood pressure readings), compared 
to patients in the less advanced clinical stages I and II. Generally, patients in WHO clinical 
stage III of HIV/AIDS present with one or more of the following signs and symptoms: 
severe weight loss that is greater than 10% of presumed or measured body weight; 
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unexplained chronic diarrhoea that has persisted for more than one month; unexplained 
intermittent or constant fever that has persisted for longer than one month; oral candidiasis 
(a fungal infection caused by Candida species and present in the buccal mucosa); oral 
hairy leukoplakia (an oral lesion caused by the Epstein-Barr virus that presents as a white, 
often hairy-looking, patch on the tongue); a history of pulmonary tuberculosis (TB) 
diagnosed within the last two years; necrotizing periodontal diseases such as acute 
necrotizing ulcerative stomatitis, gingivitis or periodontitis (severe bacterial infections 
affecting the teeth and gums); and severe bacterial infections affecting other organs and 
tissues in the body such as pneumonia (the lungs), empyema (a pus-filled cavity in any 
part of the body, but more commonly pleural in origin), pyomyositis (pus-filled abscesses 
in the skeletal muscles), bone or joint infection, meningitis (the meninges or membranes 
covering the brain and spinal cord), and bacteraemia (the blood); unexplained anaemia (a 
low red cell count in the blood), neutropenia (low white blood cell count) and 
thrombocytopaenia (low platelet count in the blood) for more than one month. 
Patients in HIV clinical stage IV present with one or more of the following AIDS-defining 
illnesses: HIV wasting syndrome (patient loses more than 10% of their body weight 
accompanied by persistent diarrhoea, generalized weakness and fever for no less than one 
month); pneumocystis pneumonia (atypical lung infection caused by the fungus 
Pneumocystis Jirovecii); recurrent severe bacterial pneumonia; chronic herpes simplex 
infection affecting buccal, genital or anorectal areas for at least one month; oesophageal 
candidiasis (a fungal infection caused by the organism Candida Albicans and present in 
the oesophageal wall); tuberculosis affecting areas other than the lungs, notably the spine 
(tuberculosis of the spine) and the abdomen (intra-abdominal tuberculosis); Kaposi’s 
sarcoma (a tumour of viral origins that affects the skin and internal organs); toxoplasmosis 
(caused by the parasite Toxoplasma gondii) affecting the central nervous system; HIV 
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encephalopathy (damage to the brain following chronic HIV infection); meningitis caused 
by Cryptococcus species; disseminated non-tuberculous mycobacteria infection; 
Progressive multifocal leukoencephalopathy (progressive inflammation of the white 
matter at different areas of the brain); tracheal, bronchial or pleural candidiasis; 
cryptosporidiosis (diarrheal disease caused by the parasite Cryptosporidium species); 
isosporiasis (disease affecting the intestines caused by the parasite Isospora belli); 
visceral herpes simplex infection; cytomegalovirus infection affecting the retina; any 
disseminated fungal infection; recurrent septicaemia following non-typhoidal salmonella 
infection; lymphoma (cerebral or B cell non-Hodgkin); invasive cervical carcinoma; and 
visceral leishmaniasis (the most severe form of leishmaniasis) (World Health 
Organisation, 2005). 
 
 
16.4 SAMPLING STRATEGY 
 
Participants who met the pre-determined criteria for inclusion were selected consecutively 
until a sample of 406 HIV-infected participants, comprising 306 antiretroviral-exposed 
and 100 antiretroviral-naive patients, was achieved. In addition to being less expensive 
and less time-consuming than probability sampling techniques that employ random 
selection, consecutive sampling was an appropriate strategy for the primary study, given 
that the criteria for selecting participants for the study were relatively stringent, 
potentially reducing the target population (Bowers, House & Owens, 2011). For instance, 
participants were eligible for the primary study on the basis of the following criteria: age, 
HIV infection status, antiretroviral treatment status, clinical staging of HIV infection, 
adherence levels to follow-up visits at the HIV clinic, pregnancy status (or lactation), most 
recent CD4 cell count investigation, clinical and immunological response to antiretroviral 
treatment, and language. The absence of an electronic database where the medical records 
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of all patients attending the HIV clinic are stored also limited access to a sampling frame 
from which to select the population sample randomly (Bowers, House & Owens, 2011). 
Moreover, previous evidence found no differential impact on antiretroviral treatment 
outcomes between HIV-infected participants recruited by random sampling and those 
recruited using consecutive sampling (Tassie et al., 2010). 
 
 
A sample of 104 HIV-negative individuals who consented to participate in the study were 
also sampled consecutively (for descriptive purposes only) from patients attending the 
Benue State University Teaching Hospital medical outpatient clinic. HIV-negative 
individuals were mostly ambulatory patients attending their follow-up appointments at 
the outpatient clinic. 
 
 
16.5 STUDY OUTCOMES 
 
The outcomes of the study were systolic and diastolic blood pressure. Blood pressure was 
measured using the Omron M10 IT Blood Pressure Monitor, with the patient’s back 
supported while in sitting position. The upper arm was supported at a level corresponding 
to the heart in order to avoid blood pressure readings that are either too high (in cases 
where the upper arm is supported below heart level) or too low (in cases where the upper 
arm is supported above heart level). Of note, blood pressure was measured on each 
patient’s preferred upper arm. Where necessary (e.g. obese persons), the blood pressure 
cuff was replaced with an appropriate-sized cuff. The average of the first two blood 
pressure readings taken no less than 20 minutes apart was recorded as the patient’s blood 
pressure (National Institute for Health and Care Excellence, 2011). A third blood pressure 
reading was taken in cases where the disparity between the first two systolic or diastolic 
blood pressure readings was 5 mmHg or greater, so that the lower of the second and third 
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measurements was recorded as the patient’s blood pressure (National Institute for Health 
and Care Excellence, 2011). Hypertension was diagnosed as blood pressure of at least 
140/90 mmHg, or the use of antihypertensive medication (National Institute for Health 
and Care Excellence, 2011). 
 
 
16.6 EXPOSURE 
 
The exposure criterion was highly active antiretroviral therapy (HAART) status. 
Exposure to HAART entailed treatment using two nucleoside reverse transcriptase 
inhibitors with either one non-nucleoside reverse transcriptase inhibitor (2NRTI + 1 
NNRTI), or one protease inhibitor (2NRTI + 1PI), for at least three months. According to 
the HIV/AIDS care and treatment guidelines in Nigeria, 
Zidovudine/Lamivudine/Nevirapine (AZT/3TC/NVP), 
Zidovudine/Lamivudine/Efavirenz (AZT/3TC/EFV), Tenofovir/Lamivudine/Nevirapine 
(TDF/3TC/NVP) and Tenofovir/Lamivudine/Efavirenz (TDF/3TC/EFV) are the 
commonly prescribed first-line HAART regimens, whereas, the protease inhibitors, 
notably Ritonavir-boosted Lopinavir (LPV-r), are considered second-line (Federal 
Ministry of Health Nigeria, 2012). In contrast, a patient was considered HAART-naïve if 
they were HIV-infected but not eligible to commence antiretroviral treatment. 
 
 
16.7 OTHER DATA SOURCES AND MEASUREMENTS 
 
Other data obtained from each participant included demographic factors (such as age, 
gender, occupational grade, educational attainment); behavioural and lifestyle factors 
(such as smoking status, drinking status, physical activity, presence of depressive 
symptoms, and sleep quality); anthropometric indices (such as body mass index and waist 
circumference); random blood glucose concentration; baseline systolic and diastolic 
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blood pressure; co-morbidities (such as overweight/obesity and central obesity); HIV- 
related characteristics (such as CD4 cell count, duration of HIV infection, HAART status, 
and duration of HAART); and other factors including health-related quality of life and 
family history of hypertension. Overweight/obesity was defined as a body mass index of 
at least 25 kg/m2, and central obesity was assessed as waist circumference of at least 80cm 
for women and at least 94cm for men (National Institute for Health and Clinical 
Excellence, 2011). 
 
 
Socioeconomic data, including educational attainment and occupational grade, were 
collected using the stepwise approach to surveillance instrument (World Health 
Organisation, 2001). Educational attainment and occupation are considered as 
conventional indicators of socio-economic status as it pertains to health research (Duncan 
et al., 2002). Educational status was dichotomised based on the number of years of formal 
education completed. Typically, patients who spent more than 12 years of formal 
education (e.g. university undergraduates, graduates and postgraduates), versus patients 
who had completed no more than 12 years of formal education (e.g. the non-educated, 
and primary and secondary school leavers). Occupational grades were also dichotomised: 
participants who belonged to the middle class (e.g. clerks; low-level managers, 
administrators and professionals; intermediate-level managers, administrators and 
professionals; and high-level managers, administrators and professionals) and those 
below the middle class (e.g. the unemployed; pensioners; unskilled, semi-skilled and 
skilled manual workers) (Market Research Society, 2006). It is worth noting that none of 
the participants in this study belonged to the upper class (the wealthiest members of 
society who wield the greatest political powers), which was expected, given that such 
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individuals are not representative of the resident population in Nigeria (or in any other 
country in the world) (Akhbar-Williams, 2010; Glover, 2007). 
 
 
All lifestyle data were self-reported, and were obtained using the World Health 
Organisation STEPS instrument (Appendix 2), which has been validated for chronic 
disease risk factor surveillance in low- and middle-income settings (World Health 
Organisation, 2001). Drinking status was classified as either ‘current drinkers’ or ‘non- 
drinkers’. Among drinkers, alcohol intake was measured in units using the equation: 
[Number of millilitres in alcoholic drink × Alcohol volume in %] / 1000 (Institute of 
Alcohol Studies, 2013). The local brew, palm wine, was considered because consumption 
levels are quite substantial. Palm wine is thought to have alcohol content of about 4%. 
Alcohol consumption categories were defined according to South African drinking 
guidelines as 21 units per week for men and 14 units per week for women (International 
Centre for Alcohol Policies, 2010). No such guideline exists for Nigeria (International 
Centre for Alcohol Policies, 2010). Smoking status was classified as either ‘ever smokers’ 
or ‘never smokers’. According to the World Health Organisation (2010b) 
recommendations, physical activity levels were dichotomised as greater or less than 150 
minutes weekly of moderate intensity physical activity. Essentially, the weekly amount 
of exercise was obtained from a combination of self-reports of the duration and 
frequency of physical activity in a typical week. Of note, physical activity was not 
restricted to regimented exercises, but included all energetic movements of the body in 
everyday life, such as house chores, manual jobs, mode of transportation, etc. 
176  
Capillary blood samples for all study participants were obtained to determine random 
glucose levels using the Accu-Check Aviva Nano blood glucose system, United 
Kingdom. The blood samples were obtained by two trained phlebotomists who were also 
members of the Benue State University Teaching Hospital staff. 
 
 
Height (in meters) and weight (in kilograms) were measured using a stadiometer and a 
weighing scale respectively. The patient was required to stand in the anatomical position 
on a flat surface without footwear or hair covering. Body mass index was derived from 
both variables using the standard formula: weight (kg)/height2 (m2). 
 
 
Sleep quality was assessed as ‘good’ or ‘poor’ using the Pittsburgh Sleep Quality Index 
(PSQI) (Appendix 3), which is a validated instrument comprising 19 self-rated questions 
designed to measure the quality and patterns of sleep in adults within the last one month 
(Buysse et al., 1989). The 19 self-rated questions assess sleep quality across seven 
domains including: subjective sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction 
(Buysse et al., 1989). The maximum obtainable PSQI score is 21; however, a patient with 
a score of 5 or more was considered to have poor sleep quality, while good sleep quality 
was defined as a PSQI score of less than 5 (Buysse et al., 1989). 
 
 
All participants were screened for the presence of depressive symptoms using the Centre 
for Epidemiologic Studies Depression scale (CES-D) (Radloff, 1977). The CES-D scale 
is a 20-item questionnaire designed to measure self-rated symptoms associated with 
depression. Each item on the questionnaire is scored a value ranging from 0 to 3, where 
0 indicates the absence or rare presence of the depressive symptom in question and 3 
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indicates presence of the symptom in question most or all of the time (Appendix 4). In 
other words, the obtainable CES-D scores range from 0 to 60 overall, with higher scores 
indicating greater depressive symptoms. The cut-off CES-D score below which a 
diagnosis of clinical depression is unlikely is 16, and this formed the basis for 
dichotomising the CES-D scores of participants in the present study (Radloff, 1977). 
 
 
Health-related quality of life (HRQL) was assessed using the Medical Outcomes Study 
12-item Short Form (SF-12) Survey, which has previously been validated on high-risk 
populations in sub-Saharan African settings (Bello-Mojeed et al., 2013). Participants 
responded to 12 questions designed to evaluate self-reported measurements of physical 
and mental well-being in eight areas: general health, physical functioning, role 
functioning as determined by physical factors, bodily pain, vitality, role functioning as 
determined by emotional factors, mental health, and social functioning (Ware, Kosinski 
& Keller, 1996). The Physical and Mental Health Composite Scores (PCS & MCS) 
derived from the 12 questions range from 0 to 100, with higher scores indicating better 
HRQL on the respective physical and mental health scales (Ware, Kosinski & Keller, 
1996) (Appendix 5). 
 
 
Baseline blood pressure referred to systolic and diastolic blood pressure of HIV-infected 
patients obtained at the time of enrolment into care (or HIV infection diagnosis). These 
data were obtained from the patients’ medical records. It was important to adjust for 
these variables in order to determine whether the effects of antiretroviral therapy on 
blood pressure were influenced by blood pressure levels prior to HIV-infection 
diagnosis (or prior to the commencement of HAART). Other data including CD4 cell 
count, duration of HIV infection, HAART status, and duration of HAART were also 
obtained from the patients’ medical records. 
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16.8 ETHICS APPROVAL 
 
Ethics approval was obtained from the University of Warwick Biomedical Science 
Research Ethics Committee, United Kingdom (REGO-2014-711) (Appendix 7), and the 
Benue State University Teaching Hospital Health Research Ethics Committee in Nigeria 
(NHREC/08/11/2013B) (Appendix 8). 
  
 
16.9 AN ACCOUNT OF THE FIELDWORK PROCESS 
 
I arrived at the Benue State University Teaching Hospital in Makurdi, Nigeria, on the 27th 
day of August in 2014, and attended a pre-scheduled meeting with the director of the 
hospital, who also doubled as my supervisor on ground. The main purpose of this meeting 
was to introduce me to the clinician in charge of the hospital’s HIV clinic and obtain 
formal access to the patients. On the 28th day of August, I began recruiting volunteer 
research assistants who would administer the questionnaires to the participants. To 
reiterate, there were four questionnaires to be administered to each participant: The 
World Health Organisation STEPS tool, the Pittsburgh Sleep Quality Index 
questionnaire, the Centre for Epidemiologic Studies Depression Scale questionnaire, and 
the Short Form-12 questionnaire. By the next working day (1 September 2014), I had 
recruited five volunteer research assistants, all of whom were ad hoc staff of the 
hospital. Having explained the purpose and scope of the study, as well as the assessments 
to be carried out on each study participant, I proceeded to conduct training sessions ― 
one hour every work day throughout the week ― to educate the research assistants on 
how to administer the questionnaires. Essentially, I administered each questionnaire to 
the volunteers as a group, 
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and had each volunteer administer each questionnaire amongst themselves subsequently, 
while I observed for any errors. I also instructed the volunteers on how to address certain 
issues raised by the patients during the participant recruitment process; this was achieved 
by reviewing the participant’s information leaflet with the research assistants (Appendix 
9). 
 
 
In the second week (taking count from the first day in September 2014), I recruited four 
study nurses and two laboratory assistants; the purpose and scope of the study were also 
explained to them. The study nurses were members of the hospital staff who were 
recruited to conduct physical examinations on the study participants. To reiterate, these 
examinations entailed blood pressure, weight, height, and waist circumference 
measurements. During this period, the study nurses were familiarized repeatedly with the 
blood pressure devices to be used for the study, as well as the standard protocol for each 
physical examination. The laboratory assistants were employed phlebotomists within the 
hospital, who were recruited to obtain capillary blood samples for random blood glucose 
estimation. The phlebotomists were also familiarized repeatedly with the blood glucose 
monitors to be used in the study, as well as the standard guidelines for capillary blood 
sampling. 
 
 
All participant recruitment and data collection were carried out from weeks three to 
thirteen. Patients were recruited during their follow-up visits to the clinic. Typically, 
patients attending their follow-up visits at the clinic are encouraged to present early for a 
short seminar just before opening time. These seminars were forums held daily, where 
members of the clinic staff would have talks with all presenting patients just before their 
appointments. The seminars entailed scheduled regular talks about health and social 
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issues that pertain to living with HIV, and served as the appropriate avenues to 
communicate the overall purpose of the study to the patients initially. At this point, 
patients who indicated interest in participating in the study were selected for further 
dialogues with the volunteer research assistants, who discussed the participant 
information leaflet with each patient until it was clear that they understood the scope of 
the study in its entirety. The volunteer research assistants also obtained signed informed 
consents from patients who would subsequently consent to participate in the study. On 
average, 10 participants were recruited every work day. Participant recruitment was 
conducted simultaneously with data collection. In addition to administering 
questionnaires, data collection also entailed retrieving relevant information from the 
patients’ medical records at the end of each day. The fieldwork was organised in three 
stations, so that participants proceeded to the second station where they were physically 
examined by the study nurses, and the third station where their blood samples were 
obtained for blood glucose estimation. HIV-infected participants in the study were 
recruited over a period of about eight weeks. 
 
 
In the following three weeks, the same volunteer research assistants, study nurses and 
laboratory assistants were involved with the recruitment and collection of data from HIV- 
negative individuals attending their follow-up visits at the medical outpatients 
department. All data collection were completed on the 28th day of November 2014. All 
data obtained were collated and reviewed with the supervisors on a weekly basis. Figure 
16.2 is a graphical illustration showing a timeline of the activities carried out during the 
fieldwork. 
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Figure 16.2: Gantt chart showing timeline for activities carried out during fieldwork 
 
 
 
 
BSUTH, Benue State University Teaching Hospital; MOPD, medical outpatient department clinic 
 
 
 
 
16.10 STATISTICAL ANALYSES 
 
All data were analysed using Stata version 14 for Windows (Stata Corp, College Station, 
Texas). Prior to data analysis, the data entered into the Stata database were cleaned by 
deleting invalid cases and values (including duplicates) within variables. All null 
hypotheses were tested against two-sided alternative hypotheses at significance level of 
5%. The effect estimates were reported with their corresponding 95% confidence 
intervals. 
 
 
16.10.1 Descriptive statistics 
For all continuous variables (e.g. age, body mass index, waist circumference, sleep 
duration, systolic blood pressure, diastolic blood pressure, blood glucose concentration, 
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alcohol consumption in units per week, physical activity in minutes per week, PSQI score, 
CES-D score, monthly household income, SF-12 physical and mental component scores, 
and number of fruit and vegetable servings), the means with standard deviations were 
compared between HAART-exposed and HAART-naïve HIV-infected patients, and HIV- 
negative individuals. The means (with standard deviations) for CD4 cell count, baseline 
systolic blood pressure, baseline diastolic blood pressure, and duration of HIV infection 
were compared between HAART-exposed and HAART-naïve HIV-infected patients 
only. Mean HAART duration (with standard deviation) was reported for HAART- 
exposed patients. Statistical significance of the comparisons was determined using the 
independent samples t-test. 
 
 
Similarly, the frequencies and proportions of categorical variables (e.g. gender, age group, 
educational attainment, occupational grade, drinking status, smoking status, alcohol 
consumption categories, physical activity categories, PSQI categories, depression status, 
overweight/obesity status, central obesity status, family history of hypertension, diabetes 
mellitus status, and hypertension status) were compared between HAART-exposed and 
HAART-naïve HIV-infected patients, and HIV-negative individuals. For categorical 
variables, statistical significance of the comparisons between these patient groups were 
determined using the chi-squared test or Fisher’s exact test where necessary. Differences 
in baseline characteristics between HAART-exposed, HAART-naïve and HIV-negative 
patients were also computed across the trend. 
 
 
16.10.2 Unadjusted analyses 
 
The differences in mean systolic and diastolic blood pressure stratified by HAART status 
were assessed using one-way analysis of variance (ANOVA). The differences in    mean 
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systolic and diastolic blood pressure stratified by subgroups of other categorical 
independent variables were also tested using one-way ANOVA. For these unadjusted 
analyses, one-way ANOVA was appropriate because it is used to test the differences in 
the means of a continuous dependent variable between two or more subgroups of a 
categorical independent variable (University of California Los Angeles [UCLA] 
Statistical Consulting Group, 2016a; Welch, 1951). The one-way ANOVA test is also 
robust to the normality assumption (UCLA Statistical Consulting Group, 2016a). 
Statistical significance for each analysis was set at P < 0.05. 
Simple linear regression models were fitted to test whether there were statistically 
significant linear relationships between each continuous independent variable and blood 
pressure. Simple linear regression was the appropriate statistical test for these analysis 
because it is used when the dependent and independent variables are continuous. Each 
linear regression model was also fitted separately for HIV-positive and HIV-negative 
participants in order to identify factors associated with systolic and diastolic blood 
pressure changes in each group. 
 
 
16.10.3 Model fit statistics ― predictive modelling of hypertension in HIV-infected 
patients 
Improved prediction has been considered essential to causation (Allison, 2014; Cox, 
2012), so that it was worthwhile to examine whether HAART status improved the clinical 
prediction of high blood pressure in HIV-infected patients. To examine whether or not 
HAART status improved the clinical prediction of hypertension in HIV-infected patients, 
the best parsimonious model for predicting hypertension in this high-risk group without 
considering HAART status was fitted. First, simple logistic regression models were fitted 
to individually assess the best predictors of hypertension. Nagelkerke’s R2  statistic for 
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each regression model was used to assess how much each variable explained the 
variability of the data (i.e. the extent of fit of each model), unlike goodness of fit tests 
which only examine whether or not a model fits the distribution of the given data (UCLA 
Statistical Consulting Group, 2016b). Nagelkerke’s R2 was used to guide the author on 
the order of inclusion of the predictor variables in the predictive model. With the 
exception of HAART status, variables were added in descending order of the magnitude 
of R2, such that the predictor variable with the largest R2 was added first, followed by the 
predictor variable with the second largest R2 and so on. Based on R2, the stopping rule 
was a failure to improve model fit following addition of the subsequent variable to the 
predictive model. Once the predictive model was fitted, HAART status was added to 
evaluate its impact on the predictive value of the model. 
 
 
Given that any observed improvement in model fit following the addition of HAART 
status essentially reflects the adjusted difference in hypertension risk between HAART- 
exposed and HAART-naïve patients, predictive margins were computed to determine the 
predicted probabilities of hypertension in HAART-exposed and HAART-naïve patients 
at different fixed values of the (other) covariates in the predictive model. The predicted 
probabilities of hypertension were also illustrated graphically. The estimated probabilities 
of hypertension for HAART-exposed and HAART-naive patients were reported based on 
the final prediction model. Assuming all patients in the study were HAART-naïve, the 
predictive margin was used to estimate the predicted probability of hypertension for 
each HAART-naïve patient and the average for all patients was calculated (Graubard & 
Korn, 1999). The probability of hypertension for HAART exposed patients was 
similarly obtained where, assuming all patients in the study were exposed to HAART, the 
predicted probability of hypertension for each HAART-exposed patient and the average 
for all patients were calculated.  
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The predictive model accuracy was measured ― before and after including HAART 
status ― by computing the area under the receiver operating characteristics (ROC) 
curve. The ROC curve plots the sensitivity of the model in predicting hypertension 
against (1 minus its specificity). The greater the area under the ROC curve (upper limit = 
1), the better the model discriminates between hypertension cases. 
 
 
16.10.4 Mediation analysis ― a structural equation modelling approach 
 
Structural equation models were fitted to test whether there were alternative causal 
pathways between HAART and blood pressure that were mediated by changes in body 
fat measures (e.g. body mass index and waist circumference), blood glucose 
concentration, sleep quality indices, or the presence of depressive symptoms. To recall, 
the aim is to test the hypotheses that HAART exposure precedes changes in body mass 
index, waist circumference, blood glucose concentration, sleep quality indices, and 
depression scores, which, in turn, precede changes in blood pressure. In other words, 
controlling for these intervening variables should reduce or eliminate the differences in 
blood pressure between HAART-exposed and HAART-naïve HIV-infected patients. 
Although, effect-modification (or moderation), which occurs when the explanatory 
variable (i.e. HAART status) has a different effect on the dependent variable (blood 
pressure) at different values of the effect-modifier, may also explain how the sequential 
steps of an exposure lead to its outcome; however, mediation analyses are more 
appropriate and more powerful to test causal hypotheses (Kenny, 2015). In fact, the 
findings of a mediation analysis are only valid if they are consistent with a causal 
hypothesis that is theoretically plausible (Judd & Kenny, 2010; Kenny, 2015). 
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Hyman (1955), MacCorquodale & Meehl (1948), and Wright (1934) were among the 
landmark studies that conceptualized the use of mediation to estimate alternative causal 
pathways between an exposure and an outcome. More recently, Kenny (2015) described 
the mediation model as a causal model, such that the causal variable is presumed to cause 
the mediator, which is, in turn, presumed to cause the outcome. Where the reverse is also 
the case, the mediation model is not likely to be correctly specified, which potentially 
invalidates the results from the mediation analysis. In other words, even though mediation 
analyses are appropriate to test causal assumptions between an exposure and an outcome, 
the results from such analyses are only valid if the presumed mediational model is 
correctly specified. 
 
 
Historically, mediation analyses have been performed using standard regression 
techniques. Baron and Kenny (1986), James and Brett (1984), and Judd and Kenny (1981) 
outlined four regression steps to ensure that a mediation model was correctly specified: 
• Step I: to show that there is an association between the causal variable (HAART status) 
and the dependent variable (blood pressure). This equation entails regressing the 
dependent variable on the causal variable. 
• Step II: to show that there is an association between the causal variable and each 
mediator variable (body mass index, waist circumference, blood glucose concentration, 
sleep quality indices, and depression scores). This equation entails regressing the 
mediator variable on the causal variable. 
• Step III: to show that there is an association between the mediator variable and the 
dependent variable, independent of the causal variable. This step entails regressing the 
dependent variable on the mediator variable, while adjusting for the causal variable. 
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• Step IV: to show that the mediator variable completely attenuates the effect of the causal 
variable on the dependent variable. This step entails regressing the dependent variable 
on the causal variable, while controlling for the mediator variable. 
 
 
The mediating effect was complete when all four steps were satisfied, and partial when 
only the first three steps were satisfied. Nonetheless, satisfying these conditions did not 
invariably mean that mediation (complete or partial) had occurred. Judd & Kenny (1981) 
affirmed that the presence of specification errors in the mediation model, notably the 
potential for confounding and reverse causation, could invalidate the findings of a 
mediation analysis. Such specification errors had to be investigated and corrected before 
any causal inferences could be made about a mediational model ― a process described 
many years later as the causal inference approach to mediation (Robins & Greenland, 
1992). Robins and Greenland (1992) were among the earliest proponents of the causal 
inference approach, which aims to provide a valid basis for making causal inferences 
about the results of a mediation analysis. The approach was predicated on the condition 
that there were no unmeasured factors that confounded the indirect effects of the causal 
variable on the outcome through the mediator in each of the previously outlined steps 
required for model specification. 
 
 
While the causal inference approach still remains relevant in mediation analysis, there is 
a growing interest in the use of structural equation modelling ― as opposed to standard 
regression methods ― to provide a more suitable inference framework for mediation 
analyses, as well as for other types of causal analyses (Gunzler et al., 2013). Structural 
equation modelling (SEM) has been described as “a very powerful multivariate technique 
that entails a conceptual model, path diagram and system of linked regression-style 
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equations to capture complex and dynamic relationships within a web of observed and 
unobserved variables” (Gunzler et al., 2013; p. 390). The technique was conceptualized 
by geneticist Wright (1921) and economists Haavelmo (1943) and Koopmans (1953) who 
sought to estimate and test hypotheses on cause-effect relationships among a set of 
associated variables. In SEM, the clear distinction between independent and dependent 
variables ― as is the case with standard regression models ― is relative in the sense that 
a dependent variable in one model equation can become an independent variable in other 
component equations of the structural equation model: a concept that makes SEM better- 
suited to infer causal associations than standard regression techniques (Gunzler et al., 
2013). 
 
 
 
Another advantage of using SEM over standard regression methods for mediation 
analysis is that the former is user-friendly and allows for the estimation and interpretation 
of complicated mediational models in a single analysis (MacKinnon, 2008); whereas, 
standard regression methods rely on combining results from two or more equations. 
Furthermore, “while standard regression methods test a statistical relationship based on a 
conditional expected value, SEM tests a functional relationship expressed via a 
conceptual model, path diagram, and mathematical equations. Thus, the causal 
relationships in a hypothesized mediation process, the simultaneous nature of the indirect 
and direct effects, and the dual role the mediator plays as both a cause for the outcome 
and an effect for the intervention are more appropriately expressed using structural 
equations than using regression analysis” (Grunzler et al., 2013; p. 391). 
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For each structural equation model, the direct effects of HAART on systolic and diastolic 
blood pressure, and the indirect effects of HAART on systolic and diastolic blood pressure 
through each potential mediator, were computed; the coefficients of the indirect effects 
correspond to the mediation coefficients. The structural equation model also computed 
the total effects of HAART on systolic and diastolic blood pressure, which were the sums 
of each direct and indirect effect. To further clarify the difference between the total and 
direct effects: the total effects were the effects of HAART on systolic and diastolic blood 
pressure unadjusted for any potential mediator; whereas, the direct effects were the effects 
of HAART on systolic and diastolic blood pressure after adjusting for the proposed 
mediator in the structural equation model (Rucker et al., 2011). The amounts of the effects 
of HAART on systolic and diastolic blood pressure that were explained by each mediator 
were derived by computing the ratios of each indirect effect to the total effect. 
 
 
In line with the causal inference approach to mediation, the mediation models were 
subsequently fitted to adjust for common potential confounders (or omitted variables), 
including traditional risk factors (age, sex, smoking status, drinking status, physical 
activity) and HIV-related characteristics (CD4 cell count and duration of HIV infection). 
The rationale for selecting potential confounders were based on potential interactions with 
HAART exposure, blood pressure and each potential mediator as described below: 
 
 
• Age: Evidence suggests that older antiretroviral-naïve HIV-infected patients may be more 
likely than their younger counterparts to commence HAART given the impact of age on 
HIV disease progression (Edwards et al., 2015). In addition, there is an age-related 
increase in body mass index (Mariz et al., 2011), blood glucose concentration (Shen et 
al., 2013) and blood pressure (Palacious et al., 2006) among people living with HIV. 
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Although the effect of ageing on sleep quality in people living with HIV remains largely 
unknown, sleep quality in the general population tends to be characterised by an age- 
related decline (Pace-Schott & Spencer, 2011). 
• Sex: Women are less likely than men to have access and optimal adherence to 
antiretroviral therapy (Tapp et al., 2011). Gender differences exist in central fat 
accumulation among people living with HIV, with women being more affected than 
men (Joy et al., 2008). In a sample comprising 2,006 HIV-infected patients, prevalence 
estimates of hyperglycaemia were found to be higher among men than women [21.5% 
versus 15.2%]) (Shen et al., 2013). Men were significantly less likely than women to 
have sleep disturbances in a sample of 1,354 HIV-infected participants (Allavena et al., 
2014). HIV- infected men are more likely than HIV-infected women to have high blood 
pressure (Thiebaut et al., 2005). 
• Lifestyle factors: Smoking and alcohol abuse have been linked to antiretroviral non- 
adherence, which precludes the essence of HAART exposure (Shuter & Bernstein, 2008; 
Chander, Lau & Moore, 2006). Among people living with HIV, smoking is associated 
with a decreased risk in overweight and obesity, whereas alcohol consumption is 
associated with a decreased risk of underweight (Mariz et al., 2011). Tobacco smoking 
and alcohol consumption have been linked to sleep disturbances in people living with 
HIV (Allavena et al., 2014). Smoking and alcohol consumption are risk factors for high 
serum glucose levels and high blood pressure in people living with HIV (Dau & Holodniy, 
2008; Klatsky, 1995). Low physical activity levels have been linked to antiretroviral non- 
adherence which may rule out the essence of HAART exposure (Blashill et al., 2013). 
There is a significant negative correlation between physical activity levels and waist 
circumference in people living with HIV (Florindo et al., 2007). While the role of physical 
activity in sleep quality has rarely been studied among people living with HIV, physical 
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activity may improve the quality of sleep ― and vice versa ― in the general population 
(Zuo et al., 2012). Physical inactivity is a known predisposing factor for hyperglycaemia 
and type II diabetes mellitus. Physical activity levels below 150 minutes per week is 
associated with endothelial dysfunction, which impairs blood pressure regulation 
(Dirajlal-Fargo et al., 2015). 
• CD4 cell count: Naturally, CD4 cell counts increase following HAART. Low CD4 cell 
counts below 200 cells/mm3 have been associated with reduced relative weight (Mariz et 
al., 2011), worsening quality of sleep (Oshinaike et al., 2014), increasing blood glucose 
concentrations (Shen et al., 2013), and sustained high blood pressure (Manner et al., 
2013). 
• HIV infection duration: Prolonged duration of HIV infection has been identified as a 
significant contributor to high blood pressure (Manner et al., 2010; Manner et al., 2012), 
increased body mass index (Crum-Cianflone et al., 2010), altered glucose metabolism 
(Kalra et al., 2011), and poor sleep quality (Allavena et al., 2014; Oshinaike et al., 2014). 
 
 
As part of the causal inference approach to mediation, the author also sought to rule out 
reverse causation and any alternate models that may potentially invalidate causal 
inferences about the mediational models (Kenny, 2015). 
 
 
Bootstrap tests of mediation with 95% confidence intervals were subsequently performed 
using 500 replications to determine whether the indirect effects were statistically 
significant. This non-parametric test ― unlike the Sobel-Goodman test ― is not affected 
by sample size, so that the relatively small size of the present study was unlikely to 
produce  inaccurate  estimates  of  the  indirect   effects  (Preacher  &  Hayes,        2008; 
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MacKinnon, Lockwood & Williams, 2004). The 95% confidence intervals of the indirect 
effects were bias-corrected to allow for potential skewness in the data (Kenny, 2015). 
 
 
16.10.5 Propensity score matching 
 
A propensity score model was fitted to estimate a balanced distribution of propensity 
scores between HAART-exposed and HAART-naïve participants. The propensity score 
model is much like a logistic regression model where a dichotomous variable, which is 
the treatment status (or exposure criterion), is regressed on a number of observed baseline 
covariates (Austin, 2011a). Subsequently, a propensity score matching model ― now 
including the study outcomes and a variable denoting the propensity score ― was fitted 
to examine the causal average effects of antiretroviral therapy on systolic and diastolic 
blood pressure. 
 
 
Propensity score matching entailed using nearest neighbour matching with a calliper 
width of 0.2, which has been recommended as most suitable for observational studies in 
which the effect estimates reflect the mean differences (Austin, 2011b). Austin (2011b) 
also argued that such a matching specification offers the best chance of achieving a 
‘variance-bias trade-off’ in which the specified caliper is not so wide as to allow 
systematic differences between matched treated and untreated patients, thereby 
introducing bias in the average treatment effect, and not so narrow that it substantially 
reduces the number of matched patients, thereby increasing the variance of the average 
treatment effect. A good overall matching performance was defined not only in terms of 
the differences in means and proportions of the baseline covariates between HAART-
exposed and HAART-naïve patients in the propensity score matched sample, but also in 
terms of the standardized bias after matching (Rosenbaum & Rubin, 1985), and a 
comparison of the variances of
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continuous variables between the matched treatment groups (Austin, 2011b). A 
standardized bias (or mean absolute bias) of 5% or less after propensity score matching 
indicated a good balance of baseline covariates between patients naïve and exposed to 
HAART (Grilli & Rampichini, 2011). Similarly, the variance ratios of the continuous 
covariates had to be below the upper limit of the range determined by the statistical 
software (Austin, 2011b). Based on these definitions, the balancing of the variables 
between HAART-exposed and HAART-naïve patients was checked using Stata’s pstest 
command after propensity score matching in order to be sure that the estimated treatment 
effect was the result of a successfully matched model. 
 
 
Given that the target population was people living with HIV in a sub-Saharan African 
setting, propensity score matching was limited to matching the baseline characteristics of 
HAART-exposed and HAART-naïve participants on the estimated propensity scores. 
Evidently, estimating propensity scores for HIV-negative individuals was considered 
redundant with respect to investigating the possibility of a causal association between 
antiretroviral therapy and increased blood pressure in people living with HIV. 
 
 
The term ‘propensity score’ was originally defined as “the conditional probability of 
assignment to a particular treatment given a vector of observed covariates” (Rosenbaum 
& Rubin, 1983; p. 41). However, Austin (2011a) explained it more clearly as a balancing 
score conditional on which the distribution of baseline characteristics is similar between 
patients exposed and naïve to a treatment ― much like a randomised controlled trial. “The 
propensity score exists in both randomized experiments and in observational studies” 
(Austin, 2011a; p. 403). In a randomised controlled trial, the true propensity score is 
determined by the randomization process. While the true propensity score is not known 
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in an observational study, it can be estimated using the study data (Austin, 2011a). Other 
similarities between the analysis of a propensity score-matched sample and that of a 
randomised controlled trial (Austin, 2011a; Imbens, 2004; Rubin & Thomas, 2000; 
Steyerberg, 2009) are summarised in Table 16.1 below. 
 
 
The idea of the propensity score originated from the need to examine cause-and-effect 
relationships in cases where controlled experiments were not feasible (Rosenbaum & 
Rubin, 1983). According to Cochran and Chambers (1965), the main objective of an 
observational study is to estimate causality, same as controlled experiments, putting into 
perspective the growing interest in using observational data for this intended purpose, as 
well as the importance of propensity score methods. To reiterate, controlled 
experimentation may not suffice to determine whether or not a causal effect exists 
between antiretroviral therapy and increased blood pressure, as randomising HIV-infected 
patients to a control group where they are administered placebos would pose considerable 
ethical constraints. In addition, any attempt to ensure that the control group comprises 
only HIV-infected patients who are not eligible to commence antiretroviral treatment 
biases the randomisation process. According to the HIV/AIDS care and treatment 
guidelines in Nigeria, HIV-infected patients are only considered eligible to commence 
antiretroviral therapy when they are in the advanced clinical stages III and IV of HIV 
infection or CD4 cell counts are below 350 cells/mm3 (Federal Ministry of Health Nigeria, 
2010). Hence, the possibility that the treatment and control groups will comprise HIV- 
infected patients for whom antiretroviral therapy is indicated and contra-indicated 
respectively, would be impossible to achieve by randomisation. Moreover, in the highly 
unlikely event that the randomisation process results in this ‘desired’ treatment allocation, 
substantial differences in baseline characteristics are bound to exist between both groups 
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of patients, and the potential for confounding, as well as selection bias, is bound to be 
high. These hypothetical scenarios are inevitable, potentially underscoring the need for 
propensity score methods in the present observational study. 
 
 
Besides propensity score matching, other propensity score methods include: stratification 
on the propensity score, which would entail stratifying the study participants according 
to quantiles of the estimated propensity scores; and covariate adjustment using the 
propensity score, which would entail regressing each of the outcome variables (systolic 
and diastolic blood pressure) on HAART status and a third variable denoting the 
propensity score (Austin, 2011a; Austin & Mamdani, 2006; Rosenbaum, 1987; 
Rosenbaum and Rubin, 1983). Among these propensity score methods, propensity score 
matching was the preferred option used in the present study because it eliminates a greater 
amount of the baseline differences between treatment-exposed and treatment-naïve 
subjects (Austin, 2009; Austin, Groontendorst & Anderson, 2007; Austin & Mamdani, 
2006). 
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Table 16.1: Similarities between the analyses of a propensity score-matched sample 
and a randomised controlled trial 
 
 
Analysis of propensity score-matched 
sample 
Analysis of randomised controlled trial 
Conditional on the propensity score, the 
propensity score-matching process ensures a 
balanced distribution of the baseline 
characteristics between treated (or exposed) 
and untreated (unexposed) patients. 
The randomisation process ensures a 
balanced distribution of the baseline 
characteristics between treated and 
untreated subjects. 
The similarity in baseline characteristics 
between treated and untreated patients 
allows for estimation of the average 
treatment effect on the treated (ATT). 
The absence of any baseline differences 
between treatment groups also allows for 
estimation of the average treatment effect 
(ATE) 
Residual differences may exist between 
treated and untreated patients even after 
propensity score matching. 
Residual differences may also exist between 
treatment groups even after randomisation. 
Bias due to residual baseline differences 
between treated and untreated patients can 
be reduced by using other propensity score 
matching specifications or by combining 
propensity score matching with regression 
adjustment. 
Regression adjustment can also be used to 
reduce bias due to residual differences in the 
baseline characteristics between treatment 
groups. 
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16.10.5.1 The average treatment effect on the treated (ATT) 
 
In randomised controlled trials, the estimated effect of the intervention on the outcome is 
the average treatment effect (ATE). Hence, the ATE measures the difference in the 
outcome measure between subjects assigned to the treatment and subjects assigned to 
the control. Austin (2011a; p. 401) defined the ATE as “the average effect, at population 
level, of moving an entire population from untreated to treated” 
 
 
Closely related to the ATE is the average treatment effect on the treated (ATT or ATET), 
which is the average effect of the treatment (or exposure) on those subjects who were 
actually treated (or exposed) (Austin, 2011a; Imbens, 2004). It may appear that the 
difference between the ATE and ATT lies with the respective target populations: a 
randomly selected sample of untreated patients at baseline ― as is often the case with 
randomised controlled trials ― versus a population sample including patients already 
treated at baseline ― as is the case with observational studies. However, both measures 
of treatment effects are valid only when the treatment is randomly assigned conditional 
on a balanced distribution of baseline characteristics. Both treatment effect measures also 
entail a statistical approach to defining causality based on the Rubin causal model, which 
holds that the causal effect of being exposed to a treatment, as opposed to being 
unexposed to the same treatment at any given time, is the difference between the outcome 
measures with and without treatment (Jasjeet, 2007; Rubin, 1974). 
 
 
For instance, with the treatment status being a dichotomous variable: 
 
 
 
ATE = E [Y1  – Y0], 
 
Where Y1 is the outcome with treatment, Y0 is the outcome without treatment; 
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ATT = E [Y1 – Y0 | W = 1], 
 
Where Y1 is the outcome with treatment, Y0 is the outcome without treatment, and W is 
the dichotomous treatment indicator where (W = 1) denotes ‘treatment’ and (W = 0) 
denotes ‘no treatment’ (Rubin, 1974). 
 
 
It is worth emphasizing that while the ATE and ATT are often measured as the estimated 
treatment effects in experimental and observational studies respectively, this ‘rule’ 
remains flexible, as the ATE may be of greater utility and interest in estimating the 
average effect of a treatment or exposure in an observational study and vice versa (Austin, 
2011a). However, regardless of the context of the research, propensity score matching is 
reserved for estimating the ATT (Austin, 2011a; Imbens, 2004). 
 
 
16.10.6 Sample size calculations 
 
16.10.6.1 Sample size estimation for mediation analysis 
 
Recall that mediation analysis was performed using the SEM approach. Although there is 
little consensus on the recommended sample size for SEM (Sivo et al., 2006), a ‘critical 
sample size’ of 200 was proposed by Garver & Mentzer (1999) and Hoelter (1983). 
Hence, as a rule of thumb, any sample size above 200 is generally understood to provide 
sufficient statistical power for SEM analysis. 
 
 
However, Fritz and MacKinnon (2007) argue that the mediation model is essentially a 
linear model, so that sample size calculation to evaluate mediation analysis for such a 
model be given by the following equation: 
! = #$% + ' + 1 
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Where n denotes the sample size. 
 #	= 7.85, which  is  the  linear  statistic  corresponding  to  ordinary  least  squares 
(OLS) regression for one predictor with a type I error of 0.05 and power of 0.8. 
'	= 1, which is the number of predictors in each OLS regression model. 
 $	is the coefficient of the regression equation corresponding to the indirect effect of the 
predictor variable on the outcome variable, through the mediator. 
Drawing on Cohen’s criteria for small effect sizes, it was assumed that the β coefficients 
for the association between the exposure (HAART) and any of the potential mediators, 
and the association between any of the potential mediators and the outcome (blood 
pressure) were 0.14 each (Cohen et al., 2003). Hence, the indirect effect ($) would 
entail the product of both β coefficients (i.e. 0.0196). 
Substituting these default values in the equation above yielded a sample size (n) of 403. 
 
 
 
 
16.10.6.2 Sample size estimation for propensity score matching 
 
Given that more than a few baseline characteristics of HAART-exposed and HAART- 
naïve participants were to be matched on the propensity score, a substantial proportion of 
patients ― who were not matched on the propensity score ― were likely to be dropped 
from the analysis (Schneeweiss, 2010). Consequently, the sample size calculation 
accounted for a hypothetical proportion of patients who were dropped out from the 
propensity score analysis (Velentgas et al., 2013). Recall that HIV-negative individuals 
were not assigned propensity scores, so that the sample size was given by: 2	(Zα/2		+	Zβ)2	!	= . δ2	
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As described in the statistical analysis section, two-sided tests at 5% significance were 
performed, and for such tests, Zα/2	= 1.96. A sample size that achieved 90% power, which 
corresponds to Zβ	= 1.28, was desired. The study was powered to detect a standardised 
mean difference (δ)	of 0.3mmHg in systolic blood pressure between HAART-exposed 
and HAART-naïve participants based the meta-analysis of the association between 
antiretroviral therapy and systolic blood pressure (Nduka et al., 2015b). Hence, 
accounting for 25% drop out of patients who were not matched on the propensity score 
(Velentgas et al., 2013), the estimated sample size of the propensity score matched sample 
was 293. 
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CHAPTER SEVENTEEN 
 
RESULTS – SAMPLE DESCRIPTION 
 
In this chapter, I describe the characteristics of participants included in the primary study. 
 
 
 
 
17.1 SAMPLE DESCRIPTION 
 
A total of 512 participants ― 306 HAART-exposed HIV-infected patients, 100 HAART- 
naïve HIV-infected patients, and 106 HIV-negative individuals ― were enrolled into the 
study. Overall, the mean (± SD) age of the study population was 37.6 ± 11.2 years, with 
participants’ age ranging from 18 to 88 years old. A majority (66%) of the participants 
were aged between 18 and 40 years. Women accounted for 64% of the study population. 
About 72% of the participants were either members of the working class or unemployed; 
45% had progressed beyond a formal secondary education. Approximately 11% had ever 
smoked cigarettes and 28% were current alcohol consumers. Among the 142 participants 
who were current alcohol users, 21% were heavy drinkers, consuming more than 21 units 
of alcohol in a typical week. Of note, men were more than twice as likely to be heavy 
drinkers, compared to women. 
 
 
The clinical characteristics of the study population are summarised as follows: 
hypertension was diagnosed in 104 (20%) of 512 participants, including 17 individuals 
who were on antihypertensive treatment; 58% of all patients diagnosed with hypertension 
were HIV-infected; mean body mass index was 24.7 ± 4.6 kg/m2, with 41% of the 
participants identified as overweight or obese; mean waist circumference was 85.9 ± 11.6 
cm, with 43% of the study participants identified as centrally obese; mean random blood 
glucose concentration was 5.2 ± 2.0 mmol/L, including a total of six participants (1%) 
with random blood glucose levels above 11.1 mmol/L, and ten participants (2%) on 
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treatment for type 2 diabetes mellitus; severe depressive symptoms (CES-D score ≥ 16) 
were found in approximately 19% of participants; 36% reported poor quality of sleep 
(PSQI ≥ 5); and 12.5% had a positive family history of hypertension. Among HIV- 
infected patients, the mean duration of HIV infection was 45.0 ± 29.4 months; mean 
duration of HAART was 45.6 ± 27.9 months; mean CD4 count was 454 ± 251 cells/mm3, 
with CD4 counts above 350 cells/mm3 in 64% of patients, and above 200 cells/mm3 in 
86% of patients; opportunistic infections or AIDS-defining illnesses were absent. 
 
 
Table 17.1 summarises other socio-demographic and clinical data in HAART-exposed, 
HAART-naïve, and HIV-negative individuals. As shown, there were notable differences 
across the three participant groups in sex distribution, socio-economic status, lifestyle 
factors, relative weight, and random blood glucose concentration. For instance, HIV- 
infected participants in the HAART-naïve group were more likely to be women (78.0% 
versus 65.4% and 48.1%; P < 0.001 for trend), members of the working class or 
unemployed (91.9% versus 68.1% and 65.7%; P < 0.001 for trend), and less educated 
(81.0% versus 52.5% and 38.7%; P < 0.001 for trend), compared to participants in the 
HAART-exposed and HIV-negative groups respectively. Likewise, HIV-negative 
individuals were more likely than HAART-exposed and HAART-naïve HIV-infected 
patients to have larger body mass indices (mean ± SD = 26.7 ± 5.0 kg/m2  versus 24.5  ± 
4.4 kg/m2  and 23.4 ± 4.3 kg/m2; P < 0.001 for trend), larger waist circumferences (mean 
 
± SD = 87.4 ± 13.7 cm versus 86.3 ± 10.3 cm and 82.9 ± 12.2 cm; P = 0.002 for trend), 
higher blood glucose concentrations (mean ± SD = 5.9 ± 2.3 mmol/L versus 5.1 ± 2.1 
mmol/L and 4.8 ± 1.3 mmol/L; P < 0.001 for trend), higher prevalence estimates of 
hypertension (42.4% versus 16.3% and 9.0%; P < 0.001 for trend), less likely to be 
physically active (mean ± SD = 122.3 ± 136.6 minutes/week versus 150.3 ± 166.3 
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minutes/week and 222.5 ± 188.5 minutes/week; P < 0.001 for trend), more likely to be 
current drinkers (39.6% versus 24.5% and 25.0%; P = 0.009 for trend), and more likely 
to have been on antihypertensive treatment within the past two weeks (9.4% versus 1.6% 
and 2.0%; P < 0.001 for trend). Among these characteristics, differences observed by sex 
distribution (P = 0.018), occupational grade (P < 0.001), educational attainment (P = 
0.028) and level of physical activity (P = 0.001) were driven by comparisons between 
HAART-exposed and HAART-naïve HIV-infected patients. 
 
 
CD4 cell counts were significantly higher among HAART-naïve patients, compared to 
HAART-exposed patients (mean ± SD = 504 ± 227 cells/mm3 versus 440 ± 256 
cells/mm3; P = 0.006), so that it was not unexpected that the mean duration of HIV 
infection was longer in HAART-exposed patients, compared to HAART-naïve patients 
(mean ± SD = 50.2 ± 29.3 months versus 29.0 ± 22.8 months; P < 0.001). At the time of 
HIV infection diagnosis, systolic and diastolic blood pressure readings were not 
significantly different between patients now classified as naïve and exposed to HAART. 
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Table 17.1: Characteristics of the study sample 
 
 
Characteristics 
HAART-exposed 
(N = 306) 
HAART-naïve 
(N = 100) 
P value 
(exposed vs naïve) 
HIV-negative 
(N = 106) 
P value 
for trend 
 
Age (years), mean ± SD 
 
38.56 ± 9.99 
 
35.63 ± 12.48 
 
0.586 
 
36.67 ± 12.77 
 
0.449 
Age group (years), n (%)      
18–40 189 (62.6)         75 (76.5)  69 (65.1)  
41–64 108 (35.8) 20 (20.4)  36 (34.0)  
≥65 5 (1.6) 3 (3.1) 0.015 1 (0.9) 0.060 
Gender, n (%)      
Female 200 (65.4) 78 (78.0)  51 (48.1)  
Male 106 (34.6) 22 (22.0) 0.018 55 (51.9) 0.000 
Occupational grade, n (%)      
Middle class 97 (31.9) 8 (8.1)  36 (34.3)  
Working class/unemployed 207 (68.1) 91 (91.9) 0.000 69 (65.7) 0.000 
Educational status, n (%)      
≤ 12 years 160 (52.5) 81 (81.0)  41 (38.7)  
> 12 years 145 (47.5) 19 (19.0) 0.028 65 (61.3) 0.000 
Smoking status, n (%)      
Never smoker 266 (89.3) 88 (89.8)  94 (88.7)  
Ever smoker 32 (10.7) 10 (10.2) 0.295 12 (11.3) 0.967 
Drinking status, n (%)      
Abstainer 231 (75.5) 75 (75.0)  64 (60.4)  
Drinker 75 (24.5) 25 (25.0) 0.397 42 (39.6) 0.009 
Physical activity (mins/wk), mean ± SD 150.3 ± 166.3 222.5 ± 188.5 0.001 122.3 ± 136.6 0.000 
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Characteristics 
HAART-exposed 
(N = 306) 
HAART-naïve 
(N = 100) 
P value 
(exposed vs naïve) 
HIV-negative 
(N = 106) 
P value 
for trend 
 
Physical activity (minutes/week), n (%) 
     
< 150 187 (61.5) 46 (46.0)  74 (69.8)  
≥ 150 117 (38.5) 54 (54.0) 0.007 32 (30.2) 0.002 
Body mass index (kg/m2), mean ± SD 24.5 ± 4.4 23.4 ± 4.3 0.931 26.7 ± 5.0 0.000 
Body mass index (kg/m2), n (%)      
< 25 175 (59.7) 70 (71.4)  45 (43.7)  
≥ 25 118 (40.3) 28 (28.6) 0.038 58 (56.3) 0.000 
Waist circumference (cm), mean ± SD 86.3 ± 10.3 82.9 ± 12.2 0.213 87.4 ± 13.7 0.002 
Central obesity, n (%)      
No 166 (54.2) 58 (58.0)  69 (65.1)  
Yes 140 (45.8) 42 (42.0) 0.513 37 (34.9) 0.149 
RBG (mmol/L), mean ± SD 5.1 ± 2.1 4.8 ± 1.3 0.320 5.9 ± 2.3 0.000 
Hyperglycaemia, n (%)      
No 284 (96.6) 92 (95.8)  95 (92.2)  
Yes 10 (3.4) 4 (4.2) 0.726 8 (7.8) 0.180 
Hypertension, n (%)      
No 256 (83.7) 90 (90.0)  61 (57.6)  
Yes 50 (16.3) 10 (10.0) 0.071 45 (42.4) 0.000 
Antihypertensive treatment, n (%)      
No 282 (92.2) 96 (96.0)  73 (68.9)  
Yes 24 (7.8) 4 (4.0) 0.256 33 (31.1) 0.000 
PSQI, mean ± SD 4.1 ± 2.9 4.2 ± 3.2 0.958 3.8 ± 2.8 0.400 
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Characteristics 
HAART-exposed 
(N = 306) 
HAART-naïve 
(N = 100) 
P value 
(exposed vs naïve) 
HIV-negative 
(N = 106) 
P value 
for trend 
 
PSQI, n (%) 
     
< 5 191 (63.7) 65 (65.7)  67 (63.2)  
≥ 5 109 (36.3) 34 (34.3) 0.720 39 (36.8) 0.719 
CES–D, mean ± SD 9.9 ± 7.4 10.1 ± 7.9 0.423 8.0 ± 6.9 0.054 
CES–D, n (%)      
< 16 249 (81.4) 78 (78.0)  89 (84.0)  
≥ 16 57 (18.6) 22 (22.0) 0.460 17 (16.0) 0.275 
HRQL score (physical), mean ± SD 50.5 ± 8.0 49.0 ± 8.5 0.171 47.5 ± 10.2 0.377 
HRQL score (mental), mean ± SD 51.9 ± 9.3 51.8 ± 9.5 0.861 51.8 ± 8.7 0.673 
Family history of hypertension, n (%)      
No 268 (88.5) 89 (89.9)  76 (81.7)  
Yes 35 (11.5) 10 (10.1) 0.457 17 (18.3) 0.165 
CD4 cell count (cells/mm3), mean ± SD 440 ± 256 504 ± 227 0.003 – – 
HIV duration (months), mean ± SD 50.2 ± 29.3 29.0 ± 22.8 0.000 – – 
HAART duration (months), mean ± SD 45.5 ± 28.2 – – – – 
Baseline SBP (mmHg), mean ± SD 111.8 ± 15.6 112.7 ± 18.5 0.376 – – 
Baseline DBP (mmHg), mean ± SD 73.6 ± 11.6 74.1 ± 12.3 0.800 – – 
CESD, Centre for Epidemiologic Studies Depression Scale questionnaire; DBP, diastolic blood pressure; HAART, highly active antiretroviral therapy; HRQL, health-related quality of 
life; PSQI, Pittsburgh Sleep Quality Index; SBP, systolic blood pressure; SD, standard deviation. 
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CHAPTER EIGHTEEN 
 
RESULTS – UNADJUSTED ANALYSES 
 
 
In this chapter, I identify factors potentially related to blood pressure in HIV-infected and 
non-infected persons, having fitted simple linear models. 
 
 
 
 
18.1 RESULTS OF UNADJUSTED ANALYSES – FACTORS RELATED TO 
BLOOD PRESSURE CHANGES IN HIV-INFECTED PARTICIPANTS. 
The results from fitting the simple linear models are presented in Table 18.1. Mean 
systolic (P < 0.001) and diastolic blood pressure (P < 0.001) were significantly higher in 
HAART-exposed patients, compared to HAART-naïve patients. Besides HAART status, 
other variables with statistically significant differences in mean systolic and diastolic 
blood pressure between subgroups included: age, sex, educational attainment, 
occupational grade, drinking status, body mass index (overweight/obesity), family history 
of hypertension, and a recent history of antihypertensive treatment. Mean systolic blood 
pressure was highest among HIV-infected patients who were 65 years and above, 
compared to HIV-infected patients aged 41 to 64 years, and 18 to 40 years) (P < 0.001), 
whereas mean diastolic blood pressure was highest among HIV-infected patients aged 41 
to 64 years, compared to those aged 18 to 40 years, and those aged 65 years and above (P 
< 0.001). Mean systolic (P = 0.005) and diastolic blood pressure (P = 0.001) were higher 
among men than women. Mean systolic (P = 0.027) and diastolic blood pressure (P = 
0.002) were higher among HIV-infected patients who had completed more than 12 years 
of formal education, compared to patients who had completed fewer years of formal 
education. HIV-infected patients who belonged to the middle class had significantly 
higher mean systolic (P = 0.038) and diastolic blood pressure (P = 0.001), compared   to 
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HIV-infected patients who were either unemployed or members of the working class. 
Mean systolic (P = 0.015) and diastolic blood pressure (P = 0.014) were significantly 
higher among HIV-infected patients who were current drinkers, compared to patients who 
abstained from alcohol. Mean systolic (P < 0.001) and diastolic blood pressure (P < 
0.001) were significantly higher among HIV-infected patients who were overweight or 
obese, compared to patients who were normal weight. HIV-infected patients with a 
positive family history of hypertension had higher mean systolic (P < 0.001) and diastolic 
blood pressure (P = 0.001), compared to those with no family history of hypertension. 
HIV-infected patients on antihypertensive treatment had significantly higher mean 
systolic (P < 0.001) and diastolic blood pressure (P < 0.001), compared to HIV-infected 
patients not on antihypertensive treatment. 
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Age group 
18 to 40 years 
41 to 64 years 
≥ 65 years 
116.33 ± 14.76 
125.26 ± 24.41 
128.94 ± 23.06 0.000 
75.08 ± 8.68 
80.87 ± 11.78 
78.13 ± 6.91 0.000 
Central obesity 
No 
Yes 
118.24 ± 19.47 
120.97 ± 18.19 0.152 
76.15 ± 10.35 
78.00 ± 9.61 0.067 
Table 18.1: Group means (± standard deviation) of systolic and diastolic blood 
pressure in HIV-infected patients. 
 
Systolic BP (mmHg) Diastolic BP (mmHg) 
Factors  
Mean ± SD 
 
P value 
 
Mean ± SD 
 
P value 
HAART status 
HAART-naïve 
HAART-exposed 
 
112.60 ± 14.33 
121.77 ± 19.69 0.000 
 
71.57 ± 8.60 
78.80 ± 9.88 0.000 
 
 
 
 
Gender 
 
 
Female 
 
 
117.70 ± 17.42 
 
 
75.88 ± 9.72 
Male 123.46 ± 21.39 0.005 79.50 ± 10.42 0.001 
Education 
≤ 12 years 117.79 ± 16.81  75.75 ± 8.98  
> 12 years 122.08 ± 21.48 0.027 78.91 ± 11.28 0.002 
Occupational grade     
Middle-income 122.77 ± 22.19  79.91 ± 10.86  
Working class/unemployed 118.22 ± 17.56 0.038 75.95 ± 9.61 0.001 
Smoking status 
Never smoker 119.17 ± 19.35 76.87 ± 10.37 
Ever smoker 121.82 ± 16.71 0.402 75.60 ± 8.30 0.667 
Drinking status     
Abstainer 118.14 ± 16.95  76.28 ± 9.50  
Drinker 123.48 ± 23.40 0.015 79.15 ± 11.37 0.014 
Physical activity     
< 150 minutes/week 119.56 ± 17.59  77.57 ± 9.42  
≥ 150 minutes/week 119.20 ± 20.61 0.849 76.11 ± 10.77 0.155 
Body mass index 
< 25 kg/m2 
≥ 25 kg/m2 
 
116.21 ± 16.59 
124.89 ± 21.42 0.000 
 
75.20 ± 9.49 
79.92 ± 10.43 0.000 
 
 
 
Hyperglycaemia 
No 
Yes 
 
 
119.13 ± 18.63 
118.79 ± 13.53 0.945 
 
 
76.86 ± 9.83 
76.21 ± 10.28 0.811 
Antihypertensive treatment 
No 
Yes 
118.93 ± 18.18 
150.64 ± 31.83 
 
0.000 
76.75 ± 9.85 
91.21 ± 12.83 
 
0.000 
PSQI 
< 5 
≥ 5 
 
118.48 ± 17.36 
121.26 ± 21.37 
 
 
0.166 
 
76.60 ± 9.71 
77.73 ± 10.76 
 
 
0.288 
CES–D 
< 16 
≥ 16 
 
119.88 ± 19.29 
117.90 ± 17.30 
 
 
0.413 
 
77.24 ± 9.98 
75.98 ± 10.35 
 
 
0.326 
Family history of hypertension 
No 
Yes 
 
118.27 ± 16.73 
129.64 ± 30.28 0.000 
 
76.44 ± 9.09 
81.78 ± 15.47 0.001 
 
CES-D, Centre for Epidemiologic Studies scale questionnaire; HAART, highly active antiretroviral therapy; PSQI, 
Pittsburgh Sleep Quality Index 
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Table 18.2 shows significant direct associations of age, systolic and diastolic blood 
pressure at the time of HIV infection diagnosis, HRQL (physical), body mass index, and 
waist circumference with systolic (P < 0.05 for each) and diastolic blood pressure (P < 
0.05 for each) in HIV-infected patients. 
 
 
 
Table 18.2: Simple linear regression coefficients with 95% confidence intervals for 
factors related to systolic and diastolic blood pressure in HIV-infected patients. 
 
Systolic blood pressure Diastolic blood pressure 
Factors Β 95% CI β 95% CI 
Age 0.37 0.19 to 0.54 0.21 0.12 to 0.30 
Physical activity -0.004 -0.02 to 0.006 -0.005 -0.01 to 0.0002 
Body mass index 1.20 0.79 to 1.62 0.70 0.48 to 0.92 
Waist circumference 0.44 0.27 to 0.61 0.29 0.20 to 0.38 
Blood glucose 0.05 -0.006 to 0.10 0.02 -0.01 to 0.05 
PSQI 0.36 -0.27 to 0.99 0.08 -0.26 to 0.42 
CESD -0.12 -0.37 to 0.13 -0.06 -0.19 to 0.08 
HRQL (physical) 0.24 0.01 to 0.47 0.12 -0.003 to 0.24 
HRQL (mental) -0.04 -0.25 to 0.16 0.03 -0.08 to 0.14 
CD4 cell count -0.006 -0.01 to 0.002 -0.001 -0.005 to 0.003 
HIV duration -0.03 -0.09 to 0.04 0.02 -0.01 to 0.06 
HAART duration -0.08 -0.16 to 0.002 -0.02 -0.06 to 0.03 
Baseline SBP 0.37 0.26 to 0.49 0.17 0.11 to 0.23 
Baseline DBP 0.43 0.27 to 0.58 0.20 0.11 to 0.28 
β, linear regression coefficient; CESD, Centre for Epidemiologic Studies scale questionnaire; CI, confidence interval; 
DBP, diastolic blood pressure; HAART, highly active antiretroviral therapy; HRQL, health-related quality of life; 
PSQI, Pittsburgh Sleep Quality Index; SBP, systolic blood pressure. 
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18.2 RESULTS OF UNADJUSTED ANALYSES – FACTORS RELATED TO 
BLOOD PRESSURE CHANGES IN HIV-NEGATIVE INDIVIDUALS. 
Tables 18.3 and 18.4 presents the group means (± standard deviation) of systolic and 
diastolic blood pressure, including the statistical significance of the mean differences, 
among HIV-negative individuals. Unlike the reported findings among HIV-infected 
participants, the only variable related to systolic and diastolic blood pressure changes in 
HIV-negative persons was occupational grade: the mean systolic (P = 0.021) and diastolic 
blood pressure (P = 0.040) were statistically significantly higher among middle-income 
HIV-negative individuals, compared to their counterparts in the working class. Among 
other variables, age groups and hyperglycaemia were associated with systolic blood 
pressure changes only: the mean values of systolic blood pressure were significantly 
higher among HIV-negative individuals aged between 41 and 64 years (P < 0.001), and 
assessed to have hyperglycaemia (P = 0.027), compared respectively to their counterparts 
who were younger, and with blood glucose concentrations within the normal range. 
Factors associated with changes in diastolic blood pressure alone were alcohol use and 
sleep quality: HIV-negative individuals who were current drinkers (P = 0.040) or assessed 
to have poor sleep quality (P = 0.045) had higher mean values of diastolic blood pressure, 
compared respectively to HIV-negative individuals who abstained from alcohol or 
without sleep problems. 
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Table 18.3: Group means (± standard deviation) of systolic and diastolic blood 
pressure in HIV-negative individuals. 
 
Systolic BP (mmHg) Diastolic BP (mmHg) 
Factors Mean ± SD P value Mean ± SD P value 
Age group 
18 to 40 years 
41 to 64 years 
 
123.20 ± 13.71 
136.25 ± 20.73 
 
 
0.000 
 
77.51 ± 18.57 
81.61 ± 13.25 
 
 
0.091 
Gender 
Female 
Male 
 
124.37 ± 15.73 
131.01 ± 18.75 
 
 
0.058 
 
76.97 ± 10.90 
80.78 ± 12.19 
 
 
0.102 
Education 
≤ 12 years 
> 12 years 
 
129.56 ± 16.79 
126.77 ± 18.16 
 
 
0.441 
 
78.74 ± 12.91 
79.11 ± 10.97 
 
 
0.878 
Occupational grade 
Middle-income 
Working class/unemployed 
 
133.44 ± 17.45 
124.92 ± 17.22 
 
 
0.021 
 
82.27 ± 10.26 
77.32 ± 12.17 
 
 
0.040 
Smoking status 
Never smoker 
Ever smoker 
 
126.81 ± 17.08 
136.41 ± 20.35 
 
 
0.090 
 
78.41 ± 11.87 
83.55 ± 9.40 
 
 
0.171 
Drinking status 
Abstainer 
Drinker 
 
126.79 ± 17.71 
129.48 ± 17.56 
 
 
0.456 
 
77.05 ± 10.95 
81.91 ± 12.31 
 
 
0.040 
Physical activity 
< 150 minutes/week 
≥ 150 minutes/week 
 
127.74 ± 15.72 
128.14 ± 21.94 
 
 
0.918 
 
78.29 ± 10.65 
80.67 ± 14.03 
 
 
0.356 
Body mass index 
< 25 kg/m2 
≥ 25 kg/m2 
 
124.83 ± 17.51 
130.10 ± 17.50 
 
 
0.138 
 
77.05 ± 11.82 
80.40 ± 11.50 
 
 
0.156 
Central obesity 
No 
Yes 
 
127.71 ± 19.10 
128.11 ± 14.81 
 
 
0.913 
 
79.45 ± 12.02 
78.10 ± 11.21 
 
 
0.579 
Hyperglycaemia 
No 
Yes 
 
127.13 ± 17.36 
141.44 ± 16.62 
 
 
0.027 
 
78.59 ± 11.83 
86.44 ± 4.55 
 
 
0.067 
Antihypertensive treatment 
No 
Yes 
 
127.20 ± 17.57 
133.75 ± 17.77 
 
 
0.267 
 
79.10 ± 11.94 
77.80 ± 9.68 
 
 
0.741 
PSQI 
< 5 
≥ 5 
 
126.68 ± 18.92 
129.72 ± 15.36 
 
 
0.401 
 
77.12 ± 12.44 
81.91 ± 9.85 
 
 
0.045 
CESD 
< 16 
≥ 16 
 
128.77 ± 18.57 
123.29 ± 11.07 
 
 
0.244 
 
79.79 ± 11.92 
74.94 ± 9.88 
 
 
0.120 
Family history of hypertension 
No 
Yes 
 
127.39 ± 18.08 
129.21 ± 14.31 
 
 
0.699 
 
79.59 ± 11.52 
77.56 ± 12.89 
 
 
0.524 
CESD, Centre for Epidemiologic Studies scale questionnaire; PSQI, Pittsburgh Sleep Quality Index 
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Table 18.4 shows that age, body mass index, and waist circumference were linearly 
associated with systolic and diastolic blood pressure respectively among the HIV- 
negative controls. As expected, there was a significant inverse association between 
health-related quality of life (physical component) and systolic blood pressure [β = - 0.08, 
95% CI = - 0.68 to - 0.01)]. 
 
 
Table 18.4: Simple linear regression coefficients with 95% confidence intervals for 
factors related to systolic and diastolic blood pressure in HIV-infected patients. 
 
Systolic blood pressure Diastolic blood pressure 
Factors Β 95% CI β 95% CI 
Age 0.53 0.28 to 0.78 0.20 0.03 to 0.38 
Physical activity -0.008 -0.03 to 0.02 0.003 -0.014 to 0.02 
Body mass index 0.94 0.25 to 1.62 0.47 0.01 to 0.93 
Waist circumference 0.38 0.13 to 0.62 0.19 0.02 to 0.36 
Blood glucose 0.06 -0.03 to 0.14 0.04 -0.02 to 0.96 
PSQI 0.72 -0.51 to 1.96 0.59 -0.23 to 1.41 
CESD 0.01 -0.49 to 0.51 -0.13 -0.46 to 0.20 
HRQL (physical) -0.35 -0.68 to -0.01 -0.03 -0.26 to 0.20 
HRQL (mental) -0.08 -0.47 to 0.32 -0.008 -0.27 to 0.26 
β, linear regression coefficient; CI, confidence interval; CESD, Centre for Epidemiologic Studies scale 
questionnaire; PSQI Pittsburgh Sleep Quality Index. 
214  
CHAPTER NINETEEN 
 
RESULTS – ANTIRETROVIRAL TREATMENT STATUS AND 
HYPERTENSION PREDICTION IN HIV-INFECTED PATIENTS. 
 
In this chapter, I identify the best parsimonious model for predicting hypertension in HIV- 
infected patients. I also determine whether HAART status improves the predictive value 
of the model. 
 
 
 
19.1 THE IMPACT OF HAART STATUS ON THE PREDICTION OF 
HYPERTENSION IN HIV-INFECTED PATIENTS 
In order to determine whether antiretroviral treatment status improved the clinical 
prediction of hypertension in HIV-infected patients, simple logistic regression models 
were first fitted to identify predictors of hypertension that formed the most parsimonious 
predictive model. Table 19.1 summarizes the data stratified by hypertension status, the 
unadjusted odds ratios for hypertension and the corresponding R2. HAART status, age, 
body mass index, sleep quality (PSQI), drinking status, and family history of hypertension 
were significantly associated with an increased risk of hypertension (P < 0.05 for each); 
whereas CD4 cell count, HAART duration, and HIV infection duration had no statistically 
significant impact on hypertension risk. 
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Table 19.1: Unadjusted odds ratios for hypertension and corresponding fit statistics 
among HIV-infected patients 
 
 
Hypertension 
 
Characteristics 
Yes 
(N=60) 
No 
(N=340) 
 
OR (95% CI) 
Nagelkerke’s 
R2 
HAART status 
HAART-naïve* 
HAART-exposed 
 
9 (15.3) 
50 (84.7) 
 
89 (26.3) 
249 (73.7) 
 
 
 
1.99 (0.99 to 4.20) 
 
 
 
0.016 
Age (years), mean±SD 43.5±10.4 36.9±10.5 1.05 (1.03 to 1.08) 0.077 
Gender, n (%) 
Female* 
Male 
 
35 (58.3) 
25 (41.7) 
 
241 (71.1) 
98 (28.9) 
 
 
 
1.76 (1.09 to 2.82) 
 
 
 
0.016 
Smoking status, n (%) 
Never smoker* 
Ever smoker 
 
50 (84.8) 
9 (15.2) 
 
298 (90.3) 
32 (9.7) 
 
 
 
1.68 (0.86 to 3.28) 
 
 
 
0.007 
Drinking status, n (%) 
Abstainer* 
Current drinker 
 
39 (65.0) 
21 (35.0) 
 
260 (76.7) 
79 (23.3) 
 
 
 
1.77 (1.08 to 2.90) 
 
 
 
0.015 
  Physical activity (mins/wk), mean±SD  148.8±152.9  171.4±178.0  0.99 (0.97 to 1.01)  0.004  
BMI (kg/m2), mean±SD 26.8±5.4 23.8±4.0 1.15 (1.08 to 1.22) 0.091 
Family history of hypertension, n (%) 
No* 
Yes 
 
40 (66.7) 
20 (33.3) 
 
310 (92.5) 
25 (7.5) 
 
 
 
6.20 (3.52 to 
10.92) 
 
 
 
0.111 
PSQI, mean±SD 5.0±3.2 4.0±2.9 1.10 (1.01 to 1.20) 0.021 
CESD, mean±SD 
HRQL (mental score), mean±SD 
9.7±8.2 
51.3±9.0 
10.0±7.4 
52.0±9.4 
1.00 (0.96 to 1.03) 
0.99 (0.97 to 1.02) 
0 
0.001 
HRQL (physical score), mean±SD 49.7±9.1 50.3±7.9 0.99 (0.97 to 1.02) 0.001 
CD4 count (cells/mm3), mean±SD 406.3±256.3 462.6±248.9 0.99 (0.98 to 1.00) 0.012 
HIV duration (months), mean±SD 41.2±31.3 45.5±28.9 1.00 (0.99 to 1.01) 0.005 
N, number of observations; CI, confidence intervals; OR, odds ratio for hypertension; R2, Nagelkerke’s fit 
statistic (explained variability); BMI, body mass index; PSQI, Pittsburgh Sleep Quality Index; HRQL, 
health-related quality of life; SD, standard deviation; CESD, Centre for Epidemiology Studies Depression 
scale; HAART, highly active antiretroviral therapy. 
*: reference category in the logistic regression model. 
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Table 19.2 shows the development of the predictive model and the improvement in degree 
of fit following the addition of HAART status. Without HAART status, the best predictive 
model for hypertension in HIV-infected patients comprised the following variables in the 
order in which they were added: family history of hypertension, body mass index, age, 
and sleep quality (Nagelkerke’s R2 = 0.265) The area under the ROC curve was 0.77, 
indicating that the predictive model fit moderately well and had good discriminatory 
ability, in the sense that the model would be able to correctly classify HIV-infected 
patients by hypertension status 77% of the time. Subsequent addition of HAART status 
improved the model fit (R2 = 0.274) albeit with only a slight increase in the area under 
the ROC curve (0.78) (Figure 19.1). 
 
 
Table 19.2: Developing the best parsimonious model for predicting hypertension 
using Nagelkerke’s R2 
 
Predictive model N Nagelkerke’s R2 
Family history of hypertension 
 
+ BMI 
395 
 
389 
0.111 
 
0.183 
+ Age 380 0.244 
+ PSQI 
 
+ HAART status 
374 
 
374 
0.265 
 
0.274 
R2, explained variability (Nagelkerke’s fit statistic); N, number of observations; BMI, body mass index; 
PSQI, Pittsburgh Sleep Quality Index; HAART, highly active antiretroviral therapy. 
Model fit (R2) was improved following addition of HAART status. 
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Figure 19.1: Receiver Operating Characteristics (ROC) curve for logistic prediction of 
hypertension 
                                 
The model is adjusted for age, body mass index, sleep quality, family history of hypertension, and HAART status 
 
 
 
Figures 19.2 to 19.5 show the predictive margins of HAART status at different fixed 
values of age, body mass index, sleep quality, and family history of hypertension 
respectively. As illustrated, the predicted probability of hypertension increased with 
increasing values of each covariate, and was progressively higher for HAART-exposed 
patients compared to HAART-naïve patients for every additional unit increase in the 
value of each covariate. 
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Figure 19.2: Predicted probability of hypertension by age and HAART status 
                         
HAART, highly active antiretroviral therapy 
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Figure 19.3: Predicted probability of hypertension by body mass index and HAART status 
 
   HAART, highly active antiretroviral therapy 
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Figure 19.4: Predicted probability of hypertension by family history and HAART status 
 
HAART, highly active antiretroviral therapy 
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Figure 19.5: Predicted probability of hypertension by sleep quality and HAART status 
 
HAART, highly active antiretroviral therapy 
 
 
 
 
Taking into account all variables in the predictive model, the predicted probability of 
hypertension was 46.9% for an average HAART-naïve patient and 48.5% for a 
HAART-exposed patient. 
 
 
Figure 19.6 illustrates a practical application the model using predictive margins. As 
shown, the predicted probability of hypertension in a hypothetical 50 year old HAART- 
naïve HIV-infected patient who is overweight (BMI = 26kg/m2), assessed to have poor 
sleep quality (PSQI = 10), and a positive family history of hypertension is estimated to be 
0.58 (95% CI 0.30 to 0.86). Conversely, if the same patient were to be HAART-exposed, 
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the predicted probability of hypertension would be increased by 
approximately 26%: (0.73, 95% CI 0.54 to 0.91). 
 
 
Figure 19.6: Covariate-adjusted probability of hypertension by HAART status 
 
Results of a practical application of the predictive model showing the predicted probability of hypertension in a 
hypothetical 50-year-old HAART-naïve HIV-infected patient who is overweight (BMI = 26kg/m2), assessed to 
have poor sleep quality (PSQI = 10) and a positive family history of hypertension, as well as a hypothetical 
HAART-exposed patient with similar characteristics. HAART, highly active antiretroviral therapy. 
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CHAPTER TWENTY 
 
RESULTS – CAUSAL MEDIATION ANALYSIS 
 
 
In this chapter, I identify alternative mediating mechanisms of the association between 
antiretroviral therapy and increased blood pressure. 
 
 
 
20.1 RESULTS OF CAUSAL MEDIATION ANALYSES 
 
As previously discussed, the mediation effect is essentially the co-efficient of the indirect 
effect, which was computed using SEM in Stata. Table 20.1 summarises the indirect 
effects of HAART on systolic and diastolic blood pressure that were mediated by body 
mass index, waist circumference, blood glucose, and quality of sleep, as well as the 
amounts of the total effects of HAART on systolic and diastolic blood pressure that 
were mediated through each proposed mediator. 
 Table 20.1: Total, direct and indirect effects of antiretroviral therapy on systolic and diastolic blood pressure 
 
Causal 
variable 
Mediator 
Variable 
Dependent 
variable 
Path A 
 
Coef. (95% CI) 
Path B 
 
Coef. (95% CI) 
Total effect 
Coef. (95% CI) 
Direct effect 
Coef. (95% CI) 
Indirect effect 
Coef. (95% CI) 
% 
 
mediated 
 
 
HAART 
Body mass index Systolic BP 
Diastolic BP 
1.16 (0.16 to 2.16) 
 
1.16 (0.16 to 2.16) 
1.11 (0.70 to 1.52) 
 
0.62 (0.42 to 0.83) 
9.57 (5.32 to 13.82) 
 
7.49 (5.30 to 9.69) 
8.28 (4.15 to 12.41) 
 
6.77 (4.65 to 8.88) 
1.29 (0.08 to 2.49) 
 
0.73 (0.06 to 1.40) 
14 
 
10 
 
 
HAART 
Waist 
circumference 
Systolic BP 
Diastolic BP 
3.42 (0.92 to 5.92) 
 
3.42 (0.92 to 5.92) 
0.39 (0.23 to 0.56) 
 
0.26 (0.17 to 0.34) 
9.34 (5.01 to 13.32) 
 
7.59 (5.35 to 9.67) 
7.96 (3.86 to 12.06) 
 
6.71 (4.60 to 8.81) 
1.38 (0.24 to 2.52) 
 
0.88 (0.19 to 1.58) 
15 
 
12 
 
 
HAART 
Blood glucose 
level 
Systolic BP 
Diastolic BP 
4.94 (-3.06 to 12.94) 
 
4.94 (-3.06 to 12.94) 
0.04 (-0.01 to 0.09) 
 
0.01 (-0.02 to 0.04) 
8.95 (4.78 to 13.11) 
 
7.15 (4.99 to 9.29) 
8.74 (4.58 to 12.91) 
 
7.09 (4.93 to 9.24) 
0.21 (-0.21 to 0.62) 
 
0.06 (-0.11 to 0.22) 
2 
 
1 
 
 
HAART 
Sleep quality 
(PSQI) 
Systolic BP 
Diastolic 
-0.02 (-0.71 to 0.67) 
 
-0.02 (-0.71 to 0.67) 
0.36 (-0.25 to 0.97) 
 
0.08 (-0.23 to 0.40) 
8.84 (4.63 to 13.04) 
 
7.19 (5.00 to 9.37) 
8.84 (4.63 to 13.04) 
 
7.19 (5.00 to 9.37) 
0.002 (-0.23 to 0.24) 
 
0.0005 (-0.05 to 0.06) 
0 
 
0 
Abbreviations: CI, confidence interval; HAART, highly active antiretroviral therapy. 
Path A – regression coefficient for the causal variable when the mediator variable is regressed on the causal variable. 
Path B – regression coefficient for the mediator variable when the dependent variable is regressed on the mediator variable, adjusted for the causal variable. 
Direct effect – the effect of the causal variable on the dependent variable adjusted for the mediator variable. 
Total effect – the effect of the causal variable on the dependent variable without adjusting for the mediator variable. 
Indirect effect – the indirect effect of the causal variable on the dependent variable through the mediator variable. 
% mediated – the amount (in percentage) of the total effect is attributed to the mediator variable. 
95% confidence intervals for indirect effects are bias-corrected. 
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20.2 THE EFFECT OF HAART ON BLOOD PRESSURE MEDIATED BY BODY 
MASS INDEX 
The indirect effect of HAART on systolic blood pressure that was mediated by body mass 
index was statistically significant (coefficient = 1.29, 95% CI 0.08 to 2.49), and accounted 
for 14% of the total effect of HAART exposure on systolic blood pressure. The mediation 
analysis also showed a statistically significant indirect effect of HAART on diastolic 
blood pressure through body mass index (coefficient = 0.73, 95% CI 0.06 to 1.40), 
accounting for 10% of the total effect of HAART on diastolic blood pressure (see path 
diagrams in Figures 20.1 and 20.2). 
 
 
Figure 20.1: Path diagram of a mediational model showing the indirect effect of 
antiretroviral therapy on systolic blood pressure through body mass index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI, body mass index; CI, confidence interval; HAART, highly active antiretroviral therapy; SBP, systolic blood 
pressure 
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Figure 20.2: Path diagram of a mediational model showing the indirect effect of 
antiretroviral therapy on diastolic blood pressure through body mass index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI, body mass index; CI, confidence interval; HAART, highly active antiretroviral therapy; DBP, diastolic blood 
pressure 
 
 
 
20.3 THE EFFECT OF HAART ON BLOOD PRESSURE MEDIATED BY WAIST 
CIRCUMFERENCE 
The indirect effect of HAART on systolic blood pressure that was mediated by waist 
circumference was statistically significant (coefficient = 1.38, 95% CI 0.24 to 2.52), 
mediating 15% of the total effect of HAART exposure on systolic blood pressure. 
Similarly, waist circumference was a statistically significant partial mediator of the effect 
of HAART exposure on diastolic blood pressure (coefficient = 0.88, 95% CI 0.19 to 1.58), 
accounting for 12% of the total effect of HAART on diastolic blood pressure (see path 
diagrams in Figures 20.3 and 20.4). 
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Figure 20.3: Path diagram of a mediational model showing the indirect effect of 
antiretroviral therapy on systolic blood pressure through waist circumference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI, confidence interval; HAART, highly active antiretroviral therapy; SBP, systolic blood pressure; WC, waist 
circumference. 
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Figure 20.4: Path diagram of a mediational model showing the indirect effect of 
antiretroviral therapy on diastolic blood pressure through waist circumference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI, confidence interval; HAART, highly active antiretroviral therapy; DBP, diastolic blood pressure; WC, waist circumference. 
DBP 
51 ? 1 
81 HAART 
.19 
.74 
WC 
83 
? 2 117 
6.6 
.25 3.5 
Indirect effect: 0.88, 95% CI 0.19 to 1.58 
% mediated: 12% 
229  
20.4 THE EFFECT OF HAART ON BLOOD PRESSURE MEDIATED BY 
BLOOD GLUCOSE LEVEL 
Blood glucose concentration was no significant mediator of the effect of HAART on 
systolic (coefficient = 0.21, 95% CI -0.21 to 0.62) or diastolic blood pressure 
(coefficient 
= 0.06, 95% CI -0.11 to 0.21), accounting only for 2% and 1% of the total effects of 
HAART on systolic and diastolic blood pressure respectively (see path diagrams in 
Figures 20.5 and 20.6). 
 
Figure 20.5: Path diagram of a mediation model showing the indirect effect of 
antiretroviral therapy on systolic blood pressure through blood glucose level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI, confidence interval; HAART, highly active antiretroviral therapy; SBP, systolic blood pressure; BG, blood glucose 
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Figure 20.6: Path diagram of a mediational model showing indirect effect of 
antiretroviral therapy on diastolic blood pressure through blood glucose level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI, confidence interval; HAART, highly active antiretroviral therapy; DBP, diastolic blood pressure; BG, blood 
glucose
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20.5 THE EFFECT OF HAART ON BLOOD PRESSURE MEDIATED BY SLEEP 
QUALITY 
The quality of sleep, as measured by the PSQI, was no mediator of the effect of HAART 
on systolic (coefficient = 0.002, 95% CI -0.23 to 0.24) or diastolic blood pressure 
(coefficient = 0.0005, 95% CI -0.05 to 0.06). The direct and total effects of HAART on 
systolic and blood pressure were equal, so that the indirect effects through sleep quality 
were non-existent (see path diagrams in Figures 20.7 and 20.8). 
 
Figure 20.7: Path diagram of a mediational model showing the indirect of 
antiretroviral therapy on systolic blood pressure through sleep quality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI, confidence interval; HAART, highly active antiretroviral therapy; SBP, systolic blood pressure; PSQI, Pittsburgh 
Sleep Quality Index 
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Figure 20.8: Path diagram of a mediation model showing the indirect effect of 
antiretroviral therapy on diastolic blood pressure through sleep quality 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
CI, confidence interval; HAART, highly active antiretroviral therapy; DBP, diastolic blood pressure; PSQI, Pittsburgh 
Sleep Quality Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DBP 
7
1 
? 1 9
2 HAART .1
9 
.7
5 
PSQI 
4.1 
? 2 9 
7.
2 
.0
8 .0059 
Indirect effect: 0.0005, 95% CI -0.05 to 0.06 
% mediated: 0 
233  
Although blood glucose level and sleep quality were not mediators of the effects of 
antiretroviral therapy on systolic and diastolic blood pressure, however it is important to 
mention that sleep quality was a strong moderator of these effects. As shown in Table 
20.2, the effects of antiretroviral therapy on systolic and diastolic blood pressure remained 
significantly greater in HIV-infected patients with poor sleep quality (PSQI ≥ 5), 
compared to those reporting a good sleep quality (PSQI < 5), even after controlling for 
potential confounders (P < 0.001 for all). 
 
 
Table 20.2: Sleep quality as a moderator of the effects of antiretroviral therapy on 
systolic and diastolic blood pressure 
 
PSQI < 5 PSQI ≥5 PSQI < 5 vs PSQI ≥5 
 SBP 
 
β (95% CI) 
DBP 
 
β (95% CI) 
SBP 
 
β (95% CI) 
DBP 
 
β (95% CI) 
SBP 
 
(P value) 
DBP 
 
(P value) 
 
 
HAART 
6.08 
 
(1.19 to 10.98) 
5.99 
 
(3.31 to 8.68) 
14.34 
 
(6.23 to 22.44) 
9.60 
 
(5.67 to 13.54) 
 
 
P < 0.001 
 
 
P < 0.001 
 
 
HAART* 
5.03 
 
(0.04 to 10.02) 
5.49 
 
(2.76 to 8.22) 
13.44 
 
(5.44 to 21.43) 
9.21 
 
(5.34 to 13.07) 
 
 
P < 0.001 
 
 
P < 0.001 
 
 
HAART† 
4.86 
 
(-0.03 to 9.74) 
5.43 
 
(2.79 to 8.07) 
11.10 
 
(2.94 to 19.25) 
8.25 
 
(4.36 to 12.14) 
 
 
P < 0.001 
 
 
P < 0.001 
 
 
HAART‡ 
4.18 
 
(-0.90 to 9.26) 
5.06 
 
(2.32 to 7.79) 
12.85 
 
(4.46 to 21.24) 
8.54 
 
(4.55 to 12.52) 
 
 
P < 0.001 
 
 
P < 0.001 
 
 
HAART§ 
5.32 
 
(-0.30 to 10.94) 
5.93 
 
(2.86 to 9.01) 
14.80 
 
(4.46 to 25.14) 
8.60 
 
(3.92 to 13.38) 
 
 
P < 0.001 
 
 
P < 0.001 
*, models adjusted age and sex; 
†, models adjusted for age, sex and body mass index; 
‡, models adjusted for age, sex, body mass index, smoking status, drinking status and physical activity; 
§, models adjusted for age, sex, body mass index, smoking status, drinking status, physical activity, CD4 cell count 
and HIV infection duration. 
β, regression coefficient; CI, confidence interval; DBP, diastolic blood pressure; HAART, highly active antiretroviral 
therapy; PSQI, Pittsburgh Sleep Quality Index; SBP, systolic blood pressure. 
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20.6 THE CAUSAL INFERENCE APPROACH TO MEDIATION 
 
To reiterate, the causal inference approach entailed fitting the mediation models while 
controlling for omitted variables (or potential confounders) and ruling out alternative 
models. Given that body mass index and waist circumference were significant mediators 
of the effects of HAART on systolic and diastolic blood pressure, results of the covariate- 
adjusted mediation effects of body mass index and waist circumference alone are 
presented in Table 20.3. 
  
 
Table 20.3: Covariate-adjusted indirect effects of body fat measures on the associations of antiretroviral therapy with systolic and 
diastolic blood pressure 
 
Causal 
Variable 
Mediator 
variable 
Outcome 
variable 
Indirect effect* 
Coef. (95% CI) 
% 
med* 
Indirect† 
Coef. (95% CI) 
% 
med† 
Indirect effect‡ 
Coef. (95% CI) 
% 
med‡ 
 
HAART 
 
Body mass index 
 
Systolic BP 
Diastolic BP 
 
1.32 (0.48 to 2.16) 
 
 
0.74 (0.05 to 1.43) 
 
14 
 
 
10 
 
1.36 (0.13 to 2.60) 
 
 
0.76 (0.08 to 1.44) 
 
14 
 
 
10 
 
0.98 (-0.44 to 2.40)NS 
 
 
0.52 (-0.23 to 1.27)NS 
 
10 
 
 
7 
HAART Waist 
circumference 
Systolic BP 
 
 
Diastolic BP 
1.18 (0.15 to 2.21) 
 
 
0.78 (0.14 to 1.41) 
13 
 
 
10 
1.05 (0.07 to 2.04) 
 
 
0.70 (0.09 to 1.30) 
11 
 
 
9 
0.94 (0.73 to 2.43) 
 
 
0.64 (0.16 to 2.09) 
10 
 
 
9 
 
 
* – indirect effect controlled for age (continuous) and sex; 
† – indirect effect controlled for age (continuous), sex, smoking status, drinking status, and physical activity (continuous); 
‡ – indirect effect controlled for age (continuous), sex, smoking status, drinking status, physical activity (continuous), CD4 cell count and HIV infection duration 
% med* – proportion of the total effect of HAART on each outcome variable that is attributed indirectly to the mediator variable, adjusted for age and sex. 
% med† – proportion of the total effect of HAART on each outcome variable that is attributed indirectly to the mediator variable, adjusted for age, sex, smoking status, drinking status, 
and physical activity (continuous). 
% med‡ – proportion of the total effect of the independent variable on the dependent variable that is attributed indirectly to the mediator variable, adjusted for age, sex, smoking status, 
drinking status, physical activity (continuous), CD4 cell count and HIV infection duration. 
NS – not statistically significant at 5% level; 95% confidence intervals for indirect effects are bias-corrected. 
CI, confidence interval; HAART, highly active antiretroviral therapy 
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20.6.1 Covariate-adjusted indirect effects of HAART exposure on blood pressure 
through waist circumference 
After controlling for age and sex, waist circumference remained a significant partial 
mediator of the effects of HAART exposure on systolic blood pressure (coefficient = 1.18, 
95% CI 0.15 to 2.21) and diastolic blood pressure (coefficient = 0.78, 95% CI 0.14 to 
1.41), accounting for 13% and 10% of the total effects of HAART on systolic and diastolic 
blood pressure respectively. Additional adjustments for lifestyle factors, including 
smoking status, drinking status, and physical activity levels, revealed that waist 
circumference accounted for 11% (coefficient = 1.05, 95% CI 0.07 to 2.04) and 9% 
(coefficient = 0.70, 95% CI 0.09 to 1.30) of the total effects of HAART on systolic and 
diastolic blood pressure respectively. Unlike body mass index, waist circumference still 
remained a statistically significant partial mediator of the total effects of HAART on 
systolic  blood  pressure  (coefficient  0.94,  95%  CI 0.73  to  2.43)  and  diastolic blood 
pressure (coefficient 0.64, 95% CI 0.16 to 2.09) even after further adjustments for 
duration of HIV infection and CD4 cell count, accounting for 10% and 9% of the 
respective total effects. 
 
 
20.6.2 Ruling out the reverse causal model 
 
Reverse causation was ruled out theoretically as a temporal relationship where blood 
pressure changes lead to increased body mass index or waist circumference is biologically 
implausible. Similarly, neither blood pressure nor body fat changes are indications for 
HAART; it is impossible for these biological changes to influence HAART exposure in 
HIV-infected patients. Kenny (2015) asserts that it is scientifically valid to rule out 
reverse causality theoretically. 
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20.6.3 Ruling out HAART status as a potential effect-modifier 
 
To reiterate, any alternative model that may explain the interaction between HAART, 
body fat measures, and blood pressure changes in HIV-infected patients could potentially 
invalidate any causal inferences about the mediation models. Hence, any such model had 
to be ruled out. As shown in Table 20.4, HAART status was not a moderator of the 
association between body fat changes and blood pressure changes. Body mass index was 
directly associated with systolic and diastolic blood pressure in HAART-exposed (P < 
0.05 for each) and HAART-naïve patients (P < 0.05 for each), and likelihood ratio tests 
revealed no statistically significant difference between models (P = 1.000 for all). 
Similarly, waist circumference was directly associated with systolic and diastolic blood 
pressure in HAART-exposed (P < 0.05 for each) and HAART-naïve patients (P < 0.05 
for each), with no statistically significant difference between models as revealed by 
likelihood ratio tests (P = 1.000 for all). 
 
 
Table 20.4: Linear regression analyses of blood pressure on body fat measures 
stratified by antiretroviral treatment status. 
 
HAART-exposed HAART-naïve HAART-exposed vs HAART-naive 
 Systolic BP 
β (95% CI) 
Diastolic BP 
β (95% CI) 
Systolic BP 
β (95% CI) 
Diastolic BP 
β (95% CI) 
Systolic BP 
(P-value) 
Diastolic BP 
(P-value) 
 
 
 
 
BMI 
 
 
1.13 
 
(0.50 to 1.75) 
 
 
0.88 
 
(0.52 to 1.23) 
 
 
1.10 
 
(0.60 to 1.61) 
 
 
0.55 
 
(0.29 to 0.80) 
 
 
 
 
P = 1.000 
 
 
 
 
P = 1.000 
 
 
 
 
WC 
 
 
0.48 
 
(0.25 to 0.70) 
 
 
0.31 
 
(0.18 to 0.44) 
 
 
0.36 
 
(0.15 to 0.58) 
 
 
0.23 
 
(0.12 to 0.34) 
 
 
 
 
P = 1.000 
 
 
 
 
P = 1.000 
BMI, body mass index; BP, blood pressure; HAART, highly active antiretroviral therapy; WC, waist 
circumference. 
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CHAPTER TWENTY-ONE 
 
RESULTS – PROPENSITY SCORE MATCHING 
 
 
In this chapter, I estimate the causal average treatment effect of antiretroviral therapy on 
blood pressure. 
 
 
 
21.1 DESCRIPTION OF THE ESTIMATED PROPENSITY SCORE 
 
In order to estimate the average treatment effect for the treated (ATT) of HAART on 
blood pressure, the propensity score analysis was restricted to matching only HAART-
exposed patients with HAART-naïve patients. The region of common support obtained 
by fitting the propensity score model was (0.1857, 0.9995), so that the estimated 
propensity scores fell within these bounds (inclusive). The mean (± standard deviation) 
propensity score (0.7642 ± 0.1994) was less than the median (0.8308 [interquartile range: 
0.6240, 0.9299]), which may suggest that the distribution of the propensity scores was 
skewed to the left. However, as determined by the Skewness value (-0.777), the extent 
to which the distribution of the propensity scores deviated from symmetry around the 
mean remained acceptable within the bounds of a normally distributed data; in fact, as a 
rule of thumb, Skewness values that range from -1 to +1 are considered good enough to 
prove a normal distribution (George & Mallery, 2010). Nonetheless, the propensity 
scores were transformed to a logarithmic scale as a measure for dealing with any 
potential consequences of non-normality such as type I or type II errors (Osborne, 
2002). 
 
 
Propensity scores were grouped into five optimal blocks, so that the mean propensity 
score in each subgroup or block was no different between HAART-exposed and HAART- 
naïve participants. In addition, the characteristics on which the propensity scores were 
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subsequently matched were also similar between patients naïve and exposed to HAART 
in all five blocks. These indicated that the balancing property of the propensity score was 
satisfied. 
 
 
21.2 MATCHING ON THE PROPENSITY SCORE 
 
The standard deviation of the logit of the propensity score was 1.6121. The propensity 
score matching entailed using nearest neighbour matching with a specified calibre width 
of 0.2, so that 0.2 of the standard deviation of the logit of the propensity score was 0.3224. 
Therefore, the logits of the propensity score differed by no more than 0.3224 between 
matched treated (HAART-exposed) and untreated (HAART-naïve) HIV-infected 
patients. 
 
 
As mentioned, there were 306 HAART-exposed and 100 HAART-naïve HIV-infected 
participants before propensity score matching was performed. However, matching these 
patients in both groups on the logit of the propensity score yielded 229 HAART-treated 
participants and 74 HAART-naïve participants. However, there still remained baseline 
covariates that were statistically significantly different between HAART-exposed and 
naïve patients after fitting this initial propensity score matching model: occupational 
grade, educational attainment, physical activity levels, baseline diastolic blood pressure, 
health-related quality of life scores on the mental scale, and depression status (P < 0.05 
for each). The standardised bias after propensity score matching was 15.4%, and the 
variance ratios were high for three continuous variables (variance ratio ranging from 0.76 
to 1.32), alluding further to the unbalanced distribution of covariates between HAART- 
exposed and HAART-naïve patients. Table 21.1 describes the characteristics of HAART- 
exposed and HAART-naïve patients in this initial propensity score matched sample. 
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Eliminating the residual differences in the baseline characteristics entailed additional 
modifications to the estimated propensity score model and repeating the matching 
process. The propensity score model was modified by adding interaction terms at random 
(Caliendo & Kopeining, 2006; Dehejia & Wahba, 1999), and re-assessed for similarity in 
the baseline covariates between HAART-exposed and HAART-naïve participants: 
adding the interaction of blood glucose concentration and body mass index to the initial 
propensity score model resulted in a propensity score matched sample, still comprising 
229 HAART-exposed patients and 74 HAART-naïve patients, but without any observed 
systematic difference in the baseline characteristics between HAART-exposed and 
HAART-naïve patients. The means and proportions of all baseline covariates were not 
significantly different between HAART-exposed and HAART-naïve patients in this 
matched sample; the standardised bias after matching was 5%; and the largest variance 
ratio was 1.66 (variance ratio ranging from 0.59 to 1.70). Hence, the distribution of 
baseline characteristics between the treatment groups was balanced. Table 21.2 describes 
the characteristics of the HAART-exposed and HAART-naïve participants in this second 
and final propensity score matched sample. 
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Table 21.1: Characteristics of HAART-exposed and HAART-naïve patients in the 
first propensity score matched sample 
 
 
 
 
Variable 
HAART- 
exposed 
(N = 229) 
HAART- 
naïve 
(N = 74) 
 
 
 
P value 
 
 
 
% bias 
 
 
 
VR 
Means / Proportions 
Age (years) 37.48 39.26 0.216 -15.4 0.29 
Males 29.95 % 29.95 % 1.000 0 – 
Education > 12 years 42.64 % 31.47 % 0.022 * 25.0 – 
Working class / unemployed 73.60 % 84.77 % 0.006 * -28.9 – 
Ever smoker 10.15 % 7.11 % 0.283 10.8 – 
Current drinker 26.40 % 22.84 % 0.414 8.2 – 
Physical activity (minutes/week) 156.28 118.98 0.026 * 20.6 1.10 
Body mass index (kg/m2) 24.18 24.92 0.109 -16.16 0.71 
Waist circumference (cm) 85.73 88.78 0.080 -25.6 0.23 
Blood glucose (mmol/L) 4.91 4.97 0.717 -4.5 0.32 
On antihypertensive treatment 1.52 % 0 0.082 10.8 – 
PSQI ≥ 5 33.00 % 24.37 % 0.058 18.1 – 
CESD ≥ 16 18.78 % 8.12 % 0.002 * 26.9 – 
HRQL (physical) 50.69 50.72 0.962 -0.5 1.29 
HRQL (mental) 51.74 54.68 0.001 -30.3 1.68† 
Family history of hypertension 10.15 % 5.58 % 0.093 13.8 – 
CD4 cell count (cells/mm3) 444.30 446.92 0.912 -1.1 1.14 
HIV infection duration (months) 45.41 46.21 0.767 -3.1 1.31 
Baseline SBP (mmHg) 112.10 115.43 0.059 -19.2 0.75 
Baseline DBP (mmHg) 74.36 77.92 0.002 * -29.2 1.35† 
–, not applicable to proportions; *, P < 0.05; †, variance ratio is greater than upper limit of 1.32 set by Stata; 
CESD, Centre for Epidemiologic Studies Depression scale; DBP, diastolic blood pressure; HRQL, health- 
related quality of life; PSQI, Pittsburgh Sleep Quality Index; SBP, systolic blood pressure; VR, variance 
ratio. Mean bias = 15.4%. 
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Table 21.2: Characteristics of HAART-exposed and HAART-naïve patients in the 
final propensity score matched sample 
 
 
 
Variable 
HAART- 
exposed 
(N = 229) 
HAART- 
naïve 
(N = 74) 
 
 
 
P value 
 
 
 
% bias 
 
 
 
VR 
Means / Proportions 
Age (years) 37.18 37.68 0.826 -4.4 0.53 
Males 29.83 % 28.07 % 0.838 3.9 – 
Education > 12 years 21.05 % 21.05 % 1.000 0 – 
Working class / unemployed 91.23 % 89.47 % 0.754 4.5 – 
Ever smoker 8.77 % 8.77 % 1.000 0 – 
Current drinker 35.09 % 28.07 % 0.425 16.2 – 
Physical activity (minutes/week) 205.44 205.88 0.991 -0.2 1.33 
Body mass index (kg/m2) 23.41 23.88 0.576 -10.7 0.98 
Waist circumference (cm) 84.60 85.11 0.835 -4.3 0.77 
Blood glucose (mmol/L) 4.91 4.82 0.701 6.4 0.43 
On antihypertensive treatment 1.75 % 1.75 % 1.000 0 – 
PSQI 4.46 4.33 0.843 4.0 0.94 
CESD 9.42 10.30 0.563 -11.3 0.87 
HRQL (physical) 49.03 49.39 0.833 -4.5 1.43 
HRQL (mental) 52.68 50.77 0.316 19.7 1.04 
Family history of hypertension 12.28 % 12.28 % 1.000 0 – 
CD4 cell count (cells/mm3) 490.07 474.44 0.727 6.8 1.66 
HIV infection duration (months) 34.14 35.47 0.776 -5.1 1.36 
Baseline SBP (mmHg) 113.96 114.21 0.944 -1.4 1.01 
Baseline DBP (mmHg) 76.07 76.14 0.976 -0.6 1.38 
Body mass index ## Blood glucose 2069.5 2075.5 0.962 -0.8 0.55 
CESD, Centre for Epidemiologic Studies Depression scale; DBP, diastolic blood pressure; HRQL, health- 
related quality of life; PSQI, Pittsburgh Sleep Quality Index; SBP, systolic blood pressure; VR, variance 
ratio. Mean bias = 5% 
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21.3 THE ESTIMATED AVERAGE TREATMENT EFFECTS ON THE 
TREATED (ATT) 
The effect of the treatment (HAART) is the difference between the mean blood pressure 
for HAART-exposed participants and the mean blood pressure for HAART-naïve 
participants in the final propensity score matched sample (Rosenbaum & Rubin, 1983). 
The mean systolic blood pressure levels in the HAART-exposed and HAART-naïve 
participants in the final propensity score matched sample were 121.25 mmHg and 113.40 
mmHg respectively, so that the estimated ATT was 7.85 mmHg, with a standard error 
(SE) of 3.05 mmHg. The 95% confidence interval for the estimated ATT was calculated 
using the formula: 
95% CI = [1.85 ± 1.96 ×	SE], where SE = 3.05. 
 
Hence, ATT = [7.85 mmHg (95% CI 3.72 to 15.68)]. 
 
 
 
Similarly, the mean diastolic blood pressure levels in HAART-exposed and HAART- 
naïve participants in the final propensity score matched sample were 78.80    mmHg and 
71.35 mmHg respectively, so that the estimated ATT was 7.45 mmHg, with SE of 2.2. 
 
Hence, ATT = [7.45 mmHg (95% CI 4.99 to 13.61)]. 
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CHAPTER TWENTY-TWO 
 
INTERPRETATIONS OF THE MAIN FINDINGS 
 
In this chapter, I interpret the results of the evidence syntheses and primary data analyses. 
 
 
 
 
22.1 INTERPRETING THE MAIN FINDINGS OF GLOBAL EVIDENCE SYNTHESIS 
 
Overall, the findings of the meta-analyses, as summarized in the forest plots below, reveal that 
antiretroviral therapy is significantly associated with increased blood pressure and other 
cardiovascular disease risk factors among people living with HIV worldwide.  
Figure 22.1: Summary estimates of the pooled associations between antiretroviral therapy and 
(continuous) cardio-metabolic outcomes 
 
ART, antiretroviral therapy; CI, confidence interval; N, number of studies included in the meta-analyses. Summary plot shows ART 
is significantly associated with increases in all cardio-metabolic outcome measures.   
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Figure 22.2: Summary estimates of the pooled associations between antiretroviral therapy and 
(categorical) cardio-metabolic outcomes 
 
CI, confidence interval; N, number of studies included in the meta-analyses. With the exception of combined overweight/obesity, 
ART is significantly associated with increased risk of cardio-metabolic disorders. 
 
 
22.1.1 Antiretroviral-associated increases in blood pressure and hypertension risk 
 
Exposure to antiretroviral therapy was associated with significantly higher blood pressure levels 
and increased risk of hypertension in HIV-infected patients. With the exception of between-study 
differences in the proportions of smokers, there was no indication of differential effects ― by the 
different study-level subgroups ― in the associations of antiretroviral therapy with increased 
blood pressure or hypertension risk. For instance, the strength of the association between 
antiretroviral therapy and increased diastolic blood pressure was significantly greater across 
studies that reported higher proportions of smokers than non-smokers, compared to studies with 
fewer smokers than non-smokers, which suggests that smoking could be a moderator of the effect 
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of antiretroviral therapy on diastolic blood pressure in HIV-infected patients. Schoenbach (2000) 
and Kamangar (2012) also defined moderation (or effect-modification) in qualitative terms: an 
association exists between two variables in one subgroup but not in the other, or one subgroup 
reports an increase in risk but the other subgroup reports a decrease in risk. Drawing on this 
definition, the subgroup meta-analyses revealed qualitative modifying effects of age, CD4 cell 
count, duration of HIV infection, and duration of antiretroviral therapy on the impact of 
antiretroviral therapy on blood pressure. For instance, antiretroviral therapy was significantly 
associated with increased blood pressure in HIV-infected patients who were above 40 years of 
age, with CD4 cell counts below 350 cells/mm3, or had been living with HIV infection for less 
than five years; whereas no significant associations were observed among their counterparts who 
were below 40 years of age, with higher CD4 cell counts and longer durations of HIV infection. 
The significant associations of antiretroviral therapy with increased blood pressure and 
hypertension risk among studies with mean duration of antiretroviral treatment of 18 months or 
greater, compared to the lack thereof among studies with mean antiretroviral treatment duration 
of less than 18 months, suggests that endothelial damage mediated by antiretroviral drugs may 
be dose-dependent. Although this hypothesis may have alluded to a possible dose-response 
relationship between antiretroviral exposure and increased blood pressure, one cannot rule out 
the limited number of small-sized studies with mean antiretroviral treatment duration of less than 
18 months, so that this subgroup analysis may have been underpowered to detect a significant 
association between antiretroviral therapy and blood pressure / hypertension risk. 
 
 
Meta-regression analysis also provided limited explanation for the observed heterogeneity in the 
pooled association between antiretroviral therapy and the odds of hypertension: the considerable 
amount of observed heterogeneity was not explained by any of the study-level characteristics. It 
is possible that the unexplained heterogeneity may be the results of individual-level differences, 
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such as: varying individual blood pressure levels prior to the initiation of antiretroviral therapy, 
differences in antihypertensive treatment accompanied by potential variations in pharmacokinetic 
interactions with antiretroviral drugs (UCSF Centre for HIV Information, 2014), and varying 
durations of antihypertensive treatment. However, these data were not available in the included 
studies, so that individual-level differences could not be investigated in the meta-analyses. 
 
22.1.2 Antiretroviral-associated increases in serum lipoprotein levels and the risks of 
dyslipidaemias 
Antiretroviral therapy was associated with significant increases in serum cholesterol and 
triglyceride levels among HIV-infected patients. In patients with markedly reduced serum 
cholesterol levels, antiretroviral-associated increases in serum lipoprotein cholesterol levels may 
indicate a return to health as opposed to an atherogenic process (Moutzouri, Elisaf & 
Liberopoulos, 2011). However, the meta-analysis also revealed significant associations between 
antiretroviral therapy and dyslipidaemias. The observed associations of antiretroviral therapy 
with increased serum cholesterol and triglyceride levels were somewhat consistent across the 
different study-level characteristics, albeit with notable differences in the strengths of the 
associations between certain subgroups given that country income, age, smoking status, CD4 cell 
count and antiretroviral regimen were determined to be quantitative moderators of the effects of 
antiretroviral therapy on serum cholesterol levels in HIV-infected patients. For instance, serum 
cholesterol levels were significantly higher among antiretroviral-exposed patients who were from 
high-income countries, above 40 years of age, current smokers, with suboptimal CD4 cell counts, 
and on protease inhibitor-based antiretroviral treatment regimens, compared to antiretroviral- 
exposed patients who were from low- and middle-income countries, less than 40 years of age, 
non-smokers, with higher CD4 cell counts, and on reverse transcriptase inhibitor-based 
antiretroviral treatment regimens respectively. Serum triglyceride levels among antiretroviral- 
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exposed patients resident in low- and middle-income countries, under 40 years of age, with high 
CD4 cell counts, on reverse transcriptase inhibitors, and non-smokers were also significantly 
higher than those of their (antiretroviral) naïve counterparts. Antiretroviral therapy was also the 
single most consistent determinant of serum triglyceride changes in HIV-infected patients despite 
variations in the pooled association by geographical region, smoking status, and antiretroviral 
treatment regimen. 
 
With the exception of the quantitative moderating effects of CD4 cell count, which accounted for 
31% of between-study variability in the association of antiretroviral therapy with increased risk 
of hypertriglyceridaemia, meta-regression analyses provided limited explanation for the observed 
heterogeneity in the impact of antiretroviral therapy on the dyslipidaemias overall. However, the 
qualitative modifying effects of antiretroviral treatment duration on these associations are worth 
emphasizing: it was observed that the risks of hypercholesterolaemia and hypertriglyceridaemia 
only emerged in HIV-infected patients who had received no less than 18 months of antiretroviral 
therapy, whereas no significant associations were observed among HIV-infected patients who 
had been on antiretroviral therapy for less than 18 months. One could argue that this observed 
interaction may also allude to a possible dose-response relationship between antiretroviral 
exposure and the risk of dyslipidaemia in HIV-infected patients. 
 
Certain study-level characteristics not included in the meta-regression analyses may have 
accounted for some of the unexplained heterogeneity in the pooled associations. For instance, 
individual-level factors, such as individual differences in dietary habits, may have explained 
partially the observed heterogeneity across the included studies, given that increased dietary fat 
intake may also be a contributing factor to the high prevalence of cardio-metabolic disorders in 
people living with HIV (Jaime et al., 2006; Joy et al., 2007). 
 
249  
Unexpectedly, it was observed that antiretroviral therapy was significantly associated with raised 
serum levels of HDL cholesterol in HIV-infected patients. HDL cholesterol, also considered 
‘good cholesterol’, helps to lower serum LDL cholesterol levels (Mayo Clinic, 2012). The 
association of antiretroviral therapy with increased HDL cholesterol levels may have been 
explained by the potential influence of lipid lowering drugs, such as the statins and fibrates, which 
may be as effective in improving HDL cholesterol levels as they are in lowering concentrations 
of the atherogenic LDL cholesterol (Mayo Clinic, 2012). In addition, it is widely acknowledged 
that lifestyle factors ― notably regular physical activity ― are the single greatest contributors to 
increased serum HDL cholesterol concentrations in the general population (Mayo Clinic, 2012). 
It is possible that physical activity levels in the study population may have influenced the 
observed antiretroviral-associated increases in mean HDL cholesterol levels. The mechanism to 
account for this hypothesis relies on the relatively young demographic of the study population, 
given that most of the participants in the included studies were less than 40 years of age, so that 
they may have been more likely to be physically active than inactive. 
 
Interestingly, the quantitative modifying effects of the year of publication on the association 
between antiretroviral therapy and serum cholesterol level suggests evidence of a secular trend. 
The mechanism accounting for a significantly greater strength of association between 
antiretroviral therapy and serum cholesterol levels among studies published prior to 2010, 
compared to studies published from 2010 onwards, are highly speculative at this time, but may 
rely on a growing awareness and surveillance of the dyslipidaemic effects of antiretroviral 
therapy in people living with HIV worldwide. 
 
 
22.1.3 Antiretroviral-associated increases in fasting blood glucose concentration and 
diabetes mellitus risk 
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Overall, antiretroviral therapy was significantly associated with increased fasting blood glucose 
concentration. In addition, HIV-infected patients on antiretroviral therapy had approximately four 
greater odds of developing diabetes mellitus, compared to patients who were naïve to 
antiretroviral therapy. There were no statistically significant differences in the pooled 
associations across different socio-demographic and clinical characteristics, which suggests that 
antiretroviral treatment may potentially be the single most consistent determinant of blood 
glucose changes and diabetes risk in people living with HIV. While heterogeneity was 
statistically significant across the included studies, meta-regression analysis provided very 
limited explanation regarding the potential sources of heterogeneity. Although, differences 
between studies in mean CD4 cell counts accounted for the largest amount of variability in the 
association between antiretroviral therapy and fasting blood glucose levels, only 12% of between- 
study variability was explained. The observed association of antiretroviral therapy with 
increasing blood glucose levels in HIV-infected patients on antiretroviral treatment for longer 
than 18 months but not in patients with shorter treatment durations may suggest a plausible dose- 
response relationship between antiretroviral exposure and blood glucose levels. 
 
Some of the unexplained heterogeneity may be driven by individual-level differences, such as 
individual differences in blood glucose concentrations prior to commencing antiretroviral 
therapy, varying histories of antidiabetic treatment, potential variations in the pharmacodynamic 
interactions between antiretroviral drugs and oral hypoglycaemic agents (Bakare-Odunola et al., 
2008), and individual differences in lifestyle behaviours, including alcohol abuse, which may 
aggravate the hepatotoxic effects of certain antiretroviral drugs, resulting in impaired glucose 
metabolism (Barve et al., 2010). 
 
Furthermore, among the studies that provided data on HIV infection staging, about a quarter of 
patients presented with AIDS-defining illnesses, which may broadly suggest a potential 
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modifying effect of the immune reconstitution inflammatory syndrome (IRIS) on antiretroviral- 
associated increases in blood glucose concentration and diabetes risk. In severely 
immunocompromised individuals, such as HIV-infected patients presenting with AIDS-defining 
illnesses, the initiation of antiretroviral treatment overstimulates the immune system, which may 
be associated with several cardio-metabolic changes, including high blood glucose levels 
(Mingote et al., 2013). 
 
22.1.4 Antiretroviral-associated increases in relative weight and body fat distribution 
 
Overall, the meta-analyses revealed that antiretroviral treatment was associated with significant 
increases in measures of relative weight (body mass index) and body fat distribution (waist 
circumference). It is unlikely that these findings reflect a return to health, given that the results 
also showed antiretroviral therapy to be associated with increased risks of generalized and central 
obesity. Factors that significantly influenced the associations between antiretroviral therapy and 
body fat changes include: geographical region of origin of the participants, CD4 cell count, 
antiretroviral regimen, duration of antiretroviral therapy, and study design. For instance, 
antiretroviral therapy was significantly associated with increased body mass index and risks of 
generalized and central obesity among HIV-infected patients from the sub-Saharan African 
region, but not among HIV-infected patients from other regions, suggesting that genetic trait 
(proxy by geographical region) might exert a strong modifying effect on the association between 
antiretroviral therapy and body fat changes. Similarly, CD4 cell counts and antiretroviral 
regimens were moderators of the effect of antiretroviral therapy on body mass index: HIV- 
infected patients with CD4 cell counts below 350 cells/mm3  and patients on non-nucleoside 
reverse transcriptase inhibitors were substantially at greater risk of antiretroviral-associated 
relative weight gain, compared to patients with higher CD4 cell counts and patients on protease 
inhibitor-based antiretroviral regimens respectively. Interestingly, the strength of the association 
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between antiretroviral therapy and body mass index was significantly greater among HIV- 
infected patients on antiretroviral therapy for less than 18 months, compared to those on 
antiretroviral therapy for greater than 18 months; however, this difference only accounted for 9% 
of between-study variability. Variations by study design in the pooled association between 
antiretroviral therapy and body mass index may be explained by the substantially higher 
proportions of participants in cohort studies, compared to cross-sectional studies. Sex also had a 
moderating effect on the impact of antiretroviral therapy on body fat changes, but only in 
qualitative terms: the associations of antiretroviral therapy with increased body mass index and 
risks of generalized and central obesity were significant among women, but not among men. 
Regional differences and variations in mean CD4 cell counts between studies accounted for most 
of the between-study variability in the pooled associations between antiretroviral therapy and 
body fat changes. 
 
22.1.5 Antiretroviral-associated increase in the risk of metabolic syndrome 
 
Antiretroviral therapy was significantly associated with increased risk of metabolic syndrome. 
HIV-infected patients on antiretroviral therapy had about 1.5 greater odds of having metabolic 
syndrome, compared to their naïve counterparts. Meta-regression analysis identified age, sex and 
income setting to be qualitative modifiers of the pooled association: antiretroviral therapy was 
significantly associated with increased risk of metabolic syndrome among patients above 40 years 
of age, women and patients from low- and middle-income settings, but not among younger 
patients, men and patients from high-income settings. 
 
22.2 INTERPRETING THE MAIN FINDINGS OF PRIMARY DATA ANALYSIS 
 
Overall, this study on a sample of HIV-infected adults in a clinic setting in semi-urban Nigeria 
presents evidence suggesting a high likelihood that a causal link exists between antiretroviral 
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therapy and increased blood pressure. 
22.2.1 The indirect effects of antiretroviral therapy on blood pressure through waist 
circumference and body mass index. 
The findings revealed alternative causal pathways between antiretroviral therapy and increased 
systolic and diastolic pressure through increases in body mass index and waist circumference. 
Precisely, the study emphasized the stronger impact of central fat distribution (measured by waist 
circumference), compared with relative weight (measured by body mass index), in mediating the 
effects of antiretroviral therapy on systolic and diastolic blood pressure, independent of factors 
that could attenuate these associations (such as age, sex, lifestyle, CD4 cell count and duration of 
HIV infection). Besides adjusting for potential confounders, additional measures of inferring a 
causal link entailed rejecting alternate explanations to the mediational models, such as reverse 
causality and antiretroviral treatment status as an effect-modifier of the association of body fat 
measures with blood pressure changes. Although blood glucose levels and sleep quality were not 
mediators of the associations of antiretroviral therapy with increasing systolic or diastolic blood 
pressure, it was interesting to observe the significant modifying effects of sleep quality on these 
associations even after controlling for all pre-selected potential confounders. 
 
 
 
22.2.2 The average treatment effect (ATT) of antiretroviral therapy on blood pressure. 
 
Secondly, the estimated average treatment effects on the treated (ATT) revealed that antiretroviral 
therapy remained significantly associated with increases in systolic and diastolic blood pressure 
after achieving a balanced distribution of baseline characteristics based on propensity score 
matching of these characteristics between patients naïve and exposed to antiretroviral treatment. 
 
 
22.2.3 The impact of antiretroviral treatment status on the clinical prediction of 
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hypertension in HIV-infected patients. 
The results from the model fit statistics were also important because an improvement in the 
prediction of hypertension following the addition of antiretroviral treatment status to the 
predictive model was considered an essential foundation for a potential causal impact of 
antiretroviral therapy on increased blood pressure (Allison, 2014; Cox, 2012). While age, body 
mass index, family history of hypertension and sleep quality offered the most rigorous method 
for predicting hypertension in HIV-infected patients in a sub-Saharan African setting, the 
inclusion of antiretroviral treatment status to the predictive model further improved the clinical 
prediction of hypertension. To reiterate, improvement in the prediction of hypertension following 
addition of antiretroviral treatment status reflected the adjusted difference in the risk of 
hypertension between patients naïve and exposed to antiretroviral therapy. This puts into 
perspective the progressively higher increase in the predicted probability of hypertension in 
antiretroviral-exposed patients, compared to antiretroviral-naïve patients, overall and at fixed 
values of the individual covariates in the predictive model. 
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CHAPTER TWENTY-THREE 
 
COMPARISON WITH PREVIOUS EVIDENCE 
 
In this chapter, I compare the findings of evidence synthesis and primary data analysis with 
previous studies. 
 
 
 
23.1 COMPARISON OF THE EVIDENCE SYNTHESIS WITH PREVIOUS STUDIES 
 
Although, the observed associations of antiretroviral therapy with increased systolic and diastolic 
blood pressure were not consistent with the findings of a previous meta-analysis (Dillon et al., 
2013), it is worth emphasizing that the latter presented evidence only from studies conducted in 
sub-Saharan African countries, including six relatively small-sized studies, two of which were 
unpublished. For these reasons, the observed associations of antiretroviral therapy with increasing 
blood glucose level and body mass index in the present meta-analyses also contradicted the 
findings of Dillon et al. (2013). Hence, one could not rule out the possibility that the studies 
included in the meta-analyses conducted by Dillon et al. (2013) may have been relatively too 
small to detect a significant impact of antiretroviral therapy on these cardio-metabolic parameters. 
Nonetheless, the association of antiretroviral therapy with increasing serum cholesterol 
concentration in the present meta-analysis is consistent with the findings of Dillon et al. (2013) 
in spite of the limitations of the latter. In fact, Dillon et al. (2013) reported a significant 
association between antiretroviral therapy and LDL cholesterol concentrations in people living 
with HIV in sub-Saharan African countries, which is in line with the antiretroviral-associated 
increase in LDL cholesterol concentrations observed in the present subgroup meta-analysis of 
studies conducted in the sub-Saharan African region. 
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The observed impact of smoking on the association between antiretroviral therapy and diastolic 
blood pressure is consistent with recent evidence that found heavy cigarette smoking to be 
associated with increasing diastolic blood pressure and a high prevalence of diastolic 
hypertension (Dong-Qing et al., 2014). The interaction between antiretroviral therapy, smoking 
and blood pressure may be explained by a potential dual effect of antiretroviral therapy and 
smoking on blood pressure, which is also coherent with previous studies suggesting endothelial 
dysfunction as one of the mechanisms by which smoking and antiretroviral therapy increase 
blood pressure (Ambrose & Barua, 2004; Benowitz, 2003; Celermajer et al., 1993; Dau & 
Holodniy, 2008; Donati, Cauda & Lacoviello, 2010; Messner & Bernhard, 2014; Puranik & 
Celermajer, 2003). 
 
 
Previous evidence of the independent associations of ageing and decreasing levels of CD4 cell- 
mediated immunity with high blood pressure among antiretroviral-exposed HIV-infected patients 
(Palacios et al., 2006) supports the observed moderating effects of age and CD4 cell count on the 
impact of antiretroviral therapy on blood pressure. In their cohort of 542 HIV-infected patients, 
Manner et al. (2010) reported an inverse association between HIV infection duration and blood 
pressure, which is consistent with the moderating effects of HIV infection duration on the 
antiretroviral-associated increase in blood pressure observed in the present meta-analysis. 
 
 
 
Seaberg et al. (2005) reported a direct relationship between the duration of antiretroviral therapy 
and blood pressure, which supports the proposed hypothesis of a dose-response relationship 
between antiretroviral exposure and blood pressure. 
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A case could also be made for a dual effect of antiretroviral therapy and tobacco smoking on the 
worsening serum lipid profiles of antiretroviral-exposed HIV-infected patients who smoke. This 
hypothesis, which potentially explains the stronger associations of antiretroviral therapy with 
increased serum cholesterol and triglyceride concentrations in studies with more smokers than 
non-smokers, as opposed to studies with fewer smokers than non-smokers, is compatible with 
evidence alluding to chronic inflammation and increased oxidative stress as important 
mechanisms by which smoking and antiretroviral therapy might alter serum lipid levels (Calvo 
et al., 2015; Fleischman et al., 2007; Harrison et al., 2011; López et al., 2004; Stein, 2003). 
 
 
 
In a study aimed at examining the impact of ageing on antiretroviral-associated comorbidities 
among people living with HIV, Orlando et al. (2006) found that serum cholesterol, triglyceride 
and glucose concentrations remained substantially higher in older HIV-infected patients, 
compared to younger controls, before and after the initiation of antiretroviral therapy ― findings 
consistent with the present meta-analyses. In addition, the direct associations of serum cholesterol 
and triglyceride concentrations with the duration of antiretroviral therapy (Orlando et al., 2006) 
are somewhat in line with the higher risks of hypercholesterolaemia and hypertriglyceridaemia 
following longer periods of antiretroviral therapy revealed in the present meta-analyses. 
 
 
 
The significantly greater impact of antiretroviral therapy on serum cholesterol levels found 
among HIV-infected patients with suboptimal CD4 cell counts, compared to those with higher 
CD4 cell counts in the present meta-analysis are also broadly consistent with previous evidence 
suggesting a link between lower CD4 cell counts and deranged lipid profiles in HIV-infected 
patients (El-Sadr et al., 2005). 
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The higher subgroup estimates of the association between antiretroviral therapy and total 
cholesterol levels among HIV-infected patients from high-income countries, compared to those 
from low- and middle-income countries, may partially explain the much stronger impact of 
protease inhibitors than other antiretroviral regimens on serum lipoprotein levels, given that 
higher proportions of patients from high-income countries rather than from low-resource 
countries had been treated with protease inhibitor-based antiretroviral regimens. The greater 
potential for cardio-metabolic toxicity following the use of protease inhibitors over non-protease 
inhibitor-based antiretroviral regimens corroborates this assertion (Data Collection on Adverse 
Events of Anti-HIV Drugs [DAD] Study Group, 2007; Mulligan et al., 2000; Stein, 2003). 
However, it is worth noting that Stanley and Grinspoon (2012) found evidence linking obesity to 
the use of non-nucleoside reverse transcriptase inhibitors over protease inhibitors, which is also 
reconcilable with the present findings that revealed treatment using non-nucleoside reverse 
transcriptase inhibitors leading to greater increases in weight and central fat accumulation, 
compared to protease inhibitors. 
 
 
 
The observation of antiretroviral-associated increases in body fat changes among HIV-infected 
patients in the sub-Saharan African region, but not among patients in other regions, essentially 
supports the well-established fact that the burden of HIV infection and its consequences are most 
severe in the sub-Saharan African region. 
 
 
 
In line with the stronger impact of antiretroviral therapy on body fat measures in 
immunocompromised HIV-infected patients than those with normal levels of cell-mediated 
immunity, Crum-Cianflone et al. (2010) ― using secondary analysis of data from 1,001 HIV- 
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infected patients ― found a significant association between decreased CD4 cell counts and 
weight gain. 
 
 
 
The greater strength of association between antiretroviral therapy and increasing body mass index 
in HIV-infected patients on antiretroviral therapy for less than 18months, compared to those who 
had been on antiretroviral treatment for longer than 18 months, is consistent with the biphasic 
pattern of antiretroviral-associated changes in body mass index described in the Swiss HIV 
Cohort Study, where increase in body mass index within the first year of antiretroviral therapy 
was substantially larger than the increases observed in subsequent years combined (Hasse et al., 
2014). 
 
 
 
The observed associations of antiretroviral therapy with increased risk of metabolic syndrome 
among HIV-infected patients above 40 years of age and in studies with more women than men, 
but not among younger patients or studies with fewer women than men, are broadly consistent 
with older age and female sex as risk factors of cardio-metabolic disorders in HIV-infected 
persons exposed to antiretroviral therapy (Dagogo-Jack, 2008; Nguyen et al., 2016). In addition, 
the moderating effects of sex on the association between ART and metabolic syndrome is broadly 
consistent with higher rates of central obesity among women (Garawi et al., 2014), especially 
given that central obesity remains a constant in the definition of metabolic syndrome 
(International Diabetes Federation, 2006). 
260  
23.2 COMPARISON OF THE PRIMARY DATA ANALYSIS WITH PREVIOUS 
STUDIES 
Unfortunately, the dearth of studies reporting the causal average treatment effects of antiretroviral 
therapy on blood pressure precluded any comparison of the estimated ATT with previous 
evidence. However, the reported crude effects of antiretroviral therapy on systolic and diastolic 
blood pressure were consistent with previous evidence from Ghana (MD = 7.90 mmHg [95% CI 
2.18 to 13.62] and 4.90 mmHg [95% CI 1.63 to 8.17] respectively) (Ngala & Fianko, 2013), as 
well as from other developing countries, including Brazil (MD = 8.75 mmHg [95% CI 5.28 to 
12.22] and 5.00 mmHg [95% CI 2.35 to 7.65] respectively) (Arruda-Junior et al., 2010) and India 
(MD = 12.72 mmHg [95% CI 9.10 to 16.34] and 7.57 mmHg [95% CI 5.00 to 10.14] respectively) 
(Mital et al., 2013). 
 
 
 
The adjusted indirect effects of antiretroviral therapy on systolic and diastolic blood pressure 
increases through body fat changes were consistent with a large body of scientific evidence on 
the predominant role of central adiposity, as opposed to relative weight, in the aetiology of cardio- 
metabolic disorders (Van Pelt et al., 2001; Janssen, Katzmarzyk & Ross, 2004; Kamath, 
Shivaprakash & Adhikari, 2011; Stranges et al., 2004; Stranges et al., 2005; Nduka et al., 2015b; 
Yusuf et al., 2004). Similarly, the pathophysiological mechanisms to account for the differential 
mediating effects of body mass index and waist circumference reside mainly in the relatively 
limited measure of body mass index, compared with waist circumference, in detecting important 
cardio-metabolic changes driven by central fat accumulation (Janssen, Katzmarzyk & Ross, 
2004; Kamath, Shivaprakash & Adhikari, 2011; Yusuf et al., 2004). 
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In ruling out an alternate explanation of the mediational model, the stratified analyses by HAART 
status may not have been adequately powered to detect effect modification of the associations 
between body fat measures and blood pressure, given the relatively small sample size of HAART- 
naïve patients (Kamangar, 2012). However, the absence of effect-modification may also be 
reconcilable with the chronic inflammatory and platelet activating effects of HIV infection ― 
known mechanisms that underlie blood pressure changes in antiretroviral-naïve HIV-infected 
patients (Blann et al., 1997). 
 
 
 
With regards to the model fit statistics, the selection of variables included in the predictive model 
for hypertension was guided solely by the degree of fit. However, one cannot dismiss the 
biological connection that exists among these variables and hypertension. For instance, the 
predictive model was coherent with the interplay between poor sleep quality, ageing, 
overweight/obesity and hypertension. Essentially, poor sleep quality interferes with metabolism 
and hormonogenesis, which underlie the aetiology of cardio-metabolic disorders (Bruno et al., 
2013; Shlisky et al., 2012; Stranges et al., 2008). In addition, the impact of HAART status in 
improving the clinical prediction of hypertension among HIV-infected patients is corroborated 
by evidence on the biological plausibility of this link, such as the endothelial damaging effects 
of antiretroviral drugs (Dau & Holodniy, 2008; Stein, 2003). 
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CHAPTER TWENTY-FOUR 
 
LIMITATIONS AND STRENGTHS 
 
In this chapter, I discuss the limitations and strengths of evidence synthesis and primary data 
analysis. I also highlight the limitations of the mini-review. 
 
 
 
24.1 LIMITATIONS AND STRENGTHS OF THE GLOBAL EVIDENCE SYNTHESIS 
 
The observational nature of the data precluded any causal inferences; however, treating HIV- 
infected patients as controls being administered placebos in a randomized controlled trial would 
have posed considerable ethical challenges.  
With more than 60% of the included studies assessed to have a high (or unclear) risk of selection 
bias, the methodological quality across the included studies may have been moderate at best. 
The high risk of selection bias observed across the included studies was not unexpected, given 
the observational nature of the evidence synthesis. Although meta-regression analyses revealed 
that selection bias had no significant impact on the pooled effects of antiretroviral therapy on 
cardio-metabolic parameters, it is worth emphasizing that meta-analyses are only as good as the 
included studies, and are prone to the same biases as the including studies. The present meta-
analyses included mostly cross-sectional studies, which were inherently prone to selection bias. 
The absence of randomisation in the included studies meant that HAART-exposed and 
HAART-naïve patients were systematically different. For instance, HAART-exposed and 
HAART-naïve patients presenting to HIV clinics may have differed in their durations of HIV 
infection, where HAART-exposed patients were more likely to have been exposed to the effects 
of HIV infection for a much longer duration than their naïve counterparts. HAART-exposed 
patients had significantly lower CD4 cell counts, compared to their naïve counterparts, which 
may not be unrelated to the observed disparity in HIV infection duration between both groups, 
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given the widely acknowledged inverse association between viral load and CD4 cell count. 
HAART-exposed patients were significantly older than HAART-naïve patients. Men were more 
likely to be HAART-exposed, whereas women were more likely to be HAART-naïve. Smoking 
status also differed by HAART status. In addition to the observed differences in the data, 
HAART-exposed and HAART-naïve patients characteristically have different times to follow-
up, where the intervals between follow-up visits are longer for HAART-exposed patients than 
they are for HAART-naïve patients. HAART status may have also been influenced by 
proximity to the clinic, suggesting that HAART-exposed and HAART-naïve patients may have 
differed in their places of residence, and potentially accounting for the higher proportion of 
HAART-exposed patients compared to HAART-naïve patients in the study: a likely occurrence 
in low- and middle-income countries.  
The systematic differences between HAART-exposed and HAART-naïve patients in the 
included studies also meant that there was a high potential that the pooled estimates were 
confounded. For instant, the modifying effect of smoking on the pooled association between 
HAART exposure and increased blood pressure may have been the result of significant 
differences in the proportions of smokers between HAART-exposed and HAART-naïve 
patients, and may also suggest that smoking was a potential confounder of the pooled effects of 
HAART on blood pressure. The differences in the proportions of smokers between HAART-
exposed and HAART-naïve subjects also accounted for the largest amount of heterogeneity in 
the study-by-study estimates of the effects of HAART on blood pressure, again suggesting that 
the pooled mean differences in blood pressure between HAART-exposed and HAART-naïve 
patients may be confounded by differences in proportions of smokers between both patient 
groups. Although smoking was incorporated in the meta-regression models to account for its 
impact on the pooled effects of HAART on blood pressure and other cardio-metabolic 
parameters, it is also important to emphasize that the other main problems associated with 
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confounding. For instance, there was a high potential for residual confounding as not all 
important confounders were accounted for in the included studies, probably because the 
investigators were unaware of them. For example, other lifestyle factors such as alcohol abuse, 
physical inactivity and poor dietary habits were not reported in most of the included studies. In 
addition, even when these potential confounders were identified in some of the included studies, 
they were not measured objectively (Shrier et al., 2007). For instance, assays for biomarkers 
such as cotinine and Gamma-glutamyltransferase are more accurate and more sensitive than 
self-reported measures for quantifying smoking and alcohol consumption levels respectively. 
Similarly, motion sensors (such as pedometers) may provide more objective estimates of 
physical activity levels, compared to self-reports. However, these investigations were not 
performed, potentially suggesting that the pooled estimates may have been confounded by these 
lifestyle factors.     
Furthermore, at the time of enrolment into care and treatment, HIV-infected patients who are 
eligible to receive HAART may have been more susceptible to blood pressure changes if 
compared to HIV-infected patients who were not eligible to receive HAART because of the 
presence of risk factors at baseline (prior to HAART exposure). For instance, patients eligible to 
commence antiretroviral therapy may have had longer duration of infection and lower CD4 cell 
counts, and may have been more likely to smoke or consume heavy amounts of alcohol, 
compared to patients not eligible for antiretroviral treatment. HIV-infected patients eligible for 
antiretroviral therapy at the time of HIV infection diagnosis may have also been older than 
those not eligible for antiretroviral therapy, given the effect of ageing on HIV disease 
progression (Edwards et al., 2015).This source of confounding which is linked to HAART 
status has been termed susceptibility bias (Delgado-Rodríguez & Llorca, 2003), as the effect 
estimates may have been biased from the onset in favour of the HAART-exposed group. 
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Less than 20% of the total study population comprised people living in low- and middle-income 
countries ― where the burden of HIV infection is most severe, and increases in antiretroviral 
treatment coverage rates are the steepest. This disparity may reduce the generalizability of the 
findings across different geographic and socio-economic settings. 
 
 
The unexplained heterogeneity in the pooled estimates may be attributed to study-level factors 
not considered in the meta-analyses, but only because these factors were seldom assessed in the 
individual primary studies. For instance, it was not known whether differences in 
antihypertensive, lipid-lowering, or hypoglycaemic treatments accounted for some of the 
between-study variability in the effect estimates. 
 
 
 
Meta-regression analyses to determine potential effect-modifiers of the associations of 
antiretroviral therapy with increased risks of combined dyslipidaemia and diabetes mellitus were 
not performed, given that the studies reporting these outcomes were insufficient for the meta- 
regression coefficients to be estimated effectively (Thompson & Higgins, 2002). 
 
 
 
The dearth of studies reporting on lifestyle factors meant that the effects of poor dietary habits, 
alcohol abuse and physical inactivity on the pooled associations between antiretroviral therapy 
and cardio-metabolic changes could not be ascertained. For instance, the author had planned to 
examine the potential impact of alcohol abuse on the effect of antiretroviral therapy on blood 
glucose concentration, especially given the higher prevalence of alcohol abuse among people 
living with HIV, compared to the general population, as well as the potential for mediating a 
range of hepatitides that tend to precede the impairment of glucose metabolism (Barve et al., 
2010). Furthermore, the interaction between heavy alcohol consumption and antiretroviral 
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exposure has been shown to increase hepatitis C virus RNA levels (Cooper & Cameron, 2005). 
However, data on co-infection between HIV and other blood-borne viruses were not reported in 
the vast majority of the included studies. 
 
More than a third of patients in studies providing data on HIV infection staging presented with 
one or more AIDS-defining illnesses. However, studies reporting AIDS-defining illnesses for 
each meta-analysis were also insufficient for meta-regression analyses to converge and be 
estimated effectively (Thompson & Higgins, 2002), potentially missing out on any information 
regarding the impact of HIV clinical staging on the pooled associations between antiretroviral 
therapy and cardio-metabolic conditions. 
 
 
 
The impact of antiretroviral adherence on the pooled effects of antiretroviral therapy on the 
cardio-metabolic parameters was not assessed because none of the included studies reported 
antiretroviral treatment adherence levels for the participants. The importance of such an 
assessment is exemplified in the Strategies for Management of Antiretroviral Therapy (SMART) 
trial, which revealed a substantially higher risk of cardiovascular disease among HIV-infected 
patients in whom antiretroviral treatment was interrupted, compared to HIV-infected patients on 
continuous antiretroviral treatment (SMART Study Group, 2006). 
 
 
 
The effect of antiretroviral therapy on glycated haemoglobin concentrations (HbA1c) could not 
be explored in the present meta-analysis. As cited in Dillon et al. (2013), no more than two 
unpublished studies have compared HbA1c levels between HIV-infected patients naïve and 
exposed to antiretroviral therapy. The dearth of primary studies on this biomarker in HIV-infected 
subjects is an important limitation of the present systematic review and meta-analysis, especially 
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with HbA1c now considered to be a better predictor of long-term diabetes risk than fasting plasma 
glucose in the general population (Selvin et al., 2010). 
 
 
The lipoprotein ratios, such as total cholesterol/HDL cholesterol ratio and triglycerides/HDL 
cholesterol ratio, are considered to be better predictors of cardiovascular risk, compared to 
conventional lipid profile (Millan et al., 2009; Tamang et al., 2014). However, the dearth of 
studies examining the impact of antiretroviral therapy on lipoprotein ratios precluded this 
investigation. 
 
 
Lastly, in assessing the effects of antiretroviral therapy on body fat changes, more sensitive 
measures of body fat, such as fat mass, were not used because of the dearth of studies reporting 
these body fat measures. 
 
 
In spite of the above limitations, the strengths of this systematic review and meta-analyses are 
important with regard to the novelty and methodological rigour used to arrive at the findings. 
 
 
 
First, the author presents the most comprehensive evidence and first pooled analyses examining 
the association of antiretroviral therapy with a range of cardio-metabolic parameters in people 
living with HIV, thus filling an important gap in the literature. 
 
 
 
Secondly, subgroup and meta-regression analyses were performed to identify interrelated and 
often interacting factors that influence qualitative and quantitative cardio-metabolic changes in 
people living with HIV on antiretroviral therapy; the findings from these analyses also represent 
evidence to advance the field. 
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The author conducted comprehensive searches of electronic databases to ensure that all relevant 
publications were identified. In addition, any potential bias in the conduct of this systematic 
review was minimized when the co-authors (supervisors) independently scanned through the 
search output and vetted the extracted data. 
 
 
 
Tests for publication bias revealed no evidence of small-study effects that could potentially 
invalidate the findings, and no indication of potentially missing studies that could have altered 
the interpretations of the pooled associations. 
 
 
 
Leave-one-out sensitivity analyses also revealed no indication of undue influence by specific 
studies as to changing the interpretations of the pooled associations. 
 
 
 
24.2 IMITATIONS AND STRENGTHS OF THE MINI-REVIEW 
 
The limitations of the mini-review essentially entail the drawbacks of using Hill’s criteria as an 
instrument for examining causality. For instance, Hill (1965) and Rothman (2002) argue that the 
only absolute essential criterion for establishing a causal inference is the temporal relationship 
between the exposure and the outcome. Rothman (2002) also implied that the other criteria for 
causation were somewhat non-essential. Although these criteria were never intended to be 
absolute, they do provide an essential framework for establishing cause and effect (Lucas & 
McMichael, 2005). 
 
 
 
Secondly, it is important to emphasize that Hill’s theories about causality were informed at a time 
which coincided with the early discoveries within the field of chronic non-communicable disease 
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epidemiology. Expectedly, the fundamental objective at the time was the study of simple, direct 
causation between an exposure and an outcome (Mirtz et al., 2009), and not so much the complex 
interplay of risk factors that characterise disease processes today. 
Furthermore, Hill’s criteria of causation do not incorporate complex statistical concepts that 
actually enhance the definition of causality (Austin, 2011a; Henneken & Buring, 1987; Kenny, 
2015). 
 
 
 
24.3 LIMITATIONS AND STRENGTHS OF THE PRIMARY DATA ANALYSIS 
 
The findings must be interpreted with caution, given the observational nature of the study and the 
potential for residual confounding and bias, which have been discussed previously (section 
24.2): the issues relating to bias and confounding in the evidence synthesis are also common 
drawbacks of primary epidemiological studies in low-resource settings.      
Importantly, caution must be applied in interpreting causal effects. Hume (2000) argued that 
causality was a term open to interpretation in the sense that it was an inference based on a 
logical assumption, and not an entity based on empirical evidence. In other words, regardless of 
the design of a study, one could never absolutely ascertain that an exposure (such as 
antiretroviral therapy) caused a disease (such as high blood pressure). Nevertheless, Buck 
(1975) suggested that applying caution in the interpretation of a causal inference should entail 
the rejection or modification of a causal hypothesis, and not the proof of causation. 
 
The study was set in semi-urban Nigeria, which may have limited generalizability of the findings 
to HIV-infected populations from rural settings and outside the sub-Saharan African region. For 
example, regional variations exist in the age groups of HIV-infected populations, as people living 
with HIV in sub-Saharan African countries tend to be generally younger than those resident in 
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less deprived settings (UNAIDS, 2013). In addition, while the reverse transcriptase inhibitors are 
the mainstay of antiretroviral therapy in sub-Saharan African countries (Bloomfield & 
Velazquez, 2013; Federal Ministry of Health Nigeria, 2010; Ministry of Medical Services Kenya, 
2011), protease inhibitors are the drugs of choice for initiating antiretroviral treatment among 
people living with HIV across European countries and the Americas (Hughes et al., 2011); hence, 
different classes of antiretroviral drugs may confer differential effect measures on body fat and 
blood pressure changes in people living with HIV. 
Obtaining dietary data from the study participants was fraught with considerably high levels of 
recall bias, so that the potential influence of diet on the effects of HAART on blood pressure was 
not assessed. However, it is important to emphasize that lifestyle factors such as poor dietary 
habits may be of limited value in predicting blood pressure changes in people living with HIV on 
antiretroviral therapy (Troll, 2011). 
 
Household income has been identified as a better predictor of health outcomes when compared 
to other known socioeconomic indicators such as education and occupational grade (Daly et al., 
2002). However, the use of household income as a socioeconomic indicator of health in the study 
was limited by differences in access to the family income among household members, as is often 
the case in resource-limited settings (Daly et al., 2002). For instance, women were more likely 
than men to have limited access to household income. In addition, household income would not 
adequately account for the social positions of retirees who do not earn monthly incomes, but may 
possess a substantial amount of financial resources (Daly et al., 2002). Expectedly, a considerable 
proportion of the participants were also wary about disclosing their income. 
 
 
The indirect effects of antiretroviral therapy on blood pressure changes through more sensitive 
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measures of adiposity (such as fat mass) could not be ascertained: the assessment of body fat 
mass would have entailed the use of sophisticated and costly investigative techniques, including 
dual energy x-ray absorptiometry (DEXA) and bioelectrical impedance analysis (Donini et al., 
2013), which are often not feasible in sub-Saharan African settings, given resource constraints. 
Similarly, 24-hour ambulatory blood pressure monitoring, which represents the gold standard for 
the clinical diagnosis of hypertension (National Institute for Health and Care Excellence, 2011), 
was not feasible in our study setting, given resource constraints. 
 
 
Unfortunately, the impact of serum lipoprotein levels on the effects of antiretroviral therapy on 
blood pressure changes could also not be ascertained given resource constraints. Such an analysis 
could have provided evidence of alternative mediating mechanisms of antiretroviral therapy on 
increased systolic and diastolic blood pressure through changes in serum lipoprotein levels, as 
supported by previous landmark studies (Bonna & Thelle, 1991; Hjermann et al., 1978; Dillon et 
al., 2013; Nduka et al., 2015b). However, as is the case in many sub-Saharan African countries, 
lipid profile assessments are rather expensive and are not subsidized by the governments of these 
countries or donor organisations (Bloomfield & Velazquez, 2013). 
 
 
 
The mediating effects of body fat measures on the association between antiretroviral therapy and 
increased blood pressure may suggest a return to health, as opposed to a pathological process. It 
could be speculated that this phenomenon would relatively be more likely to occur in HIV- 
infected patients who were in advanced clinical or immunological stages of HIV infection. For 
instance, Tate et al. (2012) reported significant increases in body mass indices in HIV-infected 
patients with CD4 cell counts below 50 cells/mm3 following the initiation of antiretroviral 
therapy. CD4 cell counts below 50 cells/mm3 have also been associated with sustained increases 
in blood pressure following the commencement of antiretroviral treatment (Manner et al., 2013). 
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Such patients, who are likely to be antiretroviral-naïve or resistant to antiretroviral treatment, tend 
to be underweight and hypotensive, so that the initiation of antiretroviral treatment is likely to 
improve body weight and blood pressure levels, albeit transiently (Chow et al., 2003; Kelly et 
al., 2002). Although antiretroviral-associated increases in blood pressure and body fat measures 
tend not to be sustained in IRIS, it is still arguable that such changes in cardio-metabolic 
parameters may be symptomatic of the exaggerated inflammatory response that follows the 
commencement of antiretroviral therapy in HIV-infected patients with advanced disease 
(Bosamiya, 2011). However, none of the participants in our study presented with an AIDS- 
defining illness or was determined to be resistant to antiretroviral treatment, as these two 
conditions were part of the exclusion criteria for the present study. 
 
Although a positive family history is among the well-established clinical predictors of 
hypertension, the potential for recall bias could not be dismissed, given that HIV-infected patients 
in the present study who were assessed as hypertensive were more than six times likely to report 
a history of hypertension in a first-degree relative. Similarly, smoking and drinking status may 
have been influenced by high rates of recall bias. Given the self-reported nature of these data, the 
higher propensity for alcohol and tobacco consumption among people living with HIV compared 
to the general population (Bonacini, 2011; Savès et al., 2003), and the demonization of chronic 
smoking and drinking in certain sub-Saharan African settings, it is plausible that the proportions 
of ever smokers and current alcohol users in our study may have been under-estimated, 
suggesting why these traditional risk factors of hypertension did not meet the criteria for inclusion 
in the predictive model. 
 
It is also possible that the low amounts of explained variability corresponding to depression and 
HRQL scores may have reduced the statistical power of these variables (UCLA Institute for 
Digital Research and Education, 2015a), thus providing some explanation as to why these known 
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predictors of hypertension (Stranges & Donahue, 2015; Thiébaut et al., 2005) were not eligible 
for inclusion in the predictive model for hypertension. 
 
Despite these limitations, the study presents important strengths. For instance, this study 
represents the first of its kind that examined the possibility of a causal association between 
antiretroviral therapy and increased blood pressure. The indirect effects of antiretroviral therapy 
on increased blood pressure through body fat changes present novel evidence to advance the field. 
 
In demonstrating that the effects of antiretroviral therapy on systolic and diastolic blood pressure 
were not attributed to any residual differences in the study covariates between patients naïve and 
exposed to HAART, the estimated ATT from propensity score matching potentially reflects a 
higher level of evidence and a substantially lower potential for residual confounding, compared 
to previous observational studies (Austin, 2011a; Seeger, Kurth & Walker, 2007). In fact, the 
odds of residual confounding or selection bias are hardly any different between analyses of a 
randomised controlled sample and a propensity score-matched sample (Austin, 2011a). 
 
The sample size of the propensity score-matched sample was powered to detect a significant ATT 
while accounting for 25% drop out of patients who were not matched on the propensity score. In 
addition, the methods employed in ensuring that the characteristics of the propensity score- 
matched sample were adequately balanced between antiretroviral-exposed and naive patients 
were rigorous and entailed a three-step process based on the differences in the means and 
proportions of the baseline characteristics, the standardised bias after matching the baseline 
characteristics on the propensity scores, and the ratio of the variances in both exposure groups 
(Austin, 2011b). 
 
The causal inference approach to mediation was employed to rule out potential influences from 
omitted variables (or confounders), reverse causality, or alternate explanations to the 
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hypothesized causal pathway. Of note, estimates of the indirect effects were less likely to be 
exaggerated, with the inclusion of important covariates as potential confounders in the mediation 
models. 
 
The exclusion of patients in advanced stages of HIV infection from the study did not allow for 
an alternate interpretation of the mediation analyses, so that the indirect effects of antiretroviral 
therapy on systolic and diastolic blood pressure through changes in body mass index and waist 
circumference were more likely to be pathological than indicative of a physiological return to 
health. 
 
Bootstrapping the indirect effect estimates with 95% confidence intervals was the preferred 
alternative to the Sobel-Goodman mediation test in ascertaining the statistical significance of the 
indirect effects. Compared to the latter, bootstrapping is more robust to sample size, so that the 
present study was unlikely to produce inaccurate estimates of the indirect effects (Preacher & 
Hayes, 2008; MacKinnon, Lockwood & Williams, 2004). The 95% confidence intervals of the 
coefficients of the indirect effects were bias-corrected, potentially controlling for any potential 
skewness in the data (Cohen, 1988; Fritz & MacKinnon, 2007). 
 
Lastly, several important clinical correlates of blood pressure, which have not been examined 
previously in connection with the impact of antiretroviral therapy on blood pressure, especially 
in sub-Saharan African settings, notably were ascertained in the analyses. For instance, the 
potential influence of certain indicators of psychological and mental wellbeing (such as sleep 
quality, presence of depressive symptoms and HRQL) on the effects of antiretroviral therapy on 
blood pressure changes were examined, taking into account the holistic nature of an individual’s 
health and wellbeing (World Health Organisation, 1946). 
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CHAPTER TWENTY-FIVE 
 
IMPLICATIONS FOR PRACTICE AND FUTURE RESEARCH 
 
In this chapter, I discuss the implications of the evidence synthesis and primary data analysis for 
public health practice/policy and future research. 
 
 
 
25.1 IMPLICATIONS OF THE GLOBAL EVIDENCE SYNTHESIS FOR PRACTICE 
AND POLICY 
The findings of the review may have important clinical and public health implications for people 
living with HIV worldwide. For instance, the results suggest that even small shifts population 
blood pressure may have a significant impact on the incidence of hypertension and its 
complications among the 37 million people living with HIV worldwide (Stamler, 1991; Stamler, 
Stamler & Neaton, 1993). To this end, people living with HIV may benefit from regular 
hypertension screening and other cardiovascular risk assessments following the initiation of 
antiretroviral therapy. However, it is worth noting that evidence from experimental studies are 
required in order to implement such policy.  
 
Antiretroviral treatment coverage across the sub-Saharan African region has been estimated to be 
about 39% (UNAIDS, 2014a). In addition, in many sub-Saharan African countries, more than 
half the people estimated be living with HIV are not aware of their HIV status. Hence, there is 
great emphasis on tackling these issues through improving HIV testing uptake and antiretroviral 
treatment coverage rates. However, this comes at the expense of tackling the burden of non-
AIDS-defining illnesses, such as the cardio-metabolic sequelae of antiretroviral use, among 
people living with HIV in sub-Saharan African settings. Cardiovascular diseases continue to be 
neglected at the population level among people living with HIV in many sub-Saharan African 
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countries (Bloomfield & Velazquez, 2013), potentially worsening the already-existing burden of 
non-communicable diseases within the general population in these countries.  
 
Preventive measures ought to be considered in tackling the potential publication health 
implications of expanding antiretroviral coverage rates, especially in sub-Saharan African 
countries, where two-thirds of all people living with HIV resides. At the very least, while we 
await evidence from randomised controlled trials supporting the clinical and cost-effectiveness 
of hypertension screening and other cardiovascular risk assessments in this high-risk group, 
hypertension and other cardio-metabolic disorders may be acknowledged as potential public 
health problems in people living with HIV. 
 
The findings also have implications for the treatment of hypertension and other cardiovascular 
conditions among people living with HIV. For the majority of people living with HIV 
worldwide, the treatment of cardiovascular disorders is often administered in isolation from the 
potential complications of antiretroviral treatment (Bloomfield & Velazquez, 2013). Such 
treatment effects tend to be transient because they are not being informed by an understanding of 
the epidemiological mechanisms between antiretroviral therapy and cardiovascular disease risk 
factors, and because they ignore the potential drug-drug interactions between antiretroviral and 
anti-hypertensive drugs.  
 
25.2   IMPLICATIONS OF THE GLOBAL EVIDENCE SYNTHESIS FOR FUTURE 
RESEARCH 
The meta-analyses highlight the need for additional evidence to investigate the possibility of a 
causal association between antiretroviral therapy and cardio-metabolic changes. Given the 
inevitable ethical ramifications of addressing this question using a randomised controlled trial, 
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estimating the causal effects of antiretroviral therapy on cardio-metabolic outcomes using 
observational data may present the only feasible alternative. Statistical methods such as 
propensity score analyses have become quite popular for estimating causal average treatment 
effects using observational data (Austin, 2011a), and could be useful in this context. Observing 
study participants for incident HIV infection, antiretroviral therapy and cardio-metabolic changes 
may also provide a suitable ― albeit challenging ― alternative for estimating a potential causal 
association. 
Although, the identification of effect-modifiers in the meta-analyses elucidates the complex 
epidemiological interactions between antiretroviral therapy and cardio-metabolic changes, effect 
measure modification models are less appropriate and less powerful than mediation models for 
testing causal inferences (Kenny, 2015). Therefore, as part of assessing the likelihood that a 
causal link exists between antiretroviral therapy and cardio-metabolic changes, it would be useful 
to examine alternative mechanisms that mediate this pathway. 
 
 
 
25.2 IMPLICATIONS OF THE PRIMARY DATA ANALYSIS FOR PRACTICE AND 
POLICY 
The findings of this study come at a time of renewed commitment by the United Nations to scale 
up universal antiretroviral treatment coverage rates (UNAIDS, 2014a). While further reductions 
in the prevalence of AIDS-defining illnesses and AIDS-specific mortality rates are the expected 
outcomes of this intervention, little is known about the potential public health implications of a 
continued global expansion of antiretroviral coverage rates, especially in sub-Saharan African 
populations. Discussions about the impact of antiretroviral therapy on cardio-metabolic disorders 
tend to ignore this region of the world where HIV infection is most prevalent. Cardiovascular 
disease risk factors are becoming exponentially more rampant. Increases in antiretroviral 
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treatment coverage rates are the steepest of all geographical regions. Concerns that the potential 
burden of antiretroviral-associated cardio-metabolic disorders may exacerbate the already- 
growing epidemic of cardiovascular disease are valid (Bloomfield & Velazquez, 2013; Dillon et 
al., 2013; Jamison et al., 2006; Nduka et al., 2016; Nduka et al., 2015c; Sarki et al., 2015). 
However, it is important to reiterate that the withdrawal of antiretroviral treatment is inevitably 
fatal for HIV-infected patients who are eligible to commence antiretroviral therapy, so that such 
a measure cannot be an option for prevention against antiretroviral-associated cardiovascular 
disease risk factors. 
The findings potentially support recognition of antiretroviral-associated hypertension as a 
separate entity from hypertension secondary to other risk factors. The fundamental differences in 
cardiovascular risk factor profile between people living with HIV and the general population, 
evidence affirming the limitations of traditional risk factors in predicting antiretroviral-associated 
cardio-metabolic disorders (Troll, 2011), and the relative inefficacy of standard cardiovascular 
risk management strategies in high-risk subgroups such as people living with HIV on 
antiretroviral therapy (Masia et al., 2009) are other scientific arguments supporting this 
recommendation. 
 
 
 
The results of the study are important particularly for the care and treatment of people living with 
HIV in Nigeria and many other countries in the sub-Saharan African region where HIV care and 
treatment guidelines do not entail comprehensive baseline and routine cardiovascular risk 
assessments, or surveillance systems for monitoring cardiovascular disease risk factors in this 
high-risk population (Bloomfield & Velazquez, 2013; Federal Ministry of Health Nigeria, 2012). 
 
With the persistent rise in living costs in Nigeria ― and even more so in the current economic 
and political climate ― it becomes necessary for HIV-infected persons needing services for 
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cardio-metabolic conditions to have free access to these services, just as they have to 
antiretroviral treatment (Bloomfield & Velazquez, 2013; Federal Ministry of Health Nigeria, 
2012). 
 
From a clinical perspective, the findings suggest that the use of waist circumference as a 
complementary body fat measure to body mass index may improve the clinical prediction of 
hypertension among HIV-infected patients on antiretroviral therapy. Additionally, the prediction 
and early detection of high blood pressure in HIV-infected patients using measures of central fat 
distribution and relative weight may potentially strengthen the surveillance of hypertension and 
its complications in clinic settings. These are important considerations given that a substantial 
number of hypertension cases are initially asymptomatic and are marked by considerable rates of 
underdiagnosis in people living with HIV in sub-Saharan African settings (Bloomfield & 
Velazquez, 2013). 
 
 
 
The findings also imply that interventions aimed at weight management may be effective for 
blood pressure control among HIV-infected patients. While lifestyle factors may be limited in 
predicting hypertension and other cardio-metabolic disorders in people living with HIV on 
HAART (Troll, 2011); therapeutic lifestyle interventions have been found to be of modest benefit 
in reducing blood pressure in this high-risk subgroup (Balasubramanyam et al., 2011). 
 
 
 
The mainstay of managing high blood pressure associated with antiretroviral therapy may warrant 
switching antiretroviral regimens. Antiretroviral switch therapy is commonly used on an 
individualized basis in hospital settings for managing patients with HAART-associated 
cardiovascular conditions such as high blood pressure (Calza et al., 2005; Rasmussen et al., 
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2011). However, such treatment options are not readily available in low-resource settings such 
as Nigeria, resulting in an overdependence on antihypertensive medications, which potentially 
interact with antiretroviral drugs. 
 
The findings also support the addition of sleep to the cluster of behavioural factors associated 
with cardiovascular risk among people living with HIV in sub-Saharan African settings. 
 
 
 
Lastly, HIV-infected patients who are eligible to commence antiretroviral therapy should be 
candidates for routine comprehensive cardiovascular risk assessments. The Data collection on 
Adverse effects of anti-HIV Drugs (DAD) risk calculator has been reported to be a more suitable 
tool for assessing cardiovascular risk in HIV-infected patients, compared to the Framingham risk 
assessment tool which tends to underestimate the risk of cardiovascular disease in people living 
with HIV (Law et al., 2006). However, its (DAD risk calculator) potential validity in sub-Saharan 
African settings may be limited, given that the algorithms were developed for European 
populations (Friis-Møller et al., 2010). The development of algorithms for a cardiovascular risk 
assessment tool that is feasible within sub-Saharan African contexts could be an important step 
forward to tackle the burden of cardiovascular disease in people living with HIV in such settings. 
 
 
 
25.3 IMPLICATIONS OF THE PRIMARY DATA ANALYSIS FOR FUTURE 
RESEARCH 
Given that this study represents the first of its kind, further studies with larger samples are needed 
to determine if the present findings would be replicated across different settings. 
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Whether or not the results are consistent in prospective cohort studies should also be investigated 
by future studies. 
 
Future studies also need to identify what phenotypes on the HIV clinical spectrum are most 
susceptible to the effects of antiretroviral therapy on blood pressure and other cardio-metabolic 
parameters. The efficacies of targeted interventions on these phenotypes should be investigated 
in clinical trials.  
 
The indirect causal effects of antiretroviral therapy on increasing blood pressure through changes 
in serum lipoprotein levels and more sensitive measures of body fat, such as fat mass, should also 
be explored by future studies.  
 
To reiterate, the results support the validation of a cardiovascular risk assessment tool in people 
living with HIV in sub-Saharan African countries.  
 
While the results do not support the integration of depression screening with cardiovascular risk 
evaluation of HIV-infected patients in Nigeria; detection of depressive symptoms occurred in 
one out of every five ― previously undiagnosed ― HIV-infected patients in this study, which 
potentially reveals that the burden of psychiatric morbidities and poor mental wellbeing among 
people living with HIV in sub-Saharan African settings has been a neglected issue in 
epidemiological research. 
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CHAPTER TWENTY-SIX 
 
CONCLUSION 
 
In this chapter, I summarise the findings of the dissertation, while reinforcing the main ideas. 
 
 
 
 
26.1 CONCLUSION 
 
The meta-analyses, comprising data on more than 80,000 HIV-infected subjects, suggest that 
antiretroviral therapy may potentially be the single most consistent correlate of cardio-metabolic 
changes in people living with HIV worldwide. Older people, current smokers, patients with 
impaired cell-mediated immunity, and patients who have been exposed to antiretroviral therapy 
for at least 18 months may be more susceptible to the effects of antiretroviral on blood pressure 
and other cardiovascular risk parameters, when compared to other HIV-infected population 
subgroups. 
 
 
 
The Hill’s criteria are still the most commonly employed epidemiological tool for determining 
whether a causal link potentially exists between an exposure (or a treatment) and an outcome. In 
spite of the limitations to using Hill’s criteria, the evidence in the literature mostly allude to a 
plausible causal link between antiretroviral therapy and increased blood pressure. 
 
 
 
The primary data analysis revealed a high probability that the association between antiretroviral 
therapy and increased blood pressure may be causal in nature, being partially mediated by central 
fat accumulation and relative weight gain. The estimated average treatment effects on the treated 
of a propensity score-matched sample of the study population also provided evidence suggestive 
of a plausible causal  link between antiretroviral  therapy and increased blood  pressure. These 
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analyses are coherent with a growing interest in using observational data to test causal 
hypotheses, especially in cases where controlled experimentation is not feasible (such as the 
present study). 
 
 
 
Overall, the findings suggest that people living with HIV in sub-Saharan African countries may 
benefit from regular hypertension screening and other cardiovascular risk assessments, especially 
after the commencement of antiretroviral therapy. Larger prospective studies would provide a 
higher level of evidence for testing causal hypotheses regarding the association of antiretroviral 
therapy with increased blood pressure. Future studies also need to investigate the phenotypes on 
the HIV clinical spectrum that are most susceptible to the effects of antiretroviral therapy on 
blood pressure and other cardio-metabolic parameters, as well as the efficacies of targeted 
therapies on these phenotypes. 
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REFLECTIONS: The Gibbs Model of Reflection (Gibbs, 1988). 
(I). Description (what happened?) 
I was admitted into the PhD program at the Warwick Medical School, University of 
Warwick in October 2013. In fulfillment of the requirements of the PhD degree award at the 
University, I was required to pass through an upgrading process from Master of Philosophy 
(MPhil) to PhD candidate within nine months of commencing the PhD program. The 
upgrade entailed submitting a 10,000-word document and an oral examination. My 
upgrade document comprised a systematic review with meta-analyses of studies regarding 
my chosen topic and a fully developed protocol for a primary research. The research 
protocol also had to be approved by the Biomedical & Scientific Research Ethics 
Committee (BSREC) of Warwick Medical School in order to progress beyond the upgrade 
process. The data for my primary research were to be collected from patients recruited at 
the Benue State University Teaching Hospital (BSUTH) in Nigeria. Hence, after passing 
my upgrade, I also obtained ethical approval from the BSUTH Health Research Ethics 
Committee. Thereafter, I began planning my trip to Nigeria. Before travelling, my 
supervisors and I had discussed several times with the Chief Medical Director of the 
teaching hospital concerning the logistics of the research project. Section 16.9 of Chapter 
16 in my dissertation is a detailed account of the fieldwork (data collection) process in 
Nigeria. After completing my data collection, I returned to the University of Warwick to 
analyse the data. I commenced data analysis early on in my second year of PhD studies. I 
wrote up the analyses for journal publication during my second year and early on in my 
third year, as agreed with my supervisors. I had also led and submitted a series of 
systematic reviews and meta-analyses for journal publication during my second year. Most 
of the articles were accepted for publication. A few of them are currently under review. I 
now had enough materials and clarity to begin writing-up my PhD dissertation early on in 
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my third year. Within three months of commencing the write-up, I had completed and 
submitted the first draft to my supervisors. With mostly minor comments regarding the 
format of presentation, my dissertation was ready for submission much earlier than 
anticipated. 
 
 
(II). Feelings (what were you thinking and feeling?) 
 
Before commencing the programme, I was aware that the (full-time) PhD journey was not 
going to be an easy road to travel. Nonetheless, I felt quite optimistic about producing good 
work. I felt motivated to make the most during my time as a PhD student, especially 
regarding publications in peer-reviewed journals. There were concerns about travelling to 
Benue state in Nigeria for the field work, given that I had never been to that region of the 
country. However, I was quite confident in the background work my supervisors and I had 
done prior to the field work. The write-up of my PhD dissertation ― as I assume it is the 
same for most PhD students ―was an iterative process that involved revising the conceptual 
framework and re-analysing the data. Going back and forth, especially at this stage, was 
stressful, which occasionally made me feel a little less motivated. However, I always felt 
better after being reminded by my supervisors and my immediate family of the progress I 
had made so far. 
 
 
(III). Evaluation (what was good and bad about the experience?) 
 
No doubt, the process of obtaining a PhD is a rigorous one. However, I have acquired an 
immense set of skills as a researcher throughout this process ― skills that have yielded 
evidence to advance the fields of HIV therapy and management. It was a great experience 
whenever an article of mine was accepted for publication. Of note, I had the best supervisors 
in the world. They offered me their support and technical expertise with great patience, and 
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allowed me to make decisions on how I wanted to be trained. 
 
(IV). Analysis (what sense can you make of the situation?) 
 
Throughout this process, I realise that I am a quick learner, and that most problems (if not 
all) have solutions. I also find that I am able to thrive in a career as a research epidemiologist, 
either in the academia or in industry. 
 
 
(V). Conclusion (what else could you have done?) 
 
Time went by rather quickly. However, I had sufficient time to complete my dissertation 
with publications in high-impact journals. I also attended several training workshops and 
seminars. To the best of my knowledge, I cannot think of anything that I would have done 
differently within the scope of my doctoral training. 
 
 
(VI). Project (if it arose again, what would you do?) 
 
I would probably want to conduct a randomized controlled trial to determine the clinical and 
cost-effectiveness of a new intervention targeting specific phenotypes on the HIV clinical 
spectrum to reduce susceptibility to the effects of antiretroviral therapy on cardio-metabolic 
disorders. 
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APPENDIX 1: Data extraction form 
 
 
GENERAL INFORMATION 
Researcher performing data extraction  
Date of data extraction  
Author  
Article title  
Citation  
Country of origin  
STUDY CHARACTERISTICS 
Study aims/objectives  
Study design  
Sampling strategy  
Inclusion criteria  
Exclusion criteria  
Exposure Highly Active Antiretroviral Therapy 
(HAART) 
Comparator HAART-naïve 
PARTICIPANT CHARACTERISTICS 
Mean age  
• HAART-exposed  
• HAART-naïve  
Gender distribution  
• HAART-exposed  
371  
• HAART-naïve  
Number of participants  
• HAART-exposed  
• HAART-naïve  
HAART regimen (%)  
• NNRTI-based  
• PI-based  
OUTCOME DATA/RESULTS 
Outcomes  
Outcome measures  
Main results (with pooled effect sizes)  
Confounders  
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APPENDIX 2 
 
 
 
WHO STEPS Instrument 
(Core and Expanded) 
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The	WHO	STEPwise	approach	to	
chronic	disease	risk	factor	
surveillance	(STEPS)	
World Health Organization 
20 Avenue Appia, 1211 Geneva 27, Switzerland 
 
 
  
 
Overview 
STEPS Instrument 
 
 
 
Introduction This is the generic STEPS Instrument which sites/countries will use to 
develop their tailored instrument.  It contains the: 
 
• CORE items (unshaded boxes) 
• EXPANDED items (shaded boxes). 
 
 
 
Core Items The Core items for each section ask questions required to calculate basic 
variables. For example: 
 
• current daily smokers 
• mean BMI. 
 Note: All the core questions should be asked, removing core questions will 
impact the analysis. 
 
Expanded items The Expanded items for each section ask more detailed information. 
Examples include: 
 
• use of smokeless tobacco 
• sedentary behaviour. 
 
 
 
Guide to the 
columns 
The table below is a brief guide to each of the columns in the Instrument. 
 
Column Description Site Tailoring 
Number This question reference number is designed 
to help interviewers find their place if 
interrupted. 
Renumber the instrument 
sequentially once the content 
has been finalized. 
Question Each question is to be read to the participants • Select sections to use. 
• Add expanded and optional 
questions as desired. 
Response This column lists the available response 
options which the interviewer will be circling 
or filling in the text boxes. The skip 
instructions are shown on the right hand side 
of the responses and should be carefully 
followed during interviews. 
• Add site specific responses 
for demographic responses 
(e.g. C6). 
• Change skip question 
identifiers from code to 
question number. 
Code The column is designed to match data from 
the instrument into the data entry tool, data 
analysis syntax, data book, and fact sheet. 
This should never be changed 
or removed. The code is used 
as a general identifier for the 
data entry and analysis. 
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Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
WHO STEPS Instrument 
for Chronic 
Disease Risk 
Factor 
Surveillance 
 
<insert country/site name> 
 
 
 
Location	 and			Date	 Response	 Code	
     
1	 Cluster/Centre/Village			ID	 └─┴─┴─┘	 I1	
2	
 
Cluster/Centre/Village	name	
 
I2	
3	 Interviewer			ID	
 
└─┴─┴─┘	 I3	
 
4	
 
Date	of	completion	of	the	instrument	
 
└─┴─┘	└─┴─┘	└─┴─┴─┴─┘		
dd	 mm	 year	
 
I4	
 
 
 
Participant	Id	Number	
Consent,	Interview	Language	 and			Name	 Response	 Code	
 
5	
 
Consent	has	been	read	and	obtained	
Yes	 1	  
I5	No	 2	 If				NO,			END	
 
 
6	
 
 
Interview	 Language	[Insert			Language]	
English	 1	   
I6	
[Add	others]	
[Add	others]	
2	
3	
 
[Add	others]	 4	  
 
7	
 
Time	of	
interview	(24	
 
└─┴─┘:			└─┴─┘	
hrs	 mins	
 
I7	
8	 Family			Surname	  I8	
9	 First			Name	  I9	
Additional	 Information	 that	 may	 be			helpful	
10	 Contact				phone				number		where					possible	  I10	
Record and file identification information (I5  to I10) separately from the completed  questionnaire. 
Survey Information 
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Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
	
	
CORE:	 Demographic	 Information	
Question	 Response	 Code	
	
11	
	
Sex	(Record	Male	/	Female				as			observed)	
Male	1	
Female	2	
	
C1	
	
12	
What	is	your	date	of	birth?	
	
Don't	 Know	 77	 77	7777	
	
└─┴─┘	└─┴─┘	└─┴─┴─┴─┘		If			known,	Go				to				C4	
dd	 mm	 year	
	
C2	
13	 How				old				are				you?	 Years	 └─┴─┘	 C3	
	
14	 In	total,	how	many	years		have			you	spent		at			school			or	in	full-time	study	 (excluding	
	
Years	
└─┴─┘	
C4	
	
EXPANDED:	 Demographic	 Information	
	
	
	
	
15	
	
	
What				is				the	highest	level	of	education	
you	have	completed?	
	
	
	
[INSERT	COUNTRY-SPECIFIC	CATEGORIES]	
No	formal	schooling	
1	Less	
than	primary	school	2	
Primary	school	completed	3	
Secondary	school	completed	
4	High	
school	completed	 5	
	
	
	
C5	
	
	
16	
	
	
What	 is	 your	[insert	relevant	ethnic	
group	/	racial	group	/	cultural	subgroup	/	
others]				background?	
[Locally				defined]	 1	
[Locally				defined]	 2	
[Locally				defined]	 3	
	
C6	
Refused	88	
	
	
	
17	
	
	
	
	
What	is	your	marital	status?	
Never				married	 1	
Currently				married				2	
Separated	3	
 
Divorced	4	 C7	
Widowed	5	
Cohabitating		6	
Refused	88	
	
	
	
	
	
18	
	
	
Which	of	the	following	best	describes	
your	main	work	
status		over		the			past	12			months?	
	
	
[INSERT	COUNTRY-SPECIFIC	CATEGORIES]	
	
	
(USE			SHOWCARD)	
Government				employee			1	
Non-government				employee		2	
	
	
	
	
	
C8	
Self-employed		3	
Non-paid	4	
Student	5	
Homemaker		6	
Retired	
7	Unemployed	(able	to	
Unemployed				(unable				 to	work)	 9	
Refused	88	
	
19	 How	many	people	older	than	18	years,	including	yourself,	live	in	your	
	
Number				of			people	
└─┴─┘	
C9	
	
Step 1 Demographic Information 
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Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
	
	
EXPANDED:	 Demographic	 Information,	Continued	
Question	 Response	 Code	
	
	
20	
	
Taking	the	past	year,	can	you	tell	me	
what	the	average	earnings	of	the	
household	have				been?	
(RECORD	 ONLY	 ONE,	NOT				ALL				 3)	
Per			 week	 └─┴─┴─┴─┴─┴─┴─┘	 Go		to	T1	 C10a	
OR		per		month	 └─┴─┴─┴─┴─┴─┴─┘	 Go		to	T1	 C10b	
OR		per		year	 └─┴─┴─┴─┴─┴─┴─┘	 Go		to	T1	 C10c	
Refused				88	 C10d	
	
	
	
21	
	
If	you	don’t	know	the	amount,		can	you		
give	an	estimate	of	the	annual	household	
income	if		I		read	some		options			to		you?	
Is				it	
[INSERT	QUINTILE	VALUES	IN	LOCAL	
CURRENCY]	(READ	OPTIONS)	
£ Quintile				(Q)				1			1	
More				than				Q				1,				£  Q				2	 2	
More				than				Q				2,				£  Q				3	 3	
More				than				Q				3,				£  Q				4	 4	
More				than				 Q				4	 5	
Don't				Know	 77	
Refused	88	
	
	
	
C11	
	
	
CORE:	 Tobacco	 Use	
Now			I			am			going			to			ask			you					some			questions	 about	various	 health	 behaviours.	 This	 includes	 things	like	
smoking,	drinking	alcohol,	eating	fruits	and	vegetables	and	physical	activity.	Let's	start	with	 tobacco.	
Question	 Response	 Code	
	
22	
Do	you	currently	smoke	any	tobacco	
products,	such	as	cigarettes,	cigars	or	
pipes?	(USE	SHOWCARD)	
Yes		1	
	
No				 2	 If				No,	 go	to				T6	
	
T1	
	
23	
	
Do	you	currently	smoke	tobacco	
products			daily?	
Yes		1	
	
No				 2	 If				No,	 go	to				T6	
	
T2	
	
24	
How		old		were		you	when	you	first	started	
smoking	daily?	
Age			(years)	
	
Don’t				know	 77	 └─┴─┘	If	Known,	
	
T3	
	
	
	
25	
	
Do	you	remember	how	long				ago				it				was?	
	
(RECORD		ONLY		1,			NOT	ALL			3)	
	
Don’t				know			77	
In			Years	
└─┴─┘	If	Known,	go				to				T5a	 T4a	
OR	 in				Months	
└─┴─┘	If	Known,	go				to				T5a	
T4b	
	
OR	 in				Weeks	
└─┴─┘	
T4c	
	
	
	
	
	
	
26	
	
	
	
On	 average,	 how	many				of				the	
following		do		you	smoke				each				day?	
	
	
(RECORD			FOR				EACH	TYPE,				USE				SHOWCARD)	
	
Don’t				Know	 77	
Manufactured			cigarettes	
└─┴─┘	 T5a	
Hand-rolled			cigarettes	
└─┴─┘	 T5b	
Pipes				full				of				tobacco	
└─┴─┘	 T5c	
Cigars,	cheroots,	cigarillos	
└─┴─┘	 T5d	
Other	 	 If				Other,	go				 to	
T5other,	
T5e	
	
Other	 (please	 specify):	 └─┴─┴─┴─┴─┴─┘	
Go				to			T9	
	
T5other	
	
Step 1 Behavioural Measurements 
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Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
	
	
EXPANDED:	 Tobacco	 Use	
Question	 Response	 Code	
	
27	
	
In	the	past,	did	you	ever				smoke				daily?	
Yes		1	
	
No					2				 If				No,	 go	to				T9	
	
T6	
 
	
28	
	
How	 old	 were	 you	when	you	stopped	
smoking				daily?	
Age			(years)	
Don’t				Know	 77└─┴─┘	If	Known,				go				 to	
	
T7	
	
	
29	
	
How	long	ago	did	you	stop				smoking				daily?	
	
(RECORD		ONLY			1,			NOT	ALL				3)	
	
Don’t				Know	 77	
Years				ago	
└─┴─┘	If	Known,				go				to					T9	 T8a	
OR	 Months				ago	
└─┴─┘	If	Known,	go				to				T9	 T8b	
OR	 Weeks				ago	
└─┴─┘	 T8c	
	
30	
	
Do	you	currently	use	any	 smokeless	tobacco	
such	as	[snuff,	chewing	tobacco,	 betel]?	(USE	
Yes		1	 	
T9	
No				 2	 If				No,				go				to		T12	
	
31	
Do	you	currently	use	smokeless	tobacco	
products	
daily?	
Yes		1	
No				 2	 If				No,				go				to		T12	
	
T10	
	
	
	
	
	
32	
	
	
	
On	average,	how	many	times		a		day		do		
you	use			….	
	
	
(RECORD	FOR	EACH	TYPE,	USE	
SHOWCARD)	
	
	
Don't				Know			77	
Snuff,				by			mouth	
└─┴─┘	
T11a	
Snuff,				by			nose	
└─┴─┘	 T11b	
Chewing			tobacco	
└─┴─┘	 T11c	
Betel,			quid	
└─┴─┘	 T11d	
If				Other,				go				to	T11other,	
└─┴─┘				else				go				to				T13	 T11e	
Other		(specify)			└─┴─┴─┴─┴─┴─┴─┘		Go				to			T13	 T11other	
	
33	
In	 the	 past,	 did	you		ever		use	smokeless	
tobacco	such	as	[snuff,	chewing	tobacco,	or	
betel]				daily?	
Yes		1	
No		2	
	
T12	
  Number				of			days	
Don't				know				77			└─┴─┘	
	
T13	
During	the	past	7	days,	on	how	many	
days		did			someone	in				your					home	
smoke		when			you	were				present?	
34	
	
35	
During	the	past		7	days,		on		how		
many	days	did	someone	smoke	in	
closed	areas	in	your	workplace	(in	the	
building,	in	a	work	area	or	a	specific	
Number	of	
	
	
	
└─┴─┘	
	
T14	
Don't	know	or	don't	
work	in	a	closed	area	
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Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
	
	
CORE:	 Alcohol	 Consumption	
The		next		questions		ask			about			the			consumption			of		alcohol.	
Question	 Response	 Code	
	
36	
Have	 you	 ever	 consumed	 an	 alcoholic	 drink	
such	as	beer,	wine,	spirits,	fermented	cider	or	
[add	other	local				examples]?	
(USE						SHOWCARD						OR		SHOW	
	
Yes	
	
No	
	
1	
	
2	
	
	
	
If		No,		go			to	D1	
	
A1a	
37	 Have	 you	 consumed	an	alcoholic	drink	within	the	past	12	months?	
Yes	
N	
1	
2	
	
If		No,		go			to	D1	
A1b	
	
	
38	
During	the	past	12	months,				how	frequently	 Daily	 1	  	
	
A2	
had	at	least	one	alcoholic			drink?	 5-6	days	per	week	 2	  
 1-4	days	per	week	 3	  
(READ	RESPONSES,	USE	SHOWCARD)	 1-3	days	per	month	 4	  
 Less		than	once				a				month	 5	  
	
39	 Have	 you	 consumed	an	alcoholic	drink	within	the	past	30	days?	
Yes	
N	
1	
2	
	
If		No,		go		to	D1	
A3	
	
40	
	
During	the	past	30	days,	on	how	many	
occasions	did	you	have	at	least	one	alcoholic	
drink?	
	
Number	
Don't	know	77	
	
	
└─┴─┘	
	
A4	
	
41	
During	the	past	30	days,	when	you	drank	
alcohol,	on	average,	how	many	standard	
alcoholic	drinks	did	you	have	during	one	
drinking	occasion?	
	
Number	
Don't	know	77	
  	
A5	
 └─┴─┘	
	
42	
During	the	past	30	days,	what	was	the	largest	
number	of	standard	alcoholic	drinks	you	had	
on	a	single	occasion,	counting	all	types	of	
alcoholic	drinks	together?	
	
Largest	number	
Don't	Know	77	
	
	
└─┴─┘	
	
A6	
	
43	
During	the	past	30	days,	 how	 many	
times		did		you		have	for		men:		five		or		
more	
for		women:			four			or	more	
Number	of	
times	Don't	
	
	
└─┴─┘	
	
A7	
	
EXPANDED:	 Alcohol	 Consumption	
	
	
44	
	
During	the	past	30	days,	when	you	consumed	
an	alcoholic	drink,	how	often	was	it	with	
meals?	Please	do	not	count			snacks.	
Usually	with	
meals	Sometimes	
1	
2	
3	
4	
	
A8	
Rarely	with	meals	
		 Never	with	meals	 	
	
	
	
	
	
	
	
45	
	
	
	
	
During	each	of	the	past	7	days,	how	many	
standard	alcoholic					drinks	did	you		have		
each	day?	
	
(USE			SHOWCARD)	
	
	
Don't				Know			77	
Monday			└─┴─┘	 A9a	
Tuesday				└─┴─┘	 A9b	
Wednesday			└─┴─┘	 A9c	
Thursday			└─┴─┘	 A9d	
Friday				└─┴─┘	 A9e	
Saturday			└─┴─┘	 A9f	
Sunday				└─┴─┘	 A9g	
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Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
	
	
CORE:	 Diet	
The		next			questions			ask			about			the			fruits			and	vegetables		that		you		usually		eat.		I		have		a			nutrition	card			here			
that			shows			you			some				examples			of	 local	fruits		and		vegetables.		Each		picture		represents			the	size		of			 a		serving.	
As			you			answer			these				questions	please	 think	 of	 a				 typical	 week	 in	 the				last			 year.	
Question	 Response	 Code	
	
46	
In	 a	 typical	 week,	on			how			many	
days			do	you				eat					fruit?	
Number	of	days	
Don't	Know	77	
	
└─┴─┘	
	
If	Zero	days,		go	to	
D1	
	
47	 How	many	servings	of	fruit		do		you		eat				on	one	of		those		days?	(USE			SHOWCARD)	
Number	of	
servings	
	
└─┴─┘	
 
D2	
	
48	 In	 a	 typical	 week,	on			how			many	days			do	you	
Number	of	days	
Don't	Know	77	
	
└─┴─┘	
	
If	Zero	days,		go	to	
D3	
	
49	 How	many	servings	of	vegetables	 do	 you	eat	on	one	of	those	days?	 (USE	
Number	of	
servings	
	
└─┴─┘	
 
D4	
	
EXPANDED:	 Diet	
	
	
	
	
	
50	
	
	
	
What	 	 	 type	 	 	 of	 	 	oil	 or	 	 	 fat	 	 	 is	 	 	most		
often	 	 	used	 	 	 for	meal	 	 	 	 preparation	 in	
your				household?	
	
(USE	SHOWCARD)	
(SELECT	ONLY	ONE)	
Vegetable			oil	 1	
2	
3	
4	
5	 If				Other,				go	 to				D5	
other	
6	
7	
	
	
	
	
D5	
Lard				or			suet	
Butter		or	ghee	
Margarine	
Other	
None	in	particular	
None			used	
Don’t			know	
Other			└─┴─┴─┴─┴─┴─┴─┘	 D5other	
	
51	
On	average,	how	many	meals					per					week	
do	you	eat	that	were	not	prepared	at	a	
home?				By				meal,				I	mean					 breakfast,	
	
Number	
Don’t	know	77	
└─┴─┘	
	
D6	
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CORE:	 Physical	 Activity	
Next		I		am		going		to		ask		you		about		the		time		you		spend	doing		different		types		of			physical			activity			in			a	typical			
week.		Please			answer			these			questions			even			if	you			do			not			consider					 yourself			to	 be	 a				physically	active	
person.	
Think			first			about			the				time			you	 spend	 doing	 work.	Think	 of	 work	 as	 the	 things	 that	 you	 have	 to	
do			such			as			paid			or				unpaid			work,	 study/training,	household	chores,	harvesting	food/crops,	fishing	or	hunting	for	food,	
seeking	employment.	[Insert	other	examples	if	needed].	In	answering	the		following	questions	'vigorous-intensity	 activities'	
     Question	 Response	 Code	
Work	
	
	
52	
Does	your	work	involve	vigorous-intensity	
activity	 that	causes	large	increases	in	
	
Yes	
	
1	
 	
	
P1	[carrying	 or	lifting	 heavy	loads,	digging	
or	construction	work]	for	at	least	10	minutes	
continuously?	
	
No	
	
2	
	
If			No,			go				to	P					4	
	
53	 In	a	typical	week,	on	how	many	days	do	you	do	vigorous-intensity	activities	as	part	
	
Number		of	days	
  	
P2	
 └─┘	
	
54	
	
How	 much	 time	 do	you	spend	doing	
vigorous-intensity	activities	at	work	on	a	
typical			day?	
	
Hours				:				minutes				└─┴─┘:	└─┴─┘	
hrs	 mins	
P3	
(a-b)	
	
	
55	
    	
	
P4	
Does	your	work	involve	moderate-intensity	
activity,		that	causes	small	increases	in	
breathing	or	heart	rate	such	as	brisk	walking	[or	
carrying	light	loads]	for	at	least	10	minutes	
continuously?	
Yes	 1	  
	
No	
	
2	
	
If			No,			go			to	P					7	
	
56	 In	a		typical		week,	on		how			many			days		do	you	do	moderate-intensity	activities	as	
	
Number		of	days	
  
P5	
 └─┘	
	
57	
	
How	much	time	do	you	spend	doing	moderate-	
intensity	activities		at			work	on			a			typical		
day?	
	
Hours				:				minutes				└─┴─┘:	└─┴─┘	
hrs	 mins	
P6	
(a-b)	
      Travel	 to	 and	 from	 places	
The	 next	 questions	 exclude	 the	 physical	 activities	at	 work	 that	 you	 have	 already			 mentioned.	
Now			I			would	 like	 to				ask		 you	 about	 the	 usual	 way	you			travel			to	 and				from	 	 places.	 For	 example	
to	work,			 for			shopping,	 to	 market,		 to				place	 of	worship.	 [Insert	 other	 	examples	 if			needed]	
	
58	
	
Do		you		walk		or		use		a	bicycle	(pedal		
cycle)	for	at	least	10	minutes	continuously	
to	get	to				and				from					places?	
Yes	
	
No	
1	
	
2	
	
	
If			No,			go			to	P				10	
	
P7	
	
59	
In		a			typical			week,	on			how				many				days	
do	 you	 walk	 or	 bicycle	 	 for	 	 at	 least	 10		
minutes	continuously										to	get	to	and		 from	
	
Number		of	days	
  	
P8	
 └─┘	
	
60	
	
How				much				time					do		you	 spend	
walking	or	bicycling	for	travel	on	a	typical	
day?	
	
Hours				:				minutes				└─┴─┘:	└─┴─┘	
hrs	 mins	
P9	
(a-b)	
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CORE:	 Physical	 Activity,	 Continued	
Question	 Response	 Code	
Recreational			activities	
The	next	questions	exclude	the	work	and	 transport	activities	 that	 you	 have	 already			mentioned.	
Now	 I	 would	 like				to				ask	 you	 about	 sports,				fitness	and		recreational		activities			(leisure),			[Insert		relevant	
	
	
61	
Do	you	do	any	vigorous-intensity	sports,	
fitness	or	recreational	(leisure)	activities	that	
cause	large	increases	in	breathing	or	heart	
rate	like	[running	or				football]	 for	at	
least	 10	minutes	continuously?	
	
Yes	
	
	
No	
	
1	
	
	
2	 If				No,				go		to				P					13	
	
	
P10	
	
62	
In	 a	 typical	week,	 on	 how	many	 days	 do	
you	do	vigorous-intensity	sports,	fitness	or	
recreational	(leisure)	activities?	
	
Number		of	days	
 	
P11	
 └─┘	
	
63	
	
How	much	time	do	you	spend	doing	vigorous-	
intensity	sports,	fitness	or	recreational	activities	
on	a	typical			day?	
	
Hours				:				minutes				└─┴─┘:	└─┴─┘	
hrs	 mins	
P12	
(a-b)	
	
	
64	
   	
	
P13	
Do	you	do	any	moderate-intensity	sports,	
fitness	or	recreational	(leisure)	activities	that	
cause	a	small	increase	in	breathing	or	heart	
rate	such	as	brisk	walking,	[cycling,	swimming,	
volleyball]	for	at	least	10	minutes	
continuously?	
Yes	
	
	
No	
1	
	
	
2	 If				No,				go				to		P16	
	
65	
	
In	a	typical	week,	on	how	many	days	do	
you	do	moderate-intensity	sports,	fitness	
or	recreational	(leisure)	activities?	
	
	
Number		of	days	
 	
P14	
 └─┘	
	
	
66	
	
How	much	time	do	you	spend	doing	moderate-	
intensity	sports,	fitness	or	recreational	(leisure)	
activities	on				a				typical				day?	
	
	
Hours	:	minutes	
	
	
	
└─┴─┘:	
└─┴─┘	
	
P15	
(a-b)	
	
EXPANDED:	 Physical	 Activity	
Sedentary	 behaviour	
The	 following	 question	 	 is	 about	 sitting	 or	reclining		at		work,		at			home,			getting			to			and				 from	places,	 or	
with	 friends	 including	 time		 spent	sitting			at			 a			desk,	 sitting	 with	 friends,	 traveling	in			car,			 bus,			train,	
reading,			playing			cards			or	watching	television,	but	do	not	include	time		spent	sleeping.		 [INSERT				EXAMPLES]	 (USE	
	
67	
	
How	much	time	do	you	usually	 spend	sitting	
or	reclining	on				a				typical				day?	
	
Hours				:				minutes				└─┴─┘:	└─┴─┘	
hrs	 mins	
P16	
(a-b)	
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CORE:	 History	 of	 Raised	 Blood	 Pressure	
Question	 Response	 Code	
	
68	
	
Have	you	ever	had	your	blood	pressure	
measured	by	a	doctor	or	other	health	
worker?	
Yes	
	
No	
1	
	
2	
	
	
If	 No,	 go	to			H6	
	
H1	
	
69	
    	
H2a	
Have	you	ever	been	told	 by	 a	 doctor	
or	other	health	worker	that	you	have	
raised	blood	pressure	or	hypertension?	
Yes	
No	
1	
2	
	
If	 No,	 go	to			H6	
	
70	
	
Have	 you	 been	 told	in				 the				past	
12	months?	
Yes	
No	
1	
2	
 	
H2b	
	
EXPANDED:	 History	 of	 Raised	 Blood	 Pressure	
	
	
	
	
	
	
	
71	
Are	you	currently	receiving	any	of	the	following	treatments/advice			for			high			blood			pressure			prescribed			by			a				doctor							or	
	
Drugs	(medication)	that	you	have	taken	in	
the				past				two	 weeks	
Yes		1	
No		2	
	
H3a	
	
Advice	 to	 reduce	salt			intake	
Yes		1	
No		2	
	
H3b	
	
Advice				or				treatment	to				lose				weight	
Yes		1	
No		2	
	
H3c	
	
Advice				or				treatment	to				stop				smoking	
Yes		1	
No		2	
	
H3d	
	
Advice	 to	 start	 or	do				more				 exercise	
Yes		1	
No		2	
	
H3e	
	
72	 Have	you	ever	seen	a	traditional	healer	for	raised	blood	pressure	or	hypertension?	
Yes		1	
No		2	
	
H4	
	
73	
	
Are	you	currently	taking	any	herbal	or	
traditional	remedy	for	your	raised	blood	
pressure?	
Yes		1	
	
No		2	
	
H5	
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CORE:	 History	 of	 Diabetes	
Question	 Response	 Code	
	
74	
	
Have	you	ever	had	your	blood	sugar	
measured	by	a	doctor	or	other	health	
worker?	
Yes		1	
	
No				 2	 If				No,				go	to					M1	
	
H6	
	
75	 Have	you	ever	been	told	by	a	doctor	or	other	health	worker	that	 you	 have	raised	
Yes		1	
No				 2	 If				No,				go	to					M1	
	
H7a	
	
76	
	
Have	 you	 been	 told	in				 the				past	
12	months?	
Yes		1	
No		2	
	
H7b	
	
EXPANDED:	 History	 of			Diabetes	
	
	
	
	
	
	
	
	
	
77	
Are	you	currently	receiving	any	of	the	following	treatments/advice				for				diabetes				prescribed				by				a				doctor	or				other							health	
	
Insulin	
Yes		1	
	
No		2	
	
H8a	
 
Drugs	(medication)	that	you	have	taken	in	
the				past				two	 weeks	
Yes		1	
No		2	
	
H8b	
	
Special	prescribed	diet	
Yes		1	
No		2	
	
H8c	
	
Advice				or				treatment	to				lose				weight	
Yes		1	
No		2	
	
H8d	
	
Advice				or				treatment	to				stop				smoking	
Yes		1	
No		2	
	
H8e	
	
Advice	 to	 start	 or	do				more				 exercise	
Yes		1	
No		2	
	
H8f	
	
78	 Have	 you	 ever	 seen	a	 traditional	healer		for		diabetes	or		raised		blood	 sugar?	
Yes		1	
No		2	
	
H9	
	
79	 Are	you	currently	taking	any	herbal	or	traditional	remedy	for	your	diabetes?	
Yes		1	
No		2	
	
H10	
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CORE:	 Height	 and	 Weight	
Question	 Response	 Code	
80	 Interviewer			ID	
	
└─┴─┴─┘	 M1	
	
81	
	
Device	 IDs	 for	height				and			 weight	
Height	
	
Weight	
└─┴─┘	
└─┴─┘	
M2a	
M2b	
	
82	
	
Height	
	
in	Centimetres	(cm)	
 
M3	
 └─┴─┴─┘.				└─┘	
	
83	 Weight	If				too				large				for	scale				666.6	
	
in	Kilograms	(kg)	
 	
M4	
 └─┴─┴─┘.└─┘	
	
84	
	
For	women:	Are	you	pregnant?	
Yes	
No	
1			If				Yes,				go	to				M				8	
2	
	
M5	
CORE:	 Waist	
85	 Device				ID				for				waist	 	 └─┴─┘	 M6	
	
86	
	
Waist			circumference	
	
in	Centimetres	(cm)	
 
M7	
 └─┴─┴─┘.└─┘	
CORE:	 Blood	 Pressure	
87	 Interviewer			ID	 	 └─┴─┴─┘	 M8	
88	 Device	ID	for	blood	pressure	
	
└─┴─┘	 M9	
	
89	
	
Cuff				size			used	
Smal	
l	
Mediu	
1	
2	
3	
	
M10	
	
90	
	
Reading			1	
Systolic		(		mmHg)	└─┴─┴─┘	 M11a	
Diastolic		(mmHg)		└─┴─┴─┘	 M11b	
	
91	
	
Reading			2	
Systolic		(		mmHg)	└─┴─┴─┘	 M12a	
Diastolic		(mmHg)		└─┴─┴─┘	 M12b	
	
92	
	
Reading			3	
Systolic		(		mmHg)	└─┴─┴─┘	 M13a	
Diastolic		(mmHg)		└─┴─┴─┘	 M13b	
	
93	
During	the	past	two	weeks,	 have	 you	
been	treated	for	raised	blood	pressure	with	
drugs	(medication)	prescribed	by	a	doctor	or	
Yes	
	
No	
1	
	
2	
	
M14	
	
EXPANDED:	 Hip	 Circumference	 and	 Heart			Rate	
94	 Hip			circumference	 in		Centimeters		(cm)	 └─┴─┴─┘.└─┘	 M15	
	
	
95	
Heart			Rate	  
Reading			1	 Beats		per		minute	 └─┴─┴─┘	 M16a	
Reading			2	 Beats		per		minute	 └─┴─┴─┘	 M16b	
Reading			3	 Beats		per		minute	 └─┴─┴─┘	 M16c	
	
Step 2 Physical Measurements 
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CORE:	 Blood	 Glucose	
Question	 Response	 Code	
	
96	
	
During	the	past	12	hours	have	you	had	
anything	to	eat	or	drink,	other	than	water?	
Yes	
No	
1	
2	
	
B1	
97	 Technician			ID	
	
└─┴─┴─┘	 B2	
	
98	
	
Device			ID	
	
└─┴─┘	
B3	
	
99	
	
Time	of	day	blood	specimen	taken	(24	hour	
clock)	
Hours				:				minutes		└─┴─┘:	└─┴─┘	
hrs	 mins	
	
B4	
	
100	
	
Fasting	 blood	glucose	
Choose	accordingly:	mmol/l				or			mg/dl	
	
mmol/l	
	
└─┴─┘.			└─┴─┘	
	
B5		
mg/dl	
	
└─┴─┴─┘.└─┘	
	
101	
Today,			have			you	taken	insulin	or	other	
drugs	(medication)	that	have	 been	
prescribed	by	a	doctor	or	other	health	worker	
Yes	
No	
1	
2	
	
B6	
CORE:	 Blood	 Lipids	
102	 Device			ID	
	
└─┴─┘	 B7	
	
103	
	
Total			cholesterol	
Choose	accordingly:	mmol/l				or			mg/dl	
	
mmol/l	
	
└─┴─┘.			└─┴─┘	
	
B8		
mg/dl	
	
└─┴─┴─┘.└─┘	
	
104	
During	the	past	two	weeks,	have	you	been	
treated	for	raised	cholesterol	with	drugs	
(medication)	prescribed			by			a	doctor			or	
Yes	
No	
1	
2	
	
B9	
	
EXPANDED:	 Triglycerides	 and	 HDL	Cholesterol	
	
105	
	
Triglycerides	
Choose	accordingly:	mmol/l				or			mg/dl	
mmol/l	
└─┴─┘.			└─┴─┘	
	
B10	
mg/dl			└─┴─┴─┘.└─┘	
	
106	
	
HDL			Cholesterol	
Choose	accordingly:	mmol/l				or			mg/dl	
mmol/l			└─┘.				└─┴─┘	
	
B11	
mg/dl			└─┴─┴─┘.└─┘	
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APPENDIX 3: The Pittsburgh Sleep Quality Index Questionnaire 
 
 
Name  Date   
 
 
Sleep Quality Assessment (PSQI) 
 
 
INSTRUCTIONS: 
 
The following questions relate to your usual sleep habits during the past month only. Your answers should indicate the most accurate reply for the 
majority of days and nights in the past month. Please answer all questions. 
 
During the past month, 
 
 
 
1. When have you usually gone to bed?     
 
2. How long (in minutes) has it taken you to fall asleep each night?    
 
3. What time have you usually gotten up in the morning?    
 
4. A. How many hours of actual sleep did you get at night?    
 
B. How many hours were you in bed?    
 
 
5. During the past month, how often have you had trouble sleeping 
because you 
Not during 
the past 
month (0) 
Less than 
once a 
week (1) 
Once or 
twice a 
week (2) 
Three or 
more 
times a 
week (3) 
A. Cannot get to sleep within 30 minutes     
B. Wake up in the middle of the night or early morning     
C. Have to get up to use the bathroom     
D. Cannot breathe comfortably     
E. Cough or snore loudly     
F. Feel too cold     
G. Feel too hot     
H. Have bad dreams     
I. Have pain     
J. Other reason (s), please describe, including how often you have 
had trouble sleeping because of this reason (s): 
    
6. During the past month, how often have you taken medicine 
(prescribed or “over the counter”) to help you sleep? 
    
7. During the past month, how often have you had trouble staying 
awake while driving, eating meals, or engaging in social activity? 
    
8. During the past month, how much of a problem has it been for you 
to keep up enthusiasm to get things done? 
    
9. During the past month, how would you rate your sleep quality 
overall? 
Very good 
(0) 
Fairly 
good (1) 
Fairly bad 
(2) 
Very bad 
(3) 
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APPENDIX 4: Centre for Epidemiologic Studies Depression (CES-D) Questionnaire 
 
 
 During the past week: Rarely or none of 
the time (less 
than 1 day) 
Some or a little of 
the time (1-2 
days) 
Occasionally or a 
moderate amount 
of time (3-4 days) 
Most or all of the 
time (5-7 days) 
1. I was bothered by things that 
usually don't bother me. 
    
2. I did not feel like eating; my 
appetite was poor. 
    
3. I felt that I could not shake off 
the blues even with help from 
my family or friends. 
    
4. I felt I was just as good as 
other people. 
    
5. I had trouble keeping my mind 
on what I was doing. 
    
6. I felt depressed.     
7. I felt that everything I did was 
an effort. 
    
8. I felt hopeful about the future.     
9. I thought my life had been a 
failure. 
    
10. I felt fearful.     
11. My sleep was restless.     
12. I was happy.     
13. I talked less than usual.     
14. I felt lonely.     
15. People were unfriendly.     
16. I enjoyed life.     
17. I had crying spells.     
18. I felt sad.     
19. I felt that people disliked me.     
20. I could not get going.     
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APPENDIX 5: The Short-Form 12 (SF-12) Questionnaire 
 
 
General Health Subdomain 
 
In general, would you say your health is excellent, very good, good, fair, or poor? 
 
1) Excellent 
 
2) Very good 
 
3) Good 
 
4) Fair 
 
5) Poor 
Physical Functioning Subdomain 
 
How does your health now limit you in moderate activities, such as moving a table, doing house chores? Would you say you 
are limited a lot, a little or not at all? 
 
1) Yes, limited a lot 
 
2) Yes, limited a little 
 
3) No, not limited at all 
 
How about climbing several flights of stairs? Would you say your health limits you a lot, a little, or not at all? 
 
1) Yes, limited a lot 
 
2) Yes, limited a little 
 
3) No, not limited at all 
Role Functioning (Physical) Subdomain 
 
Thinking about the past four weeks, have you accomplished less than you would like as a result of your physical health? 
 
1) Yes 
 
2) No 
 
During the past four weeks, were you limited in the kind of work or other activities you could do as a result of your physical 
health? 
 
1) Yes 
 
2) No 
Bodily Pain Subdomain 
 
During the past four weeks, how much did pain interfere with your normal work including both work outside the home and 
housework? 
 
1) Extremely 
 
2) Quite a bit 
 
3) Moderately 
 
4) A little bit 
 
5) Not at all 
Vitality Subdomain 
 
How much of the time during the past four weeks did you have a lot of energy? Would you say (read responses)? 
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1) None of the time 
	
2) A little of the time 
	
3) Some of the time 
	
4) Good bit of the time 
	
5) Most of the time 
	
6) All of the time 
Role Functioning (Emotional) Subdomain 
	
In the past four weeks, did you accomplish less than you would like as a result of an emotional problem, such as feeling 
depressed or anxious? 
	
1) Yes 
	
2) No 
	
During the last four weeks, did you have trouble doing work or other activities as carefully as usual as a result of an 
emotional problem, such as feeling depressed or anxious? 
	
1) Yes 
	
2) No 
Mental Health Subdomain 
	
How much of the time during the past four weeks have you felt calm and peaceful? Would you say (read responses)? 
	
1) None of the time 
	
2) A little of the time 
	
3) Some of the time 
	
4) Good bit of the time 
	
5) Most of the time 
	
6) All of the time 
	
How much of the time during the past four weeks have you felt downhearted and blue? (If necessary, read responses) 
	
1) All of the time 
	
2) Most of the time 
	
3) Good bit of the time 
	
4) Some of the time 
	
5) A little of the time 
	
6) None of the time 
Social Functioning Subdomain 
	
During the last four weeks, how much of the time has your physical health or emotional problems interfered with your social 
activities, like visiting with friends, relatives etc.? 
	
(If necessary, read responses) 
348  
Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
	
	
APPENDIX 6: Ethics approval document from Warwick Medical School, 
University of Warwick 
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APPENDIX 7: Ethics approval document from the Benue State University Teaching 
Hospital 
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APPENDIX 8: Participant information leaflet 
 
 
 
Provisional 
Study Title: 
ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR 
DISEASE RISK FACTOR PROFILES OF HIV-INFECTED 
PATIENTS IN NIGERIA: A CROSS-SECTIONAL SUDY 
 
Investigator: 
 
DR. CHIDOZIE NDUKA 
 
 
 
 
Introduction 
You are invited by the University of Warwick to take part in a research study. Before you 
decide, you need to understand why the research is being done and what it would involve 
for you. Please take the time to read the following information carefully. Talk to others 
about the study if you wish. 
 
(Part 1 tells you the purpose of the study and what will happen to you if you take part. Part 
2 gives you more detailed information about the conduct of the study) 
 
Please ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
 
 
PART 1 
 
 
What is the study about? 
HIV-infected patients have to take their HIV drugs in order to live longer. However, there 
are now concerns that these HIV drugs can cause heart problems after a long period of use. 
So we would like to compare the numbers of patients who are at risk of developing heart 
disease or stroke between HIV-infected patients who have been receiving HIV drugs and 
HIV-infected patients who are not yet required to receive their HIV drugs. It is important 
for us to determine if this association exists so that we can improve your care. 
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Why have I been asked to take part? 
You have been asked to take part in this study because you have been living with HIV for 
some time now. Only HIV-infected patients attending this clinic are eligible to participate 
in this study and we would like to assess your risk of developing heart disease or stroke 
because HIV and HIV drugs have the potential for complications or side effects that affect 
Do I have to take part? 
It is your decision to take part (or not) in this study. We will describe the study and go 
through this information sheet, which we will give you to keep. If you choose to 
participate, we will ask you to sign a consent form to confirm that you have agreed to take 
part. You will be free to withdraw at any time, without giving a reason and this will not 
affect you or your circumstances in any way. 
What will happen to me if I take part? 
After you decide to take part, we will ask you a series of questions and run some tests for 
you at no cost. The tests will include measuring the glucose and fat levels in your blood. 
We will also measure your blood pressure. As regards the questions, we would it if you 
provided us with all the answers; however, please be aware that it is within your rights to 
refuse to answer a particular question. However, we need to run the tests if you decide to 
take part in this research study. 
What are the possible disadvantages, side effects, risks, and/or discomforts of 
taking part in this study? 
The questionnaires might take a while to answer, but I will guide you through all of them. 
The tests will involve a small needle prick on one of your fingertips to get the blood 
samples. You might experience a slight sudden pain, which is only produced by the jab. 
The pain becomes a dull ache that subsides within a few minutes. You might also 
experience some slight bruising at the jabbed fingertip, but this also resolves veryshortly. 
The jabbed fingertip might be gently milked to let down more blood onto the test strip. 
However, no more than two drops of blood (0.1mL) is needed for the tests and there would 
be no need for storage. The procedure is not known to be life-threatening or constitute 
severe complications in adults; however, it will be carried out by experienced staff. We 
have also provided sufficient numbers of lancets to ensure that no lancet is used twice or 
shared. You might also experience some slight discomfort from inflating the cuff during 
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What do I gain from taking part? 
You get to know whether or not you are at a higher risk than normal of developing heart 
disease or stroke in the future. If you are, the information will be indicated in your medical 
record for your doctor to see and take necessary action. However, there should be no cause 
for worry as the risk is not immediately life-threatening and can be modified. 
	
Expenses and payments 
Transport costs will be subsidized for those patients who return to participate in the study 
in advance of their next follow-up appointment at the clinic. 
What will happen when the study ends? 
After we have gathered all the information that is needed, we will analyse them at the 
University of Warwick. We will also send a summary of the results to the clinic. 
Will my taking part be kept confidential? 
Yes. We will follow strict ethical and legal practice and all information about you will be 
handled in confidence. We will also not be requiring names. Your formation will be kept safe 
in a secure online location at all times, accessed only using the researcher’s University of 
Warwick user account. 
	
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm that you might suffer will be addressed. Detailed information is given in Part 2. 
	
	
	
This concludes Part 1. 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
 
 
 
353  
Participant	Identification	Numb	 └─┴─┴─┘└─┴─┴─┘└─┴─┴─┘	
	
	
PART 2 
 
 
 
 
 
Who is organising and funding the study? 
This study is being conducted in fulfilment of the degree of PhD at the University 
of Warwick, United Kingdom. 
 
What will happen if I don’t want to carry on being part of the study? 
 
Participation in this study is entirely voluntary. Refusal to participate will not affect you in any 
way. If you decide to take part in the study, you will need to sign a consent form, which states 
that you have given your consent to participate. 
 
If you agree to participate, you may nevertheless withdraw from the study at any time without 
affecting you in any way. 
 
You have the right to withdraw from the study completely and decline any further contact by 
study staff after you withdraw. 
 
What if there is a problem? 
 
This study is covered by the University of Warwick’s insurance and indemnity cover. If 
you have an issue, please contact Jo Horsburgh (details below). 
Who should I contact if I wish to make a complaint? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might have suffered will be addressed. Please address your complaint to the 
person below, who is a Senior University of Warwick official entirely independent of this 
study: 
 
Jo Horsburgh 
Deputy Registrar 
Deputy Registrar’s 
Office University of 
Warwick Coventry, UK, 
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What will happen to the results of the study? 
The results of the study will be summarized and sent to the clinic to be forwarded to 
participants who require a copy. We would also like to present the results in conferences 
as well as publish them in key medical journals. 
	
Who has reviewed the study? 
This study has been reviewed and given favourable opinion by the University of Warwick’s 
Biomedical and Scientific Research Ethics Committee (BSREC): (BSREC number: REGO- 
2014-711). 
What if I want more information about the study? 
If you have any questions about any aspect of the study or your participation that is not 
answered by this participant information leaflet, please contact any of the following people: 
	
Dr. Chidozie U. Nduka; C.U.Nduka@warwick.ac.uk; 
+44(0)7472730268 Dr. Saverio Stranges; S.Stranges@warwick.ac.uk; 
+44(0)2476151153 
Dr. Olalekan A. Uthman; Olalekan.uthman@warwick.ac.uk; +44(0)2476573163 
	
	
	
	
	
	
	
Thank you for taking the time to read this participant information leaflet. 
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APPENDIX 9: Participant consent form 
 
 
BIOMEDICAL AND SCIENTIFIC RESEARCH ETHICS COMMITTEE CONSENT FORM 
 
Study Number: REGO-2014-711 
 
Patient Identification Number for this study: 
 
Provisional Title of Project: ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR 
DISEASE RISK FACTOR PROFILES OF HIV-INFECTED PATIENTS IN NIGERIA 
Name of Researcher(s): Dr. Chidozie Nduka; Dr. Saverio Stranges; Dr. Olalekan Uthman; Dr. Peter 
Kimani, Professor Abraham O. Malu. 
 
Please initial all boxes 
 
1. I confirm that I have read / had the information leaflet read to me. I understand the 
information contained on the leaflet dated [DATE] for the above study. I have had the 
opportunity to consider these information, asked questions and have had these answered 
satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care being affected. 
3. I understand that a sample of my blood would be needed as part of this study. I also 
understand that the procedure for obtaining this sample may be associated with some 
discomfort, and I give consent. 
4. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from The University of Warwick and regulatory 
authorities involved in policy formulation and implementation. I give permission for 
these individuals to have access to my records. 
5. I agree to take part in the above named study. 
 
6. I understand that my physician will be informed of my participation in this study. 
 
 
Name of Participant Date Signature/thumb print 
 
 
Name of Person taking consent Date 
